Document:

Option and License Agreement, Biogen Idec International GmbH

 Execution Copy 
 Exhibit 10.26 
 Confidential Materials omitted and filed
separately with the 
 Securities and Exchange Commission. Asterisks denote omissions. 
 OPTION AND LICENSE AGREEMENT 
 BY AND BETWEEN 
 AVEO PHARMACEUTICALS, INC. 
 AND 
 BIOGEN IDEC
INTERNATIONAL GMBH 

 OPTION AND LICENSE AGREEMENT 
 This Option and License Agreement, made this 18th day of March, 2009 (the “Effective Date”), is by and between AVEO
Pharmaceuticals, Inc., a Delaware corporation, with principal offices located at 75 Sidney St., Cambridge, MA 02139 (“AVEO”) and Biogen Idec International GmbH, with principal offices located at Landis+Gyr-Strasse 3, 6300 Zug,
Switzerland (“Biogen Idec”). Each of AVEO and Biogen Idec shall be referred to, individually, as a “Party”, and, collectively, as the “Parties”. 
 RECITALS 
 WHEREAS, AVEO has a broad pipeline of preclinical stage novel antibodies directed at targets with potential utility in the oncology area, including antibodies targeting erbB3; 
 WHEREAS, Biogen Idec is in the business of researching, developing and commercializing biopharmaceutical products, and has an
interest in the area of oncology; and 
 WHEREAS, Biogen Idec is interested in obtaining an option to commercialize
AVEO’s antibodies to erbB3 outside of North America, and AVEO is willing to grant Biogen Idec such an option on the terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained in this Agreement, AVEO and Biogen Idec, intending to be legally bound, hereby agree as follows: 
 ARTICLE I. 
 DEFINITIONS 
 When used in this Agreement, each of the following capitalized terms, whether used in the singular or plural,
shall have the meanings set forth in this Article I. 
 1.1 “Affiliate” of a Person means any other Person
which, directly or indirectly, controls, is controlled by or is under common control with such Person. For the purposes of this definition, “control” refers to any of the following: (i) direct or indirect ownership of fifty
percent (50%) or more of the voting securities entitled to vote for the election of directors in the case of a corporation, or of fifty percent (50%) or more of the equity interest with the power to direct management in the case of any
other type of legal entity; (ii) status as a general partner in any partnership; or (iii) any other arrangement where a Person possesses, directly or indirectly, the power to direct the management or policies of an entity, whether through
ownership of voting securities, by contract or otherwise. 
 1.2 “Agreement” means this Option and License
Agreement, including any and all schedules, appendices, exhibits and other addenda to it, as it may be added to or amended from time to time in accordance with the provisions of this document. 
 1.3 “Agreement Term” shall mean the period commencing on the Effective Date and ending on the expiration of the Agreement
in accordance with the provisions of Section 14.1. 

 1.4 “Antibody” means any immunoglobulin molecule (such
as IgG) whether in monospecific, bispecific or any other form, and shall include any immunoglobulin fragment (such as Fv, Fab, F(ab’)2) of any such immunoglobulin molecule containing one or more complementarity determining regions, any fusion protein
comprising any such immunoglobulin molecule or immunoglobulin fragment and any single chain antibody (such as scFv), and any truncation or derivative of any of the foregoing. 
 1.5 “AVEO Collaboration Know-how” means, subject to Sections 3.6, 5.11, 5.12 and 5.13, any Know-how that is owned or
otherwise Controlled by AVEO or any of its Affiliates, patentable or otherwise, first identified, discovered, or developed solely by employees of AVEO or its Affiliates, or other persons not employed by AVEO or any of its Affiliates but acting on
behalf of AVEO or any of its Affiliates, in the conduct of Development, Manufacture or Commercialization of Licensed Product under this Agreement during the License Term, but not including AVEO’s interest in Joint Collaboration Know-how.

 1.6 “AVEO Collaboration Patent Rights” means, subject to Sections 3.6 and 3.9, any Patent Rights Covering
AVEO Collaboration Know-how that are owned or otherwise Controlled by AVEO or any of its Affiliates, but not including AVEO’s interest in Joint Collaboration Patent Rights. 
 1.7 “AVEO In-License” means, subject to Section 3.9, any agreement between AVEO or any of its Affiliates, on the one
hand, and a Third Party, on the other hand, entered into prior to the Option Exercise Date subject to the provisions of Section 2.6 or during the License Term in compliance with the provisions of Section 3.6, pursuant to which AVEO or any
of its Affiliates acquires or obtains a license or other right to use, any Know-how and/or Patent Rights that are necessary or reasonably useful to Develop, Commercialize or Manufacture Licensed Product in the Field in the Territory. 
 1.8 “AVEO Know-how” means any Know-how owned or otherwise Controlled by AVEO or any of its Affiliates as of the Effective
Date or, subject to Sections 3.6, 3.9, 5.11, 5.12 and 5.13, any Know-how as to which Control is obtained (whether by ownership, license or otherwise) by AVEO or any of its Affiliates during the Agreement Term, in each case to the extent such
Know-how is necessary or reasonably useful in the Development, Manufacture or Commercialization of Licensed Product in the Field, but not including AVEO Collaboration Know-how or AVEO’s interest in Joint Collaboration Know-how. 
 1.9 “AVEO Patent Rights” means Patent Rights Covering AVEO Know-how that are owned or otherwise Controlled by AVEO or any
of its Affiliates as of the Effective Date or, subject to Sections 3.6 and 3.9, Patent Rights covering AVEO Know-how as to which Control is obtained (whether by ownership, license or otherwise) by AVEO or any of its Affiliates at any time after the
Effective Date, including the Patent Rights in the Territory described in Exhibit A, but not including AVEO Collaboration Patent Rights or AVEO’s interest in Joint Collaboration Patent Rights. 
 1.10 “AVEO Proprietary Composition Licensed Product” means a Licensed Product the composition of matter of which is Covered
by AVEO Patent Rights. 
  

 2 

 1.11 “AVEO Technology” means, collectively, AVEO Know-how, AVEO Patent
Rights, AVEO Collaboration Know-how, AVEO Collaboration Patent Rights and AVEO’s interest in Joint Collaboration IP. 
 1.12 “AVEO Territory” means North America. 
 1.13 “Biogen Idec Collaboration
Know-how” means, subject to Sections 3.6, 5.11, 5.12 and 5.13, any Know-how that is owned or otherwise Controlled by Biogen Idec or any of its Affiliates, patentable or otherwise, first identified, discovered, or developed solely by
employees of Biogen Idec or its Affiliates, or other persons not employed by Biogen Idec or any of its Affiliates but acting on behalf of Biogen Idec or any of its Affiliates, in the conduct of Development, Manufacture or Commercialization of
Licensed Product under this Agreement during the License Term, but not including Biogen Idec’s interest in Joint Collaboration Know-how. 
 1.14 “Biogen Idec Collaboration Patent Rights” means, subject to Sections 3.6 and 3.9, Patent Rights Covering Biogen Idec Collaboration Know-how that are owned or otherwise Controlled by
Biogen Idec or any of its Affiliates, but not including Biogen Idec’s interest in Joint Collaboration Patent Rights. 
 1.15 “Biogen Idec Collaboration Technology” means, collectively, Biogen Idec Collaboration Know-how, Biogen Idec Collaboration Patent Rights and Biogen Idec’s interest in Joint Collaboration IP 
 1.16 “Biogen Idec In-License” means, subject to Section 3.9, an agreement between Biogen Idec or any of its
Affiliates, on the one hand, and a Third Party, on the other hand, entered into during the License Term in compliance with the provisions of Section 3.6, pursuant to which Biogen Idec or any of its Affiliates acquires or obtains title to, or a
license or other right to use, any Know-how and/or Patent Rights that are necessary or reasonably useful to Develop, Commercialize or Manufacture the Licensed Product in the Field in the Territory. 
 1.17 “BLA” means a biologics license application or equivalent application that is filed with the FDA to obtain Regulatory
Approval for a Licensed Product in the United States or any comparable application filed with a Regulatory Authority of a country or group of countries in the Territory other than the United States to obtain Regulatory Approval for Licensed Product
in that country or in that group of countries. 
 1.18 “Business Day” means a day that is not a Saturday or
Sunday and not a federal holiday in the United States or a state holiday in the Commonwealth of Massachusetts. 
 1.19
“Calendar Quarter” means each of the three month periods ending on March 31, June 30, September 30 and December 31 of any year. 
 1.20 “Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on
December 31; provided that the first Calendar Year of the License Term shall begin on the Option Exercise Date and end on the following December 31, and the last Calendar Year of the License Term shall end on the last day of
the License Term. 
  

 3 

 1.21 “Commercialization”, “Commercializing” or
“Commercialize” means all activities related to pre-marketing, launching, marketing, promotion (including advertising and detailing), labeling, pricing and reimbursement, distribution, storage, handling, offering for sale, selling,
importing and exporting for sale, distribution, customer service and support, and post-marketing safety surveillance and reporting, but not including Manufacturing. 
 1.22 “Collaboration Know-how” means AVEO Collaboration Know-how, Biogen Idec Collaboration Know-how and Joint Collaboration Know-how. 
 1.23 “Collaboration Patent Rights” means AVEO Collaboration Patent Rights, Biogen Idec Collaboration Patent Rights and
Joint Collaboration Patent Rights. 
 1.24 “Combination Product” means any pharmaceutical product containing a
Licensed Product and one or more other significantly active pharmaceutical ingredients. 
 1.25 “Commercially Reasonable
Efforts” in respect of a Party means efforts and resources (measured as of the time that such efforts are required to be used under this Agreement) commonly used by a company in the industry of a similar size and profile as such Party to
Develop, Manufacture or Commercialize, as the case may be, a product owned by such company or to which it has rights, which product is at a similar stage in its development or product life and is of a similar market and profitability potential to
Licensed Product and taking into account all relevant factors including the patent and other proprietary position of the product, product labeling or anticipated labeling, market potential, financial return, medical and clinical considerations,
regulatory environments and competitive market conditions, and other technical, legal, scientific, medical or commercial factors that such a company would deem to be relevant. 
 1.26 “Confidential Information” means any and all information, data and materials of a confidential or proprietary nature,
including information, data and materials regarding or included within AVEO Technology or Biogen Idec Collaboration Technology and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial or commercial
information or data, whether communicated in writing or orally or by any other method, which is provided by one Party or any of its Affiliates to the other Party or any of its Affiliates in connection with this Agreement. AVEO Technology is
Confidential Information of AVEO, and Biogen Idec Collaboration Technology is Confidential Information of Biogen Idec, provided that Joint Collaboration IP is the Confidential Information of both Parties. 
 1.27 “Control” or “Controlled”, other than for purposes of Section 1.1, means the possession of the
right to grant licenses or sublicenses or to disclose proprietary or trade secret information without violating the terms of any agreement or other arrangement with a Third Party. 
 1.28 “Cost of Goods Sold” means, with respect to Licensed Product in bulk form manufactured for use as an active
pharmaceutical ingredient or in finished final packaged and labeled product form, or in intermediate states, as the case may be, Manufactured by or on behalf of a Party under this Agreement, the reasonable internal and external costs of such Party
or any of its Affiliates incurred in Manufacturing such Licensed Product, including: (a) to the extent that such Licensed Product is Manufactured by such Party or any of its Affiliates, the cost of goods sold of such Licensed Product,
consisting of direct materials and direct labor

  

 4 

 
costs, plus Manufacturing overhead directly attributable to Licensed Product supplied (excluding facilities start-up costs, corporate administrative overhead, depreciation and costs associated
with excess capacity), all calculated in accordance with GAAP in the United States consistently applied, (b) to the extent that such Licensed Product is Manufactured by a Third Party manufacturer, the actual fees paid by such Party or any of
its Affiliates to the Third Party for the Manufacture, supply, testing, packaging, labeling and shipping of such Licensed Product, and any reasonable out-of-pocket and direct labor costs actually incurred by such Party or any of its Affiliates in
managing or overseeing the Third Party relationship, and (c) royalties, license or other fees paid by such Party or any of its Affiliates to Third Parties in respect of Manufacture of such Licensed Product. 
 1.29 “Cover”, “Covering” or “Covered” means, with respect to whether an invention or
Know-how is “Covered” by a Patent Right, that, in the absence of ownership of, or a license under, such Patent Right, the practice by such Person of such invention or Know-how would infringe a Valid Claim of such Patent Right (including in
the case of a Patent Right that is a patent application, a Valid Claim of such patent application as if such patent application were an issued patent). 
 1.30 “CPI” means the Consumer Price Index for all Urban Consumers Northeastern Urban (Boston, Brockton, Nashua, NH, ME, CT) City Average for all Items, 1982, 84-100, published by the
United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States. 
 1.31
“Data Exclusivity” means, with respect to a Licensed Product in a country, that period during which a Party or any of its Affiliates or Sublicensees has been granted the exclusive legal right by a Regulatory Authority (or is
otherwise entitled to the exclusive legal right by operation of applicable Law) in such country to market and sell such Licensed Product in such country in the approved indication in the Field. 
 1.32 “Data Package” means a complete, detailed, data-cleaned, unbiased and unblended data package that contains the results
of the first Proof of Concept Study in the following form: (i) a statistical analysis of results; (ii) analysis tables, data listings and illustrative figures; (iii) the table of adverse events; (iv) case report forms (CRFs) in
hard copy or electronic form, or, alternatively, available for review by Biogen Idec employees during normal business hours at the principal office of AVEO in the United States, commencing upon delivery of the other parts of the Data Package; and
(v) a narrative description of serious adverse events, in each case in the format compiled by AVEO, which shall be cGCP compliant and otherwise consistent with industry standards. The Data Package shall also contain (x) a copy (or rights
of access for purposes of clause (iv) above) of the relevant IND and the information specified in clauses (i) – (v) for any Phase 1 Clinical Trial or any other Phase 2 Clinical Trial completed prior to completion of the first
Proof of Concept Study, as well as all regulatory correspondence relating thereto, (y) copies of all AVEO In-Licenses entered into between the period commencing after the Effective Date through the date of delivery of the Data Package and
(z) a copy of the initial Development Plan. 
  

 5 

 1.33 “Development” or “Develop” means any and all
non-clinical and clinical drug research and development activities, whether before or after Regulatory Approval, including discovery efforts, toxicology and pharmacology work, test method development, stability testing, process development,
formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre-approval studies and Post-Approval Clinical Studies), regulatory affairs, and product
approval and clinical study regulatory activities (excluding regulatory activities directed to obtaining pricing and reimbursement approvals). 
 1.34 “Development Costs” means all costs incurred by AVEO or any of its Affiliates in Developing the Licensed Product in the Field, in accordance with this Agreement and GAAP, whether
incurred before or after Regulatory Approval, provided that except as otherwise specifically set forth in this Agreement, such activities and costs are consistent with the then current Development Plan and included in the related
budget (pursuant to the provisions of Section 5.4 and 5.5 below), including without duplication: 
 (i) all
out-of-pocket costs and expenses actually incurred; 
 (ii) the costs of internal personnel engaged in such
efforts, which costs shall be determined based on the FTE Cost, unless another basis is otherwise agreed by the Parties in writing; 
 (iii) (a) the Cost of Goods Sold and distribution costs and expenses for pre-clinical and clinical supplies needed for such efforts as set forth in the Development Plan, including the Cost of Goods Sold
for clinical supplies of the Licensed Product; (b) the costs of comparator or combination drugs, placebo or devices; (c) costs and expenses of disposal of clinical samples; (d) costs and expenses incurred in connection with
(1) manufacturing process, formulation or delivery system development or validation; (2) manufacturing scale-up and improvements; (3) stability testing; and (4) quality assurance/quality control development; and (e) internal
and Third Party costs and expenses incurred in connection with qualification, validation or auditing of Third Party contract manufacturers, in each case to the extent specific to Licensed Product, and not including the purchase of capital equipment
for the purposes of building manufacturing facilities and capabilities; 
 (iv) subject to Section 5.5(b),
(a) costs associated with threatened or pending claims or actions by a Third Party for product liability resulting from those Development activities under this Agreement as to which Development Costs are shared by the Parties or paid fully by
Biogen Idec under Section 5.4, other than those claims or actions for which Biogen Idec is entitled to indemnification under Article XII or pursuant to a Supply Agreement, provided that if there is a bona fide dispute as to
whether a Party is entitled to indemnification for any such costs, the determination as to whether such costs are Development Costs shall not be made until such dispute is resolved; and (b) product liability insurance premiums for policies
related to Development of Licensed Product in the Licensed Territory under which Biogen Idec is named as an additional insured; and 
  

 6 

 (v) other costs incurred that are explicitly included in the budgets that
are approved by the JDC and included in the Development Plan. 
 In addition to the foregoing, “Development Costs” shall also include
Pre-Option Exercise Phase 3 Manufacturing Costs, to the extent not otherwise captured by this definition. For purposes of clarity, the FTE Cost does not include travel and lodging expenses incurred by an FTE in connection with Development activities
which such expenses shall be separately included as Development Costs. The term “Development Costs” shall in no event include any payments made by either Party or its Affiliates in connection with an AVEO In-License or a Biogen Idec
In-License or in connection with any Third Party Technology Agreement, except to the extent that such payments are in respect of the Manufacture of Licensed Product and are included in Costs of Goods Sold for pre-clinical and clinical supplies
needed for such efforts as set forth in the Development Plan. Section 8.9 sets forth the Parties’ respective obligations regarding payments under AVEO In-Licenses and Biogen Idec In-Licenses, as well as the Parties’ respective rights
to offset certain payment obligations under other Third Party Technology Agreements against royalty payments obligations, that the Parties would otherwise have under this Agreement. 
 1.35 “Development Plan” means the written work-plan and budget for AVEO’s Development efforts, agreed upon by the
Parties after the Option Exercise Date in accordance with Section 5.2, and as amended from time to time in accordance with this Agreement or, if none, the Delivered Initial Development Plan. 
 1.36 “Directly Competitive Product” means any product comprising or containing an ERBB3 Antibody that is not a Licensed
Product. 
 1.37 “Drug Regulations Laws” means Laws regulating drugs and pharmaceutical products, including the
United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et seq., the Prescription Drug Marketing Act of 1987, the federal Controlled Substances Act, 21 U.S.C. §801 et seq., and policies issued by the FDA, and
similar Laws of the EMEA or other countries or jurisdictions in the Territory, each as in effect and as amended from time to time. 
 1.38 “Drug Safety Information Exchange Agreement” means an agreement between the Parties which outlines the requirements and responsibilities for drug safety reporting and monitoring within the Territory, as described in
Section 5.8. 
 1.39 “ERBB3” means the human erbB3 (aka HER3) polypeptide, including: (i) any species
variants or homologs thereof; (ii) any amino acid sequence variants or mutations of the foregoing, (iii) any post-translational modifications of the foregoing; and (iv) any derivative or fragment of the foregoing; provided
that the derivative or fragment elicits an antibody that reacts with native human erbB3, when used as an antigen. 
 1.40
“ERBB3 Antibody” means an Antibody that binds to ERBB3. 
 1.41 “EMEA” means the European
Medicines Agency or any successor agency. 
  

 7 

 1.42 “European Union” or “EU” means the countries of the
European Union, as it is constituted as of the Effective Date and as it may be expanded from time to time. 
 1.43
“FDA” means the United States Food and Drug Administration or any successor agency thereto. 
 1.44
“Field” means all diagnostic, therapeutic and prophylactic uses in humans. 
 1.45 “First Commercial
Sale” as to a particular country in the applicable Territory means the first commercial sale of a Licensed Product by a Party or its Affiliates or permitted Sublicensee to a Third Party in an arm’s length transaction in such country
after approval of the BLA, or if approval of a BLA is not required in such country, then following receipt of Regulatory Approval required to market such Licensed Product in such country. Sales for test marketing, clinical study purposes or
compassionate, named patient or similar use shall not constitute a First Commercial Sale, but may constitute a sale under the definition of Net Sales if the recipient is billed. 
 1.46 “FTE” means a full-time-equivalent person year of scientific, technical, regulatory or professional work. An FTE shall
consist of a total of [**], with any portion of an FTE calculated based upon hours worked divided by such annual total. 
 1.47
“FTE Cost” means, for any period, the product of (i) the actual total FTEs (and/or portion thereof) during such period, and (ii) the FTE Rate. 
 1.48 “FTE Rate” means [**] Dollars ($[**]) increased or decreased on the Option Exercise Date by the
cumulative percentage increase or decrease in the CPI as of the Option Exercise Date over the level of the CPI as of the Effective Date, and thereafter further increased or decreased annually during the Agreement Term by the percentage increase in
the CPI as of December 31st of each year over the
level of the CPI as of December 31st of the prior
year; provided, however, that in no event shall the FTE Rate exceed [**] Dollars ($[**]) or be less than [**] Dollars ($[**]) at any time during the Agreement Term. 
 1.49 “GAAP” means United States generally accepted accounting principles applied on a consistent basis, or any successor
accounting principles generally accepted for public companies in the United States (such as International Financial Reporting Standards (“IFRS”)). 
 1.50 “Governmental Authority” means any United States federal, state or local government or any foreign national, state, provincial, county, or city government or political subdivision
thereof or any multinational organization or authority or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, any court or tribunal (or any
department, bureau or division thereof) or any governmental arbitrator or arbitral body. 
 1.51 “ICH” means
the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 
  

 8 

 1.52 “IND” means an Investigational New Drug Application filed with FDA or
a similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application (CTA). 
 1.53 “Joint Collaboration Know-how” means Know-how, patentable or otherwise, first identified, discovered or developed jointly by the Parties or their Affiliates or others acting on
behalf of the Parties or their Affiliates in the conduct of Development, Manufacturing or Commercialization of Licensed Product under this Agreement during the Agreement Term. 
 1.54 “Joint Collaboration Patent Rights” means Patent Rights that Cover Joint Collaboration Know-how. 
 1.55 “Joint Collaboration IP” means, collectively Joint Collaboration Know-how and Joint Collaboration Patent Rights.

 1.56 “Know-how” means all biological materials and other tangible materials, inventions, practices, methods,
protocols, formulae, knowledge, know-how, trade secrets, processes, procedures, assays, skills, experience, techniques, data and results of experimentation and testing, including pharmacological, toxicological and pre-clinical and clinical test data
and analytical and quality control data, patentable or otherwise. 
 1.57 “Law” or “Laws”
means all laws, statutes, rules, codes, regulations, orders, decrees, judgments or ordinances of any Governmental Authority, or any license, permit or similar right granted under any of the foregoing, or any similar provision having the force or
effect of law. 
 1.58 “Licensed Product” means any product comprising or containing an ERBB3 Antibody
(A) that is (i) discovered, Developed or Controlled by or on behalf of AVEO or any of its Affiliates prior to or during the Agreement Term or (ii) derived from an ERBB3 Antibody discovered, Developed or Controlled by or on behalf of
AVEO or any of its Affiliates prior to or during the Agreement Term, or (B) the Development, Manufacture or Commercialization of which is Covered by Patent Rights owned or Controlled by AVEO or any of its Affiliates, but, in each case, not
including any product excluded from the definition of Licensed Product under Section 3.9. 
 1.59 “License
Term” means the period commencing upon the Option Exercise Date and ending on the date of expiration of the Agreement in accordance with the provisions of Section 14.1. 
 1.60 “Licensed Territory” means the entire world except North America. 
 1.61 “Losses” means any and all damages (including all incidental, consequential, statutory and treble damages), awards,
deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, liens, losses, and expenses (including court costs, interest and reasonable fees of attorneys, accountants and other experts)
required to be paid to Third Parties with respect to a claim as to which a Party is entitled to indemnification under Article XII, by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into in accordance with
the provisions of this Agreement, together with all

  

 9 

 
documented reasonable out-of-pocket costs and expenses incurred in complying with any judgments, orders, decrees, stipulations and injunctions that arise from or relate to a claim of a Third
Party. 
 1.62 “Manufacture” or “Manufacturing” means all activities related to the
manufacturing of any Licensed Product, in bulk form manufactured for use as an active pharmaceutical ingredient or in finished final packaged and labeled product form, or in intermediate states, including but not limited to formulation,
manufacturing scale-up, manufacturing for use in non-clinical and clinical studies, manufacturing for commercial sale, packaging, release of product, manufacturing quality assurance/quality control testing (including in-process release and stability
testing), release, storage and shipping of product or any component or ingredient thereof, regulatory activities related to all of the foregoing, and data management and recordkeeping related to all of the foregoing. 
 1.63 “Net Sales” means the gross amount invoiced on sales of the Licensed Product by a Party, its Affiliates or
Sublicensees to any Third Party, less the following reasonable deductions to the extent included in the gross invoiced sales price for the Licensed Product or otherwise directly paid, allowed, accrued, or incurred by such Party, its Affiliates or
Sublicensees with respect to the sale of such Licensed Product: 
 (i) reasonable, normal and customary trade,
cash and quantity discounts actually given; coupons for price reductions, actually taken; credits, price adjustments or allowances for damaged products, recalls, returns or rejections of products; 
 (ii) reasonable price adjustments, allowances, credits, chargeback payments and rebates (or the equivalent thereof) for the
Licensed Product granted to and actually used by group purchasing organizations or other buying groups, managed health care organizations, pharmacy benefit management companies, health maintenance organizations and any other providers of health
insurance coverage, health care organizations or other health care institutions (including hospitals), Third Party health care administrators or patient assistance or other similar programs, or to federal, state/provincial, local and other
governments, including their agencies, or to wholesalers, distributors or other trade customers; 
 (iii)
reasonable and customary freight, shipping, insurance and other transportation expenses (if actually borne by such Party or its Affiliates or Sublicensees without reimbursement from any Third Party); 
 (iv) required distribution commissions/fees payable to Third Party wholesalers for distribution of Licensed Product;

 (v) sales, value-added, excise taxes, tariffs and duties, and other taxes and government charges directly
related to the sale, to the extent that such items are included in the gross invoice price of the Licensed Product and actually borne by such Party, its Affiliates or Sublicensees without reimbursement from any Third Party (but not including taxes
assessed against the income derived from such sale); and 
  

 10 

 (vi) a reasonable amount for bad debts actually written off which are
attributable to sales of Licensed Product not to exceed [**] of Net Sales. 
 The transfer of a Licensed Product by a Party or
one of its Affiliates to another Affiliate or Sublicensee for resale shall not be considered a sale. 
 Disposal of the Licensed
Product for, or use of the Licensed Product in, clinical trials, as free samples, or under compassionate use, patient assistance, or test marketing programs or non-registrational studies or other similar programs or studies where a Licensed Product
is supplied without charge, shall not result in any Net Sales, however if a Party or its Affiliates or Sublicensees charges for such Licensed Product, the amount billed will be included in the calculation of Net Sales. 
 Net Sales will include the cash consideration received on a sale and the fair market value of all non-cash consideration. In the event
Licensed Product is sold, other than in an arm’s length transaction, Net Sales for such sale will be determined using the average per unit Net Sales amount for the preceding Calendar Quarter. 
 Net Sales shall be determined on an accrual basis from books and records maintained in accordance with GAAP, consistently applied throughout
the organization and across all products of the entity whose sales of Licensed Product are giving rise to Net Sales. 
 In the
event a Licensed Product is sold in the form of a Combination Product, then the Net Sales for any such Combination Product shall be determined by [**]. 
 1.64 “North America” or “N.A.” means the United States, Canada and Mexico and their respective territories and possessions. 
 1.65 “Patent Rights” means (i) all national, regional and international patents and patent applications, including
provisional patent applications; (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, and
continuations-in-parts; (iii) any and all patents that have issued or issue in the future from the foregoing patent applications, including author certificates, inventor certificates, utility models, petty patents and design patents and
certificates of invention; (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection
certificates and the like) of the foregoing patents or patent applications; and (v) any similar rights, including pipeline protection (where the subject matter previously disclosed was not previously patentable in a particular jurisdiction but
subsequently becomes patentable subject matter in such jurisdiction), or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications and patents.

  

 11 

 1.66 “Person” means any natural person, corporation, firm, business trust,
joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof. 
 1.67 “Phase 1 Clinical Trial” means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of Licensed Product or that would otherwise
satisfy the requirements of 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country in the Territory other than the United States. 
 1.68 “Phase 2 Clinical Trial” means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied
as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States. 
 1.69 “Phase 3 Clinical Trial” means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in the indication being investigated in a
manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. §312.21(c), or an equivalent clinical trial in a country in the Territory other than the
United States. 
 1.70 “Post-Approval Clinical Study” means (A) with respect to AVEO, any human clinical
trial or registry either (i) required to be carried out by a Regulatory Authority in the AVEO Territory for the purpose of post-marketing surveillance of Licensed Product in the AVEO Territory or (ii) otherwise requested by Regulatory
Authorities in the AVEO Territory after Regulatory Approval of Licensed Product in the AVEO Territory in an indication, designed to obtain additional information regarding Licensed Product’s risks, benefits and optimal use of that Licensed
Product in such indication, and (B) with respect to Biogen Idec, any human clinical trial or registry either (i) required to be carried out by a Regulatory Authority in the Licensed Territory for the purpose of post-marketing surveillance
of Licensed Product in the Licensed Territory or (ii) otherwise requested by Regulatory Authorities in the Licensed Territory after Regulatory Approval of Licensed Product in the Licensed Territory in an indication, designed to obtain
additional information regarding Licensed Product’s risks, benefits and optimal use of that Licensed Product in such indication. For purposes of clarity, a clinical trial of Licensed Product in an indication for which such Licensed Product is
not approved shall not be considered Post-Approval Clinical Study even if such trial occurs after such Licensed Product is approved in another indication. 
 1.71 “Pre-Option Exercise Phase 3 Manufacturing Costs” means the out-of-pocket costs and expenses incurred by AVEO or any of its Affiliates prior to the Option Exercise Date to obtain
quantities of Licensed Product (including drug substance, drug product, validation batches and material for stability and other testing) for a Phase 3 Clinical Trial or for Commercialization or for testing of Licensed Product for any such Phase 3
Clinical Trial. 
 1.72 “Proof of Concept Development Plan” means the written work-plan for AVEO’s
Development efforts in connection with the Proof of Concept Study (including a description of the Proof of Concept Study itself), prepared and finalized by AVEO in accordance with Section 2.5, and as amended from time to time in accordance with
this Agreement. 
  

 12 

 1.73 “Proof of Concept Study” means a Phase 2 Clinical Trial that is
appropriately designed (i) to demonstrate efficacy in the disease to be studied through relevant primary and/or secondary efficacy endpoints as described in the Proof of Concept Development Plan and (ii) to allow dose selection and support
generation of efficacy data that would allow movement of the product into a Phase 3 Clinical Trial that would support the regulatory strategy of seeking Regulatory Approval in both the AVEO Territory and the EU. For purpose of clarity, a clinical
study meeting the requirements of this definition will be considered a Proof of Concept Study when completed whether or not the endpoints of the study are actually met. 
 1.74 “Regulatory Approval” means any approval, including price approval, registration, license or authorization from any Governmental Authority or Regulatory Authority required for the
Manufacture, Development or Commercialization of a Licensed Product in the Territory, and shall include, without limitation, an approval, registration, license or authorization granted in connection with the BLA. 
 1.75 “Regulatory Authority” means any federal, national, multinational, state, county, city, provincial, or local
regulatory agency, department, bureau or other governmental entity with authority over the Marketing, Commercialization, Manufacture or sale of a pharmaceutical product in the Territory, including the FDA in the United States and the EMEA in the EU.

 1.76 “Safety Data” means adverse event information and other information (if any) required by one or more
Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under applicable Laws. 
 1.77
“Sales Representative” means an individual, who engages in or manages sales calls and other promotional efforts with respect to the Licensed Product and who is employed by a Party or an Affiliate of a Party. 
 1.78 “Sublicensee” means a Third Party to whom a Party, as permitted under this Agreement, grants a license or sublicense,
as the case may be, under the AVEO Technology, Biogen Idec Collaboration Technology or Joint Collaboration IP, to Develop, Manufacture, Commercialize or use Licensed Product in the Field, or otherwise grants rights to distribute, promote or sell
Licensed Product in the Field, but does not include wholesale distributors of a Party or its Affiliates who purchase Licensed Product from such Party or its Affiliates in an arm’s length transaction. For purposes of clarity, the term
“wholesale distributors” does not include those distributors whose obligations to a Party or any of its Affiliates include responsibility for sales or marketing efforts in such country or sharing of costs and expenses with respect to sales
or marketing on behalf of a Party or its Affiliates, which such distributors shall be deemed Sublicensees for purposes of this definition. 
 1.79 “Territory” means, collectively, the AVEO Territory and the Licensed Territory. 
 1.80 “Territory-Specific Clinical Trial” means, with respect to AVEO, a human clinical trial specifically required in the AVEO Territory which will generate data that will not be
applicable to Licensed Product in the Licensed Territory (other than the

  

 13 

 
applicability of safety data) and, except with respect to safety data, will not be included in a filing for Regulatory Approval for Licensed Product in the Licensed Territory, and, with respect
to Biogen Idec, a human clinical trial specifically required in the Licensed Territory which will generate data that will not be applicable to Licensed Product in the AVEO Territory (other than the applicability of safety data) and, except with
respect to safety data, will not be included in a filing for Regulatory Approval for Licensed Product in the AVEO Territory. 
 1.81 “Third Party” means any Person other than a Party or any of its Affiliates or their respective employees. 
 1.82 “United States” or “U.S.” means the United States of America and its territories and possessions. 
 1.83 “Valid Claim” means (i) a claim of an issued and unexpired patent, which has not been held permanently revoked or
held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or un-appealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through
reissue or disclaimer or otherwise or been dedicated to the public or (ii) a claim in a pending patent application that (A) is being prosecuted in good faith, (B) has not been abandoned or disclaimed or finally determined to be
unallowable by the applicable Governmental Authority in a decision from which no appeal is or can be taken, and (C) has not been pending for more than five (5) years from the date of issuance of the first substantive patent office action
considering the patentability of such claim by the applicable Governmental Authority in such country (at which time such pending claim shall cease to be a Valid Claim for purposes of this Agreement unless and until such claim becomes a claim of an
issued patent). 
 1.84 Additional Definitions. Each of the following definitions is set forth in the Section of this
Agreement indicated below: 
  

			
	 Defined Term
	  	 Section

		
	 Audited Party
	  	§8.16(a)
	 Auditing Party
	  	§8.16(a)
	 AVEO
	  	Preamble
	 AVEO Control Assumption Date
	  	§14.6(a)
	 AVEO Indemnities
	  	§12.1
	 AVEO Group
	  	§3.2(b)
	 Bankruptcy Code
	  	§13.3
	 Biogen Idec
	  	Preamble
	 Biogen Idec Control Assumption Date
	  	§14.6(b)
	 Biogen Idec Indemnitees
	  	§12.2
	 Breached Licensed Product
	  	§14.5(a)
	 [**]
	  	§8.3(b)
	 Collaboration Manager
	  	§4.5
	 Commercially Viable Indication
	  	§5.12(a)
	 Competing Acquiror
	  	§13.1

  

 14 

			
	 Defined Term
	  	 Section

		
	 Competitive Infringement
	  	§9.6(a)
	 Contract Manufacturer Notice
	  	§7.2
	 Control Assumption Option
	  	§13.1
	 Cost Payment
	  	§5.5
	 Cure Plan
	  	§14.3(b)
	 Delivered Initial Development Plan
	  	§2.9
	 Development Plan Guidelines
	  	§4.8(a)
	 Divestiture Period
	  	§13.1
	 Effective Date
	  	Preamble
	 Event Milestone
	  	§8.4
	 Event Milestone Payment
	  	§8.4
	 Force Majeure Event
	  	§16.2
	 Funding Party
	  	§5.11(a)
	 [**]
	  	§8.3(c)
	 Indication Specific Royalty
	  	§5.13(a)
	 Indemnitee
	  	§12.3
	 Initial Development Plan
	  	§2.9
	 Initial Release
	  	§10.3
	 Insolvency Control Assumption Option
	  	§13.3
	 Insolvency Event
	  	§13.3
	 JCT
	  	§6.2(a)
	 JCT Chairperson
	  	§6.2(b)
	 JDC
	  	§4.1
	 JDC Chairperson
	  	§4.2
	 M&A Control Assumption Option
	  	§13.1
	 M&A Event
	  	§3.9
	 Manufacturing Party
	  	§14.7
	 New Indication Existing Licensed Product
	  	§5.12(a)
	 New Indication Funding Party
	  	§5.12(a)
	 New Licensed Product
	  	§5.11(a)
	 Non-Manufacturing Party
	  	§14.7
	 Non-performing Manufacturing Party
	  	§7.6
	 Notified Party
	  	§14.3(b)
	 Notifying Party
	  	§14.3(b)
	 Opt-in Indication
	  	§5.13(a)
	 Opt-in Effective Date
	  	§5.13(a)
	 Opt-in New Indication Existing Licensed Product
	  	§5.13(a)
	 Opt-in Notice
	  	§5.13(a)
	 Opt-in Notice Date
	  	§5.13(a)
	 Opting-out Party
	  	§5.11
	 Option
	  	§2.1
	 Option Exercise Date
	  	§2.3
	 Option Exercise Fee
	  	§8.3(d)
	 Option Exercise Notice
	  	§2.3
	 Option Exercise Period
	  	§2.2

  

 15 

			
	 Defined Term
	  	 Section

		
	 Panel Identification
	  	§8.3(a)
	 Parties
	  	Preamble
	 Party
	  	Preamble
	 Patent Expenses
	  	§9.5
	 Pre-Exercise Milestone
	  	§8.3
	 Pre-Exercise Milestone Payment
	  	§8.3
	 Product Opt-out Effective Date
	  	§5.11
	 Product Trademarks
	  	§9.9(b)
	 Promotional Materials
	  	§6.4
	 Quarterly Cost Notice
	  	§5.5
	 Royalty Term
	  	§8.8
	 Royalty-paying Party
	  	§8.10
	 Section 5.11 Opt-out Effective Date
	  	§5.11(a)
	 Section 5.12 Opt-out Effective Date
	  	§5.12(a)
	 Senior Representative
	  	§4.1
	 Supplemental Information
	  	§2.2
	 Supply Agreement
	  	§7.7
	 Tax/Taxes
	  	§8.11
	 Third Party Technology
	  	§3.6(a)
	 Third Party Technology Agreements
	  	§3.6(a)

 ARTICLE II. 
 OPTION GRANT AND DEVELOPMENT DURING OPTION PERIOD 
 2.1. Grant of Option. AVEO hereby grants to Biogen Idec an exclusive option, exercisable during the Option Exercise Period, as defined in Section 2.2, to acquire from AVEO the licenses set forth in Section 3.1, subject to
the terms and conditions of this Agreement (the “Option”). 
 2.2. Option Exercise Period. AVEO shall
deliver the Data Package from the first Proof of Concept Study to Biogen Idec and an initial Development Plan no later than [**] after the last visit of the last patient to be dosed in such Proof of Concept Study. During the [**] following delivery
of the Data Package, (i) Biogen Idec may request, and AVEO will provide to Biogen Idec, any other data and information in AVEO’s possession and Control (and AVEO shall make reasonable efforts to procure or produce such other data and
information that is not in AVEO’s possession and Control) as Biogen Idec may reasonably request in connection with its review of the Data Package (the “Supplemental Information”), (ii) the Parties shall meet in good faith
to discuss Biogen Idec’s comments to the initial Development Plan in accordance with Section 2.9, (iii) AVEO will deliver to Biogen Idec copies of any AVEO In-Licenses entered into after the Effective Date, and (iv) AVEO will
deliver to Biogen Idec a reasonably detailed statement of Pre-Option Exercise Phase 3 Manufacturing Costs actually incurred by AVEO and its Affiliates as of such date and reasonably expected to be incurred prior to the end of the Option Exercise
Period. The Option shall be exercisable by Biogen Idec at any time during the period commencing on the Effective Date and ending on the later of (i) [**] after delivery of the Data Package, or (ii) [**] after the last to be delivered of
the Supplemental Information (the “Option Exercise Period”). 
  

 16 

 2.3. Option Exercise. In the event Biogen Idec elects to exercise the Option, it
shall, no later than the [**] of the [**] of the Option Exercise Period, deliver to AVEO (i) written notice specifying that Biogen Idec has elected to exercise the Option (the “Option Exercise Notice”), and (ii) payment of
the Option Exercise Fee. The date, if any, on which Biogen Idec has properly exercised the Option in accordance with the preceding sentence shall be the “Option Exercise Date” for purposes of this Agreement. The Option Exercise
Period will be deemed to have ended, and the License Term will be deemed to have commenced, on the Option Exercise Date. 
 2.4.
Effectiveness of License. Upon the exercise by Biogen Idec of the Option in accordance with this Article II, the provisions set forth in Article I and Articles III—XVI of this Agreement shall constitute the terms and conditions of the
license and sublicense rights granted by AVEO to Biogen Idec with respect to the AVEO Technology in the Field, and by Biogen Idec to AVEO with respect to Biogen Idec Collaboration Technology, related to all Licensed Products in the Field. During the
period commencing on the Effective Date and ending on the expiration of the Option Exercise Period, AVEO will not grant a license or other rights to any Third Party or take any other action that would prevent AVEO from being able to grant to Biogen
Idec the license set forth in Section 3.1. In the event Biogen Idec does not exercise the Option during the Option Exercise Period, the licenses and other rights granted under Articles III shall have no force or effect. 
 2.5. Proof of Concept Development Plan. As promptly as practicable after AVEO has prepared the Proof of Concept Development Plan,
AVEO shall provide a copy thereof to Biogen Idec for its review and comment. Biogen Idec shall have a period of [**] to review and comment on the Proof of Concept Development Plan. AVEO shall consider in good faith all reasonable comments made by
Biogen Idec to the Proof of Concept Development Plan. If and to the extent requested by Biogen Idec, appropriate members of the clinical development and regulatory teams of AVEO shall meet with appropriate members of the clinical development and
regulatory teams of Biogen Idec to discuss the Proof of Concept Study, including the design thereof as well as the Licensed Product and indication being studied in the Proof of Concept Study, and the Development activities and timelines contemplated
under the Proof of Concept Development Plan. AVEO may amend, modify, supplement or update the Proof of Concept Development Plan at any time and from time to time in its discretion, provided that AVEO complies with the foregoing
provisions of this Section 2.5 (but with Biogen Idec having a [**] review period instead of [**]) with respect to any such amendment, modification, supplement or update of the Proof of Concept Development Plan to the same extent as AVEO is
required in connection with the initial Proof of Concept Development Plan, and any such amendment, modification, supplement or update of the Proof of Concept Development Plan is consistent with the parameters set forth in the next sentence. The
Proof of Concept Development Plan proposed by AVEO hereunder, including any amendment, modification, supplement or update, shall meet the following parameters: [**]. 
 2.6. Development During Option Period. During the Option Exercise Period, AVEO shall have sole responsibility for Development and Manufacture of Licensed Product, at AVEO’s sole cost and
expense, and AVEO shall use Commercially

  

 17 

 
Reasonable Efforts to perform its Development activities as contemplated under the Proof of Concept Development Plan and to Develop Licensed Product through completion of the first Proof of
Concept Study. For purposes of clarity, Biogen Idec shall have no right to Develop or Manufacture Licensed Product during the Option Exercise Period. During the Option Exercise Period, AVEO shall not enter into any AVEO In-License with respect to
any Know-how or Patent Rights as to which (x) rights thereto in both the AVEO Territory and Licensed Territory will be necessary, (y) such Know-how is incorporated in any Licensed Product or such Patent Rights Cover any Licensed Product or
(z) such Know-how or Patent Rights are owned or licensed by a Sublicensee (or any of such Sublicensee’s Affiliates) to whom AVEO has granted a license or sublicense under AVEO Technology or Biogen Idec Collaboration Technology to
Commercialize Licensed Product in the AVEO Territory, unless either (i) such AVEO In-License includes rights with respect to such Know-how and Patent Rights in both the AVEO Territory and the Licensed Territory and such rights are Controlled by
AVEO during the Agreement Term or (ii) to the extent Control cannot be obtained, licenses are available, as a matter of course, separately from the licensor of such Know-how or Patent Rights for Development, Manufacture or Commercialization, as
the case may be, of Licensed Product in both the AVEO Territory and the Licensed Territory on terms that, at the time AVEO enters into such license, would be substantially the same as the terms obtained by AVEO with respect to the AVEO Territory,
and AVEO provides written notice to Biogen Idec that Control could not be obtained. For purposes of clarification and not by way limitation, it is understood and agreed that the term “necessary” as used in this Section 2.6 shall be
deemed to include any Know-how or Patent Rights as to which rights in both the AVEO Territory and Licensed Territory would be necessary for Biogen Idec to Develop, Manufacture or Commercialize, as the case may be, Licensed Product in both the AVEO
Territory and the Licensed Territory under this Agreement, including, without limitation, under Sections 5.11, 5.12, 7.5, 13.1, 13.3 or 14.5(b). 
 2.7. Decision-making during Option Period. During the Option Exercise Period, AVEO shall have sole decision-making authority with respect to Development and Manufacture of Licensed Product,
provided that AVEO complies with the provisions of Section 2.5 hereof. 
 2.8. Development Updates. On
a quarterly basis during the Option Exercise Period, AVEO and Biogen Idec will hold an in-person meeting, at either AVEO’s or Biogen Idec’s headquarters in Massachusetts, at such time as the Parties shall mutually agree, during which AVEO
shall present the results of its Development activities related to Licensed Product since the last update, and shall describe its Development plans with respect to Licensed Product for the following three months and the remainder of the then
Calendar Year. 
 2.9. Initial Development Plan. As soon as AVEO has prepared the initial Development Plan (even if prior
to delivery of the Data Package), AVEO shall deliver to Biogen Idec the initial Development Plan. During the period between Data Package delivery by AVEO and Option Exercise Date, AVEO and Biogen Idec, including appropriate members of the clinical
development and regulatory teams of both AVEO and Biogen Idec shall meet to discuss the initial Development Plan, including the design thereof as well as the indication being studied, and the Development activities and timelines contemplated
thereunder. In anticipation of Biogen Idec’s exercise of the Option, AVEO shall (x) consider in good faith all reasonable Biogen Idec proposals to such initial Development Plan and (y) deliver to Biogen Idec a revised initial
Development Plan (or if no revised initial Development Plan is delivered, the initial

  

 18 

 
Development Plan shall be deemed re-delivered) no less than thirty (30) days prior to the end of the Option Exercise Period (the “Delivered Initial Development Plan”). The
Delivered Initial Development Plan shall meet the following criteria: (i) such Delivered Initial Development Plan shall be directed only to the indication that was the subject of the Proof of Concept Study; (ii) the size of the pivotal
trial included in such Delivered Initial Development Plan shall be reasonable given the scope of the indication, in light of then prevailing industry standards and regulatory guidance; (iii) such Delivered Initial Development Plan shall in
addition include, at a minimum, study designs, assignment of responsibilities (both among the Parties and Third Parties), timelines, decision criteria, supply plans, quality standards, expected resources, costs and a budget for Development Costs;
and (iv) the budget for Development Costs in such Delivered Initial Development Plan shall be for no longer than through the end of completion of the pivotal trial for the indication that was the subject of the Proof of Concept Study.

 ARTICLE III. 
 LICENSE GRANTS 
 3.1. AVEO Grant to Biogen Idec. Subject to the
terms and conditions of this Agreement, effective immediately upon the Option Exercise Date, AVEO and its Affiliates grant the following licenses to Biogen Idec: (i) co-exclusive (with AVEO and its Affiliates), royalty-free license, with the
right to grant sublicenses, to the extent set forth under Section 3.3(a), and subject to AVEO’s rights under Section 3.3(b), under AVEO Technology, including AVEO’s interest in Joint Collaboration IP, solely to Develop, have
Developed, Manufacture and have Manufactured, Licensed Product anywhere in the world pursuant to, and in accordance with, this Agreement, and (ii) an exclusive (including with respect to AVEO and its Affiliates), royalty-bearing license, with
the right to grant sublicenses, to the extent set forth under Section 3.3(a), under AVEO Technology solely to Commercialize, have Commercialized, import, and have imported Licensed Product in the Licensed Territory within the Field. 

3.2. Biogen Idec Grant to AVEO. 
 (a) License. Subject to the terms and conditions of this Agreement, effective immediately upon the Option Exercise Date, Biogen Idec and its Affiliates grant the following licenses to AVEO:
(i) a co-exclusive (with Biogen Idec and its Affiliates), royalty-free license, with the right to grant sublicenses, to the extent set forth under Section 3.3(b), and subject to Biogen Idec’s rights under Section 3.3(a), under
Biogen Idec Collaboration Technology, including Biogen Idec’s interest in Joint Collaboration IP, solely to Develop, have Developed, Manufacture and have Manufactured, Licensed Product anywhere in the world pursuant to, and in accordance with,
this Agreement, and (ii) an exclusive (including with respect to Biogen Idec and its Affiliates), royalty-bearing license, with the right to grant sublicenses, to the extent set forth under Section 3.3(b), under Biogen Idec Collaboration
Technology, including Biogen Idec’s interest in Joint Collaboration IP, solely to Commercialize, have Commercialized, import, and have imported Licensed Product in the AVEO Territory within the Field. 
 (b) Covenant Not to Sue. In further consideration of the licenses granted to Biogen Idec under this Agreement and subject to
Section 3.9, Biogen Idec and its Affiliates grant to AVEO and its present and future Affiliates and Sublicensees (the “AVEO Group”) a covenant not to sue or bring action against any member of the AVEO Group claiming or
asserting that the Development,

  

 19 

 
Manufacture or Commercialization of any AVEO Proprietary Composition Licensed Product by any member of the AVEO Group in the AVEO Territory within the Field pursuant to, and in accordance with,
the provisions of this Agreement infringes any Patent Rights owned and Controlled by Biogen Idec or any of its Affiliates (other than any such Patent Rights that are included in Biogen Idec Collaboration Patent Rights or Joint Collaboration Patent
Rights) that Cover the composition of matter or method of use of such AVEO Proprietary Composition Licensed Product and that are necessary to the Development, Manufacture or Commercialization of such AVEO Proprietary Composition Licensed Product in
the AVEO Territory. Notwithstanding anything express or implied in the foregoing provisions of this Section 3.2(b) to the contrary, the provisions of this Section 3.2(b) shall not apply with respect to any AVEO Proprietary Composition
Licensed Product that Biogen Idec does not have the right to Develop or Commercialize under the terms of this Agreement. The provisions of this Section 3.2(b) shall not apply with respect of Patent Rights or Know-how under Third Party
Technology Agreements entered into by either Party or any of its Affiliates pursuant to Section 3.6 hereof. 
 3.3.
Licenses and Sublicenses; Contractors. 
 (a) Biogen Idec Rights. Biogen Idec shall have the right to grant any
licenses or sublicenses under Biogen Idec Collaboration Technology to Develop, have Developed, Manufacture or have Manufactured Licensed Product anywhere in the world under the terms of this Agreement or to Commercialize, have Commercialized, import
and have imported Licensed Products in the Licensed Territory, provided that any such licenses or sublicenses comply with the provisions set forth in Sections 3.3(c), 3.3(d) and 3.3(e) below, as applicable, and that Biogen Idec
provides prior written notice to AVEO of any such licenses or sublicenses to any Third Party. In addition, Biogen Idec may sublicense the rights granted to it by AVEO under Section 3.1, in whole or in part, (i) to any of its Affiliates or
(ii) to a Third Party with prior written notice to AVEO. 
 (b) AVEO Rights. AVEO shall have the right to grant any
licenses or sublicenses under AVEO Technology to Develop, have Developed, Manufacture or have Manufactured Licensed Products anywhere in the world under the terms of this Agreement or to Commercialize, have Commercialized, import and have imported
Licensed Product in the AVEO Territory, provided that (i) during the Option Exercise Period, AVEO and its Affiliates shall not grant any license or sublicense to Develop Licensed Product, (ii) after the Option Exercise
Period, AVEO and its Affiliates shall retain final decision-making authority under such license or sublicense for Development of Licensed Product, (iii) any license or sublicense granted to a Third Party with respect to Manufacture of Licensed
Product shall be subject to the terms of Article VII, (iv) in no event shall AVEO grant any such license or sublicense to any Third Party that is Developing or Commercializing a Directly Competitive Product, (v) AVEO provides prior written
notice to Biogen Idec of such licenses or sublicenses, (vi) AVEO shall have complied with the provisions of Section 3.7 hereof prior to granting such license or sublicense, and (vii) such license or sublicense complies with the
provisions set forth in Sections 3.3(c), 3.3(d) and 3.3(e) below. AVEO may only sublicense the rights granted it by Biogen Idec under Section 3.2(a), in whole or in part, (x) to any of its Affiliates or (y) to a Third Party to whom
AVEO has granted licenses or sublicenses under AVEO Technology pursuant to this Section 3.3(b), provided that AVEO provides prior written notice to Biogen Idec of any sublicense granted under clause (y). 
  

 20 

 (c) Sublicense Terms. Each permitted license or sublicense and agreement with a
Sublicensee (i) must be consistent with the terms and conditions of this Agreement, (ii) must contain a provision under which the licensing Party shall obtain an exclusive or non-exclusive license, with the right to grant a sublicense to
the other Party as set forth under this Agreement, to Develop, have Developed, Manufacture, have Manufactured, to Commercialize and have Commercialized Licensed Product in the Territory under Know-how and Patent Rights owned or licensed by such
Sublicensee or any of its Affiliates, that are (A) necessary to Develop, Manufacture or Commercialize Licensed Product, (B) incorporated in any Licensed Product, in the case of such Know-how, or that Cover any Licensed Product, in the case
of such Patent Rights, and (C) reasonably useful to Develop, Manufacture or Commercialize Licensed Product, provided, however, that notwithstanding the foregoing provisions of this clause (ii), if the applicable Sublicensee
is not granted the right under such license or sublicense to Commercialize or have Commercialized Licensed Product in the AVEO Territory or the Licensed Territory, the provisions of the foregoing subclauses (A) and (B) shall be limited
only to Know-how and Patent Rights generated by such Sublicensee or any of its Affiliates that arise directly out of the Development or Manufacture of Licensed Product under such license or sublicense agreement and the provisions of the foregoing
subclause (C) shall not apply, and (iii) must not contain provisions that result in the licensing Party not having the ability to license or sublicense to the other Party as set forth in this Agreement any Patent Rights or Know-how owned,
licensed, used or practiced by the licensing Party or any of its Affiliates. Each permitted license or sublicense by AVEO or any of its Affiliates must contain a provision that the applicable Sublicensee and its Affiliates shall not Develop,
Manufacture or Commercialize a Directly Competitive Product or collaborate with, or grant to, any other Third Party any license or right to Develop, Manufacture or Commercialize a Directly Competitive Product. 
 (d) Performance by Sublicensees. Each Party shall be responsible for the performance of all of its Sublicensees, and shall remain
fully responsible for all of its Sublicensees’ obligations under this Agreement. Each license or sublicense granted by a Party pursuant to this Article III shall be subject and subordinate to the terms and conditions of this Agreement, and
shall contain terms and conditions consistent with those in this Agreement. Each Party shall promptly provide the other Party with a copy of the fully executed license or sublicense agreement covering any license or sublicense granted hereunder, and
such license or sublicense agreement shall contain the following provisions: (i) a requirement that such Sublicensee submit applicable sales or other reports to the Party granting the license or sublicense to the extent necessary or relevant to
the reports required to be made or records required to be maintained under this Agreement; (ii) an audit requirement consistent with that set forth in Section 8.16; (iii) a requirement that such Sublicensee comply with the
confidentiality provisions and restrictions on use of Confidential Information contained in Article X with respect to both Parties’ Confidential Information; and (iv) any other provisions required under any AVEO In-License or Biogen Idec
In-License, as the case may be. If a granting Party becomes aware of a material breach of any license or sublicense by a Sublicensee of the rights granted to such Party or the other Party under this Agreement, the granting Party shall promptly
notify the other Party of the particulars of the same and use Commercially Reasonable Efforts to enforce the terms of such license or sublicense. 
  

 21 

 (e) Performance by Contractors. If, and to the extent that, either Party has the
right or obligation pursuant to, and in accordance with, the provisions of this Agreement to Develop, Manufacture or Commercialize any Licensed Product, such Party shall be entitled to utilize the services of Third Parties (including Third Party
contract research organizations, Third Party contract manufacturing organizations (“CMOs”) and Third Party contract sales organizations (“CSOs”)) to perform the Development, Manufacturing or Commercialization activities that such
Party has the right or obligation to perform under this Agreement with respect to such Licensed Product; provided that the contracting Party shall remain at all times fully liable for its responsibilities under this Agreement. Neither
Party shall use Third Party contract resources to perform any activities that the contracting Party has the right or obligation to perform under this Agreement unless the contracting Party’s rights under the agreement with the Third Party
contractor guarantee to the other Party the same rights under this Agreement as if the contracting Party had performed such activities itself, and any such Third Party contractor agreement includes a requirement that such Third Party contractor
comply with the confidentiality provisions and restrictions on use of Confidential Information contained in Article X with respect to both Parties’ Confidential Information and a requirement that such Third Party contractor comply with any
other provisions required under any AVEO In-License or Biogen Idec In-License, as the case may be. Notwithstanding anything in this Agreement to the contrary, the contracting Party under this Section 3.3(e) shall (A) obtain from any Third
Party performing any activities of the contracting Party under this Agreement a license to any Know-how and Patent Rights generated by such Third Party arising directly out of the contracting activities to the extent necessary for the Development,
Manufacture and Commercialization of Licensed Product or to the extent such Know-how is incorporated in any Licensed Product or such Patent Rights Cover any Licensed Product, (B) if such Third Party or any of its Affiliates is a Sublicensee of
the contracting Party to whom the contracting Party has granted rights to Commercialize Licensed Product in the contracting Party’s Territory, obtain from such Third Party a license to any Know-how and Patent Rights generated by such Third
Party arising directly out of the contracting activities to the extent reasonably useful for the Development, Manufacture and Commercialization of Licensed Product and (C) use Commercially Reasonable Efforts to obtain from such Third Party
(other than a Third Party referred to in the foregoing clause (B)) a license to any Know-how and Patent Rights generated by such Third Party arising directly out of the contracting activities to the extent reasonably useful for the Development,
Manufacture and Commercialization of Licensed Product. Each such license referred to in the foregoing clause (A), (B) or (C) of this Section 3.3(e) shall include rights to both the AVEO Territory and the Licensed Territory to the
extent such Know-how and Patent Rights are necessary for the Development, Manufacture or Commercialization of Licensed Product in each such Territory or to the extent such Know-how is incorporated in any Licensed Product or such Patent Rights Cover
any Licensed Product. Each such license referred to in the foregoing clause (A), clause (B) or clause (C) of this Section 3.3(e) shall include the right to sublicense to the other Party consistent with this Agreement. For purposes of
clarification and not by way of limitation, it is understood and agreed that the term “necessary” as used in this Section 3.3(e) shall be deemed to include any Know-how or Patent Rights as to which rights in both the AVEO Territory
and Licensed Territory would be necessary for the contracting Party to Develop, Manufacture or Commercialize,

  

 22 

 
as the case may be, Licensed Product in both the AVEO Territory and the Licensed Territory under this Agreement, including, without limitation, under Sections 5.11, 5.12, 7.5, 13.1, 13.3 or
14.5(b). 
 3.4. Restrictive Covenants. Except for the Development, Manufacture and Commercialization of Licensed
Products pursuant to, and in accordance with, the terms and conditions set forth in this Agreement and except for the grant of any licenses or sublicenses by AVEO with respect to Licensed Products pursuant to Section 3.3(b) above and except as
set forth in Section 3.9, during the Agreement Term neither AVEO nor any of its Affiliates (i) shall Develop, Manufacture or Commercialize any ERBB3 Antibody in the AVEO Territory or the Licensed Territory within the Field, (ii) shall
collaborate with any Third Party, shall grant to any Third Party the right, or shall engage in activities on behalf of any Third Party, to Develop, Manufacture or Commercialize any ERBB3 Antibody in the AVEO Territory or the Licensed Territory
within the Field, (iii) shall grant to any Third Party any license or other right under any AVEO Technology to Develop, Manufacture or Commercialize any ERBB3 Antibody in the AVEO Territory or the Licensed Territory within the Field or
(iv) subject to Section 16.5 hereof, shall sell, assign, convey or otherwise transfer any right, title or interest in and to any AVEO Technology or any ERBB3 Antibody (including, without limitation, any Licensed Product), provided
that the foregoing clause (iv) shall not be deemed a restriction on AVEO’s right to license AVEO Technology for any and all uses other than the Development, Manufacture or Commercialization of ERBB3 Antibodies or for any and all
uses outside the Field. 
 3.5. Retained Rights. Subject to Section 3.3(b) and Section 3.4, any rights of a
Party not expressly granted under this Agreement shall be retained by such Party. 
 3.6. Third Party Technology.

 (a) Process. The Parties agree that it may be necessary or desirable at any time and from time to time during the
License Term to enter into agreements with a Third Party to acquire, in-license or otherwise obtain or use technology, intellectual property rights, information, materials, data or know-how, patentable or otherwise, owned or Controlled by such Third
Party (“Third Party Technology”) in order for either Party to Develop, Manufacture or Commercialize Licensed Product under this Agreement (such Third Party agreements being hereinafter referred to, collectively, as the
“Third Party Technology Agreements”). Such Third Party Technology Agreements shall not conflict with the terms and conditions of this Agreement. In the event that either Party believes that entering into a Third Party Technology
Agreement is necessary or desirable in connection with the Development, Manufacture or Commercialization of Licensed Product pursuant to this Agreement, such Party shall notify the JDC and the other Party promptly and include in such notification a
summary of the Third Party Technology that would be covered by such Third Party Technology Agreement, the anticipated commercial terms of such Third Party Technology Agreement and any other relevant information. The JDC shall discuss
(i) whether the Third Party Technology that would be the subject of such Third Party Technology Agreement is necessary or desirable in connection with the Development, Manufacture or Commercialization of Licensed Product pursuant to this
Agreement, (ii) the anticipated commercial terms of such Third Party Technology Agreement, (iii) the advantages and disadvantages associated with entering into such Third Party Technology Agreement at that time or at a later point in time
and (iv) any other factors the JDC deems relevant. If the JDC determines that such Third Party Technology Agreement should be pursued, AVEO shall be

  

 23 

 
responsible for negotiating, in consultation with the JDC and Biogen Idec, any such Third Party Technology Agreements and, upon final approval of the JDC as provided below, for entering into such
Third Party Technology Agreements. AVEO shall use Commercially Reasonable Efforts to negotiate as promptly as possible such Third Party Technology Agreements that the JDC has determined to pursue and throughout such negotiation AVEO shall consider
in good faith and use Commercially Reasonable Efforts to get the applicable Third Party to agree to all reasonable comments made by the JDC and Biogen Idec with respect to such Third Party Technology Agreements and the terms thereof. Prior to
execution of any such Third Party Technology Agreement, AVEO shall present the agreement in substantially final form to the JDC for review and final approval. Unless Biogen Idec otherwise agrees, the JDC shall not provide final approval to any such
Third Party Technology Agreement unless (A) the Third Party Technology that is subject to such Third Party Technology Agreement may be used by, sublicensed to, or the benefits made available to, Biogen Idec and its Affiliates and Sublicensees
in connection with the Development, Manufacture and Commercialization of Licensed Product pursuant to, and in accordance with, the terms of this Agreement, and (B) in the event that such Third Party Technology may not be used by and sublicensed
to Biogen Idec and its Affiliates and Sublicensees in connection with the Development, Manufacture and Commercialization of Licensed Product under this Agreement, then such Third Party Technology is available for licensing, as a matter of course,
separately from the licensor of such Third Party Technology with respect of both the AVEO Territory and the Licensed Territory on terms that, at the time of final JDC approval, would be substantially the same as the terms obtained by AVEO with
respect to the AVEO Territory. Upon final review and approval by the JDC of any Third Party Technology Agreement in accordance with this Section 3.6, AVEO shall execute and deliver such Third Party Technology Agreement and such Third Party
Technology Agreement shall be an AVEO In-License for purposes of this Agreement. AVEO shall provide Biogen Idec with an unredacted copy of such fully executed Third Party Technology Agreement. Notwithstanding anything in this Agreement to the
contrary, in the event the JDC unanimously agrees that Biogen Idec shall enter into a Third Party Technology Agreement in accordance with the process outlined in this Section 3.6, then Biogen Idec shall execute and deliver such Third Party
Technology Agreement and provide an unredacted copy of such fully executed Third Party Technology Agreement to AVEO which such Third Party Technology Agreement shall be a Biogen Idec In-License. The Know-how and Patent Rights underlying a Biogen
Idec In-License shall be deemed to be Biogen Idec Collaboration Technology. As promptly as practicable after the execution of such Third Party Technology Agreement (unless already done prior to the execution of such Third Party Technology
Agreement), the Development Plan shall be amended to include actions required related to any such Third Party Technology Agreement and the Third Party Technology that is subject thereto. Except as set forth in Section 3.6(b) below, unless and
until the JDC provides final approval of a Third Party Technology Agreement as contemplated above in this Section 3.6(a), neither Party shall enter into such Third Party Technology Agreement. For the sake of clarity, the terms of this
Section 3.6 shall not apply to AVEO In-licenses entered into prior to the Option Exercise Date. 
 (b) Failure to
Agree. In the event that the JDC determines that a Third Party Technology Agreement should not be pursued or the representatives of either Party on the JDC will not agree, or do not agree in a timely manner, to the terms that the other Party or
the representatives of the other Party on the JDC proposes or propose to accept, and no further discussions are authorized by the JDC

  

 24 

 
or are ongoing by the JDC, either Party alone shall have the right to enter into an agreement with such Third Party on such terms as such Party and the Third Party shall agree in connection with
rights to Develop, Manufacture and/or Commercialize a Licensed Product in each Party’s respective territory. In addition, in the event that AVEO is required to negotiate and enter into any Third Party Technology Agreement pursuant to this
Section 3.6 but AVEO does not do so, or is unable to do so, in a timely manner, then Biogen Idec shall have the right (but not the obligation) to negotiate and enter into such Third Party Technology Agreement. In the event AVEO enters into a
Third Party Technology Agreement under this Section 3.6(b), (i) such agreement shall not be considered an AVEO In-License, (ii) the underlying Patent Rights shall not be considered AVEO Patent Rights or AVEO Collaboration Patent
Rights, and (iii) the underlying Know-how shall not be considered AVEO Know-how or AVEO Collaboration Know-how. In the event Biogen Idec or any of its Affiliates enters into a Third Party Technology Agreement under this Section 3.6(b),
(i) such agreement shall not be considered a Biogen Idec In-License, (ii) the underlying Patent Rights shall not be considered Biogen Idec Collaboration Patent Rights, and (iii) the underlying Know-how shall not be considered Biogen
Idec Collaboration Know-how. Notwithstanding anything express or implied in the foregoing provisions of this Section 3.6(b) to the contrary, (A) AVEO agrees that it and its Affiliates will not assert any rights acquired under any Third
Party Technology Agreement entered into by AVEO under the terms of this Section 3.6(b) against Biogen Idec or any of its Affiliates or Sublicensees with respect to the Development, Manufacture or Commercialization of Licensed Product by Biogen
Idec or any of its Affiliates or Sublicensees pursuant to, and in accordance with, the terms of this Agreement, and (B) Biogen Idec agrees that it and its Affiliates will not assert any rights acquired under any Third Party Technology Agreement
entered into by Biogen Idec under the terms of this Section 3.6(b) against AVEO or any of its Affiliates or Sublicensees with respect to the Development, Manufacture or Commercialization of Licensed Product by AVEO or any of its Affiliates or
Sublicensees pursuant to, and in accordance with, the terms of this Agreement; provided, however, that nothing in this sentence shall prevent or restrict, or be deemed a representation with respect to, the ability of a Third
Party licensor to fully assert its rights against a Party, and notwithstanding anything express or implied in the foregoing provisions of this sentence to the contrary, the provisions of clause (A) of this sentence shall not apply with respect
to any Licensed Product if Biogen Idec is not required to pay royalties to AVEO pursuant to Section 8.5 hereof on Net Sales by Biogen Idec and its Affiliates and Sublicensees of such Licensed Product in the Licensed Territory, and the
provisions of clause (B) of this sentence shall not apply with respect to any Licensed Product if the license rights granted by AVEO to Biogen Idec and its Affiliates pursuant to, and in accordance with, Section 3.1 hereof are not
applicable to such Licensed Product for any reason or if AVEO is not required to pay royalties to Biogen Idec pursuant to Section 8.6 hereof on Net Sales by AVEO and its Affiliates and Sublicensees of such Licensed Product in the AVEO
Territory. Each Party that enters into a Third Party Technology Agreement that is not considered an AVEO In-License or a Biogen Idec In-License, as the case may be, by virtue of the foregoing provisions of this Section 3.6(b) shall, at the
request of the other Party made at any time during the License Term, agree to include any rights under such Third Party Technology Agreement that such Party Controls in the licenses granted to the other Party under Article III, as AVEO Technology or
Biogen Idec Collaboration Technology, as the case may be, provided that the other Party makes payment to such Party of all amounts that the other Party would have been required

  

 25 

 
to pay under this Agreement in connection with such Third Party Technology Agreement if such Third Party Technology Agreement had been considered an AVEO In-License or a Biogen Idec In-License,
as the case may be, under this Agreement from and after the date that such Party entered into such Third Party Technology Agreement, in which case such Third Party Technology Agreement shall be considered an AVEO In-License or a Biogen Idec
In-License, as the case may be. 
 3.7. Right of First Negotiation. In the event that AVEO proposes to license or
sublicense or otherwise grant to a Third Party all or any portion of the rights of AVEO to Commercialize Licensed Product in a particular country of the AVEO Territory, other than solely for purposes of a relationship of the type described in
Section 3.3(e), regardless of whether AVEO or a Third Party makes the initial proposal, then AVEO will promptly notify Biogen Idec in writing thereof. As soon as practicable, Biogen Idec will respond to AVEO in writing regarding its interest in
entering into negotiations to obtain such rights and the Parties will promptly commence exclusive, good faith negotiations through and until the [**] following the date that AVEO gives such written notice to Biogen Idec. Upon commencement of such
negotiations, AVEO shall advise Biogen Idec of the factors that AVEO considers to be commercially material to its decision to grant Commercialization rights with respect to Licensed Product in such country of the AVEO Territory. If AVEO and Biogen
Idec are unable to agree on material terms within [**] after receipt by Biogen Idec of AVEO’s notice of its intent to transfer Commercialization rights, AVEO shall thereafter be free to negotiate and /or enter into an agreement with any Third
Party on such terms as AVEO may decide in its sole discretion 
 3.8. No Inconsistent Third Party Agreements; Amendments.
During the Agreement Term, neither Party nor any of its Affiliates shall enter into any in-license of Third Party intellectual property pursuant to which such Party or any of its Affiliates grants to such Third Party rights under or to AVEO
Technology or Biogen Idec Collaboration Technology, as the case may be, that would contravene or be inconsistent or in conflict with the rights of the other Party under this Agreement. During the Agreement Term, neither Party nor any of its
Affiliates shall amend, modify or terminate any in-license of Third Party intellectual property (including, without limitation, any such in-license that is in effect as of the Effective Date) without the prior written consent of the other Party
(which may be granted or withheld by such other Party in its absolute discretion) if such amendment, modification or termination would materially adversely affect any of the rights that such other Party or any of its Affiliates would have under this
Agreement if such amendment, modification or termination were not effected. 
 3.9. M&A Events. In the event of an
M&A Event, as defined below, to which AVEO is a party, (i) the Patent Rights owned or otherwise Controlled by the Third Party acquiror or any of its Affiliates immediately prior to the effectiveness of the M&A Event will be specifically
excluded from the definition of AVEO Patent Rights and AVEO Collaboration Patent Rights, (ii) the Know-how owned or otherwise Controlled by the Third Party acquiror or any of its Affiliates prior to the effective date of the M&A Event will
be specifically excluded from the definition of AVEO Know-how, (iii) in no event shall any agreement that such Third Party acquiror or any of its Affiliates is a party prior to the effective date of the M&A Event be considered an AVEO
In-License, (iv) any product owned or otherwise Controlled by the Third Party acquiror or any of its Affiliates immediately prior to the effectiveness of the M&A Event shall be specifically excluded from the definition of Licensed Product,
and (v) the restrictive covenants set forth in Section 3.4

  

 26 

 
shall not apply to any ERBB3 Antibody that is not a Licensed Product by reason of the foregoing clause (iv) (it being understood and agreed that the provisions of this clause (v) shall
not limit Biogen Idec’s rights under Section 13.1 or Section 14.5(e)). In the event of any M&A Event to which Biogen Idec is a party, the Patent Rights owned or Controlled by the Third Party acquiror or any of its Affiliates
immediately prior to the effectiveness of the M&A Event and the Patent Rights covering Know-how developed or acquired after the effective date of the M&A Event (other than Biogen Idec Collaboration Patent Rights) and any ERBB3 Antibody that
is not a Licensed Product by reason of the foregoing clause (iv) shall not be subject to the covenant not to sue granted to AVEO under Section 3.2(b) or Section 3.6(b). For purposes of this Agreement, an M&A Event with respect to
a Party shall mean any of the following: (a) the sale or disposition of all or substantially all of the assets of such Party or its direct or indirect parent corporation to a Third Party, (b) the acquisition by a Third Party which
constitutes one person, as such term is used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), together with any such person’s “affiliates” or
“associates”, as such terms are defined in the Exchange Act, other than an employee benefit plan (or related trust) sponsored or maintained by such Party or any of its Affiliates, of more than 50% of the outstanding shares of voting
capital stock of such Party or its direct or indirect parent corporation, or (c) the merger or consolidation of such Party or its direct or indirect parent corporation with or into another corporation, other than, in the case of this clause
(c), an acquisition or a merger or consolidation of a Party or its direct or indirect parent corporation in which holders of shares of the voting capital stock of the Party or its direct or indirect parent corporation, as the case may be,
immediately prior to the acquisition, merger or consolidation will have at least fifty percent (50%) of the ownership of voting capital stock of the acquiring Third Party or the surviving corporation in such merger or consolidation, as the case
may be, immediately after the merger or consolidation. 
 ARTICLE IV. 
 GOVERNANCE DURING LICENSE TERM 
 4.1. Joint Development Committee Formation. As soon as reasonably practicable after the Option Exercise Date, and in any event not later than thirty (30) days after the Option Exercise Date,
the Parties shall establish a joint development committee (the “JDC”). The JDC shall consist of three (3) representatives designated by each Party, or such other number as the Parties may from time to time mutually agree. Each
Party shall appoint its initial representatives on the JDC at the time of formation, but may, from time to time, substitute one or more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. Each
Party shall have at least one JDC representative who is a senior employee (vice president level or above) and shall designate him/her upon designation to the JDC as its senior representative (such representative, such Party’s “Senior
Representative”). All JDC representatives shall have appropriate expertise and ongoing familiarity with Development of biopharmaceutical products. Additional representatives or consultants may from time to time, by mutual consent of the
Parties, be invited to attend JDC meetings, provided that such representatives and consultants are subject to written obligations that are no less stringent than the confidentiality obligations and restrictions on use set forth in
Article X. Each Party shall bear its own expenses relating to attendance at JDC meetings by its representatives. 
  

 27 

 4.2. Chairperson. The chairperson of the JDC (the “JDC Chairperson”)
shall be a representative of AVEO. The JDC Chairperson’s responsibilities shall include (i) scheduling meetings as described in Section 4.3, or more frequently if the JDC determines it necessary; (ii) setting agendas for meetings
with solicited input from other members; and (iii) confirming and delivering minutes to the JDC for review and final approval. 
 4.3. Meetings. The first JDC meeting shall be held within sixty (60) days after the Option Exercise Date, and the JDC shall meet in accordance with a schedule established by mutual agreement of the Parties, but, unless the
Parties otherwise agree, the JDC shall meet no less frequently than once each Calendar Quarter, with the location for such meetings alternating between AVEO and Biogen Idec facilities in Massachusetts (or such other locations as determined by the
JDC). Alternatively, the JDC may meet by means of teleconference, videoconference or other similar communications equipment, but at least one (1) meeting per Calendar Year shall be conducted in person. 
 4.4. JDC Responsibilities. The JDC shall have the following responsibilities with respect to the Development of Licensed Product
during the License Term: 
 (i) reviewing and approving (A) the Development Plan, (B) each annual
update to the Development Plan, (C) any other modifications to the Development Plan, in each case within thirty (30) days after each submission thereof to the JDC (or sooner as circumstances warrant), and (D) guidelines for conduct of
Territory-Specific Clinical Trials and Post-Approval Clinical Studies; 
 (ii) monitoring and overseeing
Development of Licensed Product in the Field in the Territory, and monitoring the Parties’ respective commitments relating to shared Development Costs; 
 (iii) reviewing updates from AVEO regarding the Development of the Licensed Product in the Territory, and updates from Biogen
Idec regarding the conduct of Territory-Specific Clinical Trials and Post Approval Clinical Studies, including, in each case a review of (a) the status of such Development efforts; (b) the results of pre-clinical and clinical studies of
Licensed Product in the Field completed since the last update; (c) the design of proposed pre-clinical and clinical studies, and (d) the content of proposed regulatory filings related to Licensed Product in the Field in the Territory;

 (iv) regularly assessing the progress of conduct of the Development Plan against the timelines and budgets
contained therein, and reviewing relevant data, and considering issues of priority; and 
 (v) coordinate on
issues related to Manufacture of Licensed Product for the Field in the Territory, subject to Article VII. 
 For purposes of clarity, it is
expected that with respect to the sharing of information regarding the Licensed Product, each Party will, through the JDC and through regular communication between each Party’s designated Collaboration Manager, keep the other Party informed at
a detailed level about all activities related to the Development and Manufacture of the Licensed Product in the Field under this Agreement, and will provide all information requested by the other Party related to the Development and Manufacture of
the Licensed Product in the Field. 
  

 28 

 The JDC shall not have the authority to modify the terms of this Agreement. 
 4.5. Appointment of Subcommittees, Project Teams and Collaboration Managers. The JDC shall be empowered to create such subcommittees
of itself and project teams as it may deem appropriate or necessary. Each such subcommittee and project team shall report to the JDC, which shall have authority to approve or reject recommendations or actions proposed thereby subject to the terms of
this Agreement. Each Party shall also designate a collaboration manager (each a “Collaboration Manager”), who shall be responsible for day-to-day coordination between the Parties and will serve to facilitate communication between
the Parties with respect to Development, Manufacture and Commercialization of Licensed Product under this Agreement. Each Party may change its designated Collaboration Manager from time to time upon written notice to the other Party. 
 4.6. Meeting Materials and Minutes. 
 (a) Meeting Materials. Each Party will provide the members of the JDC with copies, which may be in electronic format, of all materials it intends to present at a JDC meeting. The JDC may also
request at any time specific data or information related to Development activities or any other data to which the JDC is entitled under this Agreement or that a written report be prepared in advance of any meeting summarizing certain material data
and information arising out of the conduct of the Development of Licensed Product or any other data to which the JDC is entitled under this Agreement and the Party or appropriate committee to whom such request is made shall promptly provide to the
other Party or the JDC such report, data or information. 
 (b) Minutes. A secretary shall be appointed for each meeting
and shall prepare minutes of the meeting, which such minutes shall be subject to approval by the JDC. 
 4.7. Decisions.

 (a) Day-to-Day Management. The Parties agree that (i) decisions with respect to the day-to-day management of
Development of Licensed Product in the Field in the Territory (other than the conduct of Territory-Specific Clinical Trials and Post-Approval Clinical Studies in the Licensed Territory) shall not be within the purview of the JDC, but instead shall
be the sole responsibility of AVEO, and (ii) decisions with respect to the day-to-day management of Territory-Specific Clinical Trials and Post-Approval Clinical Studies in the Licensed Territory shall not be within the purview of the JDC, but
instead shall be the sole responsibility of Biogen Idec, in each case provided such decisions are consistent with the Development Plan, and, subject, in each case to the restrictions contained in Section 4.8(a) and 4.8(b). 
 (b) JDC Decisions. During the License Term, decisions within the purview of the JDC shall be made by the JDC by consensus, with the
representatives of each Party collectively having one vote on behalf of such Party. For each meeting of the JDC, at least two (2) representatives of each Party shall constitute a quorum. Action on any matter may be taken at a meeting, by
teleconference, videoconference or by written agreement. 
  

 29 

 4.8. Deadlocks. The JDC shall attempt to resolve any and all disputes relating to
Development of Licensed Product during the License Term by consensus. If the JDC is unable to reach a consensus with respect to a dispute within its purview related to Development of Licensed Product then the dispute shall be submitted to the Senior
Representatives for review. If the Senior Representatives cannot reach an agreement regarding such dispute within thirty (30) days after submission to them for resolution, then, if the dispute is one over which the JDC has authority pursuant to
this Agreement: (i) Biogen Idec shall have final-decision-making authority with respect to decisions related to Territory-Specific Clinical Trials and Post-Approval Clinical Trials required or reasonably useful in connection with Regulatory
Approval or Commercialization of Licensed Product in the Licensed Territory, and (ii) AVEO shall have the final decision-making authority with respect to all other decisions related to Development, subject in each case to paragraphs
(a) and (b) of this Section 4.8. Notwithstanding anything in this Agreement to the contrary, any decision within the purview of the JDC for which one of the Parties has exercised its final decision-making authority, as set forth in
this Agreement, shall be considered a decision or approval of the JDC. 
 (a) Limitations on Decision-Making Authority.
Neither Party may exercise its final decision-making authority during the License Term: (i) to require the other Party to perform any Development activities for which it is not responsible under this Agreement or, subject to Section 5.2,
to amend the Development Plan in such a way that it no longer meets the Development Plan Guidelines set forth in Exhibit B (the “Development Plan Guidelines”); (ii) to resolve any dispute as to what level of effort
constitutes Commercially Reasonable Efforts; (iii) to decide to conduct, sponsor, fund or otherwise support a clinical study, including a Territory-Specific Clinical Trial or a Post-Approval Clinical Study that would materially and adversely
affect the Development or Commercialization of the Licensed Product in the other Party’s Territory; (iv) to decide to pursue or not to pursue the negotiation and execution of a Third Party Technology Agreement subject to, and in accordance
with, Section 3.6 hereof; (v) to require a Party to take any action that would, or fail to take any action where the failure to take such action would, violate any applicable Law, rule or regulation or infringe the intellectual property
rights of Third Parties; (vi) to expand or narrow the responsibilities of the JDC; (vii) to increase or change the budget for Development Costs; (viii) to establish guidelines for the conduct by Biogen Idec of any of the Development
activities contemplated under Section 5.1(b) hereof or (ix) to amend this Agreement. For the avoidance of doubt, subject to Section 5.2, any decision by the JDC with respect to any of the items referred to in the foregoing clauses
(i)-(viii) of this Section 4.8(a) must be unanimous and, in the event of any disagreement or deadlock at the JDC with respect to any of such items, neither Party may exercise its final decision-making authority with respect to such matter
during the License Term. 
 (b) Other Disputes. With respect to all disputes between the Parties during the License Term
related to Development or Manufacture of Licensed Product under this Agreement that are not subject to either Party’s final decision-making authority as set forth in Section 4.7 or this Section 4.8, the dispute resolution provisions
of Article XV shall apply. 
  

 30 

 ARTICLE V. 
 DEVELOPMENT DURING LICENSE TERM 
 5.1.
Development. 
 (a) General. Except as set forth in paragraph (b), AVEO shall be solely responsible for
Development of Licensed Product in the Field for both the Licensed Territory and the AVEO Territory during the License Term, and shall use Commercially Reasonable Efforts during the License Term to Develop Licensed Product in the Field for both the
Licensed Territory and the AVEO Territory. Each Party shall use Commercially Reasonable Efforts to conduct the Development activities contemplated under the Development Plan approved by the JDC, as amended from time-to-time in accordance with
Section 5.2, in accordance with the terms of such Development Plan. 
 (b) Territory Specific. Biogen Idec shall be
solely responsible for conducting Territory-Specific Clinical Trials and Post-Approval Clinical Studies of Licensed Product in the Field where the data or other Know-how generated will have applicability only to the Licensed Territory and, except
with respect to safety data, will only be used in filings for Regulatory Approval in the Licensed Territory, and shall use Commercially Reasonable Efforts to conduct such Development activities during the License Term in accordance with guidelines
for such activities established by the JDC. 
 5.2. Development Plan. 
 (a) The “Initial Development Plan” shall hereafter mean the Delivered Initial Development Plan which shall be the Development Plan
unless and until amended or updated by the JDC. 
 (b) The JDC shall review the Development Plan not less frequently than
annually and shall develop detailed and specific Development Plan updates, which shall update or include an overall Development multi-year budget for specified activities and an annual Development budget for Development of Licensed Product for the
upcoming Calendar Year. The JDC’s review shall continue until the completion of Licensed Product Development activities in both the Licensed Territory and the AVEO Territory. Either Party may also develop and submit to the JDC from time to time
other proposed substantive amendments to the Development Plan, including, without limitation, any proposed substantive amendments to the Development Plan for purpose of Developing new Licensed Products in any indication or indications or new
indications for Licensed Products already in Development or Commercialization. The JDC shall review such proposed amendments and may approve such proposed amendments or any other proposed amendments that the JDC may consider from time to time in its
discretion and, upon such approval by the JDC, the Development Plan shall be amended accordingly; provided, that in all cases any such amendments are in accordance with the Development Plan Guidelines. For the sake of clarity, (x) if the JDC
cannot agree on an amendment to a Development Plan, the dispute resolution mechanism set forth in Section 4.8 shall apply, and (y) if the JDC cannot agree on an upcoming Calendar Year’s budget for Development Costs under any
Development Plan, the budget for the upcoming Calendar Year shall be identical in amount to the amount budgeted for the relevant activities included in the last-approved multi-year budget showing the relevant activities. 
  

 31 

 5.3. Records and Information. Each Party will maintain scientific records related to
its Development efforts with respect to Licensed Product in the Field, in sufficient detail and in a good scientific manner appropriate for patent and regulatory purposes, and which will fully and properly reflect all work done and results achieved
in the performance of the Development activities with respect to the Licensed Product in the Field under this Agreement. During the License Term, each Party will have the right, during normal business hours and upon reasonable notice, at its own
expense, to inspect and copy (or request the other Party to copy) all records of the other Party maintained in connection with the work done and results achieved in the performance of Development activities performed under this Agreement, but solely
to the extent to which such records relate to Development of Licensed Product in the Field. All such records, and the information disclosed therein, as well as all disclosures made pursuant to Section 5.4, will be maintained in confidence by
the Party receiving the information in accordance with Article X and will only be used for purposes permitted under Article X. 
 5.4. Development Costs. 
 (a) Cost Sharing. The Parties shall share Development Costs during the License
Term as follows: (i) all Development Costs incurred by or on behalf of AVEO, Biogen Idec and their respective Affiliates with respect to Development of Licensed Product in the Field, other than those Development Costs specified in clauses
(ii) and (iii) and other than Pre-Option Exercise Phase 3 Manufacturing Costs (which are covered by Section 5.4(b) below), will be shared equally by the Parties; (ii) all Development Costs incurred by or on behalf of AVEO or its
Affiliates with respect to Territory-Specific Clinical Trials or Post-Approval Clinical Studies in the AVEO Territory where the data or other Know-how generated (other than safety data) will not be used in filings to support Regulatory Approval in
the Licensed Territory, shall be borne one hundred percent (100%) by AVEO; and (iii) all Development Costs incurred by Biogen Idec or its Affiliates with respect to Territory-Specific Clinical Trials or Post-Approval Clinical Studies in
the Licensed Territory where the data or other Know-how generated (other than safety data) will not be used in filings to support Regulatory Approval in the AVEO Territory, shall be borne one hundred percent (100%) by Biogen Idec. The Parties
shall discuss and attempt to mutually determine in good faith how specific Development Costs are allocated in accordance with the foregoing sentence. 
 (b) Pre-Option Exercise Phase 3 Manufacturing Costs. [**] of Pre-Option Exercise Phase 3 Manufacturing Costs shall be reimbursed by Biogen Idec to AVEO as an additional payment upon delivery of the
Option Exercise Fee. 
 5.5. Development Cost Reimbursement. 
 (a) Cost Reimbursement. No later than [**] prior to the end of each Calendar Quarter during the License Term, AVEO shall provide
Biogen Idec with a non-binding, good-faith estimate of the Development Costs expected to be incurred by AVEO and its Affiliates during such Calendar Quarter. Within [**] after the end of each Calendar Quarter during the License Term, AVEO shall
provide Biogen Idec with a reasonably detailed statement of the Development Costs actually incurred by AVEO and its Affiliates in

  

 32 

 
the Calendar Quarter just ended (a “Quarterly Cost Notice”). Within [**] of Biogen Idec’s receipt of a Quarterly Cost Notice, Biogen Idec shall pay to AVEO an amount equal
to [**] of the total Development Costs shown for such Calendar Quarter on the Quarterly Cost Notice, except that if any such Development Costs are to be borne one hundred percent (100%) by Biogen Idec under Section 5.4 then such costs
shall be identified separately in the Quarterly Cost Notice, and Biogen Idec shall pay AVEO one hundred percent (100%) of such Development Costs (the “Cost Payment”). Such statement shall include, but not be limited to, the
number of individuals doing the work, the amount of time spent on the work, the nature of the work and supporting documentation for disbursements, including, to the extent requested by Biogen Idec, copies of invoices received from Third Parties.
Notwithstanding anything in this Agreement to the contrary, except as set forth in paragraph (b), the total actual Development Costs incurred by AVEO or any of its Affiliates for a Calendar Year shall not exceed [**] of the budgeted Development
Costs for such Calendar Year, as shown on the then current version of the Development Plan, or if no budget has been approved for such Calendar Year, on the last approved multi-year budget showing the relevant activities, except to the extent the
JDC unanimously approves the increase over [**] of the budgeted Development Costs. Decisions of the JDC with respect to Development Cost overruns shall be made in accordance with Section 4.7 and 4.8. Biogen Idec shall pay invoices received from
AVEO under this paragraph within [**] of receipt. 
 (b) Product Liability Costs. Notwithstanding anything in this
Agreement to the contrary, Biogen Idec will reimburse AVEO for its share of the Development Costs specified in clause (iv) of Section 1.34 whether or not such costs are consistent with the Development Plan or budget, provided that if any
settlement amounts are to be included in Development Costs, both Parties must approve such settlement in advance. 
 5.6.
Other Expenses. Except as expressly set forth in this Agreement, each of Biogen Idec and AVEO shall be solely responsible for its own out-of-pocket costs and disbursements incurred, and for providing the necessary facilities, supplies,
personnel and other resources necessary, in the performance of its obligations under this Agreement. 
 5.7. Regulatory.
Except as may be otherwise specified by the JDC and except with respect to Territory-Specific Clinical Trials or Post-Approval Clinical Studies conducted by or on behalf of Biogen Idec or any of its Affiliates or Sublicensees, AVEO (or its
Affiliates or Sublicensees) shall be responsible for, and shall be the holder of, all INDs (including IND submissions) for Licensed Product in the Field in both the AVEO Territory and the Licensed Territory and for all Regulatory Approvals
(including BLA submissions) for Licensed Product in the Field in the AVEO Territory. Except as may be otherwise specified by the JDC, after the Option Exercise Date, Biogen Idec (or its Affiliates or Sublicensees) shall be responsible for, and shall
be the holder of, all INDs (including IND submissions) with respect to Territory-Specific Clinical Trials or Post-Approval Clinical Studies conducted by or on behalf of Biogen Idec or any of its Affiliates or Sublicensees, and all Regulatory
Approvals (including BLA submissions) for the Licensed Product in the Field in the Licensed Territory. Following the Option Exercise Date, Biogen Idec, after an agreed-upon time (such time to be determined by the JDC), Biogen Idec shall assume
responsibility for the INDs for the Licensed Territory. The Party responsible for a submission shall (i) oversee, monitor and coordinate all regulatory actions, communications and filings with each Regulatory Authority related to such
submission, (ii) be responsible for interfacing, corresponding and meeting with each Regulatory

  

 33 

 
Authority related to such submission, and (iii) be responsible for maintaining all regulatory filings; provided, that, the other Party shall have a right to have one or more of its employees
attend, as an observer, any meetings with Regulatory Authorities for which the other Party is responsible under this Section 5.7, and to participate in major planning meetings occurring before or after any such meeting with Regulatory
Authorities, and shall be provided in advance with the materials prepared for any such meeting. Notwithstanding anything in this Agreement to the contrary, each Party shall have the right to review and comment on any regulatory submission related to
Licensed Product in the Field made by the other Party under this paragraph, through the JDC, and such other Party shall consider in good faith the comments made by the commenting Party. In addition, each Party shall provide the other Party, in a
timely manner, with written notice and copies of: (a) all IND submissions with respect to Licensed Product; (b) all filings and submissions for Regulatory Approval regarding the Licensed Product; and (c) all Regulatory Approvals
obtained or denied, with respect to Licensed Product, in each case within the Field. Except as set forth in Section 5.11 and 5.12, and subject to Section 5.13, each Party shall have access to all data contained or referenced in any
regulatory submissions or applications for Regulatory Approvals with respect to Licensed Product made by the other Party, in each case as may be reasonably necessary to enable the Party accessing such data to exercise its rights, and fulfill its
obligations, under this Agreement to Develop, Manufacture and Commercialize Licensed Product. Each Party shall provide appropriate notification of such data access right of the other Party to the appropriate Regulatory Authorities. In addition,
except as set forth in Section 5.11 and 5.12, and subject to Section 5.13, each Party shall have the right to cross-reference and make any other use of the other Party’s INDs for Licensed Product that it would have if it were the
owner, including without limitation access to all data contained or referenced in such INDs, in each case as may be reasonably necessary to enable such Party exercising such right of cross-reference to exercise its rights, and fulfill its
obligations, under this Agreement to Develop, Manufacture and Commercialize Licensed Product. Notwithstanding anything in this Agreement to the contrary, the provisions of this Section 5.7 shall not apply to regulatory submissions or Regulatory
Approvals for New Licensed Product or New Indication Existing Licensed Product that a Party Develops pursuant to, and in accordance with, Section 5.11 or Section 5.12, which such regulatory submissions and Regulatory Approvals shall be the
sole responsibility of and solely owned by such Party. 
 5.8. Adverse Event and Complaint Reporting Procedures.

 (a) Each Party will maintain a record of any and all complaints it or its Affiliates or Sublicensees receives with respect to
Licensed Product in connection with Development or Commercialization of Licensed Product during the License Term. Each Party will notify the other Party in reasonable detail of any complaint received by it or its Affiliates or Sublicensees with
respect to Licensed Product within sufficient time to allow the other Party and its Affiliates or Sublicensees to comply with any and all regulatory and other requirements imposed upon them in any jurisdiction in which Licensed Product is tested in
clinical studies, including Post-Approval Studies, or being marketed or sold. 
 (b) AVEO will maintain a global safety database
for Licensed Product. The cost of implementing and maintaining the global safety database shall be included as Development Costs, and shared equally by the Parties. Biogen Idec will have access to all data in the global safety database, subject to
reasonable procedures to be mutually agreed upon by the Parties and set forth in the Drug

  

 34 

 
Safety Information Exchange Agreement, as defined below. Biogen Idec will provide AVEO with all adverse event information and safety data relating to Licensed Product in its control through
access to the global safety database. Biogen Idec will ensure that each of its Affiliates and Sublicensees will report to Biogen Idec or directly to AVEO the details around any adverse events and serious adverse events relating to Licensed Product
in its control within the time periods for such reporting as specified in the Drug Safety Information Exchange Agreement. The holder of the relevant IND shall be responsible for submitting adverse event reports with respect to Licensed Product in
the Field to applicable Regulatory Authorities; provided that, upon Regulatory Approval, Biogen Idec shall be responsible for submitting all required adverse event reports with respect to Licensed Product to the applicable Regulatory Authorities in
the Licensed Territory. Biogen Idec’s costs associated with submitting adverse event reports in the Licensed Territory shall be borne by Biogen Idec. Upon Regulatory Approval, AVEO shall be responsible for submitting all other required adverse
event reports with respect to the Licensed Product to the applicable Regulatory Authorities in the AVEO Territory. AVEO’s costs associated with submitting adverse event reports in the Licensed Territory as the IND holder during Development, to
the extent applicable, shall be treated as a Development Costs to be borne by the Parties as specified in Section 5.4. AVEO’s costs associated with submitting adverse event reports with respect to the Licensed Product to the applicable
Regulatory Authorities in the AVEO Territory shall be borne by AVEO. 
 (c) At such time as is deemed appropriate by the JDC,
the Parties will develop and agree in writing on a Drug Safety Information Exchange Agreement that will include safety data exchange procedures governing the coordination of collection, investigation, reporting, and exchange of information
concerning any adverse experiences, and any product quality and product complaints involving adverse experiences, related to the Licensed Product, sufficient to enable each Party to comply with its legal and regulatory obligations and consistent
with the terms of this Agreement. 
 5.9. Recalls, Market Withdrawals or Corrective Actions. If any Regulatory Authority
issues or requests a recall or takes a similar action in connection with Licensed Product, or if either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal, the Party
notified of such recall or similar action, or the Party that desires such recall, withdrawal or similar action, shall within twenty-four (24) hours, advise the other Party thereof by telephone or facsimile. Biogen Idec, in consultation with
AVEO (except in the case of a government mandated recall, when Biogen Idec may, if there is not sufficient time, act without such consultation, but shall notify AVEO as soon as possible), shall decide whether to conduct a recall or product
withdrawal of Licensed Product in the Licensed Territory and the manner in which any such recall or withdrawal shall be conducted. AVEO, in consultation with Biogen Idec (except in the case of a government mandated recall, when AVEO may, if there is
not sufficient time, act without such advance consultation, but shall notify Biogen Idec as soon as possible) shall decide whether to conduct a recall or product withdrawal of Licensed Product in the AVEO Territory and the manner in which any such
recall or withdrawal shall be conducted. Each Party shall make available to the other Party, upon request, all pertinent records in its control that may reasonably be needed by the requesting Party in effecting a recall or withdrawal of Licensed
Product. 
  

 35 

 5.10. Medical Inquiries. Upon Regulatory Approval, Biogen Idec, at its sole cost,
shall handle all medical questions or inquiries from members of the medical profession in the Licensed Territory regarding Licensed Product in the Field. AVEO shall handle all medical questions or inquiries from members of the medical profession
regarding the Licensed Product in the Field in the Licensed Territory prior to Regulatory Approval in the Licensed Territory. The costs of such activities shall be treated as Development Costs to be borne by the Parties as specified in
Section 5.4. AVEO, at its sole cost, shall handle all medical questions or inquiries from members of the medical profession in the AVEO Territory regarding Licensed Product in the Field. 
 5.11. Opt-out Rights for New Products. 
 (a) Opt-out Process. In the event that either Party proposes an amendment, modification or update of the Development Plan for purposes of Developing a new Licensed Product for an existing or a new
indication (a “New Licensed Product”), and the other Party’s representatives on the JDC do not approve or consent to such amendment, modification or update, then, notwithstanding anything express or implied elsewhere in this
Agreement to the contrary, the Party that proposed the New Licensed Product (the “Funding Party”) may, by written notice to the other Party given within [**] of the JDC’s vote, elect to trigger the provisions of this
Section 5.11 with respect to such New Licensed Product, in which case the provisions of this Section 5.11 shall become applicable to such New Licensed Product on the date such written notice is given (in each case, the “Section
5.11 Opt-out Effective Date”). From and after the Section 5.11 Opt-out Effective Date with respect to a New Licensed Product, and subject to the provisions of Section 5.11(b), (i) the Funding Party may proceed with
Development and Manufacturing of such New Licensed Product in the AVEO Territory and/or the Licensed Territory at its sole cost, and such Development and Manufacturing activities with respect to such New Licensed Product shall be the responsibility
and within the control of such Funding Party, (ii) the Funding Party may Develop or Manufacture such New Licensed Product through Affiliates and Sublicensees and may grant to Affiliates and Sublicensees the right to Develop or Manufacture such
New Licensed Product, subject to all of the provisions of Article III, (iii) neither the non-Funding Party nor any of its Affiliates or Sublicensees shall have any rights in or to the clinical data generated after the Section 5.11 Opt-out
Effective Date by the Funding Party or any of its Affiliates or Sublicensees with respect to such New Licensed Product, (iv) neither the Funding Party nor any of its Affiliates or Sublicensees may Commercialize such New Licensed Product in the
non-Funding Party’s Territory and (v) neither the non-Funding Party nor any of its Affiliates or Sublicensees may Commercialize such New Licensed Product in the non-Funding Party’s Territory. 
 (b) Effect of Opt-out. For purposes of clarity the following provisions will apply with respect to any New Licensed Product from and
after the Section 5.11 Opt-out Effective Date: 
 (i) Responsibility and control over the Development of
such New Licensed Product shall be entirely in the control of the Funding Party and the JDC shall have no decision-making authority with respect to such Development, provided that the Funding Party shall keep the JDC reasonably informed of the plan
for Development of the New Licensed Product, the progress of Development activities, and, subject to the other terms of this Section 5.11, the results of such Development efforts; 
  

 36 

 (ii) Neither Party shall have any obligation under Article V hereof with
respect to such New Licensed Product; 
 (iii) Any and all clinical data related to such New Licensed Product
that is generated by the Funding Party or any of its Affiliates or Sublicensees from and after the Section 5.11 Opt-out Effective Date shall be specifically excluded from the definition of AVEO Collaboration Know-how and AVEO Know-how, in the
event AVEO is the Funding Party or from the definition of Biogen Idec Collaboration Know-how in the event Biogen Idec is the Funding Party; 
 (iv) Neither the non-Funding Party nor any of its Affiliates or Sublicensees shall have the right to access any data related to such New Licensed Product generated solely by or on behalf of the Funding
Party or any of its Affiliates or Sublicensees from and after the Section 5.11 Opt-out Effective Date, including to the extent contained in any INDs, BLAs or other submissions related to such New Licensed Product, or to include any such data,
in any regulatory filings or submissions in such Party’s Territory or to cross-reference or otherwise make use of or use such data, except for any adverse event data required by Law to be disclosed by the non-Funding Party or any of its
Affiliates or Sublicensees; 
 (v) If the Funding Party is not at such time responsible for Manufacturing under
Article VII, the Funding Party shall be entitled to Manufacture such New Licensed Product for its needs, and shall have the right to deal directly with any Third Party contract manufacturer of the other Party to arrange for such Third Party contract
manufacturer to Manufacture and supply such New Licensed Product to such Party and its Affiliates and Sublicensees for the purposes contemplated in this Section 5.11; 
 (vi) The provisions of Section 8.4 shall not be applicable with respect to such New Licensed Product; and 
 (vii) The provisions of Article VIII (other than Section 8.4) and Article IX shall continue to be applicable with
respect to such New Licensed Product. 
 5.12. Opt-out Rights for New Indications. 
 (a) Opt-out Process. In the event that either Party proposes an amendment, modification or update of the Development Plan for
purposes of Developing an existing Licensed Product in a new indication (a “New Indication Existing Licensed Product”) and such new indication is commercially viable in the AVEO Territory and EU (a “Commercially Viable
Indication”), and the other Party’s representatives on the JDC do not approve or consent to such amendment, modification or update, then, notwithstanding anything express or implied elsewhere in this Agreement to the contrary, the
Party that proposed such new indication (the “New Indication Funding Party”) may, by written notice to the other Party, given within [**] of the JDC’s vote, elect to trigger the

  

 37 

 
provisions of this Section 5.12 with respect to such New Indication Existing Licensed Product, in which case the provisions of this Section 5.12 shall become applicable to such New
Indication Existing Licensed Product on the date such written notice is given (in each case, the “Section 5.12 Opt-out Effective Date”). From and after the Section 5.12 Opt-out Effective Date with respect to a New Indication
Existing Licensed Product, and subject to the provisions of Section 5.12(b) and Section 5.13 below, (i) the New Indication Funding Party may proceed with Development and Manufacturing of such New Indication Existing Licensed Product
in the AVEO Territory and/or the Licensed Territory at its sole cost, and such Development and Manufacturing activities with respect to such New Indication Existing Licensed Product shall be the responsibility and within the control of the New
Indication Funding Party, (ii) the New Indication Funding Party may Develop or Manufacture such New Indication Existing Licensed Product through Affiliates and Sublicensees and may grant to Affiliates and Sublicensees the right to Develop or
Manufacture such New Indication Existing Licensed Product, subject to all of the provisions of Article III, (iii) the non-New Indication Funding Party and its Affiliates and Sublicensees shall not have any rights in or to the clinical data
generated after the Section 5.12 Opt-out Effective Date by the New Indication Funding Party or any of its Affiliates or Sublicensees with respect to such New Indication Existing Licensed Product, other than safety data; (iv) neither the
New Indication Funding Party nor any of its Affiliates or Sublicensees may Commercialize such New Indication Existing Licensed Product in the other Party’s Territory; and (v) neither the non-New Indication Funding Party nor any of its
Affiliates or Sublicensees may Commercialize such New Indication Existing Licensed Product in the non-New Indication Funding Party’s Territory. 
 (b) Effect of Opt-out. For purposes of clarity, and subject to Section 5.13 below, the following provisions will apply with respect to any New Indication Existing Licensed Product from and
after the Section 5.12 Opt-out Effective Date: 
 (i) Responsibility and control over the Development of
such New Indication Existing Licensed Product shall be entirely in the control of the New Indication Funding Party and the JDC shall have no decision-making authority with respect to such Development, provided that the New Indication Funding Party
shall keep the JDC reasonably informed of the plan for Development of the New Indication Existing Licensed Product, the progress of Development activities, and, subject to the other terms of this Section 5.12, the results of such Development
efforts; 
 (ii) Neither Party shall have any obligation under Article V hereof with respect to such New
Indication Existing Licensed Product except under Sections 5.8 and 5.9; 
 (iii) Any and all clinical data
related to such New Indication Existing Licensed Product that is generated by the New Indication Funding Party or any of its Affiliates or Sublicensees from and after the Section 5.12 Opt-out Effective Date shall be specifically excluded from
the definition of AVEO Collaboration Know-how or AVEO Know-how, in the event AVEO is the New Indication Funding Party, and from the definition of Biogen Idec Collaboration Know-how in the event Biogen Idec is the New Indication Funding Party,
subject, in each case, to Section 5.8; 
  

 38 

 (iv) Neither the non-New Indication Funding Party nor any of its Affiliates
or Sublicensees shall have the right to access any data related to such New Indication Existing Licensed Product generated solely by or on behalf of the New Indication Funding Party or any of its Affiliates or Sublicensees from and after the
Section 5.12 Opt-out Effective Date, including to the extent contained in any INDs, BLAs or other submissions related to such New Indication Existing Licensed Product, or to include any such data, in any regulatory filings or submissions in
such Party’s Territory or to cross-reference or otherwise make use of or use such data; 
 (v) If the New
Indication Funding Party is not, at such time, responsible for Manufacturing the applicable Licensed Product under Article VII, at the request of the New Indication Funding Party, the other Party shall Manufacture and supply, or cause to be
Manufactured and supplied, the reasonable requirements of the New Indication Funding Party and its Affiliates and Sublicensees for such New Indication Existing Licensed Product pursuant to, and in accordance with, the provisions of Article VII;

 (vi) The provisions of Section 8.4 shall not be applicable with respect to such New Indication Existing
Licensed Product; and 
 (vii) The provisions of Article VIII (other than Section 8.4) and Article IX shall
continue to be applicable with respect to such New Indication Existing Licensed Product. 
 5.13. Opt-in. 
 (a) Opt-in. Following a Section 5.12 Opt-out Effective Date with respect to a New Indication Existing Licensed Product, in the
event that (i) the New Indication Funding Party receives Regulatory Approval to Commercialize such New Indication Existing Licensed Product in such Commercially Viable Indication in the New Indication Funding Party’s Territory (such new
indication being hereinafter referred to as the “Opt-in Indication”), and (ii) the pivotal trial(s) with respect to such New Indication Existing Licensed Product for which Regulatory Approval was received were initially
designed to support Regulatory Approval in both the AVEO Territory and the Licensed Territory (and the Regulatory Approval was received from the FDA (in the case that AVEO was the New Indication Funding Party) or either (A) EMEA or (B) the
applicable Regulatory Authority in any one of Germany, France, Spain, Italy or the United Kingdom (in the case that Biogen Idec was the New Indication Funding Party)), then the New Indication Funding Party shall give written notice (in each case,
the “Opt-in Notice”) to the other Party that the New Indication Funding Party has received a Regulatory Approval to Commercialize such New Indication Existing Licensed Product in such Opt-in Indication in the New Indication Funding
Party’s Territory under this Agreement, in which case the provisions of this Section 5.13 shall become applicable to such New Indication Existing Licensed Product with respect to such Opt-in Indication (in each case, an “Opt-in New
Indication Existing Licensed Product”) on the date such written notice is given (in each case, the “Opt-in Notice Date”). From and after the Opt-in Notice Date with respect to an Opt-in New Indication Existing Licensed
Product, and subject to the provisions of Section 5.13(b), the non-New Indication Funding Party (the “Opt-in Party”) shall be required to make a cash payment to the New Indication Funding Party, within [**] of the Opt-in Notice
Date, equal to one hundred percent (100%) of the aggregate Development

  

 39 

 
Costs incurred by the New Indication Funding Party from and after the Section 5.12 Opt-out Effective Date to the date of the Regulatory Approval that was the subject of the Opt-in Notice to
the extent such Development Costs are specific to such Opt-in New Indication Existing Licensed Product and would have been shared equally under Section 5.4 if the Opt-in Party had not opted out under Section 5.12 (the “Opt-in
Payment”). “Development Costs” for purposes of this paragraph shall mean the category of costs set forth in Section 1.34, but without the requirement that such costs be set forth in a Development Plan approved by the JDC, and
provided such Development Costs shall be subject to the auditing provisions of Section 8.16(b) to the same extent as applicable to Development Costs incurred by AVEO under this Agreement. Commencing upon the date of full payment of the Opt-in
Payment(the “Opt-in Effective Date”), the Opt-in Party and its Affiliates and Sublicensees shall have rights in or to the clinical data generated after the Section 5.12 Opt-out Effective Date by the New Indication Funding Party
or any of its Affiliates or Sublicensees with respect to such Opt-in New Indication Existing Licensed Product for purposes of seeking and obtaining Regulatory Approval of such Opt-in New Indication Existing Licensed Product in the Opt-in
Party’s Territory under this Agreement, and for all purposes of this Agreement shall be treated as though the Opt-in Party had not triggered its rights under Section 5.12(a) hereof in the first place with respect to such Opt-in New
Indication Existing Licensed Product in such Opt-in Indication. 
 (b) Effect of Opt-in. For purposes of clarity the
following provisions will apply with respect to any Opt-in New Indication Existing Licensed Product from and after the Opt-in Effective Date: 
 (i) Responsibility and control over the Development and Regulatory Approval of such Opt-in New Indication Existing Licensed Product in the Opt-in Party’s Territory under this Agreement shall be
entirely in the control of the Opt-in Party and the JDC shall have no decision-making authority with respect to such Development and Regulatory Approval, provided that the Opt-in Party shall keep the JDC reasonably informed of the plan for
Development and Regulatory Approval of the Opt-in New Indication Existing Licensed Product, the progress of Development activities, and, subject to the other terms of this Section 5.13, the results of such Development efforts; 
 (ii) Neither Party shall have any obligation under Article V hereof with respect to such Opt-in New Indication Existing
Licensed Product other than under Section 5.8 and 5.9; 
 (iii) If Biogen Idec is the Opt-in Party, any and
all clinical data related to such Opt-in New Indication Existing Licensed Product that was generated by AVEO or any of its Affiliates or Sublicensees from and after the Section 5.12 Opt-out Effective Date with respect to such Opt-in New
Indication Existing Licensed Product shall be specifically included in the definition of AVEO Collaboration Know-how or AVEO Know-how; 
 (iv) If AVEO is the Opt-in Party, any and all clinical data related to such Opt-in New Indication Existing Licensed Product that was generated by Biogen Idec or any of its Affiliates or Sublicensees from
and after the Section 5.12 Opt-out Effective Date with respect to such Opt-in New Indication Existing Licensed Product shall be specifically included in the definition of Biogen Idec Collaboration Know-how; 
  

 40 

 (v) The Opt-in Party and its Affiliates and Sublicensees shall have the
right to access any data related to such Opt-in New Indication Existing Licensed Product generated by or on behalf of the other Party or any of its Affiliates or Sublicensees from and after the Section 5.12 Opt-out Effective Date with respect
to such Opt-in New Indication Existing License Product, including to the extent contained in any INDs, BLAs or other submissions related to such Opt-in New Indication Existing Licensed Product, or to include any such data, in any regulatory filings
or submissions in the Opt-in Party’s Territory or to cross-reference or otherwise make use of or use such data; 
 (vi) At the request of the Opt-in Party if the other Party is at such time responsible for Manufacturing under Article VII, such other Party shall Manufacture and supply, or cause to be Manufactured and supplied, the reasonable requirements
of the Opt-in Party and its Affiliates and Sublicensees for such Opt-in New Indication Existing Licensed Product pursuant to, and in accordance with, the provisions of Article VII; 
 (vii) If Biogen Idec is the Opt-in Party, the provisions of Section 8.4 shall be applicable with respect to such Opt-in
New Indication Existing Licensed Product; and 
 (viii) The provisions of Article VIII and Article IX shall
continue to be applicable with respect to such Opt-in New Indication Existing Licensed Product. 
 ARTICLE VI. 

COMMERCIALIZATION DURING LICENSE TERM 
 6.1. General. Biogen Idec shall be solely responsible for all Commercialization activities relating to the Licensed Product in the Field in the Licensed Territory during the License Term, and shall
use Commercially Reasonable Efforts to Commercialize Licensed Products in those countries in the Licensed Territory in which Regulatory Approval has been obtained, including by providing appropriate incentives consistent with its normal business
practices to Sales Representatives involved in the Commercialization of the Licensed Product in the Licensed Territory. AVEO shall be solely responsible for all Commercialization activities relating to the Licensed Product in the Field in the AVEO
Territory and shall use Commercially Reasonable Efforts to Commercialize Licensed Products in those countries in the AVEO Territory in which Regulatory Approval has been obtained, including by providing appropriate incentives consistent with its
normal business practices to Sales Representatives involved in the Commercialization of the Licensed Product in the AVEO Territory. 
 6.2. Joint Commercialization Team. 
 (a) Formation. Commencing with the initiation of the first Phase 3
Clinical Study of the Licensed Product in the Territory, the Parties shall establish a joint commercialization team (“JCT”) to serve as a forum to discuss Commercialization of the Licensed Product in the Field in the Parties’
respective Territory. The JCT shall consist of three (3) representatives designated by each Party, or

  

 41 

 
such other number as the Parties may from time to time mutually agree. Each Party shall appoint its initial representatives on the JCT at the time of formation, but may, from time to time,
substitute one or more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. Each Party shall have at least one JCT representative who is a senior employee (vice president level or above), and all
JCT representatives shall have appropriate expertise and ongoing familiarity with Commercialization of biopharmaceutical products. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to
attend JCT meetings, provided such representatives and consultants are subject to written obligations that are no less stringent than the confidentiality obligations and restrictions on use set forth in Article X. Each Party shall bear its own
expenses relating to attendance at JCT meetings by its representatives. 
 (b) Chairperson. The chairperson of the JCT
(the “JCT Chairperson”) shall alternate at one-year intervals between a representative of AVEO and a representative of Biogen Idec, with the initial JCT Chairperson being a representative of AVEO. The JCT Chairperson’s
responsibilities shall include (i) scheduling meetings at such frequency as described in paragraph (c) or as the JCT otherwise determines is necessary; (ii) setting agendas for meetings with solicited input from other members; and
(iii) confirming and delivering minutes to the JCT for review and final approval. 
 (c) Meetings. The JCT shall
meet in accordance with a schedule established by mutual agreement of the Parties, but, unless the Parties otherwise agree, the JCT shall meet no less frequently than once each Calendar Year, with the location for such meetings alternating between
AVEO and Biogen Idec facilities in Massachusetts (or such other locations as are determined by the JCT). Alternatively, the JCT may meet by means of teleconference, videoconference or other similar communications equipment. 
 (d) Responsibilities. The responsibilities of the JCT include: 
 (i) discussing global branding and positioning and publications strategy of Licensed Product in the Territory; 
 (ii) receiving updates from each Party regarding the Commercialization of the Licensed Product in the Territory; 

(iii) coordinating with the JDC regarding Development matters as necessary or appropriate with respect to
Commercialization of Licensed Product in the Territory; and 
 (iv) to the extent consistent with Article VII,
coordinating Manufacturing activities related to the Commercialization of the Licensed Product in the Territory. 
 (e)
Decision-Making. Notwithstanding anything in this Agreement to the contrary the JCT shall have no decision-making authority. Biogen Idec shall have sole decision-making authority with respect to Commercialization of Licensed Product in the
Field in the Licensed Territory, and AVEO shall have sole decision-making authority with respect to Commercialization of Licensed Product in the Field in the AVEO Territory. 
  

 42 

 6.3. Commercialization Costs. The costs of Commercialization activities in the
Licensed Territory shall be borne one hundred percent (100%) by Biogen Idec. The costs of Commercialization activities in the AVEO Territory shall be borne one hundred percent (100%) by AVEO. 
 6.4. Advertising and Promotional Materials. Biogen Idec will be responsible for the creation, preparation, production, reproduction
and filing with the applicable Regulatory Authorities, of relevant written sales, promotion and advertising materials relating to the Licensed Product (“Promotional Materials”) for use in the Licensed Territory, and AVEO will
responsible for the creation, preparation, production, reproduction and filing with the applicable Regulatory Authorities, of all Promotional Materials in the AVEO Territory. All such Promotional Materials will be compliant with all applicable Laws.
Subject to any limitations imposed by applicable Law, all such Promotional Materials and all documentary information and oral presentations (where practicable) regarding the marketing and promotion of the Licensed Product in the Field in the
Licensed Territory shall acknowledge the Parties’ license arrangement with respect to the Licensed Product. Copies of all Promotional Materials used in the Licensed Territory will be archived by Biogen Idec in accordance with applicable Law.
Copies of all Promotional Materials used in the AVEO Territory will be archived by AVEO in accordance with applicable Law. Upon AVEO’s reasonable request, copies of the core Promotional Materials used by Biogen Idec in the Licensed Territory
shall be translated into English (where applicable) and provided to AVEO. Upon Biogen Idec’s reasonable request, copies of core Promotional Materials for Licensed Product used by AVEO or any of its Affiliates or Sublicensees in the Field in the
AVEO Territory shall be provided in English to Biogen Idec. 
 6.5. Sales and Distribution. Biogen Idec shall be
responsible for booking sales and shall warehouse and distribute the Licensed Product in the Licensed Territory. AVEO shall be responsible for booking sales and shall warehouse and distribute Licensed Product in the AVEO Territory. If Biogen Idec or
any of its Affiliates or Sublicensees receive any orders for Licensed Product in the Field for the AVEO Territory, they shall refer such orders to AVEO. If AVEO or any of its Affiliates or Sublicensees receive any orders for Licensed Product in the
Field in the Licensed Territory, they shall refer such orders to Biogen Idec. 
 6.6. Reporting. Commencing upon the
first Regulatory Approval of Licensed Product in the Field in the applicable Territory, each Party shall prepare and deliver to the JCT, by no later than each March 31 (for the period ending December 31 of the prior Calendar Year), a
written report summarizing such Party’s Commercialization activities for the Licensed Product in the Field performed to date (or updating such report for activities performed since the last such report submitted hereunder, as applicable).

 6.7. Other Responsibilities. Without intending to limit in any way Biogen Idec’s overall responsibility for
Commercialization of Licensed Product in the Field in the Licensed Territory during the License Term and AVEO’s responsibility for Commercialization of Licensed Product in the AVEO Territory during the License Term, the Parties agree that
Biogen Idec shall be solely responsible for the following functions in the Licensed Territory and AVEO shall be solely responsible for the following functions in the AVEO Territory during the License Term: 
 (i) handling all returns of the Licensed Product; and 
  

 43 

 (ii) handling all aspects of Licensed Product order processing, invoicing
and collection, distribution, inventory and receivables. 
 6.8. Export Monitoring. Biogen Idec and its Affiliates and
Sublicensees will use Commercially Reasonable Efforts to monitor and prevent exports of the Licensed Product from the Licensed Territory to the AVEO Territory, using methods commonly used in the industry for such purpose, and shall promptly inform
AVEO of any such exports of the Licensed Product from the Licensed Territory to the AVEO Territory, and the actions taken to prevent such exports. Biogen Idec agrees to take any actions reasonably requested in writing by AVEO that are consistent
with applicable Law and regulation to prevent exports of the Licensed Product from the Licensed Territory to the AVEO Territory. Biogen Idec shall ensure that it has in effect provisions with those of its Affiliates or Sublicensees who are
Commercializing Licensed Products in the Licensed Territory that require such Affiliates and Sublicensees to use efforts consistent with those required of Biogen Idec in this Section 6.8. AVEO and its Affiliates and Sublicensees will use
Commercially Reasonable Efforts to monitor and prevent exports of the Licensed Product from the AVEO Territory to the Licensed Territory, using methods commonly used in the industry for such purpose, and shall promptly inform Biogen Idec of any such
exports of the Licensed Product from the AVEO Territory to the Licensed Territory, and the actions taken to prevent such exports. AVEO agrees to take any actions reasonably requested in writing by Biogen Idec that are consistent with applicable Law
and regulation to prevent exports of the Licensed Product from the AVEO Territory to the Licensed Territory. AVEO shall ensure that it has in effect provisions with those of its Affiliates or Sublicensees who are Commercializing Licensed Products in
the AVEO Territory that require such Affiliates and Sublicensees to use efforts consistent with those required of AVEO in this Section 6.8. 
 ARTICLE VII. 
 MANUFACTURE 
 7.1. Development Supply. Subject to the provisions set forth below in this Section 7.1 and Sections 7.3, 7.5 and 7.6 hereof,
AVEO, itself or through an Affiliate or Third Party contractor, shall have the sole right to, and shall be solely responsible for, the Manufacture of supplies of Licensed Product required for all Development of Licensed Product by AVEO, Biogen Idec
and their respective Affiliates and Sublicensees in the AVEO Territory and the Licensed Territory pursuant to this Agreement. AVEO shall use Commercially Reasonable Efforts to meet its Manufacturing obligations under this Section 7.1. Subject
to the provisions set forth below in Sections 7.3, 7.5 and 7.6 hereof, at the written request of Biogen Idec, which request may be made at any time and from time to time after the Option Exercise Date and shall in any event be made by Biogen Idec
with sufficient advance notice to be commercially reasonable (or with such other period of advance notice as the Parties may otherwise agree), AVEO, itself or through an Affiliate or Third Party contractor, shall use Commercially Reasonable Efforts
to Manufacture and supply Licensed Product to Biogen Idec and its Affiliates and Sublicensees in sufficient quantities to satisfy their respective reasonable requirements for use thereof in Development activities of Licensed Product pursuant to this
Agreement. 
  

 44 

 7.2. Commercial Supply. Subject to the provisions set forth below in this
Section 7.2 and Sections 7.4, 7.5, 7.6 and 7.7 hereof, AVEO, itself or through an Affiliate, shall have the sole right to, and shall be solely responsible for, the Manufacture of supplies of Licensed Product required for all Commercialization
of Licensed Product by AVEO, Biogen Idec and their respective Affiliates and Sublicensees in the AVEO Territory and the Licensed Territory pursuant to this Agreement. AVEO shall use Commercially Reasonable Efforts to meet its Manufacturing
obligations under this Section 7.2. In the event that AVEO elects not to exercise its right under this Section 7.2 to Manufacture itself or through an Affiliate and determines to Manufacture supplies of Licensed Product through a Third
Party contractor, AVEO shall provide prompt written notice to Biogen Idec of its determination (which notice shall be given not later than [**] prior to the target date of commencement of the first Phase 3 Clinical Trial with respect to any
Licensed Product (or with such other period of advance notice as the Parties may otherwise agree) (a “Contract Manufacturer Notice”). Subject to the provisions set forth below in 7.4, 7.5, 7.6 and 7.7 hereof, at the written request
of Biogen Idec, which request may be made at any time and from time to time commencing upon the initiation of the first Phase 3 Clinical Trial with respect to any Licensed Product (or with such other period of advance notice as the Parties may
otherwise agree), AVEO, itself or through an Affiliate or Third Party contractor, shall use Commercially Reasonable Efforts to Manufacture and supply Licensed Product to Biogen Idec and its Affiliates and Sublicensees in sufficient quantities to
satisfy their respective reasonable requirements for use thereof in Commercialization of such Licensed Product in the Field in the Licensed Territory. 
 7.3. Manufacturing Costs for Development. The Cost of Goods Sold of Licensed Product Manufactured pursuant to Section 7.1 hereof shall be included as Development Costs and shall be borne by
the Parties as set forth in Section 5.4 hereof. Except as set forth in the preceding sentence and except for Pre-Option Exercise Phase 3 Manufacturing Costs, Biogen Idec and its Affiliates and Sublicensees shall otherwise have no responsibility
or obligation to pay or reimburse AVEO for quantities of Licensed Product Manufactured by or on behalf of AVEO pursuant to Section 7.1 hereof. 
 7.4. Transfer Price for Commercial Supply. The purchase price payable by Biogen Idec and its Affiliates and Sublicensees for quantities of Licensed Product Manufactured and supplied by or on behalf
of AVEO pursuant to Section 7.2 hereof shall be equal to the Cost of Goods Sold applicable to such quantities of Licensed Product. 
 7.5. Biogen Idec Right to Become Sole Phase 3 and Commercial Supplier. Notwithstanding the provisions of Section 7.1 or 7.2 above and subject to the provisions of this Section 7.5 and
Sections 5.11, 7.6 and 7.7, Biogen Idec shall have the option to become the sole manufacturer and supplier of all quantities of any Licensed Product required for all Phase 3 Clinical Trials with respect to any Licensed Product and
Commercialization of such Licensed Product by AVEO, Biogen Idec and their respective Affiliates and Sublicensees in the AVEO Territory and the Licensed Territory pursuant to this Agreement. Biogen Idec may exercise such option with respect to any
Licensed Product by (i) giving written notice of exercise to AVEO no later than [**] after receipt by Biogen Idec of the Contract Manufacturer Notice and (ii) executing a Supply Agreement with AVEO in accordance with Section 7.7,
including the

  

 45 

 
timelines set forth in such Section, in which case Biogen Idec shall become the sole manufacturer and supplier of such Licensed Product required for Phase 3 Clinical Trials and commercial
quantities of such Licensed Product, provided, that, unless AVEO agrees otherwise, Biogen Idec may not exercise its option to become the sole manufacturer if, (i) at the time Biogen Idec gives such written notice of exercise, AVEO is utilizing
or planning to utilize a Third Party contract manufacturer as the commercial manufacturer and supplier of such Licensed Product and (ii) the per unit price of such Licensed Product quoted by Biogen Idec is higher than [**] of the lowest quote
submitted by any Third Party contract manufacturer that, at the time of submitting such quote, has capacity in an FDA-approved manufacturing facility adequate for the manufacture of such Licensed Product. In the event that, pursuant to the foregoing
provisions of this Section 7.5, Biogen Idec becomes the sole commercial manufacturer and supplier of any Licensed Product, then the provisions of Sections 7.1, 7.2, 7.3 and 7.4 shall thereafter apply to Biogen Idec with respect to such Licensed
Product to the same extent that they previously applied to AVEO and the rights of Biogen Idec in Sections 7.1, 7.2, 7.3 and 7.4 shall thereafter apply to AVEO with respect to such Licensed Product to the same extent they previously applied to Biogen
Idec. Notwithstanding anything in this Agreement, unless the Supply Agreement otherwise specifies, in the event Biogen Idec becomes the Party responsible for Manufacturing any Licensed Product pursuant to the terms of this Section 7.5 during
the Option Exercise Period, but elects not the exercise the Option, Biogen Idec shall have the right to terminate its supply obligation under this Section effective eighteen (18) months following written notice of such termination, given after
such election, having been provided to AVEO, or such lesser amount of time as AVEO may specify in writing to Biogen Idec. In such event, Biogen Idec shall engage in a technology transfer process, at Biogen Idec’s cost, for the purpose of
enabling AVEO or a Third Party contract manufacturer designated by AVEO to Manufacture Licensed Product by or on behalf of AVEO and its Affiliates and Sublicensees. 
 7.6. Back-Up Supply Rights. In the event that, at any time during the period in which either Party has an obligation to Manufacture and supply Licensed Product pursuant to Section 7.1 or
Section 7.2 hereof, such Party (the “Non-performing Manufacturing Party”) is unable to Manufacture and supply sufficient quantities of such Licensed Product pursuant to Section 7.1 and/or Section 7.2, as the case may
be, to meet the requirements therefor of the other Party and its Affiliates and Sublicensees as indicated in any good faith forecasts to be provided pursuant to the Supply Agreement or Section 7.1 and/or Section 7.2, as the case may be,
then such other Party shall have the right (but not the obligation) to Manufacture or have Manufactured such Licensed Product and thereafter to satisfy all of the requirements of such other Party and its Affiliates and Sublicensees for quantities of
such Licensed Product, except if and to the extent otherwise provided in the Supply Agreement. Such other Party may exercise its rights under this Section 7.6 with respect to any Licensed Product by giving thirty (30) days prior written
notice to the Non-performing Manufacturing Party. Upon receipt by the Non-performing Manufacturing Party of written notice from the other Party to the effect that such other Party is exercising its rights under this Section 7.6, the
Non-performing Manufacturing Party shall provide reasonable assistance, at its sole cost and expense, to enable such other Party to Manufacture or have Manufactured and supplied such Licensed Product. Such assistance shall include, without
limitation, (i) engaging in any technology transfer process required in order to enable such other Party or any Third Party contract manufacturer engaged by such other Party to Manufacture such Licensed Product and/or

  

 46 

 
(ii) introducing such other Party to any Third Party contract manufacturers utilized by the Non-performing Manufacturing Party and working with such other Party and such Third Party contract
manufacturers and taking such actions as may be reasonably required in order to enable such other Party to obtain supply of such Licensed Product from such Third Party contract manufacturers. The Parties hereby acknowledge and agree that the Supply
Agreement may provide for back-up supply rights that are different than those set forth in this Section 7.6 and to the extent of any conflict between any provisions of the Supply Agreement with respect to back-up supply rights and the
provisions of this Section 7.6, the provisions of the Supply Agreement with respect to back-up supply rights shall control. 
 7.7. Supply Agreement. Prior to the initiation of the first Phase 3 Clinical Trial with respect to any Licensed Product, the Parties shall negotiate in good faith and enter into a supply agreement pursuant to which AVEO, itself or
through an Affiliate or Third Party contractor, will Manufacture and supply to Biogen Idec and its Affiliates and Sublicensees such Licensed Product as required under Section 7.1 or 7.2 hereof, unless the Parties, as contemplated under
Section 7.5 hereof, shall have agreed that Biogen Idec will be the manufacturer of such Licensed Product, in which case (i) such supply agreement must be entered into at least [**] prior to commencement of the first Phase 3 Clinical Trial,
and (ii) such supply agreement will provide that Biogen Idec, itself or through an Affiliate or Third Party contractor, will Manufacture and supply to AVEO and its Affiliates and Sublicensees such Licensed Product as required under Sections
7.1, 7.2 and 7.5 hereof. Such supply agreement shall include the applicable terms set forth in Sections 7.1, 7.2, 7.4 and 7.6 and shall contain such other provisions as the Parties mutually agree upon that are customary for supply agreements of this
type. Pending the execution and delivery of such supply agreement, each of the Parties shall perform their respective obligations under this Article VII in accordance with its terms. Any supply agreement that is entered into by the Parties pursuant
to this Section 7.7 is referred to in this Agreement as the “Supply Agreement.” 
 ARTICLE VIII.

 FINANCIAL PROVISIONS 
 8.1. Initial Fee. Within five (5) Business Days after the Effective Date, Biogen Idec shall pay to AVEO a non-creditable, non-refundable up-front option fee of five million U.S. dollars
($5,000,000). 
 8.2. Equity Purchase. Concurrent with the execution of this Agreement, Biogen Idec shall purchase thirty
million U.S. dollars ($30,000,000) of AVEO’s Series E Convertible Preferred Stock, $.001 par value per share, at a purchase price of $4.00 per share, pursuant to, and in accordance with the terms of, the form of Stock Purchase Agreement
attached to this Agreement as Exhibit C. 
 8.3. Payments by Biogen Idec During Option Exercise Period. Subject to
the terms and conditions of this Agreement, Biogen Idec shall pay AVEO a milestone payment (each, a “Pre-Exercise Milestone Payment”) upon occurrence of each of the following events (each, a “Pre-Exercise
Milestone”), on a one-time basis, in the particular amounts specified below, no later than [**] after written notice from AVEO of the occurrence of the applicable Pre-Exercise Milestone (which notice shall be accompanied by supporting
documentation and information as is reasonably necessary and appropriate to demonstrate completion of the applicable Pre-Exercise Milestone: 
 (a) Panel Identification. Upon Panel Identification, Biogen Idec shall pay to AVEO five million U.S. dollars ($5,000,000). “Panel Identification” shall mean the first identification and
in vitro and biochemical characterization of a panel of erbB3-specific murine antibodies. 
  

 47 

 (b) [**]. Upon [**], Biogen Idec shall pay to AVEO [**] U.S. dollars ($[**]).
“[**]” shall mean [**] under this Agreement. 
 (c) [**]. Upon [**], Biogen Idec shall pay to AVEO [**] U.S. dollars
($[**]). “[**]” shall mean [**]. 
 (d) Option Exercise Fee. In the event Biogen Idec elects to exercise the
Option, it shall pay to AVEO a non-creditable, non-refundable option exercise fee of [**] U.S. dollars ($[**]) (the “Option Exercise Fee”) on or before the end of the Option Exercise Period. 
 (e) One Payment. Each of the Pre-Exercise Milestone Payments shall be payable only once during the Agreement Term (and for the
avoidance of doubt, shall not be payable on a Licensed Product-by-Licensed Product basis) irrespective of how many times any of the events specified herein may occur. 
 8.4. Milestones Payments by Biogen Idec After Exercise of Option. Subject to the terms and conditions of this Agreement, and only following exercise (if any) of the Option, Biogen Idec shall pay
AVEO a milestone payment (each, an “Event Milestone Payment”) upon occurrence of each of the following events (each, an “Event Milestone”), on a Licensed Product-by-Licensed Product basis, in the particular amounts
specified below, no later than [**] after the occurrence of the Event Milestone: 
  

				
	 Event Milestone
	  	Event Milestone Payment
	 [**]
	  	$	[**]
	 [**]
	  	$	[**]

 Each Event Milestone Payments shall be payable only once per Licensed Product, upon the first
occurrence of the applicable Event Milestone with respect to such Licensed Product, regardless of the number of indications for which [**] is ultimately achieved. 
 8.5. Royalty Payments by Biogen Idec. Subject to the provisions of Section 8.8 and subject also to the adjustment, if any, to be made under Section 8.9(d), following exercise (if any) of
the Option, Biogen Idec shall pay to AVEO royalties on Net Sales of Licensed Product in the Field by Biogen Idec and its Affiliates and Sublicensees in the Licensed Territory, as follows: 
  

				
	 Net Sales Per Licensed Product
	  	Royalty Percentage	 
	 On that portion of annual Net Sales Per Licensed Product less than or equal to $[**]
	  	[**]	% 
	 On that portion of annual Net Sales Per Licensed Product greater than $[**] but less than or equal to $[**]
	  	[**]	% 
	 On that portion of annual Net Sales Per Licensed Product greater than $[**]
	  	[**]	% 

  

 48 

 8.6. Royalty Payments by AVEO. Subject to the provisions of Section 8.8
and subject also to the adjustment, if any, to be made under Section 8.9(d), following exercise (if any) of the Option, AVEO shall pay to Biogen Idec royalties on Net Sales by AVEO and its Affiliates and Sublicensees of Licensed Product in the
Field in the AVEO Territory, as follows: 
  

				
	 Net Sales Per Licensed Product
	  	Royalty Percentages	 
	 On that portion of annual Net Sales Per Licensed Product less than or equal to $[**]
	  	[**]	% 
	 On that portion of annual Net Sales Per Licensed Product greater than $[**] but less than or equal to $[**]
	  	[**]	% 
	 On that portion of annual Net Sales Per Licensed Product greater than $[**]
	  	[**]	% 

 8.7. Restriction on Bundling. If a Party or its Affiliates or Sublicensees
sell Licensed Product to a Third Party who also purchases other products or services from such Party or its Affiliates, such Party shall not, and shall require its Affiliates and Sublicensees not to, (i) bundle or include any Licensed Product
as part of any incentive programs, chargebacks, disease management programs or similar programs based on multiple product offerings or (ii) discount or price the Licensed Product, in the case of either of the foregoing clauses (i) or (ii),
such that the applicable rebate, discount, other form of reimbursement for, or the price of, the Licensed Product in such arrangement is inconsistent with the rebate, discount, or other form of reimbursement for, or price of, the Licensed Product
when sold separately to such Person from any such other products or services sold to such Person. 
 8.8. Royalty Term.
On a country-by-country and Licensed Product-by-Licensed Product basis, royalties shall be payable under Section 8.5 or 8.6, as the case may be, during the period commencing on the first sale of such Licensed Product in the Field in such
country for any purpose and ending upon the later of (a) the date of expiration, unenforceability or invalidation of the last Valid Claim of AVEO Patent Rights or Collaboration Patent Rights Covering Licensed Product in such country, or
(b) expiration of Data Exclusivity in such country (the “Royalty Term”). The royalties payable with respect to Net Sales of a Licensed Product shall be reduced, on a country-by-country and Licensed Product-by-Licensed Product
basis, to [**] of the amounts otherwise payable pursuant to Section 8.5 or 8.6, as the case may be, during any portion of the Royalty Term when there is no Valid Claim of an AVEO Patent Right or Collaboration Patent Right Covering such Licensed
Product in such country. Upon expiration of the Royalty Term applicable to a Party in a particular country with respect to a particular Licensed Product, the license granted to such Party under Article III with respect to such Licensed Product shall
convert to a fully paid-up, non-royalty-bearing license in the applicable country. 
  

 49 

 8.9. Third Party Licenses. 
 (a) Existing Third Party Licenses. As of the Effective Date, there are no AVEO In-Licenses except as set forth in Exhibit D,
and there are no Biogen Idec In-Licenses. 
 (b) For Licensed Territory. Subject to Section 8.9(d), Biogen Idec
shall bear [**] of any royalties, upfront fees, milestones and other payments under AVEO In-Licenses or Biogen Idec In-Licenses to the extent reasonably allocable to the Commercialization (or Development and Manufacturing in support of
Commercialization) of a Licensed Product in the Field in the Licensed Territory. Any such amounts shall be paid by Biogen Idec or paid by AVEO and reimbursed by Biogen Idec; provided that if such amounts are paid by AVEO, AVEO shall
invoice Biogen Idec for the amounts identified on a Calendar Quarter basis, and Biogen Idec shall pay such invoices within thirty (30) days after receipt of AVEO’s invoice. 
 (c) For AVEO Territory. Subject to Section 8.9(d), AVEO shall bear [**] of any royalties, upfront fees, milestones and other
payments under AVEO In-Licenses and Biogen Idec In-Licenses to the extent reasonably allocable to the Commercialization (or Development and Manufacturing in support of Commercialization) of a Licensed Product in the Field in the AVEO Territory. Any
such amounts shall be paid by AVEO or Biogen Idec and reimbursed by AVEO; provided that if such amounts are paid by Biogen Idec, Biogen Idec shall invoice AVEO for the amounts identified on a Calendar Quarter basis, and AVEO shall pay
such invoices within thirty (30) days after receipt of Biogen Idec’s invoice. 
 (d) Reduction. Royalties
payable by Biogen Idec to AVEO pursuant to Section 8.5 shall be reduced by an amount equal to [**] of all royalties, upfront fees, milestones and other payments under (i) the AVEO In-Licenses, (ii) the Biogen Idec In-Licenses and
(iii) any other Third Party Technology Agreement pursuant to which Biogen Idec or any of its Affiliates or Sublicensees acquired Know-how or Patent Rights that are necessary for the Development, Manufacture or Commercialization of Licensed
Product in the Licensed Territory, in each case to the extent actually paid by Biogen Idec or any of its Affiliates; provided that in no event shall the royalty payable to AVEO under Section 8.5 be reduced to less than [**] of the
full royalty determined at the rates set forth in Section 8.5. Royalties payable by AVEO to Biogen Idec pursuant to Section 8.6 shall be reduced by an amount equal to [**] of all royalties, upfront fees, milestones and other payments under
(i) the AVEO In-Licenses, (ii) the Biogen Idec In-Licenses and (iii) any other Third Party Technology Agreement pursuant to which AVEO or any of its Affiliates or Sublicensees acquired Know-how or Patent Rights that are necessary for
the Development, Manufacture or Commercialization of Licensed Product in the AVEO Territory, in each case to the extent actually paid by AVEO or any of its Affiliates; provided that in no event shall the royalty payable to Biogen Idec
under Section 8.6 be reduced to less than [**] of the full royalty determined at the rates set forth in Section 8.6. Amounts not otherwise used by a Party to reduce royalties as a result of the limitations set forth in this
Section 8.9(d) in a period incurred may be used to reduce royalties in future periods until fully utilized. 
  

 50 

 (e) Disagreements. In the event that a Party disagrees with the other Party’s
assessment of the necessity of a Third Party Technology Agreement that is not a Biogen Idec In-license or AVEO In-license, the objecting Party shall send written notice to such effect to the other Party, and the Parties shall appoint a mutually
agreed upon independent Third Party intellectual property lawyer with expertise in the patenting of biologics, and appropriate professional credentials in the relevant jurisdiction, to determine the question of the necessity of the relevant Patent
Right, taking into account such Third Party’s assessment of the validity and enforceability of such Patent Right in addition to an infringement assessment. The determination of the Third Party expert engaged under the preceding sentence shall
be binding on the Parties solely for purposes of applying the offsets under this Section 8.9. The costs of any Third Party expert engaged under this paragraph shall be paid by the Party against whose position the Third Party’s
determination is made. 
 (f) Exclusions. Notwithstanding anything express or implied in this Section 8.9 to the
contrary, the provisions of this Section 8.9 shall not apply to any royalties, license fees or other fees paid by either Party or any of its Affiliates to Third Parties in respect of the Manufacture of Licensed Product and included in Cost of
Goods Sold. 
 8.10. Payments; Reports. Within [**] after the end of each Calendar Quarter for which royalties are
payable by one Party to the other Party under either Section 8.5 or Section 8.6, the Party that owes the royalty (the “Royalty-paying Party”) shall submit to the other Party a report, on a country-by-country basis,
providing in reasonable detail an accounting of all Net Sales by the Royalty-paying Party and its Affiliates and Sublicensees in the Licensed Territory with respect to Net Sales by Biogen Idec and its Affiliates and Sublicensees and with respect to
the AVEO Territory with respect to Net Sales by AVEO and its Affiliates and Sublicensees (including, in each case, an accounting of all unit sales of the Licensed Product and a calculation of the deductions from gross invoice price to Net Sales in
accordance with Section 1.63) made during such Calendar Quarter and the calculation of the applicable royalties under Section 8.5 or 8.6, as the case may be. The Royalty-paying Party shall, at the time the Royalty-paying Party submits the
report, pay to the other Party all amounts due to such other Party under Section 8.5 or 8.6, as the case may be, as indicated in the applicable report. 
 8.11. Taxes. The Royalty-paying Party will make all payments to the other Party under this Agreement without deduction or withholding except to the extent that any such deduction or withholding is
required by applicable Law to be made on account of Taxes (as that term is defined below). Any Tax required to be withheld under applicable Law on amounts payable under this Agreement will promptly be paid by Royalty-paying Party on behalf of the
other Party to the appropriate governmental authority, and the Royalty-paying Party will furnish the other Party with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of and borne by the Party receiving the
payment. The Royalty-paying Party will give notice of its intention to begin withholding any such Tax in advance and cooperate to use reasonable and legal efforts to reduce such Tax on payments made to the other Party hereunder. Upon the written
request of the Royalty-paying Party, the other Party shall instruct the Royalty-paying Party as to the applicable withholding rate and related regulations for any country (or all countries) within the applicable Territory. The Royalty-paying Party
shall be entitled to rely upon the other Party’s withholding instructions without verification thereof, and shall withhold in accordance therewith and shall remit payment to the appropriate governmental authority in accordance with this

  

 51 

 
Section 8.11. The Parties will cooperate with respect to all documentation required by any relevant government taxing authority or reasonably requested by either Party to secure a reduction
in the rate of applicable withholding Taxes. Solely for purposes of this Section 8.11, “Tax” or “Taxes” means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including
interest, penalties and additions thereto) that are imposed by a Government Authority. 
 8.12. United States Dollars.
All dollar ($) amounts specified in this Agreement are United States dollar amounts. 
 8.13. Currency Conversion.
All payments to be made by either Party to the other Party shall be made in U.S. Dollars, to a bank account designated by the Party to be paid. In the case of sales outside the United States, royalty payments shall be converted to U.S. Dollars in
accordance with the following: the rate of currency conversion shall be calculated using the month-end spot rates as published by The Wall Street Journal, Eastern Edition. 
 8.14. Blocked Payments. If, by reason of applicable laws or regulations in any country, it becomes impossible or illegal for a Party
or any of its Affiliates or Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to the other Party, the Royalty-paying Party shall promptly notify the other Party of the conditions preventing such transfer and
such royalties or other payments shall be deposited in local currency in the relevant country to the credit of the Party to whom the royalty is owed in a recognized banking institution designated by such Party or, if none is designated by such Party
within a period of thirty (30) days, in a recognized banking institution selected by the other Party or its Affiliates or Sublicensees, as the case may be, and identified in a notice given to the Party on whose account the funds are deposited.

 8.15. Late Payments. The paying Party shall pay interest to the receiving Party on the aggregate amount of any
payments that are not paid on or before the date such payments are due under this Agreement at a simple rate per annum equal to the lesser of [**] percent ([**]%) per month or the highest rate permitted by applicable law, calculated on the number of
days such payments are paid after the date such payments are due. 
 8.16. Records and Audits. 
 (a) Royalties. Each Party shall keep complete and accurate records of the underlying revenue and expense data relating to the
calculations of Net Sales and payments required by Sections 8.5, 8.6 and 8.9. Each Party (the “Auditing Party”) shall have the right, [**] at its own expense, to have an nationally recognized, independent, certified public
accounting firm, selected by it and reasonably acceptable to the other Party, review any such records of the other Party and its Affiliates and Sublicensees (the “Audited Party”) in the location(s) where such records are maintained
by the audited Party upon reasonable notice (which shall be no less than [**] prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under
Sections 8.5, 8.6 and 8.9 within the [**] period preceding the date of the request for review. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such inspection lead to the discovery
of a discrepancy to the Auditing Party’s detriment, the Audited Party shall pay within [**] after its

  

 52 

 
receipt from the accounting firm of the certificate any undisputed amount of the discrepancy. The Auditing Party shall pay the full cost of the review unless the underpayment of royalties is
greater than five percent (5%) of the amount due for the entire period being examined, in which case the Audited Party shall pay the reasonable cost charged by such accounting firm for such review. Any overpayment of royalties by the Audited
Party revealed by an examination shall be paid back by the Auditing Party to the Audited Party within [**]. 
 (b)
Development Costs. AVEO shall keep complete and accurate records of Development Costs. Biogen Idec shall have the right, [**] at its own expense, to have an independent, certified public accounting firm, selected by Biogen Idec and reasonably
acceptable to AVEO, review any such records of AVEO in the location(s) where such records are maintained by AVEO upon reasonable notice (which shall be no less than [**] prior notice) and during regular business hours and under obligations of strict
confidence, for the sole purpose of verifying the basis and accuracy of its reimbursements made for Development Costs under Sections 5.4 within the [**] period preceding the date of the request for review. AVEO shall receive a copy of each such
report concurrently with receipt by Biogen Idec. Should such inspection lead to the discovery of a discrepancy to Biogen Idec’s detriment, AVEO shall pay within [**] after its receipt from the accounting firm of the certificate any undisputed
amount of the discrepancy. Biogen Idec shall pay the full cost of the review unless there has been an overpayment of Development Costs by Biogen Idec for the period being examined in an amount greater than five percent (5%) of the amount due
for the entire period being examined, in which case AVEO shall pay the reasonable cost charged by such accounting firm for such review. Any underpayment of Development Costs by Biogen Idec revealed by an examination shall be paid by Biogen Idec
within [**]. 
 ARTICLE IX. 
 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED 
 MATTERS 

 9.1. Inventorship. Inventorship for patentable inventions conceived or reduced to practice during the course of the
performance of activities pursuant to this Agreement shall be determined in accordance with United States patent laws for determining inventorship. 
 9.2. Ownership. Subject to the licenses and rights granted to Biogen Idec under this Agreement, AVEO shall own the entire right, title and interest in and to all inventions and discoveries (and
Patent Rights claiming patentable inventions therein) first made or discovered solely by employees or consultants of AVEO or acquired solely by AVEO in the course of Development, Manufacture or Commercialization of Licensed Product. Subject to the
licenses and rights granted to AVEO under this Agreement, Biogen Idec shall own the entire right, title and interest in and to all inventions and discoveries (and Patent Rights claiming patentable inventions therein) first made or discovered solely
by employees or consultants of Biogen Idec or acquired solely by Biogen Idec in the course of Development, Manufacture or Commercialization of Licensed Product. The Parties shall jointly own any inventions and discoveries (and Patent Rights claiming
patentable inventions therein) first made or discovered jointly in the course of Development, Manufacture or Commercialization of Licensed Product. 
  

 53 

 9.3. Prosecution and Maintenance of Patent Rights. 
 (a) AVEO Technology. AVEO shall have the sole right to, at AVEO’s discretion, file, conduct prosecution, and maintain (including
the defense of any interference or opposition proceedings), all Patent Rights comprising AVEO Technology (other than Joint Collaboration IP), in AVEO’s name. AVEO shall provide to Biogen Idec copies of all prosecution filings related to AVEO
Patent Rights and AVEO Collaboration Patent Rights comprising claims Covering Licensed Product sent to or received from patent offices in the Licensed Territory, unless otherwise directed by Biogen Idec, and, with respect to patent applications
having information not previously filed that is intended to be submitted to patent offices in the Licensed Territory, shall use reasonable efforts to provide Biogen Idec with a draft of each such filing reasonably in advance of submission, provide
Biogen Idec an opportunity to provide comments on and make request of AVEO concerning such filings and shall consider in good faith any comments regarding such draft application that Biogen Idec may timely provide. In addition, AVEO shall provide to
Biogen Idec such other information related to prosecution of the AVEO Patent Rights and AVEO Collaboration Patent Rights in the Licensed Territory as Biogen Idec may from time to time reasonably request to allow Biogen Idec to track prosecution and
maintenance of such Patent Rights. In the event AVEO decides not to file a patent application on AVEO Know-how or AVEO Collaboration Know-how specific to Licensed Product in a country of the Licensed Territory, or decides to abandon prosecution of
any claim of an AVEO Patent Right or AVEO Collaboration Patent Right comprising claims Covering Licensed Product in a country of the Licensed Territory or decides to not otherwise maintain or extend any AVEO Patent Rights or AVEO Collaboration
Patent Right comprising claims Covering Licensed Product in a country of the Licensed Territory, AVEO shall give Biogen Idec written notice sufficiently in advance of any loss of rights to allow Biogen Idec to file, prosecute, maintain or extend, as
the case may be, such AVEO Patent Rights or AVEO Collaboration Patent Rights, in AVEO’s name, in such country. 
 (b)
Biogen Idec Collaboration Technology. Biogen Idec shall have the sole right, at Biogen Idec’s discretion, to file, conduct prosecution, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights
comprising Biogen Idec Collaboration Technology (other than Joint Collaboration IP), in Biogen Idec’s name. In the event Biogen Idec decides not to file a patent application on Biogen Idec Collaboration Know-how in a country of the Territory
specific to Licensed Product, or decides to abandon prosecution of any claim of Biogen Idec Collaboration Patent Right in a country of the Territory comprising claims Covering Licensed Product or decides to not otherwise maintain or extend any
Biogen Idec Collaboration Patent Right comprising claims Covering Licensed Product in a country of the Territory, Biogen Idec shall give AVEO written notice sufficiently in advance of any loss of rights to allow AVEO optionally to file, prosecute,
maintain or extend, as the case may be, such Biogen Idec Collaboration Patent Rights, in Biogen Idec’s name, in such country. 
 (c) Joint Collaboration IP. 
 (i) AVEO shall have the first right, at AVEO’s discretion, to
file, conduct prosecution, and maintain (including the defense of any interference or opposition proceedings), all Patent Rights included in Joint Collaboration IP, in the names of both AVEO and Biogen Idec. Biogen Idec shall use Commercially
Reasonable Efforts to make available to AVEO or its

  

 54 

 
authorized attorneys, agents or representatives, such of its employees as AVEO in its reasonable judgment deems necessary in order to assist it in obtaining patent protection for such Joint
Collaboration IP. Each Party shall sign, or use Commercially Reasonable Efforts to have signed, all legal documents necessary to file and prosecute patent applications or to obtain or maintain patents in respect of such Joint Collaboration IP, at
its own cost. 
 (ii) If AVEO elects not to seek or continue to seek or maintain patent protection on any Joint
Collaboration IP in the Licensed Territory, Biogen Idec shall have the right, at Biogen Idec’s discretion, to seek, prosecute and maintain in any country in the Licensed Territory patent protection on such Joint Collaboration IP in the names of
both AVEO and Biogen Idec. AVEO shall use Commercially Reasonable Efforts to make available to Biogen Idec its authorized attorneys, agents or representatives, such of AVEO’s employees as are reasonably necessary to assist Biogen Idec in
obtaining and maintaining the patent protection described under this Section 9.3(c)(ii). AVEO shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary to file and prosecute such patent applications or to
obtain or maintain such patents. 
 (iii) With respect to Patent Rights included in the Joint Collaboration IP,
the Party filing, prosecuting and maintaining such Patent Rights shall provide the other Party, within ten (10) Business Days after submitting or receiving such filings or correspondence, with copies of all filings and correspondence submitted
to and received from patent offices in the Licensed Territory and, with respect to substantive filings and correspondence to be submitted to patent offices in the Licensed Territory, shall use reasonable efforts to provide the other Party with
drafts of such filings and correspondence reasonably in advance of submission and shall consider in good faith any comments regarding such filings and correspondence that the other Party may timely provide. 
 9.4. Patent Term Extensions. The Parties shall cooperate, if necessary and appropriate, with each other in gaining patent term
extension (including those extensions available under U.S. Drug Price Competition and Patent Term Restoration Act of 1984, the Supplementary Certificate of Protection of Member States of the EU and other similar measures in any other country)
wherever applicable to Patent Rights Controlled by either Party that Cover the Licensed Product in the Territory. The Parties shall, if necessary and appropriate, use reasonable efforts to agree upon a joint strategy relating to patent term
extensions, but, in the absence of mutual agreement with respect to any extension issue, the patent or the claims of the patent shall be selected on the basis of the scope, enforceability and remaining term of the patent in the relevant country or
region. All filings for such extensions shall be made by the Party owning such patent or, in the case of Patent Rights included in the Joint Collaboration IP, by the Party responsible for filing, prosecuting and maintaining such Patent Rights in
accordance with this Section 9.4. 
 9.5. Patent Expenses. The patent filing, prosecution and maintenance expenses
incurred after the Option Exercise Date under Section 9.3 with respect to AVEO Patent Rights, AVEO Collaboration Patent Rights, Biogen Idec Collaboration Patent Rights and Joint Collaboration Patent Rights, in each case with claims covering
Licensed Product in the Licensed Territory shall be borne by

  

 55 

 
Biogen Idec. The patent filing, prosecution and maintenance expenses incurred under Section 9.3 with respect to AVEO Patent Rights, AVEO Collaboration Patent Rights, Biogen Idec
Collaboration Patent Rights and Joint Collaboration Patent Rights in each case with claims covering Licensed Product in the AVEO Territory shall be borne by AVEO. In all other cases, the patent filing, prosecution and maintenance expenses incurred
during the Agreement Term with respect to Patent Rights comprised of AVEO Technology and Biogen Idec Collaboration Technology (“Patent Expenses”) shall be borne by the Party responsible for filing, prosecuting and maintaining such
Patent Rights under this Section 9.5. 
 9.6. Third Party Infringement. 
 (a) Notices. Each Party shall promptly report in writing to the other Party any (i) known or suspected infringement of any AVEO
Technology or Biogen Idec Collaboration Technology, including any Joint Collaboration IP or (ii) unauthorized use or misappropriation of any Confidential Information or Know-how of a Party by a Third Party of which it becomes aware, in each
case only to the extent relevant to the Licensed Product or the Development, Manufacture or Commercialization of the Licensed Product and involving a competing product (“Competitive Infringement”) in the Territory, and shall provide
the other Party with all available evidence supporting such infringement, or unauthorized use or misappropriation. 
 (b)
Rights to Enforce. 
 (i) AVEO’s First Right. Subject to the provisions of any Third Party
agreement under which AVEO’s rights in AVEO Technology are granted and subject to paragraph (ii), AVEO shall have the sole and exclusive right to initiate an infringement or other appropriate suit anywhere in the world against any Third Party
who at any time has infringed, or is suspected of infringing, any Patent Rights, or of using without proper authorization any Know-how comprising AVEO Technology or Joint Collaboration IP for which AVEO has prosecution responsibility under
Section 9.3. 
 (ii) Biogen Idec’s First Right. Subject to the provisions of any Third Party
agreement under which Biogen Idec’s rights in Biogen Idec Collaboration Technology are granted, Biogen Idec shall have the sole and exclusive right to initiate an infringement or other appropriate suit anywhere in the world against any Third
Party who at any time has infringed, or is suspected of infringing, any Patent Rights, or of using without proper authorization any Know-how, comprising Biogen Idec Collaboration Technology or Joint Collaboration IP for which Biogen Idec has
prosecution responsibility under Section 9.3. 
 (iii) Requests to Initiate Enforcement Action. AVEO
will consider in good faith any request from Biogen Idec to initiate an infringement or other appropriate suit in the Licensed Territory against any Third Party with respect to a Competitive Infringement of AVEO Technology or Joint Collaboration
I.P. for which AVEO has prosecution responsibilities under Section 9.3; provided, however, that AVEO shall not be required to initiate any such suit. If, however, AVEO elects not to initiate such suit, or otherwise does not
commence suit within one-hundred eighty (180) days of Biogen Idec’s request made under the preceding sentence, Biogen Idec shall have the right to initiate such suit and to

  

 56 

 
join AVEO as a party. Biogen Idec will consider in good faith any request from AVEO to initiate an infringement or other appropriate suit against any Third Party with respect to a Competitive
Infringement in the AVEO Territory of a Biogen Idec Collaboration Patent Right or any Joint Collaboration I.P. for which Biogen Idec has prosecution responsibilities under Section 9.3; provided, however, that Biogen Idec shall not
be required to initiate any such suit. If, however, Biogen Idec elects not to initiate such suit, or otherwise does not commence suit within one-hundred eighty (180) days of AVEO’s request made under the preceding sentence, AVEO shall have
the right to initiate such suit and to join Biogen Idec as a party. For the sake of clarity, in no event shall Biogen Idec have the right to enforce in the AVEO Territory any AVEO Patent Rights, AVEO Collaboration Patent Rights or Joint
Collaboration IP for which Biogen Idec has prosecution responsibilities under Section 9.3, and in no event shall AVEO have the right to enforce in the Licensed Territory Biogen Idec Collaboration Patent Rights or Joint Collaboration IP for
which AVEO has prosecution responsibilities under Section 9.3. 
 (c) Procedures; Expenses and Recoveries. The Party
having the right to initiate any infringement suit under Section 9.6(b) above shall have the sole and exclusive right to select counsel for any such suit and shall pay all expenses of the suit, including attorneys’ fees and court costs and
reimbursement of the other Party’s reasonable out-of-pocket expense in rendering assistance requested by the initiating Party; provided that with respect to any such suit, the Parties may mutually agree to jointly bear such costs
and expenses, in which case the allocation of recoveries described below may be adjusted as mutually agreed by the Parties. If required under applicable law in order for the initiating Party to initiate or maintain such suit, or if either Party is
unable to initiate or prosecute such suit solely in its own name or it is otherwise advisable to obtain an effective legal remedy, in each case, the other Party shall join as a party to the suit and will execute and cause its Affiliates to execute
all documents necessary for the initiating Party to initiate litigation to prosecute and maintain such action. In addition, at the initiating Party’s request, the other Party shall provide reasonable assistance to the initiating Party in
connection with an infringement suit at no charge to the initiating Party except for reimbursement by the initiating Party of reasonable out-of-pocket expenses incurred in rendering such assistance. The non-initiating Party shall have the right to
participate and be represented in any such suit by its own counsel at its own expense. If the Parties obtain from a Third Party, in connection with such suit, any damages, license fees, royalties or other compensation (including any amount received
in settlement of such litigation) in respect of a Competitive Infringement, such amounts shall be allocated, subject to any adjustment to such allocation agreed by the Parties in connection with an agreement to jointly bear the costs and expenses of
the infringement action as described above, as follows: 
 (i) first, to reimburse each Party for all expenses of
the suit incurred by such Party, including attorneys’ fees and disbursements, court costs and other litigation expenses; 
 (ii) second, [**] percent ([**]%) of the balance to be paid to (x) AVEO, in respect of a Competitive Infringement in the AVEO Territory, and (y) Biogen Idec, in respect of a Competitive
Infringement in the Licensed Territory, as the case may be; and 
  

 57 

 (iii) third, the remainder to be paid to the Party that did not receive the
balance under clause (ii). 
 9.7. Third Party Infringement Claims. If a Party becomes aware of any claim that the
Development, Manufacture or Commercialization of the Licensed Product in the Field infringes the Patent Rights of any Third Party in the Licensed Territory, such Party shall promptly notify the other Party. In any such instance, the Parties shall
cooperate and shall mutually agree upon an appropriate course of action which may include settlement of such claim. Each Party shall have an equal right to participate in any settlement discussions that are held with such Third Parties. 

9.8. Patent Marking. Each Party agrees to comply with the patent marking statutes in each country in which the Licensed Product is
sold by such Party or its Affiliates or Sublicensees. 
 9.9. Trademarks. 
 (a) Corporate Names and Logos. Each Party and its Affiliates shall retain all right, title and interest in and to its and their
respective corporate names and logos. 
 (b) Creation and Registration of Trademarks. AVEO or its Affiliates or
Sublicensees will create and register product trademarks for use with Licensed Product throughout the AVEO Territory, and Biogen Idec or its Affiliates or Sublicensees will create and register product trademarks for use with Licensed Product
throughout the Licensed Territory (collectively, the “Product Trademarks”). Each Party (or its Affiliates or Sublicensees, as appropriate) shall own all rights to its Product Trademarks, and all goodwill associated therewith,
throughout the world, and to any Internet domain names incorporating the applicable Product Trademarks or any variation or part of such Product Trademarks used as its URL address or any part of such address. 
 (c) License to Trademarks. AVEO shall grant to Biogen Idec and its Affiliates and Sublicensees an exclusive license to use
AVEO’s Product Trademarks to Commercialize the Licensed Product in the Field in the Licensed Territory, and Biogen Idec shall grant to AVEO and its Affiliates and Sublicensees an exclusive license to use Biogen Idec’s Product Trademarks to
Commercialize the Licensed Product in the Field in the AVEO Territory. If a Party uses the Product Trademark of the other Party with respect to Licensed Product, as permitted under this Agreement, such Party agrees that the quality of the Licensed
Product and the Commercialization thereof shall be consistent with the quality standards applied by the owner of the Product Trademark thereto. In addition, the Party using the Product Trademark of the other Party under this Section 9.9 shall
comply strictly with the trademark style and usage standards of the Party that owns the Product Trademark as communicated to such Party from time to time with respect to the Product Trademarks. The Party using the Product Trademark of the other
Party, shall, at the request and expense of the Party that owns the Product Trademark, from time to time, submit to the Party that owns the Product Trademark for approval a reasonable

  

 58 

 
number of production samples of the Licensed Product and related packaging materials. If the Party that owns the Product Trademark reasonably objects to the quality of the Licensed Product or the
usage of the Product Trademarks in connection with any sample, it shall give written notice of such objection to the other Party within sixty (60) days after receipt of the relevant sample, specifying the way in which such usage of the Product
Trademarks fails to meet the style, usage or quality standards for the Licensed Product set forth in the second and third sentences of this Section 9.9(c), and such Party shall immediately cease sale and distribution of the Licensed Product
using such Product Trademark. If the Party using such Product Trademark wishes to continue to distribute and sell the Licensed Product, it must remedy the failure and submit further samples to the Party that owns the Product Trademark for approval.

 (d) Maintenance and Costs. If a Product Trademark owned by AVEO or any of its Affiliates or Sublicensees is used by
Biogen Idec or any of its Affiliates or Sublicensees to promote and sell the Licensed Product in the Licensed Territory, then AVEO will use Commercially Reasonable Efforts to establish, maintain and enforce such Product Trademarks in the applicable
countries of the Licensed Territory. Biogen Idec shall be responsible for [**] of the costs of such efforts in the Licensed Territory and Biogen Idec shall reimburse AVEO for all such costs incurred by AVEO within [**] after receiving any invoice
from AVEO for such costs. If a Product Trademark owned by Biogen Idec or any of its Affiliates or Sublicensees is used by AVEO or any of its Affiliates or Sublicensees to promote and sell the Licensed Product in the AVEO Territory, then Biogen Idec
will use Commercially Reasonable Efforts to establish, maintain and enforce such Product Trademarks in the applicable countries in the AVEO Territory. AVEO shall be responsible for [**] of the costs of such efforts in the AVEO Territory and AVEO
shall reimburse Biogen Idec for all such costs incurred by Biogen Idec within [**] after receiving any invoice from AVEO for such costs. 
 (e) Infringement of Trademarks. If either Party becomes aware of any infringement of any Product Trademark by a Third Party in the Licensed Territory, such Party shall promptly notify the other
Party and the Parties shall consult with each other and jointly determine the best way to prevent such infringement, including by the institution of legal proceedings against such Third Party. 
 ARTICLE X. 
 CONFIDENTIALITY 
 10.1. Confidential Information. During the Agreement Term and for a period of ten (10) years after any termination or expiration
hereof, each Party agrees to keep in confidence and not to disclose to any Third Party, or use for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement, any Confidential Information of the other
Party. The terms of this Agreement shall be considered Confidential Information of both Parties hereunder. The restrictions on the disclosure and use of Confidential Information set forth in the first sentence of this Section 10.1 shall not
apply to any Confidential Information that: 
 (i) was known by the receiving Party prior to disclosure by the
disclosing Party hereunder (as evidenced by the receiving Party’s written records or other competent evidence); 
  

 59 

 (ii) is or becomes part of the public domain through no fault of the
receiving Party; 
 (iii) is disclosed to the receiving Party by a Third Party having a legal right to make such
disclosure without violating any confidentiality or non-use obligation that such Third Party has to the disclosing Party and provided such third party is not disclosing such information on behalf of the disclosing Party; or 
 (iv) is independently developed by personnel of the receiving Party who did not have access to the relevant Confidential
Information of the other Party (as evidenced by the receiving Party’s written records or other competent evidence). 
 In addition, if
either Party is required to disclose Confidential Information of the other Party by regulation, law or legal process, including by the rules or regulations of the United States Securities and Exchange Commission, or similar regulatory agency in a
country other than the United States, or of any stock exchange or Nasdaq, such Party shall provide prior written notice and a copy of such intended disclosure to such other Party if possible under the circumstances to enable such other Party to seek
a protective order or other appropriate remedy concerning any such disclosure, shall consider in good faith the other Party’s comments and reasonably cooperate (at the expense of the Party seeking to restrict such disclosure) to obtain any such
order or other remedy, and shall disclose only such Confidential Information of such other Party as is legally required to be disclosed. In addition, either Party may disclose to bona fide potential investors or lenders, potential
acquirors/acquirees, existing or potential collaborators or licensees or to such Party’s consultants and advisors, the existence and terms of this Agreement to the extent necessary in connection with a proposed equity or debt financing of such
Party, or a proposed acquisition or business combination, so long as such recipients are bound in writing to maintain the confidentiality of such information in accordance with the terms of this Agreement 
 10.2. Permitted Disclosures. Each Party agrees that it and its Affiliates shall provide or permit access to Confidential Information
received from the other Party and such Party’s Affiliates and representatives only to the receiving Party’s employees, consultants, advisors and permitted subcontractors, Sublicensees and sub-distributors, and to the employees,
consultants, advisors and permitted subcontractors, Sublicensees and sub-distributors of the receiving Party’s Affiliates, who in such Party’s reasonable judgment have a need to know such Confidential Information to assist the receiving
Party with the activities contemplated by this Agreement and who are subject to obligations of confidentiality and non-use with respect to such Confidential Information similar to the obligations of confidentiality and non-use of the receiving Party
pursuant to Section 10.1; provided that AVEO and Biogen Idec shall each remain responsible for any failure by its Affiliates, and its and its Affiliates’ respective employees, consultants, advisors and permitted
subcontractors, Sublicensees and sub-distributors, to treat such Confidential Information as required under Section 10.1 (as if such Affiliates, employees, consultants, advisors and permitted subcontractors, Sublicensees and sub-distributors
were Parties directly bound to the requirements of Section 10.1). Each Party may also disclose Confidential Information of the other Party to Regulatory Authorities, but solely in connection with the activities contemplated by this Agreement.

  

 60 

 10.3. Publicity. Upon the execution of this Agreement, AVEO shall be entitled to
issue a mutually agreed press release regarding the subject matter of this Agreement in the form attached as Exhibit E (the “Initial Release”). After such Initial Release, neither Party shall issue a press release or public
announcement relating to this Agreement without the prior written approval of the other Party, which approval shall not be unreasonably withheld or delayed, except that (i) a Party may issue such a press release or public announcement if the
contents of such press release or public announcement have been previously been made public pursuant to the Initial Release or otherwise, other than through a breach of this Agreement by the issuing Party, (ii) a Party may issue such a press
release or public announcement if required by applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission (SEC) or similar regulatory agency in a country other than the United States or of any stock
exchange or Nasdaq, (iii) either Party may, to the extent required by applicable Law, disclose in SEC filings or filings with a similar regulatory agency in a country other than the United States or with any stock exchange or Nasdaq, the terms
of this Agreement, including by filing a copy of this Agreement, or the amounts paid to or received from the other Party under this Agreement, and (iv) AVEO may issue such a press release or public announcement regarding Development of Licensed
Product (without use of Biogen Idec’s or any of its Affiliates name), subject in each case to the next sentence. In the event of disclosures under clause (ii) or (iii) of the foregoing sentence, and during the License Term, under
clause (iv), the Party planning to make such disclosure shall first notify the other Party of such planned press release or public announcement at least three Business Days in advance of issuing such press release or making such public announcement
(or, with respect to press releases and public announcements made pursuant to the foregoing clause (ii) or (iii), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least three Business
Days in advance) for the sole purpose of allowing the other Party to review the proposed press release or public announcement for the inclusion of its Confidential Information or the use of its name; provided that the Party subject to
the requirement shall include in such press release or public announcement made pursuant to the foregoing clause (ii) or (iii) only such information relating to the Licensed Product or this Agreement as is required by such applicable Law.

 10.4. Publications. 
 (a) Option Exercise Period. During the Option Exercise Period, AVEO shall be free to publish the results of Development carried out on the Licensed Product. 
 (b) License Term. During the License Term, subject to the restrictions provided below, the JDC shall determine the publication
strategy for the Territory. In the event, either Party, consistent with the publication strategy adopted by the JDC, proposes to publish or present the results of Development carried out on the Licensed Product, such publication or presentation
shall be subject to the prior review by the other Party for patentability and protection of such other Party’s Confidential Information. Each Party shall provide to the other Party the opportunity to review any proposed abstracts, manuscripts
or summaries of presentations that cover the results of Development of the Licensed Product during the License Term. Each Party shall designate a person or persons who shall be responsible for reviewing such publications. Such designated person
shall respond in writing promptly and in no event later than thirty (30) days after receipt of the proposed material with either approval of the proposed material or a specific statement of concern, based upon either the need to seek patent
protection or concern regarding competitive disadvantage arising from the proposal. In the

  

 61 

 
event of concern, the submitting Party agrees not to submit such publication or to make such presentation that contains such information until the other Party is given a reasonable period of time
(not to exceed sixty (60) days) to seek patent protection for any material in such publication or presentation that it believes is patentable or to resolve any other issues, and the submitting Party shall remove from such proposed publication
any Confidential Information of the other Party as requested by such other Party. With respect to any proposed abstracts, manuscripts or summaries of presentations by investigators or other Third Parties, including Affiliates or Sublicensees, such
materials shall be subject to review under this Section 10.4 to the extent that the contracting Party has the right to do so, provided that each Party agrees to use Commercially Reasonable Efforts to include in any agreement with investigators
and other Third Parties a right for both Parties to review publications and presentations consistent with the terms of this Section 10.4. 
 ARTICLE XI. 
 REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS

 11.1. Representations of Authority. AVEO and Biogen Idec each represents and warrants to the other Party that, as
of the Effective Date, it has full right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement and that it has the right to grant to the other the licenses and sublicenses granted pursuant
to this Agreement. 
 11.2. Consents. AVEO and Biogen Idec each represents and warrants to the other Party that, except
for any Regulatory Approvals, pricing or reimbursement approvals, manufacturing approvals or similar approvals necessary for the Development, Manufacture or Commercialization of Licensed Product, all necessary consents, approvals and authorizations
of all government authorities and other persons required to be obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained by the Effective Date. 
 11.3. No Conflict. AVEO and Biogen Idec each represents and warrants to the other Party that, notwithstanding anything to the
contrary in this Agreement, the execution and delivery of this Agreement by such Party, the performance of such Party’s obligations hereunder and the licenses and sublicenses to be granted by such Party pursuant to this Agreement (a) do
not conflict with or violate any requirement of applicable Laws existing as of the Effective Date and applicable to such Party and (b) do not conflict with, violate, breach or constitute a default under any contractual obligations of such Party
or any of its Affiliates existing as of the Effective Date. 
 11.4. Compliance with Laws. Each Party shall comply with
all Laws applicable to the Development, Manufacture and Commercialization of Licensed Product, including applicable Drug Regulation Laws. 
 11.5. Enforceability. AVEO and Biogen Idec each represents and warrants to the other Party that, as of the Effective Date, this Agreement is a legal and valid obligation binding upon it and is
enforceable against it in accordance with its terms. 
  

 62 

 11.6. Additional Representations and Warranties of AVEO. AVEO represents and warrants
to Biogen Idec that, as of the Effective Date: 
 (a) Patent Rights. Exhibit A sets forth a complete and accurate
list of AVEO Patent Rights owned by AVEO in the (i) Licensed Territory and (ii) the AVEO Territory that Cover AVEO Know-how necessary for the Development, Manufacture or Commercialization of Licensed Product as contemplated on the
Effective Date. AVEO owns all right, title and interest in and to the AVEO Patent Rights listed on Exhibit A. 
 (b)
No Conflict. AVEO has not granted, and will not grant during the term of this Agreement, rights to any Third Party under the AVEO Technology that conflict with the rights granted to Biogen Idec hereunder. AVEO has not granted rights to any
Third Party under the AVEO Technology to Develop, Manufacture or Commercialize Licensed Product in the Field in the AVEO Territory or the Licensed Territory. 
 (c) U.S. Government Funding. Neither AVEO nor any of its Affiliates is or has been a party to any agreement with the U.S. federal government or an agency thereof pursuant to which the U.S. federal
government or such agency provided funding for the Development of Licensed Product. 
 (d) No Infringement. To the
knowledge of AVEO, except as otherwise disclosed to Biogen Idec, the use or practice of AVEO Technology and the Development, Manufacture and Commercialization of Licensed Product in the manner contemplated under this Agreement will not infringe any
Patent Rights or result in the misappropriation or misuse of Know-How of any Third Party. No claim of infringement of the Patent Rights of any Third Party has been made, nor to AVEO’s knowledge threatened, against AVEO or any of its Affiliates
with respect to the Development, Manufacture or Commercialization of Licensed Product, and there are no other claims, judgments or settlements against or owed by AVEO or any of its Affiliates or to which AVEO or any of its Affiliates is a party or,
to AVEO’s knowledge, pending or threatened claims or litigation, in either case relating to the AVEO Technology or Licensed Product. To AVEO’s knowledge, (i) no claim of infringement of the Patent Rights of any Third Party has been
made, nor threatened, against any of AVEO’s Sublicensees with respect to the Development, Manufacture or Commercialization of Licensed Product and (ii) there are no other claims, judgments or settlements against or owed by any of
AVEO’s Sublicensees, nor any pending or threatened claims or litigation, in either case relating to the AVEO Technology or Licensed Product. 
 (e) Available Information. AVEO has made available to Biogen Idec all material information in AVEO’s possession or Control relating to Licensed Product that is material to an assessment of the
feasibility of the Development, Manufacture and Commercialization of Licensed Product as conducted by or on behalf of AVEO to date. 
 (f) Compliance with Law. To AVEO’s knowledge, all of the studies, tests and pre-clinical and clinical trials of Licensed Product conducted prior to, or being conducted as of, the Effective Date by or on behalf of AVEO have been
and are being conducted in all material respects in accordance with applicable laws, rules and regulations. 
  

 63 

 (g) In-licenses. Except as set forth in Exhibit D, there are no agreements
between AVEO or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which AVEO has (i) in-licensed any Patent Rights or Know-how owned or Controlled by such Third Party to the extent that such Patent
Rights or Know-how are included in AVEO Technology, or (ii) agreed to make any payments (including royalties) to any Third Party or agreed to undertake or observe any restrictions or obligations with respect to the Development, Manufacture or
Commercialization of Licensed Product. 
 11.7. No Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, AND EACH PARTY HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH
RESPECT TO LICENSED PRODUCT. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF THE LICENSED PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL
WITH RESPECT TO LICENSED PRODUCT WILL BE ACHIEVED. 
 11.8. No Debarment. Neither Party nor any of its Affiliates has
been debarred or is subject to debarment and neither Party nor any of its Affiliates will use in any capacity, in connection with the Development, Manufacture or Commercialization of the Licensed Product, any Person who has been debarred pursuant to
Section 306 of the United States Federal Food, Drug, and Cosmetic Act, or who is the subject of a conviction described in such section. Each Party agrees to inform the other Party in writing immediately if it or any Person who is performing
services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to the best of such Party’s knowledge, is
threatened, relating to the debarment or conviction of such Party or any Person used in any capacity by such Party or any of its Affiliates in connection with the Development, Manufacture or Commercialization of the Licensed Product. 
 11.9. Additional Representation of Biogen Idec. Biogen Idec represents and warrants to AVEO that, as of the Effective Date, Biogen
Idec is an indirect wholly-owned subsidiary of Biogen Idec Inc., a corporation organized and existing under the laws of the State of Delaware. 
 ARTICLE XII. 
 INDEMNIFICATION 
 12.1. Indemnification by Biogen Idec. Biogen Idec shall indemnify, hold harmless, and defend AVEO, its Affiliates, and their
respective directors, officers, employees and agents (the “AVEO Indemnitees”) from and against any and all Losses incurred or suffered by the AVEO Indemnitees in connection with any third party claim arising out of or resulting
from, directly or indirectly, (i) any breach of, or inaccuracy in, any representation or warranty made by Biogen Idec in this Agreement, or any breach or violation of any covenant or agreement of Biogen Idec in or pursuant to this Agreement,
(ii) the negligence or willful misconduct by or of Biogen Idec, its Affiliates and their respective Sublicensees, or their respective directors, officers, employees and agents in the

  

 64 

 
performance of Biogen Idec’s obligations under this Agreement, (iii) the Commercialization or use of Licensed Product in the Licensed Territory or any other activities of Biogen Idec or
any of its Affiliates or Sublicensees in the Licensed Territory or (iv) AVEO’s observance of, or reliance upon, Biogen Idec’s withholding instructions provided pursuant to Section 8.11 of this Agreement. Biogen Idec shall have no
obligation to indemnify the AVEO Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, (a) any breach of, or inaccuracy in, any representation or warranty made by AVEO in this Agreement, (b) any
breach or violation of any covenant or agreement of AVEO in or pursuant to this Agreement, (c) the negligence or willful misconduct by or of any of the AVEO Indemnitees or any of AVEO’s Sublicensees, distributors or contractors or any of
their respective employees or agents, (d) any manufacturing defect in any Licensed Product supplied to Biogen Idec or its Affiliates, Sublicensees, distributors or contractors by or on behalf of AVEO as defined in and subject to the terms of
the Supply Agreement, (e) actual or alleged infringement or misappropriation by Biogen Idec or any of its Affiliates, Sublicensees, distributors or contractors of the Patent Rights or Know-how of any Third Party to the extent arising from the
use or practice of AVEO Technology or Joint Collaboration IP pursuant to, and in accordance with, the provisions of this Agreement or (f) any Loss arising from or related to the Commercialization or use of Licensed Product in the AVEO
Territory. 
 12.2. Indemnification by AVEO. AVEO shall indemnify, hold harmless, and defend Biogen Idec, its Affiliates
and their respective directors, officers, employees and agents (the “Biogen Idec Indemnitees”) from and against any and all Losses incurred or suffered by the Biogen Idec Indemnitees arising out of or resulting from, directly or
indirectly, (i) any breach of, or inaccuracy in, any representation or warranty made by AVEO in this Agreement, or any breach or violation of any covenant or agreement of AVEO in or pursuant to this Agreement, (ii) the negligence or
willful misconduct by or of AVEO, its Affiliates and their respective Sublicensees, or their respective directors, officers, employees and agents in the performance of AVEO’s obligations under this Agreement, or (iii) the Commercialization
or use of Licensed Product in the AVEO Territory or any other activities of AVEO or any of its Affiliates or Sublicensees in the AVEO Territory, or (iv) Biogen Idec’s observance of, or reliance upon, AVEO’s withholding instructions
provided pursuant to Section 8.11 of this Agreement. AVEO shall have no obligation to indemnify the Biogen Idec Indemnitees to the extent that the Losses arise out of or result from, directly or indirectly, (a) any breach of, or inaccuracy
in, any representation or warranty made by Biogen Idec in this Agreement, (b) any breach or violation of any covenant or agreement of Biogen Idec in or pursuant to this Agreement, (c) the negligence or willful misconduct by or of any of
the Biogen Idec Indemnitees, or any of Biogen Idec’s Sublicensees, distributors or contractors or any of their respective employees or agents, (d) any manufacturing defect in any Licensed Product supplied to AVEO or any of its Affiliates,
Sublicensees, distributors or contractors by or on behalf of Biogen Idec as defined in and subject to the terms of the Supply Agreement, (e) actual or alleged infringement or misappropriation by AVEO or any of its Affiliates, Sublicensees,
distributors or contractors of the Patent Rights or Know-how of any Third Party to the extent arising from the use or practice of Biogen Idec Collaboration Technology or Joint Collaboration IP pursuant to, and in accordance with, the provisions of
this Agreement or (f) any Loss arising from or related to the Commercialization or use of Licensed Product in the Biogen Idec Territory. 
  

 65 

 12.3. Indemnification Procedure. In the event of any such claim against any Biogen
Idec Indemnitee or AVEO Indemnitee (individually, an “Indemnitee”), the Indemnitee shall promptly notify the other Party in writing of the claim and the indemnifying Party shall manage and control, at its sole expense, the defense
of the claim and its settlement. The Indemnitee shall cooperate with the indemnifying Party and may, at its option and expense, be represented in any such action or proceeding. The indemnifying Party shall not be liable for any settlements,
litigation costs or expenses incurred by any Indemnitee without the indemnifying Party’s written authorization. Notwithstanding the foregoing, if the indemnifying Party believes that any of the exceptions to its obligation of indemnification of
the Indemnitees set forth in this Article XII may apply, the indemnifying Party shall promptly notify the Indemnitees, and the Indemnitees shall then have the right to be represented in any such action or proceeding by separate counsel at their
expense; provided that the indemnifying Party shall be responsible for payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the indemnifying Party. 
 12.4. Limitation of Liability. NEITHER PARTY HERETO WILL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES ARISING
OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A PARTY’S WILLFUL MISCONDUCT OR
WILLFUL BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN ARTICLE X. NOTHING IN THIS SECTION 12.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY. 
 12.5. Insurance. Each Party shall maintain insurance during the License Term and for a period of at least [**] after the last
commercial sale of a Licensed Product in the Field in the Territory under this Agreement, or, if Development of Licensed Products ceases prior to Regulatory Approval, [**] after termination of such Development, with a reputable, solvent insurer in
an amount appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under this Agreement. Specifically, each Party shall maintain product and clinical trial liability insurance of at least
[**] per occurrence on a worldwide basis. Notwithstanding the foregoing, either Party may satisfy its obligations under this Section 12.5 through a program of self-insurance, provided such Party has assets and earnings sufficient to cover the
potential indemnified Losses. Each Party will further ensure compliance with all foreign local clinical trial liability insurance requirements that may apply with respect to Licensed Product(s). Upon request, each Party shall provide the other
Party with evidence of the existence and maintenance of such insurance coverage. 
 ARTICLE XIII. 
 CONTROL ASSUMPTION OPTIONS 
 13.1. M&A Event Control Assumption Option. If, at any time during the Agreement Term, an M&A Event occurs involving AVEO (or any of its Affiliates) and a Person that, at the time of the
consummation of such M&A Event, directly or indirectly (including by any Affiliate of such Person), is Developing or Commercializing a Directly Competitive Product in the AVEO Territory or the Licensed Territory within the Field or, at any time
after such consummation of the M&A Event, develops or acquires a Directly

  

 66 

 
Competitive Product (such Person being hereinafter referred to as a “Competing Acquiror”) and such Competing Acquiror has not, within six (6) months of either consummation
of the M&A Event in the event the Directly Competitive Product is being Developed or Commercialized as of such consummation date or otherwise within six (6) months of the date of first development or acquisition of such Directly Competitive
Product (the “Divestiture Period”) divested the Directly Competitive Product, terminated Development and Commercialization of such Directly Competitive Product or assigned this Agreement pursuant to Section 16.5 to a Third
Party that is not itself Developing or Commercializing a Directly Competitive Product, then Biogen Idec may exercise, in the manner set forth further below in this Section 13.1, its right to trigger the provisions of this Section 13.1 (the
“M&A Control Assumption Option”), whereupon (A) Biogen Idec shall assume the rights, responsibilities and obligations of AVEO under Articles IV and V of this Agreement with AVEO assuming the rights, responsibilities and
obligations of Biogen Idec under such provisions, provided that notwithstanding anything to the contrary contained in Section 4.8(b), in the event the M&A Control Assumption Option is triggered, Biogen Idec will have final decision-making
authority to increase or change the budget for Development Costs, and (B) Biogen Idec shall have the right (but not the obligation) to assume any or all of the rights, responsibilities and obligations of AVEO under Article VII and/or Article IX
by giving AVEO at least 30 days prior written notice at any time and from time to time after the exercise of the M&A Control Assumption Option, which written notice shall specify the rights, responsibilities and obligations of AVEO under Article
VII and/or IX being assumed by Biogen Idec. In the event that Biogen Idec exercises the M&A Control Assumption Option prior to the Option Exercise Date, (i) the provisions of Article II shall terminate (except to the extent otherwise
provided in clause (iii) below), (ii) the exercise of the M&A Control Assumption Option shall be deemed, for all purposes of this Agreement, to be the exercise of the Option by Biogen Idec, (iii) Biogen Idec shall be responsible
for preparing and delivering to AVEO the Delivered Initial Development Plan and, if at the time of delivery of such plan, AVEO has not previously delivered the Data Package to Biogen Idec, such plan shall set forth Biogen Idec’s Development
efforts in connection with the Proof of Concept Study, and, if at the time of the delivery of such plan, AVEO has previously delivered the Data Package to Biogen Idec, such plan shall meet the criteria therefor set forth in clauses (ii) and
(iii) of Section 2.9 and (iv) if the Delivered Initial Development Plan provides for the conduct of the Proof of Concept Study in accordance with the provisions of the foregoing clause (iii), AVEO shall be obligated to pay and
reimburse Biogen Idec for all costs and expenses incurred by Biogen Idec in connection with the Development and Manufacture of Licensed Product through the completion of the Proof of Concept Study for a single indication, and upon completion of the
Proof of Concept Study Biogen Idec shall reimburse AVEO for [**] of the Pre-Phase 3 Manufacturing Costs. For purposes of this Section 13.1, (x) any reference in the definition of “Proof of Concept Study” to the Proof of Concept
Development Plan shall be deemed to be a reference to the Delivered Initial Development Plan provided pursuant to this Section 13.1, and (y) any reference in the definition of “Pre-Phase 3 Manufacturing Costs” to the Option
Exercise Date shall be deemed to be a reference to the date of the completion of the Proof of Concept Study. In addition, upon exercise of the M&A Control Assumption Option, the royalties payable by Biogen Idec under Section 8.5 shall be
reduced by [**]. The M&A Control Assumption Option shall be exercised by providing written notice to AVEO no later than [**] after the date that AVEO and/or the Competing Acquiror sends written notice to Biogen Idec stating that the Divestiture
Period has expired and that Biogen Idec may exercise its rights under this Section 13.1. In addition to the foregoing

  

 67 

 
obligations, in the event Biogen Idec exercise its M&A Control Assumption Option under this paragraph, it shall thereafter provide to AVEO copies of filings, submissions and correspondence
with respect to AVEO Technology under Section 9.3(a) in the AVEO Territory and consider AVEO’s comments to the same extent as AVEO provides such information and considers Biogen Idec’s comments with respect to AVEO Technology under
Section 9.3(a) prior to the exercise of the M&A Control Assumption Option. 
 13.2. Termination Right. The
provisions of Section 13.1 shall not be deemed to limit Biogen Idec’s right under Section 14.5 with respect to consummation of an M&A Event involving AVEO or any of its Affiliates and a Competing Acquiror. 
 13.3. Insolvency Control Assumption Option. Without limiting any legal or equitable remedies that Biogen Idec may have, including
under this Article XIII, if, at any time during the Agreement Term, an Insolvency Event involving AVEO occurs, then Biogen Idec may exercise, in the manner set forth further below in this Section 13.3, its right to trigger the provisions of
this Section 13.3 (the “Insolvency Control Assumption Option”), whereupon (A) Biogen Idec shall assume the rights, responsibilities and obligations of AVEO under Articles IV and V of this Agreement with AVEO assuming the
rights, responsibilities and obligations of Biogen Idec under such provisions, provided that notwithstanding anything to the contrary contained in Section 4.8(b), in the event the Insolvency Control Assumption Option is triggered, Biogen Idec
will have final decision-making authority to increase or change the budget for Development Costs, and (B) Biogen Idec shall have the right (but not the obligation) to assume any or all of the rights, responsibilities and obligations of AVEO
under Article VII and/or Article IX by giving AVEO at least 30 days prior written notice at any time and from time to time after the exercise of the Insolvency Control Assumption Option, which written notice shall specify the rights,
responsibilities and obligations of AVEO under Article VII and/or IX being assumed by Biogen Idec. In the event that Biogen Idec exercises the Insolvency Control Assumption Option prior to the Option Exercise Date, (i) the provisions of Article
II shall terminate (except to the extent otherwise provided in clause (iv) below), (ii) the exercise of the Insolvency Control Assumption Option shall be deemed, for all purposes of this Agreement, to be the exercise of the Option by
Biogen Idec, (iii) the royalties payable by Biogen Idec under Section 8.5 shall be reduced by [**], (iv) Biogen Idec shall be responsible for preparing and delivering to AVEO the Delivered Initial Development Plan and, if at the time
of delivery of such plan, AVEO has not previously delivered the Data Package to Biogen Idec, such plan shall set forth Biogen Idec’s Development efforts in connection with the Proof of Concept Study, and, if at the time of the delivery of such
plan, AVEO has previously delivered the Data Package to Biogen Idec, such plan shall meet the criteria therefor set forth in clauses (ii) and (iii) of Section 2.9 and (v) if the Delivered Initial Development Plan provides for the
conduct of the Proof of Concept Study in accordance with the provisions of the foregoing clause (iv), AVEO shall be obligated to pay and reimburse Biogen Idec for all costs and expenses incurred by Biogen Idec in connection with the Development and
Manufacture of Licensed Product through the completion of the Proof of Concept Study for a single indication, and upon completion of the Proof of Concept Study Biogen Idec shall reimburse AVEO for [**] of the Pre-Phase 3 Manufacturing Costs. For
purposes of this Section 13.3, (x) any reference in the definition of “Proof of Concept Study” to the Proof of Concept Development Plan shall be deemed to be a reference to the Delivered Initial Development Plan provided pursuant
to this Section 13.3, and (y) any

  

 68 

 
reference in the definition of “Pre-Phase 3 Manufacturing Costs” to the Option Exercise Date shall be deemed to be a reference to the date of the completion of the Proof of Concept
Study. The Insolvency Control Assumption Option shall be exercised by providing written notice to AVEO no later than [**] after the Insolvency Event with respect to AVEO. In addition to the foregoing obligations, in the event Biogen Idec exercise
its Insolvency Control Assumption Option under this paragraph, it shall thereafter provide to AVEO copies of filings, submissions and correspondence with respect to AVEO Technology under Section 9.3(a) in the AVEO Territory and consider
AVEO’s comments to the same extent as AVEO provides such information and considers Biogen Idec’s comments with respect to AVEO Technology under Section 9.3(a) prior to the exercise of the Insolvency Control Assumption Option. For
purposes of this Agreement, the term “Insolvency Event” means that AVEO (i) commits an act of bankruptcy, is declared bankrupt, voluntarily files or has filed against it a petition for bankruptcy or reorganization unless such
petition is dismissed within sixty (60) days of filing or such petition is for a reorganization under Chapter 11 of the Bankruptcy Code (as defined below) or any relevant foreign equivalent thereof and AVEO is not in default at the time of the
filing of such petition or at any time during such reorganization of any of its obligations under this Agreement, (ii) enters into a procedure of winding up or dissolution, or (iii) should a trustee or receiver be appointed for its
business assets or operations. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for the purposes of Section 365(n) of Title 11, U.S. Code (“Bankruptcy Code”) license
rights to “intellectual property” as defined under Section 101(60) of the Bankruptcy Code. The Parties agree that any Party, as a licensee hereunder, shall retain and may fully exercise all of its rights and elections under the
Bankruptcy Code or any relevant foreign equivalent thereof. 
 ARTICLE XIV. 
 TERM; TERMINATION AND REMEDIES FOR BREACH 
 14.1. Term. This Agreement shall become effective as of the Effective Date, and, in the event Biogen Idec does not exercise the Option by the end of the Option Exercise Period, shall terminate at
the end of the Option Exercise Period, unless earlier terminated in accordance with this Article XIV. In the event Biogen Idec exercises the Option in accordance with Article II (or is deemed to have exercised the Option pursuant to Sections
13.1, 13.3 or 14.5(b)), this Agreement shall continue in full force until the later of (a) the last to expire Royalty Term and (b) such time as any Development activities that were pending before the expiration of the last to expire
Royalty Term are no longer being conducted by either Party under this Agreement. 
 14.2. Termination for Convenience.
Biogen Idec shall have the right to terminate this Agreement with respect to any Licensed Product at any time upon at least three months (3) months’ prior written notice to AVEO. 
 14.3. Remedies for Breach. 
 (a) Breach in Respect of Monetary Obligation. In the event that a Party is in material breach of this Agreement with respect to one of its financial obligations hereunder and has not cured such
material breach within [**] after written notice describing the nature of such material breach is provided to the breaching Party, the non-breaching Party shall have the immediate right to elect its remedies for material breach set forth in
Section 14.5. 
  

 69 

 (b) Breach in Respect of Non-Monetary Obligation. In the event a Party (the
“Notifying Party”) is concerned that there has been or may be a failure by the other Party (the “Notified Party”) to meet one or more of its non-financial obligations under this Agreement and such failure
constitutes, or could reasonably be expected to give rise to, a material breach of this Agreement, the Notifying Party shall send written notice to the Notified Party specifying in detail the nature of the concern and specifically referencing this
Section 14.3(b) (a “Section 14.3 Notice”). Within [**] of delivery of such Section 14.3 Notice, the Parties shall meet to discuss the circumstances surrounding the perceived failure, the impediments that are impacting
performance, the actions that the Parties believe are reasonably necessary to address such failure, and each Party’s view of the plan and timeline within which such failure could reasonably be remedied. If not originally provided with the
Section 14.3 Notice, within [**] after the meeting held under the preceding sentence, the Notifying Party shall provide the Notified Party with a written plan that is prepared with a good faith intent to allow the Notified Party an adequate
amount of time to address the perceived performance issues as determined in the reasonable discretion of the Notifying Party, and which shall include specific activities to be performed and the timeline for performance of such activities (the
“Cure Plan”). Within [**] of receipt, the Notified Party shall provide written notice to the Notifying Party of its election to implement or not implement the Cure Plan. In the event the Notified Party either (A) fails to
respond within such [**] period, (B) elects not to implement the Cure Plan within [**] of receipt of such Cure Plan, or (C) elects to implement the Cure Plan, and thereafter fails to meet any milestone included in the Cure Plan, following
written notice thereof by the Notifying Plan, and a one-time [**] opportunity to cure such milestone failure, then the Notifying Party shall have the right to elect its remedies for material breach as set forth in Section 14.5; provided that
(i) the failure giving rise to the Section 14.3 Notice constitutes a material breach of this Agreement by the Notified Party and (ii) such material breach has not otherwise been cured on or prior to the [**] following the delivery of
the Section 14.3 Notice applicable to such material breach. In the event the Notified Party elects to implement the Cure Plan within [**] of receipt thereof, and is continuing to execute in full compliance with such Cure Plan (subject to the
one-time cure period for the first failed milestone under such Cure Plan), the Notifying Party’s right to elect its remedies for material breach as set forth in Section 14.5 shall be suspended until such time, if any, as the Notified Party
fails to continue to execute in full compliance with the Cure Plan (e.g., such suspension shall immediately terminate upon the second failure to meet a milestone). Notwithstanding anything in this Agreement to the contrary, a Party’s
decision whether or not to implement the Cure Plan shall not be deemed an admission or acknowledgement of breach nor will a failure to execute in accordance with the Cure Plan be considered a separate and independent breach of this Agreement.

 14.4. Termination by Biogen Idec Upon Certain M&A Events. Without limiting any legal or equitable remedies that
Biogen Idec may have, including under Section 13.1, in the event an M&A Event occurs involving AVEO (or any of its Affiliates) and a Person that, at the time of the consummation of such M&A Event, or at any time thereafter during the
Agreement Term, directly or indirectly (including by any Affiliate), is Developing or Commercializing any Directly Competitive Product in the AVEO Territory or the Licensed Territory within the Field, then Biogen Idec shall have the right under this
Section 14.4 to terminate this Agreement in

  

 70 

 
its entirety by giving written notice of termination to AVEO and/or such Person. Such written notice of termination shall specify that it is being given by Biogen Idec pursuant to this
Section 14.4 and must be given within [**] after the later of (i) the date of the consummation of the M&A Event and (ii) the date that AVEO and/or such Person sends written notice to Biogen Idec stating that the M&A Event has
been consummated and that Biogen Idec may terminate this Agreement pursuant to this Section 14.4. Any termination of this Agreement pursuant to this Section 14.4 shall become effective on the date (the “Section 14.4 Termination
Effective Date”) that is the later of (i) the effective date of termination specified in such written notice of termination given by Biogen Idec pursuant to this Section 14.4 or (ii) the last [**] of the [**] following the
date in which such written notice of termination is given by Biogen Idec pursuant to this Section 14.4, if on or prior to such Section 14.4 Termination Effective Date such Person has not divested such Directly Competitive Product,
terminated Development and Commercialization of such Directly Competitive Product or assigned this Agreement pursuant to Section 16.5 to a Third Party that is not itself Developing or Commercializing a Directly Competitive Product. 

14.5. Special Remedies for Breach. 
 (a) AVEO Remedy for Breach by Biogen Idec. Without limiting any other legal or equitable remedies that AVEO may have, in the event of any material breach of the Agreement by Biogen Idec that occurs
during the Option Exercise Period, that has not been cured by Biogen Idec in accordance with the provisions of Section 14.3 and in respect of which AVEO elects, in accordance with the provisions of Section 14.3, to pursue its remedies
under this Section 14.5(a), the Option shall immediately terminate, and Biogen Idec shall have no further right to exercise the Option. Without limiting any other legal or equitable remedies that AVEO may have, in the event of any material
breach of the Agreement by Biogen Idec that occurs during the License Term, that has not been cured by Biogen Idec in accordance with the provisions of Section 14.3 and in respect of which AVEO elects, in accordance with the provisions of
Section 14.3, to pursue its remedies under this Section 14.5(a), this Agreement shall continue in full force and effect subject to the automatic modification thereof as follows: 
 (i) Biogen Idec shall no longer have the right under Section 5.11 or 5.12 to proceed with Development of New Licensed
Products or a New Indication Existing Licensed Products in the event the JDC does not approve or consent to such Development; 
 (ii) The licenses and rights granted to Biogen Idec under Section 3.1 hereof shall immediately terminate with respect to the Licensed Product that was the subject of the applicable breach (each such
Licensed Product being referred to as a “Breached Licensed Product”); 
 (iii) The licenses and
rights granted to AVEO pursuant to Section 3.2(a) shall continue with respect to the Breached Licensed Product and be converted automatically to worldwide licenses and rights with respect to the Breached Licensed Product such that AVEO and its
Affiliates and Sublicensees shall have the right under such converted worldwide licenses and rights to Develop, Manufacture and Commercialize such Breached Licensed Product in the AVEO Territory and the

  

 71 

 
Licensed Territory, and AVEO shall continue to have the right to grant sublicenses (subject to provisions similar to those set forth in Section 3.3 (other than subclauses (i), (ii) and
(vi) of Section 3.3(b)) that are applicable to sublicenses of licenses granted by Biogen Idec to AVEO pursuant to Section 3.2(a) hereof); 
 (iv) Responsibility and control over the Development of the Breached Licensed Product shall rest solely with AVEO and the JDC shall have no decision-making authority with respect to such Breached Licensed
Product and AVEO shall use Commercially Reasonable Efforts during the License Term to Develop the Breached Licensed Product in the Field for both the Licensed Territory and the AVEO Territory; 
 (v) Responsibility and control over the Commercialization of the Breached Licensed Product in the AVEO Territory and the
Licensed Territory shall rest solely with AVEO and AVEO shall use Commercially Reasonable Efforts to Commercialize such Breached Licensed Products in those countries in the AVEO Territory and the Licensed Territory in which Regulatory Approval has
been obtained, including by providing appropriate incentives consistent with its normal business practices to Sales Representatives involved in the Commercialization of the Licensed Product in the AVEO Territory; 
 (vi) Neither Party shall have any further obligation under Article V or Article VI with respect to the Breached Licensed
Product; 
 (vii) Biogen Idec’s obligations under Article VIII with respect to the Breached Licensed Product
shall terminate; 
 (viii) AVEO’s obligations under Article VIII with respect to the Breached Licensed
Product shall continue (including, without limitation, the obligation thereunder to make payment of royalties), provided that the royalties that AVEO is required to pay Biogen Idec under Article VIII with respect to the Breached Licensed Product
shall be increased by [**] if AVEO exercises its rights under this Section 14.5(a) with respect to the Breached Licensed Product prior to Regulatory Approval thereof in the Licensed Territory and shall be increased by [**] if AVEO exercises its
rights under this Section 14.5(a) with respect to the Breached Licensed Product after Regulatory Approval thereof in the Licensed Territory; 
 (ix) AVEO shall make payment to Biogen Idec of royalties on Net Sales of the Breached Licensed Product in the Licensed Territory by AVEO and its Affiliates and Sublicensees (the terms of Article VIII and
the foregoing clause (viii) shall apply to AVEO’s obligation to pay royalties under this clause (ix) to the same extent as they apply to AVEO’s obligation to pay royalties on Net Sales of the Breached Licensed Product in the AVEO
Territory by AVEO and its Affiliates and Sublicensees); 
 (x) AVEO shall have the right (but not the obligation)
to assume any or all of the rights, responsibilities and obligations of Biogen Idec under Article IX with respect to the Breached Licensed Product by giving Biogen Idec at least [**] prior written notice at any time and from time to time after the
exercise by AVEO of its special remedies under this

  

 72 

 
Section 14.5(a), which written notice shall specify the rights, responsibilities and obligations of Biogen Idec under Article IX with respect to the Breached Licensed Product being assumed
by AVEO; 
 (xi) Biogen Idec shall as promptly as practicable transfer to AVEO or AVEO’s designee
(A) possession and ownership of all governmental or regulatory correspondence, conversation logs, filings and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) relating to the Development, Manufacture or
Commercialization of the Breached Licensed Product in the Licensed Territory, (B) copies of all data, reports, records and materials, commercialization plans, marketing plans, Promotional Materials, and other sales and marketing related
information in Biogen Idec’s possession or Control to the extent that such data, reports, records, materials or other information relate to the Commercialization of the Breached Licensed Product in the Licensed Territory, including customer
lists and customer contact information and all Safety Data and other adverse event data in Biogen Idec’s possession or Control, and (C) all records and materials in Biogen Idec’s possession or Control containing Confidential
Information of AVEO with respect to the Breached Licensed Product; 
 (xii) If the Breached Licensed Product is
being Commercialized by Biogen Idec in any country in the Licensed Territory, then, if requested by AVEO, Biogen Idec shall appoint AVEO as its exclusive distributor of the Breached Licensed Product in the Licensed Territory and grant AVEO the right
to appoint sub-distributors, until the earlier of (A) such time as all Regulatory Approvals in the Licensed Territory with respect to the Breached Licensed Product have been transferred to AVEO or its designee and (B) [**] after AVEO has
exercised its special remedies under this Section 14.5(a) with respect to the Breached Licensed Product; 
 (xiii) If AVEO so requests, Biogen Idec shall transfer to AVEO any Third Party agreements to which Biogen Idec is a party relating to the Development, Manufacture or Commercialization of the Breached Licensed Product in the AVEO Territory
or the Licensed Territory, subject to any required consents of such Third Party; 
 (xiv) The provisions of
Section 12.1(clauses (iii) and (f) thereof) shall apply to both the AVEO Territory and the Licensed Territory with respect to such Breached Licensed Product; 
 (xv) The provisions of Section 13.1 shall not apply with respect to such Breached Licensed Product; 
 (xvi) The provisions of Section 3.7 shall not apply with respect to such Breached Licensed Product; and 
 (xvii) Each Party shall execute all documents and take all such further actions, including, where applicable, the prompt
assignment by Biogen Idec of regulatory submissions and Third Party agreements, as may be reasonably requested by the other Party in order to give effect to the foregoing clauses (i) through (xvi) as soon as practicable and in order to
enable AVEO to Develop, Manufacture and Commercialize the Breached Licensed Product in the AVEO Territory and the Licensed Territory. 
  

 73 

 (b) Biogen Idec Remedy for Breach by AVEO. Without limiting any other legal or
equitable remedies that Biogen Idec may have, in the event of any material breach of the Agreement by AVEO that occurs during the Agreement Term, that has not been cured by AVEO in accordance with the provisions of Section 14.3 and in respect
of which Biogen Idec elects, in accordance with the provisions of Section 14.3, to pursue its remedies under this Section 14.5(b), this Agreement shall continue in full force and effect subject to the automatic modification thereof as
follows: 
 (i) AVEO shall no longer have the right under Section 5.11 or 5.12 to proceed with Development
of New Licensed Products or New Indication Existing Licensed Products in the event the JDC does not approve or consent to such Development; 
 (ii) In the event that Biogen Idec pursues its remedies under this Section 14.5(b) prior to the Option Exercise Date, (i) the provisions of Article II shall terminate, (ii) the exercise by
Biogen Idec of its rights and remedies under this Section 14.5(b) shall be deemed, for all purposes of this Agreement, to be the exercise of the Option by Biogen Idec and (iii) the provisions of Section 8.3 shall terminate and Biogen
Idec shall have no obligation to make any of the payments contemplated thereunder; 
 (iii) The licenses and
rights granted to AVEO under Section 3.2 shall immediately terminate with respect to the Breached Licensed Product; 
 (iv) The licenses and rights granted to Biogen Idec pursuant to Section 3.1 shall continue with respect to the Breached Licensed Product and be converted automatically to worldwide licenses and
rights with respect to the Breached Licensed Product such that Biogen Idec and its Affiliates and Sublicensees shall have the right under such converted worldwide licenses and rights to Develop, Manufacture and Commercialize such Breached Licensed
Product in the AVEO Territory and the Licensed Territory, and Biogen Idec shall continue to have the right to grant sublicenses (subject to provisions similar to those set forth in Section 3.3 that are applicable to sublicenses of licenses
granted by AVEO to Biogen Idec pursuant to Section 3.1 hereof); 
 (v) Responsibility and control over the
Development of the Breached Licensed Product shall rest solely with Biogen Idec and the JDC shall have no decision-making authority with respect to such Breached Licensed Product and Biogen Idec shall use Commercially Reasonable Efforts during the
License Term to Develop the Breached Licensed Product in the Field for both the Licensed Territory and the AVEO Territory; 
 (vi) Responsibility and control over the Commercialization of the Breached Licensed Product in the AVEO Territory and the Licensed Territory shall rest solely with Biogen Idec and Biogen Idec shall use
Commercially Reasonable Efforts to Commercialize such Breached Licensed Products in those countries in the AVEO Territory and the Licensed Territory in

  

 74 

 
which Regulatory Approval has been obtained, including by providing appropriate incentives consistent with its normal business practices to Sales Representatives involved in the Commercialization
of the Licensed Product in the Licensed Territory; 
 (vii) Neither Party shall have any further obligation under
Article V or Article VI with respect to the Breached Licensed Product; 
 (viii) AVEO’s obligations under
Article VIII with respect to the Breached Licensed Product shall terminate; 
 (ix) Biogen Idec’s
obligations under Section 8.4 with respect to the Breached Licensed Product shall terminate; 
 (x) Biogen
Idec’s obligations under Section 8.5 and Sections 8.7-8.16 with respect to the Breached Licensed Product shall continue, provided that the royalties that Biogen Idec is required to pay AVEO under Article VIII with respect to the
Breached Licensed Product shall be increased by [**] if Biogen Idec exercises its rights under this Section 14.5(b) with respect to the Breached Licensed Product prior to Regulatory Approval thereof in the AVEO Territory and shall be increased
by [**] if Biogen Idec exercises its rights under this Section 14.5(b) with respect to the Breached Licensed Product after Regulatory Approval thereof in the AVEO Territory; 
 (xi) Biogen Idec shall make payment to AVEO of royalties on Net Sales of the Breached Licensed Product in the AVEO Territory
by Biogen Idec and its Affiliates and Sublicensees (the terms of Article VIII and the foregoing clause (x) shall apply to Biogen Idec’s obligation to pay royalties under this clause (xi) to the same extent as they apply to Biogen
Idec’s obligation to pay royalties on Net Sales of the Breached Licensed Product in the Licensed Territory by Biogen Idec and its Affiliates and Sublicensees); 
 (xii) Biogen Idec shall have the right (but not the obligation) to assume any or all of the rights, responsibilities and
obligations of AVEO under Article IX with respect to the Breached Licensed Product by giving AVEO at least [**] prior written notice at any time and from time to time after the exercise by Biogen Idec of its special remedies under this
Section 14.5(b), which written notice shall specify the rights, responsibilities and obligations of AVEO under Article IX with respect to the Breached Licensed Product being assumed by Biogen Idec; 
 (xiii) AVEO shall as promptly as practicable transfer to Biogen Idec or Biogen Idec’s designee (A) possession and
ownership of all governmental or regulatory correspondence, conversation logs, filings and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) relating to the Development, Manufacture or Commercialization of the
Breached Licensed Product in the AVEO Territory, (B) copies of all data, reports, records and materials, commercialization plans, marketing plans, Promotional Materials, and other sales and marketing related information in AVEO’s
possession or Control to the extent that such data, reports, records, materials or other information

  

 75 

 
relate to the Commercialization of the Breached Licensed Product in the AVEO Territory, including customer lists and customer contact information and all Safety Data and other adverse event data
in AVEO’s possession or Control, and (C) all records and materials in AVEO’s possession or Control containing Confidential Information of Biogen Idec with respect to the Breached Licensed Product; 
 (xiv) If the Breached Licensed Product is being Commercialized by AVEO in any country in the AVEO Territory, then, if
requested by Biogen Idec, AVEO shall appoint Biogen Idec as its exclusive distributor of the Breached Licensed Product in the AVEO Territory and grant Biogen Idec the right to appoint sub-distributors, until the earlier of (A) such time as all
Regulatory Approvals in the AVEO Territory with respect to the Breached Licensed Product have been transferred to Biogen Idec or its designee and (B) [**] after Biogen Idec has exercised its special remedies under this Section 14.5(b) with
respect to the Breached Licensed Product; 
 (xv) If Biogen Idec so requests, AVEO shall transfer to Biogen Idec
any Third Party agreements to which AVEO is a party relating to the Development, Manufacture or Commercialization of the Breached Licensed Product in the AVEO Territory or the Licensed Territory, subject to any required consents of such Third Party;

 (xvi) The provisions of Section 12.2 (clauses (iii) and (f) thereof) shall apply to both the
AVEO Territory and the Licensed Territory with respect to such Breached Licensed Product; and 
 (xvii) Each
Party shall execute all documents and take all such further actions, including, where applicable, the prompt assignment by AVEO of regulatory submissions and Third Party agreements, as may be reasonably requested by the other Party in order to give
effect to the foregoing clauses (i) through (xvi) as soon as practicable and in order to enable Biogen Idec to Develop, Manufacture and Commercialize the Breached Licensed Product in the AVEO Territory and the Licensed Territory.

 (c) Termination by Biogen Idec for Convenience. If Biogen Idec terminates this Agreement for convenience under
Section 14.2 during the Option Exercise Period, the Option shall immediately terminate, and Biogen Idec shall have no further right to exercise the Option. If Biogen Idec terminates this Agreement for convenience under Section 14.2 with
respect to any Licensed Product during the License Term, then (i) Biogen Idec shall continue to pay its share of all Development Costs for such Licensed Product for a period of [**] following the date of such termination, and, if longer, shall
also continue to pay its share of the Development Costs for such Licensed Product related to any ongoing clinical trials included in the then current Development Plan until such trials are completed, (ii) the licenses and rights granted to AVEO
pursuant to Section 3.2(a) with respect to such Licensed Product shall survive and be converted automatically to worldwide licenses and rights such that AVEO and its Affiliates and Sublicensees shall have the right under such converted
worldwide licenses and rights to Develop, Manufacture and Commercialize such Licensed Product in the AVEO Territory and the Licensed Territory, and AVEO shall continue to have the right to grant sublicenses (subject to provisions similar to those
set forth in Section 3.3), (iii) Biogen Idec’s obligations under Article VIII shall

  

 76 

 
terminate with respect to such Licensed Product, (iv) AVEO’s obligations under Article VIII shall survive with respect to such Licensed Product (including, without limitation, the
obligation thereunder to make payment of royalties); (v) AVEO shall make payment to Biogen Idec of royalties on Net Sales of such Licensed Product in the Licensed Territory by AVEO and its Affiliates and Sublicensees (the terms of Article VIII
shall apply to AVEO’s obligation to pay royalties under this clause (v) to the same extent as it applies to AVEO’s obligation to pay royalties on Net Sales of Licensed Product in the AVEO Territory by AVEO and its Affiliates and
Sublicensees), (vi) the rights and obligations of each Party under Article IX with respect to such Licensed Product shall survive with respect to any intellectual property rights that are subject to surviving licenses granted by, or for the
benefit of, AVEO under this Agreement, (vii) Biogen Idec shall as promptly as practicable transfer to AVEO or AVEO’s designee (A) possession and ownership of all governmental or regulatory correspondence, conversation logs, filings
and approvals (including all Regulatory Approvals and pricing and reimbursement approvals) relating to the Development, Manufacture or Commercialization of such Licensed Product in the Licensed Territory, (B) copies of all data, reports,
records and materials, commercialization plans, marketing plans, Promotional Materials, and other sales and marketing related information in Biogen Idec’s possession or Control to the extent that such data, reports, records, materials or other
information relate to the Commercialization of such Licensed Product in the Licensed Territory, including customer lists and customer contact information and all Safety Data and other adverse event data in Biogen Idec’s possession or Control,
and (C) all records and materials in Biogen Idec’s possession or Control containing Confidential Information of AVEO with respect to such Licensed Product, (viii) if the effective date of termination is after the First Commercial Sale
of such Licensed Product in any country in the Licensed Territory, then, if requested by AVEO, Biogen Idec shall appoint AVEO as its exclusive distributor of such Licensed Product in the Licensed Territory and grant AVEO the right to appoint
sub-distributors, until the earlier of (1) such time as all Regulatory Approvals in the Licensed Territory with respect to such Licensed Product have been transferred to AVEO or its designee and (2) [**] after the effective date of
termination, (ix) if AVEO so requests, Biogen Idec shall transfer to AVEO any Third Party agreements relating to the Commercialization of such Licensed Product in the Licensed Territory to which Biogen Idec is a party, subject to any required
consents of such Third Party, and (x) all rights and obligations of the Parties under this Agreement (except for those contemplated in this Section 14.5(c) and those contemplated below in Sections 14.7, 14.8, 14.9 and 14.10) shall
terminate with respect to such Licensed Product. Each Party shall execute all documents and take all such further actions, including, where applicable, the prompt assignment by Biogen Idec of regulatory submissions and Third Party agreements, as may
be reasonably requested by AVEO in order to give effect to the foregoing clauses (i) through (x) as soon as practicable and in order to enable AVEO to Develop, Manufacture and Commercialize such Licensed Product in the AVEO Territory and
the Licensed Territory. 
 (d) Termination by Biogen Idec Upon Certain M&A Events. If Biogen Idec terminates this
Agreement under Section 14.4 during the Agreement Term, then (i) Biogen Idec shall continue to pay its share of all Development Costs for a period of [**] following the date of such termination, (ii) the licenses and rights granted to
Biogen Idec under Section 3.1 hereof shall survive; (iii) the license and rights granted to AVEO under Section 3.2 shall survive; (iv) the rights and obligations of the Parties under Article III shall survive (other than
Section 3.6(a) and the first four sentences of Section 3.6(b), which shall not survive); (v) AVEO’s

  

 77 

 
obligations under Article VIII shall survive (including, without limitation, the obligation thereunder to make payment of royalties) provided that such royalty obligations shall be reduced by
[**]; (vi) Biogen Idec’s obligations under Article VIII shall survive (including, without limitation, the obligation thereunder to make payment of royalties), provided that such royalty obligations shall be reduced by [**]; (vii) the
rights and obligations of each Party under Article IX shall survive with respect to any intellectual property rights that are subject to surviving licenses granted by, or for the benefit of, such Party under this Agreement; and (viii) all
rights and obligations of the Parties under this Agreement except for those contemplated by this Section 14.5(d), those set forth in Section 5.8 and 5.9, those set forth in Section 5.4 as they related to Development Costs incurred in
connection with Section 5.8, and those contemplated below in Sections 14.6, 14.7, 14.8 and 14.9) shall terminate. For purposes of clarification, if Biogen Idec terminates this Agreement under Section 14.4 during the Agreement Term, then
(a) each Party and its Affiliates and Sublicensees shall have the right to engage in Development and Manufacture of Licensed Product in the AVEO Territory and the Licensed Territory, and the JDC shall have no decision-making authority or
oversight with respect to the Development or Manufacturing activities of the Parties, (b) AVEO and its Affiliates and Sublicensees shall have the right to Commercialize Licensed Product in the AVEO Territory but not the Licensed Territory and
(c) Biogen Idec and its Affiliates and Sublicensees shall have the right to Commercialize Licensed Product in the Licensed Territory but not the AVEO Territory. 
 14.6. Manufacturing. In the event that this Agreement terminates for any reason or that a Party exercises its special remedies under Section 14.5 as a result of the material breach of this
Agreement by the other Party, and in the event that the Party that is not then responsible for Manufacturing under Article VII and/or the Supply Agreement retains rights to Develop and Commercialize Licensed Product under this Agreement following
such termination or the exercise by such Party of its special remedies under Section 14.5, (A) the obligations under such Article VII and/or the Supply Agreement of the Party that is then responsible for Manufacturing shall continue in
effect for a period of at least [**] following such termination or the exercise by the other Party of its special remedies under Section 14.5, as the case may be, or such longer period as the Parties may mutually agree, and (B) the Party
that is not responsible for Manufacturing (the “non-Manufacturing Party”) shall have the right to require the Party responsible for Manufacturing (the “Manufacturing Party”) to engage in a technology transfer
process, at the Manufacturing Party’s costs, in the event the cause of the termination is breach by the Manufacturing Party, or at Biogen Idec’s cost for a termination under Section 14.2, otherwise at the cost of the non-Manufacturing
Party, for purposes of enabling the non-Manufacturing Party or any of its Affiliates or Third Party contract manufacturers to Manufacture Licensed Product by or on behalf of the non-Manufacturing Party and its Affiliates and Sublicensees for
purposes of enabling the non-Manufacturing Party to exercise its rights under this Agreement, and the non-Manufacturing Party shall have the right to deal directly with any Third Party contract manufacturer of the Manufacturing Party or any of its
Affiliates to arrange for such Third Party contract manufacturer to Manufacture and supply Licensed Product to the non-Manufacturing Party and its Affiliates and Sublicensees for the purposes of enabling the non-Manufacturing Party to exercise its
rights under this Agreement. 
  

 78 

 14.7. Accrued Obligations. Expiration or termination of this Agreement shall not
relieve the Parties of any obligation accruing prior to such expiration or termination. 
 14.8. Treatment of
Sublicensees. In the event the license granted to Biogen Idec under Section 3.1 terminates for any reason or in the event that the license granted to AVEO under Section 3.2(a) terminates for any reason, each Sublicensee at such time
under any such license that terminates shall continue to have the rights and licenses set forth in their sublicense agreements; provided, that such Sublicensee agrees in writing that (i) the Party that is the licensor in connection with such
terminated license is entitled to enforce all relevant provisions of the applicable sublicense agreement directly against such Sublicensee and (ii) the Party that is the licensor in connection with such terminated license shall not assume, and
shall not be responsible to such Sublicensee for, any representations, warranties or obligations made to such Sublicensee by the Party that was the licensee in connection with such terminated license, other than to permit such Sublicensee to
exercise any rights to Licensed Product that are sublicensed under such sublicense agreement. 
 14.9. Survival. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination,
including payment obligations arising prior to such expiration or termination. The provisions of Section 8.16, Articles X, XII, XIV, XV and XVI shall survive any expiration or termination of this Agreement and all other provisions contained in
this Agreement that by their explicit terms survive expiration or termination of this Agreement, shall survive. In addition, in the event of an expiration of this Agreement in accordance with the provisions of Section 14.1, the licenses granted
in Sections 3.1 and 3.2(a) shall survive as perpetual, fully paid-up, non-royalty-bearing licenses. Except as set forth in this Article XIV, upon expiration of this Agreement in accordance with the provisions of Section 14.1 all other
rights and obligations of the Parties under this Agreement terminate.  
 ARTICLE XV. 
 DISPUTE RESOLUTION 
 15.1. Continuance of Rights and Obligations During Pendency of Dispute Resolution. If there are any disputes in connection with this Agreement, including termination of this Agreement under Article XIV, all rights and obligations of
the Parties shall continue until such time as any dispute has be resolved in accordance with the provisions of this Article XV. 
 15.2. Referral of Unresolved Matters to Senior Representatives. In the event that the Parties are unable to resolve a dispute within thirty (30) days from the date such dispute is first brought to the other Party’s
attention, the matter shall be referred to the Senior Representatives of each Party to be resolved by negotiation in good faith as soon as is practicable but in no event later than thirty (30) days after referral. A resolution, if any, of an
issue referred to the Senior Representatives set forth in a writing signed by both Parties shall be final and binding on the Parties. 
 15.3. Equitable Relief. Notwithstanding anything to the contrary, each of the Parties hereby acknowledges that a breach of their respective obligations under this Agreement may cause irreparable harm and that the remedy or remedies
at law for any such breach may be inadequate. Each of the Parties hereby agrees that, in the event of any such breach, in addition to all other available remedies hereunder, the non-breaching Party shall have the right to seek equitable relief to
enforce the provisions of this Agreement. 
  

 79 

 ARTICLE XVI. 
 MISCELLANEOUS 
 16.1. Governing Law and
Jurisdiction. The validity, construction and performance of this Agreement will be governed by and construed in accordance with the substantive laws of the Commonwealth of Massachusetts excluding any conflicts or choice of law rule or principle
that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 
 16.2. Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term, other than an
obligation to make payments hereunder, when such failure or delay is caused by or results from fire, floods, embargoes, government regulations, prohibitions or interventions, war, acts of war (whether war be declared or not), insurrections, riots,
civil commotions, acts of God or any other cause beyond the reasonable control of the affected Party to anticipate, prevent, avoid or mitigate (a “Force Majeure Event”); provided that (i) the affected Party provides prompt
notice to the other Party of such failure or delay, (ii) the affected Party uses commercially reasonable efforts to mitigate the effects of the Force Majeure Event, and (iii) the affected Party immediately resumes performance upon
cessation of the Force Majeure Event. Notwithstanding the foregoing, any failure or delay in fulfilling a term shall not be considered a result of a Force Majeure Event if it arises from a failure of Biogen Idec or AVEO to comply with applicable
Laws. 
 16.3. Further Assurances. Each Party hereto agrees to perform such acts, execute such further instruments,
documents or certificates, and provide such cooperation in proceedings and actions as may be reasonably requested by the other Party in order to carry out the intent and purpose of this Agreement, including the registration or recordation of the
rights granted hereunder. 
 16.4. Notices. Any notice required or permitted to be given hereunder shall be in writing
and shall be deemed to have been properly given if delivered in person by a internationally recognized overnight courier, or by facsimile (and promptly confirmed by an overnight courier delivery), to the addresses given below or such other addresses
as may be designated in writing by the Parties from time to time during the Agreement Term. Any notice sent by internationally recognized overnight courier as aforesaid shall be deemed to have been given three (3) days after being sent.

 In the case of AVEO: 
 AVEO Pharmaceuticals, Inc. 
 75 Sidney St. 
 Cambridge, MA 02139 
 Facsimile: 617-995-4995 
 Attention: Chief Business Officer 
  

 80 

 With a copy to: 
 AVEO Pharmaceuticals, Inc. 
 75 Sidney St. 
 Cambridge, MA 02139 
 Facsimile: 617-995-4995 
 Attention: Corporate Counsel 
 In the case of Biogen Idec: 
 Biogen Idec International GmbH 
 Landis+Gyr-Strasse 3 
 6300 Zug 
 Switzerland 

	 	Attention:	VP, Chief International Counsel 

	 	Facsimile:	+41-41-392-1718 

 With a copy
(which shall not constitute notice) to: 
 Biogen Idec Inc. 
 14 Cambridge Center 
 Cambridge, MA 02142 
 Attention: General Counsel 
 Facsimile: 617-679-3112 
 With an additional copy (which shall not constitute notice) to: 
 Bingham McCutchen LLP 
 One Federal Street 
 Boston, MA 02110 

	 	Attention:	Julio E. Vega 

 William S.
Perkins 

	 	Facsimile:	617-951-8736 

 16.5.
Assignment. This Agreement may not be assigned or otherwise transferred by either Party, without the written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed; provided, however,
that either Party may, without such consent, assign this Agreement, in whole or in part, (i) to any of its Affiliates (provided the assigning Party continues at all times to remain liable for all obligations of such Party under this
Agreement without regard to such assignment) and (ii) either Party, without such consent, may assign its rights and delegate its duties under this Agreement, whether by contract or operation of law, to a Third Party successor or purchaser of
all or substantially all of such Party’s business and assets, whether in a merger, sale of stock, sale of assets or other similar transaction, provided that the Third Party successor or purchaser provides written notice to the other Party that
such Third Party agrees to be bound by the terms of this Agreement. Any purported assignment in violation of this

  

 81 

 
Section 16.5 shall be void. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Without limiting the generality or applicability of any other provision
of this Agreement that may be applicable, the rights of AVEO under this Section 16.5 shall be subject to the rights of Biogen Idec under Sections 13.1 and 14.5 hereof. 
 16.6. Affiliate Performance. Any obligation of either Party under or pursuant to this Agreement may be satisfied, met or fulfilled,
in whole or in part, at such Party’s sole and exclusive option, either by such Party directly or by any Affiliate of such Party that such Party causes to satisfy, meet or fulfill such obligation, in whole or in part. 
 16.7. Amendment. The Parties hereto may amend, modify or alter any of the provisions of this Agreement, but only by a written
instrument duly executed by both Parties hereto. 
 16.8. Entire Agreement. This Agreement, along with all schedules and
exhibits attached hereto, contains the entire understanding of the Parties with respect to the subject matter hereof and supersedes all prior agreements, whether written or oral. Each Party confirms that it is not relying on any
representations, warranties or covenants of the other Party except as specifically set out in this Agreement. 
 16.9. No
Benefit to Third Parties. The provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other Persons. 
 16.10. Waiver. The failure of a Party to enforce at any time for any period any of the provisions hereof shall not be construed as a
waiver of such provisions or of the rights of such Party thereafter to enforce each such provision. 
 16.11. No Implied
Licenses. Except as expressly and specifically provided under this Agreement, the Parties agree that neither Party is granted any implied rights to or under any of the other Party’s current or future patents, trade secrets, copyrights,
moral rights, trade or service marks, trade dress, or any other intellectual property rights. 
 16.12. Relationship of the
Parties. The Parties agree that their relationship established by this Agreement is that of independent contractors. Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish a
partnership or joint venture, and nor shall this Agreement create or establish an employment, agency or any other relationship. Except as may be specifically provided herein, neither Party shall have any right, power or authority, nor shall they
represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the other Party for any purpose. 
 16.13. Severability. If any provision of this Agreement is held unenforceable by a court or tribunal of competent jurisdiction in a
final unappealable order because it is invalid or conflicts with any Law of any relevant jurisdiction, then such provision shall be inoperative in such jurisdiction and the remainder of this Agreement shall remain binding upon the Parties hereto.

  

 82 

 16.14. Interpretation. 
 (a) General. Unless the context of this Agreement otherwise requires, (a) words of one gender include the other gender; and
(b) words using the singular or plural number also include the plural or singular number, respectively. Whenever this Agreement refers to a number of days, unless otherwise specified, such number shall refer to calendar days. 
 (b) Other Definitional and Agreement References. References to any agreement, contract, statute, act, or regulation are to that
agreement, contract, statute, act, or regulation as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. 
 (c) Capitalization. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein, shall have the meaning as defined in this Agreement. 
 (d) Date References. References from or through any date mean, unless otherwise specified, from and including or through and
including, respectively. 
 (e) Schedules and Exhibits. All Schedules and Exhibits annexed hereto or referred to herein
are hereby incorporated in and made a part of this Agreement as if set forth in full herein. 
 (f) Person References.
References to any Person include the successors and permitted assigns of that Person. 
 (g) References to Parts of this
Agreement. References to Articles, Sections, Schedules, and Exhibits are to Articles, Sections, Schedules, and Exhibits of this Agreement unless otherwise specified. 
 (h) Other Definitional and Interpretative Provisions. The words “hereof”, “herein” and “hereunder” and words of like import used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this Agreement. Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words
“without limitation”, whether or not they are in fact followed by those words or words of like import. The word “or” is used in the inclusive sense (and/or). Writing”, “written” and comparable terms refer to
printing, typing and other means of reproducing words (including electronic media) in a visible form. 
 (i) Headings.
The Article and Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 
 (j) Expenses. Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and expenses of its respective
lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 
  

 83 

 16.15. Counterparts. This Agreement may be executed in any number of counterparts
(including by facsimile), each of which shall be deemed an original, but all of which together shall constitute one and the same document. 
 [Signature Page Follows] 
  

 84 

 IN WITNESS WHEREOF, AVEO and Biogen Idec have caused this Agreement to be duly executed by
their authorized representatives under seal, in duplicate on the Effective Date. 
  

			
	AVEO PHARMACEUTICALS, INC.

			
		
	By:	 	   /s/ Tuan Ha-Ngoc

			
	Name:	 	   Tuan Ha-Ngoc

			
	Title:	 	   President and Chief Executive Officer

			
	
	BIOGEN IDEC INTERNATIONAL GMBH

			
		
	By:	 	   /s/ Hans Peter Hasler

			
	Name:	 	   Hans Peter Hasler

			
	Title:	 	   Geschaftsführer

 Exhibit A 
 List of Existing AVEO Patent Rights 
 None 

 Exhibit B 
 Development Plan Guidelines 
 For purposes of this Agreement, a
Development Plan, or any amendment, modification or update thereto, shall be deemed to meet the “Development Plan Guidelines” on any date if the Development activities contemplated in such Development Plan are designed and selected so
that, to the maximum extent possible, [**]. 

 Exhibit C 
 Stock Purchase Agreement 

 EXECUTION 
 AVEO PHARMACEUTICALS, INC. 
 SERIES E CONVERTIBLE PREFERRED
STOCK 
 PURCHASE AGREEMENT 
 Dated as of March 18, 2009 

 TABLE OF CONTENTS 
  

					
	 	 	 	  	PAGE NO.
		
	 1. SALE OF SHARES; AUTHORIZATION
	  	1
			
		 	1.1 Sale of Shares	  	1
		 	1.2 Use of Proceeds	  	1
		 	1.3 Authorization	  	1
		
	 2. CLOSINGS
	  	2
			
		 	2.1 The Initial Closing	  	2
		 	2.2 Additional Closings	  	3
		
	 3. REPRESENTATIONS OF THE COMPANY
	  	4
			
		 	3.1 Organization and Standing	  	4
		 	3.2 Subsidiaries, Etc	  	4
		 	3.3 Capitalization	  	4
		 	3.4 Issuance of Shares	  	6
		 	3.5 Authority for Agreement; No Conflict	  	6
		 	3.6 Governmental Consents	  	7
		 	3.7 Litigation	  	7
		 	3.8 Financial Statements	  	7
		 	3.9 Absence of Undisclosed Liabilities	  	8
		 	3.10 Property and Assets	  	8
		 	3.11 Intellectual Property	  	8
		 	3.12 Material Contracts and Obligations	  	9
		 	3.13 Compliance	  	10
		 	3.14 Books and Records	  	10
		 	3.15 Disclosures	  	10
		 	3.16 Taxes	  	10
		 	3.17 ERISA	  	11
		 	3.18 Transactions With Affiliates	  	11
		 	3.19 Employees	  	11
		 	3.20 Certain Agreements of Officers and Key Employees	  	11
		 	3.21 Assumptions or Guaranties of Indebtedness of Other Persons	  	12
		 	3.22 Insurance	  	12
		 	3.23 Environmental Matters	  	12
		
	 4. REPRESENTATIONS OF THE PURCHASERS
	  	12
			
		 	4.1 Investment	  	12
		 	4.2 Authority	  	12
		 	4.3 Experience	  	13

					
	 5. TRANSFER OF SHARES
	  	13
			
		 	5.1 Restricted Shares	  	13
		 	5.2 Requirements for Transfer	  	13
		 	5.3 Legend	  	14
		 	5.4 Rule 144A Information	  	14
		
	 6. MISCELLANEOUS
	  	14
			
		 	6.1 Successors and Assigns	  	14
		 	6.2 Survival of Representations and Warranties	  	15
		 	6.3 Brokers	  	15
		 	6.4 Severability	  	15
		 	6.5 Specific Performance	  	15
		 	6.6 Governing Law	  	15
		 	6.7 Notices	  	15
		 	6.8 Complete Agreement	  	16
		 	6.9 Amendments and Waivers	  	16
		 	6.10 Pronouns	  	16
		 	6.11 Counterparts; Facsimile Signatures	  	16
		 	6.12 Section Headings and References	  	16

 EXHIBITS 
  

			
	Exhibit A	  	– List of Purchasers and Shares Purchased
	Exhibit B-1	  	– Investment Financing Signature Page
	Exhibit B-2	  	– Existing Investor Financing Signature Page
	Exhibit C	  	– Certificate of Amendment
	Exhibit D	  	– Investor Rights Agreement
	Exhibit E	  	– Voting Agreement
	Exhibit F	  	– Co-Sale Agreement
	Exhibit G	  	– Opinion of Counsel
	Exhibit H	  	– Exceptions to Representations

  

 -ii- 

 AVEO PHARMACEUTICALS, INC. 
 SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT 
 This
Agreement dated as of March 18, 2009, is entered into by and among AVEO Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the individuals and entities listed on Exhibit A hereto under the heading “Initial
Purchasers” (the “Initial Purchasers”), who shall become parties to this Agreement by executing and delivering a financing signature page in the form of Exhibit B-1 hereto or such other form as may be acceptable to the Company
(the “Investment Financing Signature Page”), and the individuals and entities who become parties to this Agreement after the date hereof in accordance with Section 2.2 hereof by executing and delivering (i) in the case of
individuals and entities that were not holders of Preferred Stock, $0.001 par value per share (“Preferred Stock”), of the Company prior to the date of the applicable Closing (as defined below) (the “New Investors”), an Investment
Financing Signature Page or (ii) in the case of individuals and entities that were holders of Preferred Stock of the Company prior to the date of the applicable Closing (as defined below) (“Existing Investors” and, collectively with
the New Investors, the “Additional Purchasers”), a financing signature page in the form of Exhibit B-2 hereto or such other form as may be acceptable to the Company (the “Existing Investor Financing Signature Page”).
Investment Financing Signature Pages and Existing Investor Financing Signature Pages are collectively referred to as “Financing Signature Pages”. The Initial Purchasers and any Additional Purchasers are collectively referred to as the
“Purchasers”. 
 In consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree as
follows: 
 1. Sale of Shares; Authorization. 
 1.1 Sale of Shares. Subject to the terms and conditions of this Agreement, at the Closings (as defined in Section 2.2), the
Company will sell and issue to each of the Purchasers, and each of the Purchasers will purchase, the number of shares of the Company’s Series E Convertible Preferred Stock, $0.001 par value per share (the “Series E Preferred”),
set forth opposite such Purchaser’s name on Exhibit A, for the purchase price of $4.00 per share (the “Purchase Price”). The shares of Series E Preferred sold under this Agreement are referred to as the “Shares.”

 1.2 Use of Proceeds. The Company will use the proceeds from the sale of the Shares for product development and other
general corporate purposes. 
 1.3 Authorization. Before the Initial Closing (as defined in Section 2.1), the
Company will have duly authorized the sale and issuance, pursuant to the terms of this Agreement, of up to 15,000,000 shares of Series E Preferred, having the rights, privileges, preferences and restrictions set forth in the Certificate of Amendment
of Certificate of Incorporation attached hereto as Exhibit C (the “Certificate of Amendment”). Before the Initial Closing, the Company will have adopted and filed the Certificate of Amendment with the Secretary of State of the
State of Delaware. 

 2. Closings. 
 2.1 The Initial Closing. Subject to the terms and conditions of this Agreement, the initial closing (the “Initial Closing”)
of the sale and purchase of 7,500,000 Shares under this Agreement shall take place at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts (or remotely via the exchange of documents and signatures) on a
date mutually agreed to by the Company and the Initial Purchasers, provided that the Company and the Initial Purchasers agree that such Initial Closing shall be consummated on or prior to May 31, 2009, in the event that the Company has
completed the actions set forth in this Section 2.1 on or prior to such date (the “Initial Closing Date”). Prior to or at the Initial Closing: 
 (a) the Company and the other parties named therein shall execute and deliver the Fourth Amended and Restated Investor Rights Agreement in the form attached hereto as Exhibit D (the
“Investor Rights Agreement”); 
 (b) the Company and the other parties named therein shall execute and deliver the
Fourth Amended and Restated Stockholders’ Voting Agreement in the form attached hereto as Exhibit E (the “Voting Agreement”); 
 (c) the Company and the other parties named therein shall execute and deliver the Fourth Amended and Restated Right of First Refusal and Co-Sale Agreement in the form attached hereto as
Exhibit F (the “Co-Sale Agreement”); 
 (d) the Company shall deliver to the Initial Purchasers
certificates, as of the most recent practicable dates, (i) as to the corporate good standing of the Company issued by the Secretary of State of the State of Delaware and (ii) as to the due qualification of the Company as a foreign
corporation issued by the Commonwealth of Massachusetts; 
 (e) the Company shall deliver to the Initial Purchasers the
Certificate of Incorporation of the Company, as amended and in effect as of the Initial Closing Date (including the Certificate of Amendment), certified by the Secretary of State of the State of Delaware; 
 (f) the Company shall deliver to the Initial Purchasers a Certificate of the Secretary or Assistant Secretary of the Company attesting as
to (i) the By-laws of the Company; (ii) the signatures and titles of the officers of the Company executing this Agreement or any of the other agreements to be executed and delivered by the Company at the Initial Closing; and
(iii) resolutions of the Board of Directors and stockholders of the Company, authorizing and approving all matters in connection with this Agreement and the transactions contemplated hereby; 
 (g) Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Company, shall deliver to the Initial Purchasers an opinion, dated the
Initial Closing Date, in substantially the form attached hereto as Exhibit G; 
  

 - 2 - 

 (h) the Company shall deliver to the Initial Purchasers a Certificate of the President of
the Company certifying that (i) each of the representations and warranties made by the Company in Section 3 hereof is true and correct as of the Initial Closing Date as if then made, except to the extent that such representations and
warranties were made as of a specific date; and (ii) the Company has performed and complied with all agreements and conditions contained in this Agreement required to be performed or complied with by the Company prior to or at the Initial
Closing; 
 (i) the Company shall deliver to each Initial Purchaser a certificate for the Shares being purchased at the Initial
Closing by such Initial Purchaser, registered in the name of such Initial Purchaser; and 
 (j) each Initial Purchaser shall
pay to the Company, by wire transfer of immediately available funds, the Purchase Price for the Shares being purchased at the Initial Closing by such Initial Purchaser. 
 2.2 Additional Closings. Additional sales of up to an aggregate of 7,500,000 Shares may be made by the Company to Additional Purchasers at one or more additional closings (each, an “Additional
Closing”) up to 120 days after the Initial Closing Date; provided, however, that the composition of the Additional Purchasers (other than any Existing Investor) shall be subject to the approval of a majority of the members of the Board of
Directors. Each Additional Closing and the Initial Closing are collectively referred to as the “Closings” and the date of each Additional Closing and the Initial Closing Date are collectively referred to as the “Closing Dates.”
Each Additional Closing shall take place at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, Massachusetts (or remotely via the exchange of documents and signatures). At each Additional Closing, (i) each
Additional Purchaser that is a New Investor shall execute and deliver an Investment Financing Signature Page, and each Additional Purchaser that is an Existing Investor shall execute and deliver an Existing Investor Financing Signature Page, and
upon acceptance by the Company of such Financing Signature Page, such Additional Purchaser shall become a “Purchaser” hereunder; (ii) the Company shall (A) issue and deliver to each Additional Purchaser a certificate for the
number of Shares being purchased at such Additional Closing by such Additional Purchaser, registered in the name of such Additional Purchaser, against payment to the Company of the Purchase Price for the number of Shares being purchased by such
Additional Purchaser, (B) deliver to each of the Additional Purchasers, the documents set forth in Sections 2.1(a) through (c) and (f) and (C) deliver to each of the Additional Purchasers, the certificates set forth in Sections
2.1(d) and (e) and a certificate, executed by the President of the Company, certifying that each representation and warranty contained in Section 3 shall be true on and as of the Additional Closing with the same effect as though such
representation and warranty had been made on and as of that date, except as set forth on Exhibit H hereto, which shall be supplemented as of the date of such Additional Closing, and certifying to the fulfillment of the conditions specified in
Section 2.1(h), dated as of the date of each such Additional Closing; (iii) Wilmer Cutler Pickering Hale and Dorr LLP shall deliver to each of the Additional Purchasers an opinion, dated as of the date of such Additional Closing, in
substantially the form attached hereto as Exhibit G; and (iv) the Company shall cause Exhibit A to this Agreement and Exhibit A to each of the Ancillary Agreements (as defined in

  

 - 3 - 

 
Section 3.1) to be amended to include each Additional Purchaser and all corresponding information specified in each such Exhibit. The Purchase Price shall be paid by wire transfer of
immediately available funds. 
 3. Representations of the Company. Except as disclosed by the Company in Exhibit H
hereto, the Company hereby represents and warrants to each Purchaser that the statements contained in this Section 3 are complete and accurate as of the date of this Agreement. Exhibit H shall be arranged in sections corresponding to the
numbered and lettered sections and subsections contained in this Section 3, and the disclosures in any section or subsection of Exhibit H shall qualify only the corresponding section or subsection of this Section 3 unless otherwise
specified. 
 3.1 Organization and Standing. The Company is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has full corporate power and authority to conduct its business as presently conducted and as presently proposed to be conducted by it and to enter into and perform this Agreement and all other
agreements required to be executed by the Company at or prior to the Initial Closing pursuant to Section 2.1 (the “Ancillary Agreements”) and to carry out the transactions contemplated by this Agreement and the Ancillary Agreements.
The Company is duly qualified to do business as a foreign corporation and is in good standing in the Commonwealth of Massachusetts and in any other jurisdictions wherein the character of the property owned or leased, or the nature of the activities
conducted, by it makes such licensing or qualification necessary. The Company has furnished to the Purchaser complete and accurate copies of its Certificate of Incorporation and By-laws, each as amended to date and presently in effect. The Company
has at all times complied with all provisions of its Certificate of Incorporation and By-laws in all material respects and is not in default under, or in violation of, any such provision. 
 3.2 Subsidiaries, Etc. The Company has no subsidiaries and does not own or control, directly or indirectly, any shares of capital
stock of any other corporation or any interest in any partnership, limited liability company, joint venture or other non-corporate business enterprise. 
 3.3 Capitalization. 
 (a) The authorized capital stock of the Company
(immediately prior to the Initial Closing) consists of (i) 102,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”), of which 6,367,751 shares are issued and outstanding and no shares are held in the treasury of
the Company, (ii) 12,448,000 shares of Series A Convertible Preferred Stock, $0.001 par value per share, of which 12,400,000 shares are issued and outstanding, (iii) 27,215,385 shares of Series B Convertible Preferred Stock, $0.001 par
value per share, of which 26,906,354 shares are issued and outstanding, (iv) 4,166,668 shares of Series C Convertible Preferred Stock, $0.001 par value per share, all of which are issued and outstanding, (v) 21,794,310 shares of Series D
Convertible Preferred Stock, $0.001 par value per share, of which 21,165,510 are issued and outstanding, and (vi) 15,000,000 shares of Series E Preferred, none of which are issued or outstanding. 
  

 - 4 - 

 (b) Exhibit H includes a complete and accurate list, as of the date of the
Agreement, of the holders of capital stock of the Company, showing the number of shares of capital stock, and the class or series of such shares, held by each stockholder and (for shares other than Common Stock) the number of shares of Common Stock
(if any) into which such shares are convertible. Exhibit H also indicates all outstanding shares of Common Stock that constitute restricted stock or that are otherwise subject to a repurchase or redemption right, indicating the name of the
applicable stockholder, the vesting schedule (including any acceleration provisions with respect thereto), and the repurchase price payable by the Company. All of the issued and outstanding shares of capital stock of the Company have been duly
authorized and validly issued and are fully paid and nonassessable. All of the issued and outstanding shares of capital stock of the Company have been offered, issued and sold by the Company in compliance with all applicable federal and state
securities laws. 
 (c) Exhibit H includes a complete and accurate list, as of the date of this Agreement of:
(i) all stock option plans and other stock or equity-related plans of the Company (the “Company Stock Plans”), indicating for each Company Stock Plan the number of shares of Common Stock issued to date under such Plan, the number of
shares subject to outstanding options under such Plan and the number of shares reserved for future issuance under such Plan; (ii) all holders of outstanding options to purchase shares of Common Stock (“Company Stock Options”),
indicating with respect to each Company Stock Option the Company Stock Plan under which it was granted, the number of shares of Common Stock subject to such Company Stock Option, the exercise price and the date of grant; and (iii) all holders
of warrants or other rights (other than Company Stock Options and convertible preferred stock) to purchase or acquire shares of capital stock of the Company (“Company Warrants”), indicating with respect to each Company Warrant the
agreement or other document under which it was granted, the number of shares of capital stock, and the class or series of such shares, subject to such Company Warrant, the exercise price, the date of issuance and the expiration date thereof. The
Company has furnished to the Purchaser complete and accurate copies of all Company Stock Plans, forms of all stock option agreements evidencing Company Stock Options and all Company Warrants. All of the shares of capital stock of the Company subject
to Company Stock Options and Company Warrants will be, upon issuance pursuant to the exercise of such instruments, duly authorized, validly issued, fully paid and nonassessable. 
 (d) Except as set forth in this Section 3.3 or Exhibit H, (i) no subscription, warrant, option, convertible security or
other right (contingent or otherwise) to purchase or acquire any shares of capital stock of the Company is authorized or outstanding, (ii) the Company has no obligation (contingent or otherwise) to issue any subscription, warrant, option,
convertible security or other such right, or to issue or distribute to holders of any shares of its capital stock any evidences of indebtedness or assets of the Company, (iii) the Company has no obligation (contingent or otherwise) to purchase,
redeem or otherwise acquire any shares of its capital stock or any interest therein or to pay any dividend or to make any other distribution in respect thereof, and (iv) there are no outstanding or authorized stock appreciation, phantom stock
or similar rights with respect to the Company. 
  

 - 5 - 

 (e) Except for the Ancillary Agreements, there is no agreement, written or oral, between
the Company and any holders of its securities, or, to the best of the Company’s knowledge, among any holder of its securities, relating to the sale or transfer (including without limitation agreements relating to rights of first refusal,
co-sale rights or “drag-along” rights), registration under the Securities Act of 1933, as amended (the “Securities Act”), or voting, of the capital stock of the Company. 
 3.4 Issuance of Shares. The issuance, sale and delivery of the Shares in accordance with this Agreement, and the issuance and
delivery of the shares of Common Stock issuable upon conversion of the Shares, have been, or will be on or prior to the applicable Closing, duly authorized by all necessary corporate action on the part of the Company, and all such shares have been
duly reserved for issuance. The Shares when so issued, sold and delivered against payment therefor in accordance with the provisions of this Agreement, and the shares of Common Stock issuable upon conversion of the Shares, when issued upon such
conversion, will be duly and validly issued, fully paid and nonassessable with no personal liability attaching to the ownership thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the
Company except as set forth in the Investor Rights Agreement. 
 3.5 Authority for Agreement; No Conflict. The execution,
delivery and performance by the Company of this Agreement and the Ancillary Agreements, and the consummation by the Company of the transactions contemplated hereby and thereby, have been duly authorized by all necessary corporate action. This
Agreement has been, and the Ancillary Agreements when executed at the Initial Closing will be, duly executed and delivered by the Company and constitute valid and binding obligations of the Company enforceable in accordance with their respective
terms, subject as to enforcement of remedies to applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting generally the enforcement of creditors’ rights and subject to a court’s discretionary authority with
respect to the granting of a decree ordering specific performance or other equitable remedies. 
 The execution and delivery of
this Agreement and the Ancillary Agreements, the consummation of the transactions contemplated hereby and thereby and the compliance with their respective provisions by the Company will not (a) conflict with or violate any provision of the
Certificate of Incorporation or By-laws of the Company, (b) require on the part of the Company any filing with, or any permit, order, authorization, consent or approval of, any court, arbitrational tribunal, administrative agency or commission
or other governmental or regulatory authority or agency (each of the foregoing is hereafter referred to as a “Governmental Entity”) except for any filing, permit, order, authorization, consent or approval, the absence of which would not
reasonably be expected to have a material adverse effect on the Company’s business, financial condition or results of operations (a “Company Material Adverse Effect”), (c) conflict with, result in a breach of, constitute (with or
without due notice or lapse of time or both) a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease,
license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of indebtedness, Security Interest (as defined below) or other arrangement to which the

  

 - 6 - 

 
Company is a party or by which the Company is bound or to which its assets are subject except for any of the foregoing events listed in this clause (c) which, individually or in the
aggregate, would not reasonably be expected to have a Company Material Adverse Effect, (d) result in the imposition of any Security Interest upon any assets of the Company or (e) violate any order, writ, injunction, decree, statute, rule
or regulation specifically naming the Company or applicable to any of its assets. For purposes of this Agreement, “Security Interest” means any mortgage, pledge, security interest, encumbrance, charge, or other lien (whether arising by
contract or by operation of law). 
 3.6 Governmental Consents. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any Governmental Entity is required on the part of the Company in connection with the offer, issuance, sale and delivery of the Shares, the issuance and delivery of the shares of
Common Stock issuable upon conversion of the Shares or the other transactions to be consummated at the Initial Closing, as contemplated by this Agreement and the Ancillary Agreements, except such filings as shall have been made prior to and shall be
effective on and as of the Initial Closing and such filings required to be made after the Initial Closing under applicable federal and state securities laws. Based on the representations made by each of the Purchasers in Section 4 of this
Agreement, the offer and sale of the Shares to each of the Purchasers will be in compliance with applicable federal and state securities laws. 
 3.7 Litigation. There is no action, suit or proceeding, or governmental inquiry or investigation, pending, or, to the Company’s knowledge, any basis therefor or threat thereof, against the
Company, any of which, singly or in the aggregate, could reasonably be expected to have a Company Material Adverse Effect. There is no litigation pending, or, to the Company’s knowledge, any basis therefor or threat thereof, against the Company
by reason of the proposed activities of the Company, or negotiations by the Company with possible investors in the Company. Neither the Company, nor, to the Company’s knowledge, any of its officers is subject to any outstanding judgment, order
or decree specifically naming the Company. There is no action, suit or proceeding initiated by the Company currently pending or which the Company currently intends to initiate. 
 3.8 Financial Statements. The Company has furnished to each of the Purchasers a complete and accurate copy of the (i) audited
balance sheet of the Company at December 31, 2007 and the related audited statements of operations and cash flows for the fiscal year then ended and (ii) the unaudited balance sheet (the “Balance Sheet”) of the Company at
November 30, 2008 the (“Balance Sheet Date”) and the related unaudited statements of operations and cash flows for the 11-month period then ended (collectively, the “Financial Statements”). The Financial Statements are in
accordance with the books and records of the Company, present fairly the financial condition and results of operations of the Company, at the dates and for the periods indicated, and have been prepared in accordance with generally accepted
accounting principles (“GAAP”) consistently applied, except that the unaudited Financial Statements may not be in accordance with GAAP (x) due to non-cash adjustments related to Financial Accounting Standards Board Statement 123R, and
(y) because of the absence of footnotes normally contained therein and are subject to normal year-end audit adjustments which in the aggregate will not be material. 
  

 - 7 - 

 3.9 Absence of Undisclosed Liabilities. The Company does not have any liability
(whether known or unknown and whether absolute or contingent), except for (a) liabilities shown on the Balance Sheet, (b) liabilities not in excess of $500,000 in the aggregate, which have arisen since the Balance Sheet Date in the
ordinary course of business and which are similar in nature and amount to the liabilities which arose during the comparable period of time in the immediately preceding fiscal period and (c) contractual and other liabilities incurred in the
ordinary course of business which are not required by GAAP to be reflected on a balance sheet and which would not, either individually or in the aggregate, have or result in a Company Material Adverse Effect. 
 3.10 Property and Assets. The Company has good title to, or a valid leasehold interest in, all of its material properties and assets,
including all properties and assets reflected in the Balance Sheet, except those disposed of since the date thereof in the ordinary course of business. 
 3.11 Intellectual Property. 
 (a) 
 (i) Exhibit H lists each patent, patent application, copyright registration or application therefor, mask work registration or
application therefor, and trademark, service mark and domain name registration or application therefor owned by the Company. Except as set forth in Exhibit H, there is no pending adverse claim that would interfere with the Company’s
right to use the licenses, software or any Intellectual Property (as defined in Section 3.11(e) hereof) being used in the Company’s business as now operated. Except as set forth in Exhibit H, the conduct of the Company’s
business as now operated does not conflict and to the best of the Company’s knowledge will not conflict with any license, or other Intellectual Property of any other Person. Except as set forth in Exhibit H, to the best of the
Company’s knowledge, no product or process presently used or under development by the Company infringes or will infringe on any Intellectual Property of any other Person. 
 (ii) Except pursuant to an agreement set forth in Schedule 3.11(a) (ii) in Exhibit H, the Company has no obligation to
compensate any Person for the use of any Intellectual Property. 
 (b) Except as identified in Exhibit H, to the best of
the Company’s knowledge, the Company owns or has the right to use all Intellectual Property necessary in the conduct of its business as contemplated on the date hereof. Except as identified in Exhibit H, the Company has the right to
bring actions for infringement of all Intellectual Property owned or exclusively licensed by the Company. Except as identified in Exhibit H, the Company has taken reasonable measures to protect the proprietary nature of each item of Company
Intellectual Property (as defined in Section 3.11(e) hereof); to perfect the Company’s title in Company Intellectual Property, including recording in the U.S. Patent and Trademark Office invention assignments for each of the named
inventors on

  

 - 8 - 

 
each of the U.S. patents and patent applications owned by the Company; and to maintain in confidence all trade secrets and confidential information, that it owns or uses and desires to retain in
confidence. No other person or entity has any rights to any of the Company Intellectual Property owned by the Company (except pursuant to an agreement or license specified in Exhibit H), and, to the Company’s knowledge, no other person
or entity is infringing, violating or misappropriating any of the Company Intellectual Property. No claim is pending or, to the Company’s knowledge, threatened to the effect that any Company Intellectual Property is invalid or unenforceable by
the Company, and, to the Company’s knowledge, except as set forth in Exhibit H, there is no basis for any such claim (whether or not pending or threatened). 
 (c) Exhibit H identifies each license or other agreement pursuant to which the Company has licensed, distributed or otherwise granted any rights to any third party with respect to, any Company
Intellectual Property. Except as disclosed on Exhibit H, the Company has not agreed to indemnify any person or entity against infringement, violation or misappropriation of any Intellectual Property with respect to any Company Intellectual
Property. 
 (d) Exhibit H identifies each license or other agreement pursuant to which the Company uses Company
Intellectual Property that is owned by a party other than the Company (excluding off the shelf software programs licensed by the Company pursuant to “shrink wrap” licenses). 
 (e) For purposes of this Agreement, the following terms shall have the following meanings: 
 (i) “Intellectual Property” shall mean (A) patents, patent applications, patent disclosures and all related continuation,
continuation-in-part, divisional, reissue, reexamination, utility model, certificate of invention and design patents, patent applications, registrations and applications for registrations; (B) trademarks, service marks, trade dress, trade names
and corporate names and registrations and applications for registration thereof; (C) copyrights and registrations and applications for registration thereof; (D) mask works and registrations and applications for registration thereof;
(E) trade secrets; (F) inventions, know how and improvements; and (G) all rights relating to or associated with any of the foregoing. 
 (ii) “Company Intellectual Property” shall mean all Intellectual Property necessary in the conduct of its business as contemplated on the date hereof and owned by or licensed to the Company, or
to which the Company otherwise has a right to use. 
 3.12 Material Contracts and Obligations. Exhibit H sets
forth a list of all material agreements or commitments of any nature (whether written or oral) to which the Company is a party or by which it is bound, including without limitation (a) any employment and consulting agreements, employee benefit,
bonus, pension, profit-sharing, stock option, stock purchase and similar plans and arrangements, (b) any agreement with any current or former stockholder, officer or director of the Company, or any “affiliate” or “associate”
of such persons (as such terms are defined in the rules and regulations promulgated under the Securities Act), including without limitation any agreement or other arrangement providing for the furnishing of services by, rental of real or

  

 - 9 - 

 
personal property from, or otherwise requiring payments to, any such person or entity, or (c) any agreement relating to indebtedness for borrowed money (including any assumptions,
guarantees, endorsements or other direct or contingent liability), or (d) any agreement which requires future expenditures by the Company in excess of $250,000 in the aggregate or which might result in payments to the Company in excess of
$250,000 in the aggregate. Neither the Company, nor, to the Company’s knowledge, any other party thereto, is in default of any of its obligations under any of the agreements or contracts listed on any Schedule in Exhibit H, in a manner
which could have a Company Material Adverse Effect, nor does the Company have a reasonable basis to believe that it will not continue to remain in compliance with its obligations (including milestone obligations) under such agreements or contracts.
To the Company’s knowledge, all agreements and contracts listed on any Schedule in Exhibit H are valid, binding and in full force and effect in all material respects, subject to laws of general application relating to bankruptcy,
insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies and to general principles of equity. 
 3.13 Compliance. The Company has, in all material respects, complied with all laws, regulations and orders applicable to its present business and has all material permits and licenses required
thereby. 
 3.14 Books and Records. The minute books of the Company contain complete and accurate records, in all
material respects, of all meetings and other corporate actions of its stockholders and its Board of Directors and committees thereof. The stock ledger of the Company is complete and accurate in all material respects and reflects all issuances,
transfers, repurchases and cancellations of shares of capital stock of the Company. 
 3.15 Disclosures. Neither this
Agreement nor any Exhibit hereto, nor any Ancillary Agreement nor any report, certificate or instrument furnished to the Purchasers or their counsel in connection with the transactions contemplated by this Agreement, when read together, contains or
will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances under which they were made, not misleading. To
the Company’s knowledge, there is no material fact directly relating to the business, operations or financial condition of the Company (including any competitive developments but other than facts that relate to general economic or industry
trends or conditions or are otherwise generally known through publicly available information) that materially adversely affect the same that has not been disclosed to the Purchasers. 
 3.16 Taxes. The Company has filed or has obtained presently effective extensions with respect to all federal, state, county, local
and foreign tax returns which are required to be filed by it, such returns are complete and accurate in all material respects and all taxes shown thereon to be due have been timely paid with exceptions not material to the Company. Federal income tax
returns of the Company have not been audited by the Internal Revenue Service, and no controversy with respect to taxes of any type is pending or, to the best of the Company’s knowledge, threatened. The Company has established adequate reserves
for all taxes accrued but not

  

 - 10 - 

 
yet payable to the extent required by generally accepted accounting principles. There is no tax lien (other than for current taxes not yet due and payable), whether imposed by any Federal, state,
county or local taxing authority, outstanding against the assets, properties or business of the Company. Neither the Company nor any of its present or former stockholders has ever filed an election pursuant to Section 1362 of the Internal
Revenue Code of 1986, as amended, that the Company be taxed as an S corporation. 
 3.17 ERISA. Except as set forth on
Exhibit H, the Company does not have or otherwise contribute to or participate in any employee benefit plan subject to the Employee Retirement Income Security Act of 1974, as amended, or any plan of deferred compensation, medical plan, life
insurance plan, long-term disability plan, dental plan, excess benefit plan, bonus or incentive plan (including but not limited to stock options, restricted stock, stock bonus and deferred bonus plans), salary reduction agreement, change-of-control
agreement, consulting agreement or any other benefit program or contract, except as required by law. The Company has complied in all material respects with all applicable laws relating to wages, hours and collective bargaining. 
 3.18 Transactions With Affiliates. Except as set forth on Exhibit H, no director, officer, employee or stockholder of the
Company, or member of the family of any such person, or any corporation, partnership, trust or other entity in which any such person, or any member of the family of any such person, has a substantial interest or is an officer, director, trustee,
partner or holder of more than 5% of the outstanding capital stock thereof, is a party to any transaction with the Company, including any contract, agreement or other arrangement providing for the employment of, furnishing of services by, rental of
real or personal property from or otherwise requiring payments to any such person or firm, other than employment-at-will arrangements in the ordinary course of business. 
 3.19 Employees. All current and former employees of the Company who have or have had access to confidential or proprietary information of the Company have executed and delivered non-disclosure and
assignment of inventions agreements in the form provided to the Purchasers and all of such agreements are in full force and effect. All current and former Key Employees (as defined in Section 7 of the Co-Sale Agreement) of the Company have
executed and delivered non-competition and non-solicitation agreements in the form provided to the Purchasers and all of such agreements are in full force and effect. 
 3.20 Certain Agreements of Officers and Key Employees. 
 (a) Except as
listed in Exhibit 3.12, the Company is not a party to or obligated in connection with its business with respect to (i) outstanding contracts with employees, agents, consultants, advisers, sales representatives, distributors, sales agents
or dealers or (ii) collective bargaining agreements or contracts with any labor union or other representative of employees or any employee benefits provided for by any such agreement. 
 (b) To the knowledge of the Company, no officer or Key Employee of the Company is in violation of any term of any employment contract,
patent disclosure agreement, proprietary information agreement, noncompetition agreement, or any other

  

 - 11 - 

 
contract or agreement or any restrictive covenant relating to the right of any such officer or Key Employee to be employed by the Company because of the nature of the business conducted or to be
conducted by the Company or relating to the use of trade secrets or proprietary information of others, and to the knowledge of the Company, the continued employment of the Company’s officers and Key Employees does not subject the Company or any
Purchaser to any liability to third parties. 
 3.21 Assumptions or Guaranties of Indebtedness of Other Persons. Except
as contemplated hereby or consented to by the Purchaser in accordance with this Agreement, the Company has not assumed, guaranteed, endorsed or otherwise become directly or contingently liable on (including, without limitation, liability by way of
agreement, contingent or otherwise, to purchase, to provide funds for payment, to supply funds to or otherwise invest in the debtor or otherwise to assure the creditor against loss), any indebtedness of any other person. 
 3.22 Insurance. The Company has in full force and effect general liability insurance policies and any other insurance policies the
Company deems necessary and as set forth on Exhibit H, with extended coverage, which the Company deems reasonably sufficient in amount (subject to reasonable deductibles) to allow it to replace any of its current properties that might be
damaged or destroyed or otherwise to protect the current assets of the Company. 
 3.23 Environmental Matters. To the
Company’s knowledge, (i) no material quantity of hazardous wastes, substances or materials or oil or petroleum products have been generated, transported, used, disposed, stored or treated by the Company and (ii) no material quantity
of hazardous wastes, substances or materials, or oil or petroleum products have been released, discharged, disposed, transported, placed or otherwise caused by the Company to enter the soil or water in, under or upon any real property owned, leased
or operated by the Company. 
 4. Representations of the Purchasers. Each of the Purchasers severally represents and
warrants to the Company as follows: 
 4.1 Investment. Such Purchaser is acquiring the Shares, and the shares of Common
Stock into which the Shares may be converted, for his, her or its own account for investment and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same; and,
except as contemplated by this Agreement and the Exhibits hereto, such Purchaser has no present or contemplated agreement, undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. Such Purchaser is an
“accredited investor” as defined in Rule 501(a) under the Securities Act. 
 4.2 Authority. Such Purchaser has
full power and authority to enter into and to perform this Agreement and the Ancillary Agreements in accordance with their terms. Any Purchaser that is a corporation, limited liability company, partnership or trust represents that it has not been
organized, reorganized or recapitalized specifically for the purpose of investing in the Company. 
  

 - 12 - 

 4.3 Experience. Such Purchaser has carefully reviewed the representations concerning
the Company contained in this Agreement, has made detailed inquiry concerning the Company, its business and its personnel; the officers of the Company have made available to such Purchaser any and all written information which he, she or it has
requested and have answered to such Purchaser’s satisfaction all inquiries made by such Purchaser; and such Purchaser has sufficient knowledge and experience in finance and business that he, she or it is capable of evaluating the risks and
merits of his, her or its investment in the Company and such Purchaser is able financially to bear the risks thereof. 
 5.
Transfer of Shares. 
 5.1 Restricted Shares. “Restricted Shares” means (i) the Shares,
(ii) the shares of Common Stock issued or issuable upon conversion of the Shares, (iii) any shares of capital stock of the Company acquired by the Purchasers pursuant to the Investor Rights Agreement or Co-Sale Agreement, and (iv) any
other shares of capital stock of the Company issued in respect of such shares (as a result of stock splits, stock dividends, reclassifications, recapitalizations, or similar events); provided, however, that shares of Common Stock which
are Restricted Shares shall cease to be Restricted Shares (x) upon any sale pursuant to a registration statement under the Securities Act, Section 4(1) of the Securities Act or Rule 144 under the Securities Act or (y) at such
time as (i) a period of at least one year, as determined in accordance with paragraph (d) of Rule 144 under the Securities Act, has elapsed since the later of the date the Restricted Shares were acquired from the Company or an affiliate of
the Company, and (ii) they become eligible for sale under Rule 144(b)(1)(i) under the Securities Act. 
 5.2
Requirements for Transfer. 
 (a) Restricted Shares shall not be sold or transferred unless either (i) they first
shall have been registered under the Securities Act, or (ii) the Company first shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is exempt from the
registration requirements of the Securities Act. 
 (b) Notwithstanding the foregoing, no registration or opinion of counsel
shall be required for (i) a transfer by a Purchaser to an affiliate (as such term is defined in the Securities Act) of such Purchaser, (ii) a transfer by a Purchaser which is a partnership to a partner of such partnership or a retired
partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner, or (iii) a transfer by a Purchaser which is a limited liability company to a member of such limited liability company or a
retired member who resigns after the date hereof or to the estate of any such member or retired member, provided that the transferee in each case agrees in writing to be subject to the terms of this Section 5 to the same extent as if it were
the original Purchaser hereunder, or (iv) a transfer made in accordance with Rule 144 under the Securities Act. 
  

 - 13 - 

 5.3 Legend. Each certificate representing Restricted Shares shall bear a legend
substantially in the following form: 
 “The shares represented by this certificate have not been registered under the
Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless and until such shares are registered under such Act or an opinion of counsel satisfactory to the Company is obtained to the
effect that such registration is not required.” 
 The foregoing legend shall be removed from the certificates representing
any Restricted Shares, at the request of the holder thereof, at such time as (a) a period of at least one year, as determined in accordance with paragraph (d) of Rule 144 under the Securities Act, has elapsed since the later of the date
the Restricted Shares were acquired from the Company or an affiliate of the Company, and (b) the Restricted Shares become eligible for resale pursuant to Rule 144(b)(1)(i) under the Securities Act. 
 5.4 Rule 144A Information. The Company shall, at all times during which it is neither subject to the reporting requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor exempt from reporting pursuant to Rule 12g3-2(b) under the Exchange Act, upon the written request of any Purchaser, provide in
writing to such Purchaser and to any prospective transferee of any Restricted Shares of such Purchaser the information concerning the Company described in Rule 144A(d)(4) under the Securities Act (“Rule 144A Information”). The
Company also shall, upon the written request of any Purchaser, cooperate with and assist such Purchaser or any member of NASDAQ’s PORTAL system in applying to designate and thereafter maintain the eligibility of the Restricted Shares for
trading through PORTAL. The Company’s obligations under this Section 5.4 shall at all times be contingent upon receipt from the prospective transferee of Restricted Shares of a written agreement to take all reasonable precautions to
safeguard the Rule 144A Information from disclosure to anyone other than persons who will assist such transferee in evaluating the purchase of any Restricted Shares. 
 6. Miscellaneous. 
 6.1 Successors and Assigns. This Agreement, and
the rights and obligations of each party hereunder shall inure to the successors and assigns of each party hereto, provided that, this Agreement and the rights and obligations of any Purchaser may be assigned by such Purchaser only to (a) any
person or entity to which Shares are transferred by such Purchaser in accordance with this Agreement, or (b) to any affiliate, partner, member, stockholder or subsidiary of such Purchaser, and, in each case, such transferee shall be deemed a
“Purchaser” for purposes of this Agreement; and further provided that such assignment of rights shall be contingent upon the transferee providing a written instrument to the Company notifying the Company of such transfer and assignment and
agreeing in writing to be bound by the terms of this Agreement. The Company may not assign its rights under this Agreement. 
  

 - 14 - 

 6.2 Survival of Representations and Warranties. All representations and warranties
contained herein shall survive the execution and delivery of this Agreement and the closing of the transactions contemplated hereby for a period of one year following the Initial Closing. 
 6.3 Brokers. Each of the Company and each Purchaser (i) represents and warrants to the other parties hereto that he, she or it
has not retained a finder or broker in connection with the transactions contemplated by this Agreement, and (ii) will indemnify and save the other parties harmless from and against any and all claims, liabilities or obligations with respect to
brokerage or finders’ fees or commissions, or consulting fees in connection with the transactions contemplated by this Agreement asserted by any person on the basis of any statement or representation alleged to have been made by such
indemnifying party. 
 6.4 Severability. The invalidity or unenforceability of any provision of this Agreement shall not
affect the validity or enforceability of any other provision of this Agreement. 
 6.5 Specific Performance. In addition
to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive
or other equitable relief as may be granted by a court of competent jurisdiction. 
 6.6 Governing Law. This Agreement
shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts (without reference to the conflicts of law provisions thereof). 
 6.7 Notices. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be deemed
delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next
business day delivery, in each case to the intended recipient as set forth below: 
 If to the Company, at AVEO Pharmaceuticals,
Inc., 75 Sidney Street, Fourth Floor, Cambridge, Massachusetts 02139, Attention: President, or at such other address as may have been furnished in writing by the Company to the other parties hereto, with a copy to Wilmer Cutler Pickering Hale and
Dorr LLP, 60 State Street, Boston, MA 02109, Attention: Steven D. Singer, Esq.; or 
 If to a Purchaser, at its address set
forth on Exhibit A, or at such other address as may have been furnished in writing by such Purchaser to the other parties hereto. 
 Any party may give any notice, request, consent or other communication under this Agreement using any other means (including, without limitation, personal delivery, messenger service, telecopy, first
class mail or electronic mail), but no such notice, request, consent or other communication shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Any party may change the address to
which notices, requests, consents or other communications hereunder are to be delivered by giving the other parties notice in the manner set forth in this Section. 
  

 - 15 - 

 6.8 Complete Agreement. This Agreement (including its Exhibits) constitutes the
entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. 
 6.9 Amendments and Waivers. This Agreement may be amended or terminated and the observance of any term of this Agreement may be
waived with respect to all parties to this Agreement (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holders of at least 51% of the Shares then held by all
Purchasers. Notwithstanding the foregoing, (a) except as provided in clause (c) below, this Agreement may not be amended or terminated and the observance of any term hereunder may not be waived with respect to any Purchaser without the
written consent of such Purchaser unless such amendment, termination or waiver applies to all Purchasers in the same fashion, (b) Exhibit A hereto may be amended by the Company from time to time in accordance with Section 2.2 to add
information regarding Additional Purchasers without the consent of the other parties hereto, and (c) Section 2.2 may, without the consent of the other parties hereto, be (i) waived with respect to a particular Additional Purchaser
with the written consent of the Company and such Additional Purchaser, and (ii) amended by the Company from time to time to extend the time period in which Additional Closings may occur. The Company shall give prompt written notice of any
amendment or termination hereof or waiver hereunder (other than under clause (c) above) to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment, termination or waiver effected in accordance
with this Section 6.9 shall be binding on all parties hereto, even if they do not execute such consent. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or
construed as, a further or continuing waiver of any such term, condition or provision. 
 6.10 Pronouns. Whenever the
context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 
 6.11 Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts (including, in the case of the
Purchasers, Financing Signatures Pages), each of which shall be deemed to be an original, and all of which shall constitute one and the same document. This Agreement (including the Financing Signature Pages) may be executed by facsimile signatures.

 6.12 Section Headings and References. The section headings are for the convenience of the parties and in no way alter,
modify, amend, limit or restrict the contractual obligations of the parties. Any reference in this agreement to a particular section or subsection shall refer to a section or subsection of this Agreement, unless specified otherwise. 
 [Remainder of Page Intentionally Left Blank] 
  

 - 16 - 

 Executed as of the date first written above. 
  

			
	COMPANY:
	
	 AVEO PHARMACEUTICALS, INC.

		
	 By:
	 	  

	 Name: Tuan Ha-Ngoc

	 Title: President and Chief Executive Officer

	
	PURCHASERS:
	
	 [Signature Pages Follow]

 Exhibit A 
 List of Purchasers and Shares Purchased 
 Initial
Purchasers 
  

						
	 Name and Address
 of Initial Purchasers
	  	 No. of Shares of
 Series E Preferred
	  	 Aggregate
 Purchase Price

			
	 Biogen Idec Inc.
 14 Cambridge Center
 Cambridge, MA 02142
 Attn: General Counsel
  
 With a copy to:
 Bingham McCutchen LLP
 One Federal Street
 Boston, MA 02110
 Attn: William S. Perkins
	  	7,500,000	  	$	30,000,000.00
		  	 	  	 	 
	 Total:
	  	7,500,000	  	$	30,000,000.00
		  	 	  	 	 

 Additional Purchasers 
  

					
	 Name and Address
 of Additional Purchasers
	  	 No. of Shares of
 Series E Preferred
	  	 Aggregate
 Purchase Price

 EXHIBIT B-1 
 Investment Financing Signature Page 
 By execution and
delivery of this signature page, the undersigned hereby agrees to become a Purchaser, as defined in that certain Series E Convertible Preferred Stock Purchase Agreement (the “Purchase Agreement”) by and among AVEO Pharmaceuticals, Inc., a
Delaware corporation (the “Company”), and the Purchasers (as defined in the Purchase Agreement), dated as of March     , 2009, acknowledges having read the representations in the Purchase Agreement section entitled
“Representations of the Purchasers,” and hereby represents that the statements contained therein are true and correct with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be bound by the terms and
conditions of (i) the Purchase Agreement as a “Purchaser” thereunder, (ii) the Stockholders’ Voting Agreement (as defined in the Purchase Agreement) as a “Purchaser” thereunder, (iii) the Investor Rights
Agreement (as defined in the Purchase Agreement) as a “Purchaser” thereunder and (iv) the Co-Sale Agreement (as defined in the Purchase Agreement) as a “Purchaser” thereunder, and authorizes this signature page to be
attached to the Purchase Agreement, the Stockholders’ Voting Agreement, the Investor Rights Agreement and the Co-Sale Agreement, or counterparts thereof. 
 Executed, in counterpart, as of the date set forth below. 
  

			
	PURCHASER:
		
	By:	 	  

	Title:
		
	Date:	 	  

	
	Contact Person:
	Telephone No.:
	Telecopy No.:
	Email Address:

 EXHIBIT B-2 
 Existing Investor Financing Signature Page 
 By
execution and delivery of this signature page, the undersigned hereby agrees to become a Purchaser, as defined in that certain Series E Convertible Preferred Stock Purchase Agreement (the “Purchase Agreement”) by and among AVEO
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Purchasers (as defined in the Purchase Agreement), dated as of March     , 2009, acknowledges having read the representations in the Purchase
Agreement section entitled “Representations of the Purchasers,” and hereby represents that the statements contained therein are true and correct with respect to the undersigned as a Purchaser. The undersigned further hereby agrees to be
bound by the terms and conditions of the Purchase Agreement as a “Purchaser” thereunder, and authorizes this signature page to be attached to the Purchase Agreement, or counterparts thereof. 
 Executed, in counterpart, as of the date set forth below. 
  

			
	PURCHASER:
	
	BIOGEN IDEC INC.
		
	By:	 	  

	Title:
		
	Date:	 	  

	
	Contact Person:
	Telephone No.:
	Telecopy No.:
	Email Address:

 Exhibit D 
 List of Existing AVEO In-licenses 
 Research and Commercialization License Agreement
between Evogenix Pty Limited (now Arana Therapeutics) and AVEO Pharmaceuticals, Inc., dated as of September 25, 2007. 

 Exhibit E 
 Form of Initial Release 

 Exhibit E 
 (Form of Initial Release) 
  

			
	

	  	NEWS RELEASE

 DRAFT NOT FOR IMMEDIATE RELEASE 
 Contacts: 
 Michael Christiano, AVEO Pharmaceuticals, Inc. 
 (617) 299-5925 
 Sheryl Seapy, Pure Communications

 (949) 608-0841 
 AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization 
 of ErbB3-Targeted
Antibodies 
 Biogen Idec to Obtain to Commercialize ErbB3 Antibodies Outside of North America 
 CAMBRIDGE, Mass., February xx, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer
biology to discover, develop and commercialize targeted oncology therapies, today announced a definitive agreement with Biogen Idec, Inc. (NASDAQ:BIIB), for the development and commercialization of AVEO’s novel discovery-stage ErbB3-targeted
antibodies (the “ErbB3 program”) for the potential treatment of cancer and other diseases. 
 Under the terms of the agreement, AVEO
will receive an up-front payment and is eligible to receive milestone payments based upon the achievement of specified development goals. Biogen Idec will have an option exercisable at proof of concept to development and commercialization rights to
ErbB3 binding antibodies for territories outside of North America. AVEO retains all North American commercialization rights, and is responsible for leading global development of the ErbB3 program. Financial terms of the transaction were not
disclosed. 
 “We are very please to enter into this alliance with Biogen Idec,” stated Tuan Ha-Ngoc, president and chief executive
officer of AVEO. “This agreement for the development and commercialization of our discovery-stage ErbB3-targeted antibodies facilitates our strategy to develop a balanced portfolio of small molecule drugs and antibodies for the treatment of
cancer. These alliances highlight AVEO’s ability to generate value from our antibody discovery programs and advance these candidates to the clinic, reinforcing the broad potential of our rapidly maturing proprietary antibody pipeline and the
quality of our science. The terms of this alliance with Biogen Idec support our strategy to become a fully-integrated company offering first- and best-in-class cancer medicines through AVEO’s own North American-based commercial
organization.” 

 ErbB3 is a type 1 tyrosine kinase receptor of the EFGR family that is widely expressed in human carcinomas,
with demonstrated overexpression – correlated with poor prognosis – in several different tumor types, including breast, ovarian, prostate, colorectal, pancreatic, gastric and head & neck cancers. In vivo studies conducted
by AVEO demonstrated that elevated ErbB3 levels can potently drive breast tumor growth and may provide an escape mechanism to Herceptin® treatment. ErbB3 is also implicated in the development of resistance to EGFR tyrosine kinase inhibitors in
non small cell lung cancer. AVEO has focused its ErbB3 antibody discovery efforts on identifying high affinity, high specificity antibodies that recognize ErbB3 on the cell surface and inhibit its activity. The market attractiveness of AVEO’s
ErbB3 portfolio is bolstered by the success of other EFGR family inhibitors such as erlotinib, gefitinib and transtuzumab, which have unique patterns of resistance that may be addressed by an effective ErbB3 antibody. 
 About AVEO 
 AVEO is a late-stage
biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in
oncology that increase the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and
promising novel targets (HGF, FGFR, ERBB3), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec. The company’s lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is
in a Phase 2 clinical trial in patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a
diversified product pipeline and moving toward its vision of becoming a fully integrated pharmaceutical company. For more information, please visit the company’s website at www.aveopharma.com. 
 ###Amended and Restated Collaboration and License Agreement, OSI Pharmaceuticals

 FINAL EXECUTION VERSION 
 Exhibit 10.27 
 Confidential Materials omitted and filed
separately with the 
 Securities and Exchange Commission. Asterisks denote omissions. 
 AMENDED AND RESTATED 
 COLLABORATION AND LICENSE AGREEMENT 
 This Amended and Restated Collaboration and License Agreement (the
“Agreement”), is entered into by and between OSI PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware (“OSI”), and AVEO PHARMACEUTICALS, INC., a corporation organized and existing
under the laws of Delaware (“AVEO”) effective as of the last date on which it has been executed by duly authorized officers of both Parties (the “Restatement Effective Date”). 
 INTRODUCTION 
 WHEREAS, AVEO has developed proprietary in vivo models and related proprietary bioinformatics tools useful in oncology and other disease target discovery, target validation and biomarker research; 
 WHEREAS, OSI has developed small-molecule drug discovery, development and commercialization capabilities and know-how; 
 WHEREAS, OSI has developed proprietary data, know-how and expertise related to the process known as Epithelial-Mesenchymal Transition
(“EMT”) and the process known as Mesenchymal-Epithelial Transition (“MET”), processes of emerging significance in human tumor development and disease progression, and is applying this expertise to the development of
novel agents, and combinations of novel agents, for the treatment of cancer and other diseases; 
 WHEREAS OSI wishes to
identify and validate genes and targets of importance to cancer and other diseases, with a particular focus on those genes and targets involved in EMT or EMT/MET processes, and access to in vivo models and biomarker technology in order to
expedite drug discovery and development against these targets; 
 WHEREAS, AVEO and OSI entered into a Collaboration and License
Agreement dated as of September 28, 2007, as amended on August 12, 2008 and as further amended on May 11, 2009 (the “Original Agreement”), which, among other things, focused on the identification and validation of
target genes implicated in cancer and other diseases and supported compound screening, biomarker discovery and translational research related to OSI’s discovery and development compounds and related to EMT and EMT/MET processes and other
factors in cancer and other disease development and progression; and 
 WHEREAS, effective as of the Restatement Effective Date,
AVEO and OSI wish, in the manner set forth in this Agreement, to (i) expand the Research Program (as defined below), (ii) provide OSI with continued rights to certain AVEO technology after the termination of the Research Program, and
(iii) amend and restate certain other provisions of the Original Agreement; 
 NOW, THEREFORE, in consideration of the
mutual covenants contained herein, and other good and valuable consideration, the receipt of which is hereby acknowledged, and intending to amend and restate the Original Agreement in its entirety, AVEO and OSI agree as follows: 

 ARTICLE I 
 DEFINITIONS 
 Unless specifically set forth to
the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 
 1.1 “Act”. Act means, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq., and/or the Public Health Service Act, 42 U.S.C. §§ 262 et seq., as such may be
amended from time-to-time. 
 1.2 “Affiliate”. Affiliate means with respect to a Party, any person or entity
that directly or indirectly controls, is controlled by, or is under common control with such Party. As used in this definition, the term “control” means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a person or entity, whether through ownership of voting securities, by contract or otherwise. For purposes of this definition, “control” shall be presumed to exist if one of the following conditions are
met: (a) in the case of corporate entities, direct or indirect ownership of more than [**] percent ([**]%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct
or indirect ownership of more than [**] percent ([**]%) of the equity interest with the power to direct the management and policies of such non-corporate entities. 
 1.3 “Additional Antibody Targets”. Additional Antibody Targets means up to [**] additional Antibody Targets which may be mutually agreed upon by the Parties after the Restatement
Effective Date and prior to the termination or expiration of the Research Program Term. 
 1.4 “Additional Tumor Model
Translational Research Intellectual Property”. Additional Tumor Model Translational Research Intellectual Property means the Additional Tumor Model Translational Research Know-How and the Additional Tumor Model Translational Research Patent
Rights. 
 1.5 “Additional Tumor Model Translational Research Know-How”. Additional Tumor Model Translational
Research Know-How means Know-How developed through the use of the Additional Tumor Models during the Research Program Term: (a) related to biomarkers and their role in signaling and signaling pathways, cell–to–cell adhesion, cell
migration, metastasis, cellular morphology, markers of epithelial-like cells, markers of mesenchymal-like cells, transcriptional reprogramming events, and survival of mesenchymal-like cells; (b) related to proteins, nucleic acids, carbohydrates
or metabolites linked to a selected target and targeted pathways or processes linking the target to EMT and MET events; (c) related to biomarkers leading to the diagnosis, treatment, development or progression of cancer; (d) comprising
data useful in selecting patient populations for diagnosis or treatment with a

  

 - 2 - 

 
particular compound; (e) related to the selection of indications for treatment with a particular compound; (f) comprising data useful in evaluating and addressing drug response and
resistance; (g) comprising data useful in determining the suitability of a drug combination for a patient; or (h) comprising data on a method of use of an Antibody or Non-Antibody Compound. 
 1.6 “Additional Tumor Model Translational Research Patent Rights”. Additional Tumor Model Translational Research Patent
Rights means Patent Rights that claim Additional Tumor Model Translational Research Know-How. 
 1.7
“Antibody”. Antibody means (a) an antibody or antibody-related polypeptide including Fab, F(ab’)2, Fab’, Fv, and single chain antibodies (scFv) containing a V[L] and/or V[H] domain joined by a peptide linker, where
the scFv is covalently or noncovalently linked to form antibodies having two or more binding sites; or (b) other peptides which bind to the Antibody Target (as hereinafter defined in this Section 1.7) for example by having a binding domain
(protein ligand of the target, extracellular domain of a receptor, or a domain created by selection from random sequences such as by phage display) that may be genetically fused or chemically conjugated to a protein scaffold (e.g., Adnectin) or a
stabilizing protein (such as the Fc domain of an antibody) or to other macromolecules (e.g., polyethelyene glycol) for delivery purposes or to increase the valency of the biological; or (c) aptamers or other nucleic acid based polymers selected
to bind tightly to the Antibody Target, said aptamers may be chemically modified to improve stability and/or may be coupled to other macromolecules to enhance in vivo delivery as in (b) above; or (d) any other macromolecule having a
molecular weight greater than 10,000 daltons that behaves similarly to an antibody. For clarity, (x) molecules including siRNA which act inside the cell to modulate gene expression of specified targets are not considered Antibodies for purposes
of this Agreement, and (y) molecules including an Antibody linked to a Non-Antibody Compound are not considered Antibodies for purposes of this Agreement, except where such Non-Antibody Compound is a radioisotope or toxin conjugate (e.g., ricin
or DM1). As used in this Section 1.7, “Antibody Target” means an extracellular drug target that can be inhibited or activated through the use of an appropriate “biologic” that acts via direct binding to the
“antibody target” or the ligand of such target. For purposes of clarity, the use of “Antibody Target” in this definition in no way precludes Antibody Targets from being Candidate Targets, Nominated Targets or Collaboration
Targets under this Agreement. 
 1.8 “Antibody Product(s)”. Antibody Product means any preparation in final
form, either for sale by prescription, over-the-counter or any other method or for administration to human patients in Clinical Trials, which preparation contains an Antibody, other than any preparation which contains a Collaboration Antibody.

 1.9 “AVEO Bioinformatics Data”. AVEO Bioinformatics Data means the following microarray datasets and results
populating the AVEO Bioinformatics Tools: (a) [**] as more specifically described in Schedule 1.9. AVEO Bioinformatics Data shall not include (i) any data in the public domain, (ii) any results or data generated solely by OSI
through the use by OSI of the AVEO Bioinformatics Data, the AVEO Bioinformatics Tools or the Bioinformatics Tools Source Code, or (iii) any results or data generated by OSI’s permitted Sublicensees through the use of the AVEO
Bioinformatics Data, which shall be owned by OSI. 
  

 - 3 - 

 1.10 “AVEO Bioinformatics Tools”. AVEO Bioinformatics Tools means the
software tools and processes described in Schedule 1.10 to this Agreement. 
 1.11 “AVEO Existing
Target”. AVEO Existing Target means any Target in the database of recurrent integration sites identified from AVEO’s moloney murine leukemia virus induced tumors (the “AVEO Genetic Screens”), including any Target
identified in the AVEO Genetic Screens related to kinases, G-protein coupled receptors, phosphatases, peptidases, transmembrane receptors, ion channels, transporters, growth factors, cytokines, transporters, enzymes, ligand-dependent nuclear
receptors, histone regulators and transcription and translation regulators. The AVEO Existing Targets were identified to OSI prior to the Original Effective Date. The AVEO Existing Targets exclude the Excluded Targets and the OSI Active Program
Targets. 
 1.12 “AVEO Intellectual Property”. AVEO Intellectual Property means the AVEO Know-How and the AVEO
Patent Rights. 
 1.13 “AVEO Know-How”. AVEO Know-How means Know-How other than Collaboration Know-How that is
(a) Controlled by AVEO as of the Original Effective Date or during the Research Program Term, and (b) necessary or useful to conduct the Research Program or for OSI to research, develop, make and have made, use, offer for sale, sell or
import a Product. Notwithstanding the foregoing, AVEO Know-How excludes any information and materials, including discoveries, processes, methods, protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise that are
necessary or useful in connection with or that claim or Cover any method, material, tool or technology conceived or used by or on behalf of AVEO for the discovery of any Target other than a Pre-Collaboration Target, Candidate Target, Nominated
Target or Collaboration Target. 
 1.14 “AVEO Patent Rights”. AVEO Patent Rights means any Patent Rights
Controlled by AVEO during the Term that claim AVEO Know-How. 
 1.15 “AVEO [**] Know-How”. AVEO [**] Know-How
means Know-How that is controlled by AVEO as of the Restatement Effective Date which relates to the AVEO [**] Index, as defined on Schedule 1.15 attached hereto. 
 1.16 “AVEO [**] Program”. AVEO [**] Program means a drug discovery or development program conducted by or on behalf of AVEO or its Affiliates with respect to the Target known as
[**]”) or products Directed thereto. 
 1.17 “AVEO Platform Intellectual Property”. AVEO Platform
Intellectual Property means the AVEO Platform Know-How and the AVEO Platform Patent Rights. 
 1.18 “AVEO Platform
Know-How”. AVEO Platform Know-How means Know-How that is: 
  

	 	(a)	Controlled by AVEO as of the Expansion Date, and necessary or useful to research, develop, make and use chimeric mouse tumor models, directed complementation
(“DC”) tumor models and human-in-mouse (“HIM”) models; or 

  

 - 4 - 

	 	(b)	Controlled by AVEO as of the Expansion Date and necessary or useful to utilize the Tumor Archives. 

 Notwithstanding the foregoing, AVEO Platform Know-How excludes any Know-How and materials that were or are discovered or created by AVEO
that specifically relate to (i) the Excluded Targets (other than molecular profiling data related to Excluded Targets), or (ii) any specific tumor model created or discovered by AVEO prior to the Expansion Date in connection with an
existing AVEO compound, product or program. 
 1.19 “AVEO Platform Patent Rights”. AVEO Platform Patent Rights
means any Patent Rights Controlled by AVEO during the Term that claim AVEO Platform Know-How. 
 1.20 “AVEO Reserved
Target(s)”. AVEO Reserved Targets mean the [**] specific reserved Targets, or products Directed thereto, identified by AVEO to OSI prior to the Original Effective Date. 
 1.21 “AVEO Target(s)”. AVEO Target means any (a) AVEO Existing Target that is not designated as a Candidate Target;
(b) Candidate Target that is not designated as a Nominated Target prior to the expiration of the Candidate Target Exclusivity Period; (c) Nominated Target or Additional Antibody Target that is not designated as a Collaboration Target prior
to the expiration of the Research Program Term (or, if an Option Period pursuant to Section 3.7(c)(i) is pending as of such date, as of the expiration of such Option Period); (d) Reverted Target as defined in Section 3.7(c)(ii); and
(e) Target (including an OSI Existing Target) that is deemed to be an AVEO Target pursuant to this Agreement, including pursuant to Sections 3.7(b)(i), 3.7(b)(v), 4.3, 9.3(b)(iii) and 9.5. Notwithstanding the foregoing, in no event will an OSI
Active Program Target be deemed an AVEO Target. 
 1.22 “Bioinformatics Tools Source Code”. Bioinformatics
Tools Source Code means human-readable computer programming code and associated procedural code underlying the version of the AVEO Bioinformatics Tools in existence as of the Restatement Effective Date. 
 1.23 “Business Day”. Business Day means a day that is not a Saturday, Sunday or a day on which banking institutions in New
York, New York or Boston, Massachusetts are authorized by Law to remain closed. 
 1.24 “Calendar Quarter”.
Calendar Quarter means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 
 1.25 “Calendar Year”. Calendar Year means each successive period of twelve (12) months commencing on January 1
and ending on December 31. 
  

 - 5 - 

 1.26 “Candidate Target”. Candidate Target means any Target (other than the
OSI Active Program Targets and the Excluded Targets) that was identified by the JSC during the first [**] days after the Research Program Term as worthy for consideration for validation due to its having potential relevance in tumorigenesis through
its role in EMT or otherwise. 
 1.27 “Candidate Target Exclusivity Period”. Candidate Target Exclusivity
Period means the period commencing on the Original Effective Date and ending on the earlier of (a) December 31, 2009, or (b) the termination of this Agreement pursuant to Article IX. 
 1.28 “Candidate Target List”. Candidate Target List means the list of Candidate Targets included in the Research Plan
finalized pursuant to Section 2.1, as such list may be amended from time to time pursuant to Section 3.7(b)(i). 
 1.29 “Clinical Trial(s)”. Clinical Trial(s) means a Phase I Clinical Trial, a Phase II Clinical Trial, a Phase III Clinical Trial, a Phase IV Clinical Trial and/or an investigator sponsored trial. 
 1.30 “Collaboration Antibody”. Collaboration Antibody means any Antibody Directed to (i) a Pre-Selected Antibody
Target, and (ii) an Additional Antibody Target to which OSI has exercised its Option pursuant to Section 3.7(c) below. 
 1.31 “Collaboration Compound”. Collaboration Compound means, with respect to a Collaboration Target, any Non-Antibody Compound or a Collaboration Antibody Directed to such Collaboration Target. 
 1.32 “Collaboration Intellectual Property”. Collaboration Intellectual Property means the Collaboration Know-How and the
Collaboration Patent Rights. 
 1.33 “Collaboration Know-How”. Collaboration Know-How means Know-How that is
developed or made (a) by or on behalf of a Party, or by the Parties jointly, in the conduct of the Research Program or Technology Transfer, or (b) through the use of any Collaboration Model by OSI. 
 1.34 “Collaboration Model”. Collaboration Model means (a) with respect to a Pre-Collaboration Target and on a
Pre-Collaboration Target-by-Pre-Collaboration Target basis, the Target-specific tumor models developed by AVEO prior to the Original Effective Date or during the Research Program Term pursuant to a Pre-Collaboration Target Package plan, or
(b) on a Nominated Target-by-Nominated Target basis, the Target-specific tumor model developed by AVEO and/or OSI pursuant to a Nominated Target Package Plan. Collaboration Model excludes [**] Models, Additional Tumor Models, [**] Models and
the OSI Active Program Models. 
 1.35 “Collaboration Patent Rights”. Collaboration Patent Rights means Patent
Rights that claim Collaboration Know-How. 
  

 - 6 - 

 1.36 “Collaboration Target”. Collaboration Target means (a) an
Additional Antibody Target, a Nominated Target or a Non-Validated Collaboration Target with respect to which OSI has exercised its Option pursuant to Section 3.7(c) and (b) a Pre-Selected Antibody Target; provided that a
Collaboration Target shall cease to constitute a Collaboration Target if at any time such Target is deemed to be an AVEO Target pursuant to this Agreement. For avoidance of doubt, none of the OSI Active Program Targets shall be deemed a
Collaboration Target for purposes of this Agreement. 
 1.37 “Combination Product”. Combination Product means a
Royalty-Bearing Product that includes one or more Collaboration Compound(s) in combination with one or more clinically active components that are not Collaboration Compounds or [**] Compounds, as the case may be. All references to Product, [**]
Product or Royalty-Bearing Product in this Agreement shall be deemed to include Combination Product. 
 1.38
“Commercially Reasonable Efforts”. Commercially Reasonable Efforts means the efforts required in order to carry out a task in a diligent and sustained manner without undue interruption, pause or delay, which level is at least
commensurate with the level of effort that a Party would devote to a product of similar potential and having similar commercial and scientific advantages and disadvantages resulting from its own research efforts, taking into account its safety and
efficacy, the competitiveness of alternative products, its proprietary position, pricing, reimbursement and other market-specific factors, and all other relevant factors. Commercially Reasonable Efforts requires (without limitation) that the Party
exerting such efforts (a) promptly assign responsibility for its obligations to specific employee(s) who are held accountable for progress and monitor such progress, on an ongoing basis, (b) set and continue to seek to achieve specific and
meaningful objectives for carrying out such obligations, and (c) make and implement decisions and allocate resources designed to advance progress with respect to such objectives, in each case in a commercially reasonable manner. 
 1.39 “Confidential Information”. Confidential Information means any and all information and data, including all OSI
Know-How, AVEO Know-How, AVEO Platform Know-How, [**] Know-How and Collaboration Know-How, any password and other access information provided by AVEO pursuant to Section 2.15 and all other scientific, pre-clinical, clinical, regulatory,
manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement. Notwithstanding the
foregoing, Confidential Information excludes information that, in each case as demonstrated by competent written documentation: 
 (a) is publicly disclosed and made generally available to the public by the disclosing Party, either before or after it becomes known to the receiving Party; 
 (b) was known to the receiving Party, without obligation to keep it confidential, prior to the date of disclosure by the disclosing Party; 
  

 - 7 - 

 (c) is subsequently disclosed to the receiving Party by a Third Party lawfully in
possession thereof without obligation to keep it confidential and without a breach of such Third Party’s obligations of confidentiality; 
 (d) has been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party in breach of this Agreement; or 
 (e) has been independently developed by the receiving Party without the aid, application or use of the disclosing Party’s Confidential
Information (the competent written proof of which must be contemporaneous with such independent development). 
 1.40
“Control, Controls or Controlled by”. Control, Controls or Controlled by means, with respect to any item of or right under Patent Rights or Know-How, the possession of (whether by ownership or license, other than pursuant to this
Agreement) the ability of a Party to grant access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party
would be required hereunder to grant the other Party such access or license or sublicense; provided that any Patent Right, Know-How or other intellectual property right that is licensed or acquired by a Party and that would otherwise be
considered to be under the Control of a Party shall not be deemed to be under the Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require
the granting Party to make any additional payments or royalties to a Third Party in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third Party. 
 1.41 “Cover”, “Covering” or “Covered”. Cover, Covering or Covered means, with respect to
a product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method
would infringe such Valid Claim. 
 1.42 “Development Candidate”. Development Candidate means a Collaboration
Compound or Product with respect to which OSI has commenced [**]. 
 1.43 “Directed”. Directed means that a
Collaboration Compound, [**] Compound or other composition is intended to primarily modulate the expression or activity of a Target, and actually primarily modulates, increases or decreases the expression or activity of such Target, as measured by a
cellular or biochemical assay. 
 1.44 “[**] Model”. [**] Model means an [**] tumor model (a) delivered by
AVEO to OSI on December 18, 2007 pursuant to the terms of the Original Agreement, or (b) developed by AVEO and listed on Schedule 1.44 (in quantities to be mutually determined pursuant to the Research Program) including, in each
case, the related tumor samples and accompanying documentation (e.g., non-enabling SOPs and user manuals). 
  

 - 8 - 

 1.45 “EMEA”. EMEA means The European Medicines Agency, or any successor
agency. 
 1.46 “European Union”. European Union means the countries that are members of the European Union, as
redefined from time to time. 
 1.47 “Excluded Target”. Excluded Target means the Targets identified on
Schedule 1.47 and the Third Party Targets. 
 1.48 “Existing Licensee”. Existing Licensee means
Merck & Co., Inc., a corporation organized and existing under the laws of the state of New Jersey. 
 1.49
“FDA” or “Food and Drug Administration”. FDA or Food and Drug Administration means the United States Food and Drug Administration and any successor agency. 
 1.50 “Field”. Field means the use of a Royalty-Bearing Product for the diagnosis, treatment, palliation and/or prevention
of a disease or medical condition in humans. 
 1.51 “Filing”. Filing means the acceptance by the applicable
Regulatory Authority of an NDA for filing. 
 1.52 “First Commercial Sale”. First Commercial Sale means, with
respect to any Royalty-Bearing Product, the first sale for end use or consumption of such Royalty-Bearing Product in a country after all required approvals, including Regulatory Approval, have been granted by the Regulatory Authority of such
country. 
 1.53 “Governmental Authority”. Governmental Authority means any United States federal, state or
local or any foreign government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or
taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 
 1.54 “Human Response PredictionTM Research”. Human Response PredictionTM Research means the use of proprietary AVEO tumor models (the “HRP Model”) and human tumor
samples to discover, through the testing of Non-Antibody Compounds or Collaboration Antibodies Directed to the OSI Active Program Targets or Collaboration Targets, one or more genes, whether individually or any combination thereof, whose level of
gene expression is identified in the performance of the Research Plan as being correlated, either positively or negatively, with the HRP Model phenotype, level of oncogene induction, or response to a treatment regimen, wherein the response is
oncogene expression level, tumor size, or tumor morphology. 
 1.55 “IND”. IND means an Investigational New
Drug application or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 
  

 - 9 - 

 1.56 “Invention”. Invention means any new and useful process, article of
manufacture, compound, composition of matter, formulation or apparatus, or any improvement thereof, patentable or unpatentable, discovery or finding. 
 1.57 “Know-How”. Know-How means any and all proprietary ideas, inventions, trade secrets, know-how, discoveries, information (including Confidential Information), data, results, formulae,
designs, specifications, methods, processes, formulations, techniques, ideas, technical information (including structural and functional information), process information, pre-clinical information, clinical information, and any and all proprietary
biological, chemical, pharmacological, toxicological, assay, control and manufacturing data. 
 1.58 “Label Claim
Product”. Label Claim Product means a Product, the Regulatory Approval for which includes a labeling claim for the identification of a targeted patient population (including where such population is characterized by one or more biomarkers)
and where (i) such label claim is Covered by Translational Research Patent Rights, or (ii) with respect solely to Products Directed at Non-Validated Collaboration Targets, such label claim is Covered by OSI Patent Rights. 
 1.59 “Law”. Law means all laws, statutes, rules, codes, regulations, orders, judgments or ordinances applicable to the
Parties, this Agreement or the activities contemplated hereunder. 
 1.60 “Major EU Country”. Major EU Country
means any of the following countries: United Kingdom, France, Germany, Italy or Spain. 
 1.61 “Major
Countries”. Major Countries means Japan, all of the Major EU Countries and the United States. 
 1.62
“Marketing Exclusivity”. Marketing Exclusivity means, with respect to a Royalty-Bearing Product, that such Royalty-Bearing Product has been granted marketing exclusivity afforded approved drug products pursuant to (a) Sections
505(c), 505(j), and 505A of the Act, and the regulations promulgated thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (b) the orphan drug exclusivity afforded approved drugs designated
for rare diseases or conditions under Sections 526 and 527 of the Act, and the regulations promulgated thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) applicable Law covering the
Royalty-Bearing Product which precludes the Regulatory Authority in a country from granting Regulatory Approval for another product that contains the same active ingredient as that which is contained in the applicable Royalty-Bearing Product.

 1.63 “Models”. Models means the Additional Tumor Models, Collaboration Models, the [**] Models and the OSI
Active Program Models. 
  

 - 10 - 

 1.64 “Model Intellectual Property”. Model Intellectual Property means any
Collaboration Intellectual Property directly relating to any Model. 
 1.65 “MWH”. MWH means the Japanese
Ministry of Health and Welfare. 
 1.66 “NDA”. NDA means a New Drug Application, as defined by the FDA and
regulations promulgated thereunder or any successor application or procedure required to sell a Royalty-Bearing Product in the United States or an equivalent application filed with the Regulatory Authority of a country or jurisdiction other than the
United States. 
 1.67 “Net Sales”. Net Sales means the gross amounts billed or invoiced by or on behalf of
OSI, its Affiliates or Sublicensees to any unaffiliated Third Party for sales, leases, transfers or other dispositions of Royalty-Bearing Products throughout the Territory, less the following deductions: 
 (a) allowances for doubtful accounts that are attributable to sales of Royalty-Bearing Product; 
 (b) trade, quantity and cash discounts actually paid, granted or accrued; 
 (c) refunds, chargebacks and any other allowances actually paid, granted or accrued that effectively reduce the net selling price;

 (d) actual product returns, credits and allowances actually paid, granted or accrued to customers in the ordinary course of
business, including adjustments granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, and recalls; 
 (e) rebates actually paid, granted or accrued to any Governmental Authority (or branch thereof) or to any Third Party payor, administrator or contractee; 
 (f) discounts mandated (whether paid or accrued) by, or granted to meet the requirements of, applicable Law, including required chargebacks
and retroactive price reductions; 
 (g) transportation, freight, postage charges and other charges, such as insurance,
relating thereto, in each case included in the invoice, to such Third Parties; and 
 (h) taxes (including excise taxes, sales
taxes and VAT), excises or other governmental charges upon or measured by the production, sale, transportation, delivery or use of goods, in each case included as a specific line item on an invoice to such Third Parties, and duties and fees relating
to sales and any payments in respect of sales to any Governmental Authority. 
  

 - 11 - 

 Notwithstanding the foregoing, the following shall not be included in Net Sales:
(1) OSI’s or any of its Affiliates’ or Sublicensees’ transfer of Royalty-Bearing Products to another OSI Affiliate or Sublicensee, (2) Royalty-Bearing Products provided by OSI, an OSI Affiliate or Sublicensee for
administration to patients enrolled in clinical trials or distributed through a not-for-profit foundation or entity at no charge to eligible patients provided that OSI, its Affiliates and Sublicensees receive no consideration from such clinical
trials or not-for-profit foundation for such use of Royalty-Bearing Products and (3) Royalty-Bearing Products used as samples to promote additional Net Sales, in amounts consistent with normal business practices of OSI or its Affiliates or
Sublicensees. 
 Net Sales shall be determined from books and records maintained in accordance with U.S. Generally Accepted
Accounting Principles (GAAP). 
 If any sales, leases, transfers or other dispositions to Third Parties are made in transactions
that are not at arm’s length between the buyer and the seller, then the gross amount to be included in the calculation of Net Sales shall be the amount that would have been invoiced had the transaction been conducted at arm’s length. Such
amount that would have been invoiced shall be determined, wherever possible, by reference to the average selling price of the relevant Royalty-Bearing Product in arm’s-length transactions in the relevant jurisdiction. 
 If OSI, its Affiliate or a Sublicensee sells a Royalty-Bearing Product in unfinished form to a Third Party for resale, then the gross amount
to be included in the calculation of Net Sales arising from such sale shall be the amount invoiced by a Third Party upon the first resale of the Royalty-Bearing Product in finished form, in lieu of the amounts invoiced by OSI, its Affiliate or
Sublicensee when selling the Royalty-Bearing Product in unfinished form, which amounts will not be included in the calculation of Net Sales. 
 If, in addition to or in lieu of a transfer price paid for quantities of Royalty-Bearing Product supplied, any Third Party provides consideration to OSI, its Affiliate or Sublicensee in connection with
any Royalty-Bearing Product or such Third Party’s rights or relationship with OSI, its Affiliate or Sublicensee in relation thereto, then such consideration shall be included in the calculation of Net Sales in the Calendar Quarter in which it
becomes due to OSI, its Affiliate or Sublicensee (as applicable). 
 If a Royalty-Bearing Product is sold as part of a
Combination Product in a country, the Net Sales of the Royalty-Bearing Product, for the purposes of determining payments based on Net Sales, shall be determined by multiplying the Net Sales of the Combination Product in such country, during the
applicable Net Sales reporting period, by the fraction, A/(A+B), where: 
 A is the average sale price of the
Royalty-Bearing Product by OSI, its Affiliates or Sublicensees when sold separately in finished form in such country and B is the average sale price by OSI, its Affiliates or Sublicensees of the other product(s) included in the Combination Product
when sold separately in finished form in such country, in each case during the applicable Net Sales reporting period or, if sales of both the Royalty-Bearing Product and the other product(s) did not occur in such period, then in the most recent Net
Sales reporting period in which sales of both occurred. 
  

 - 12 - 

 If the Royalty-Bearing Product is sold as part of a Combination Product and is sold
separately in finished form in such country, but the other product(s) included in the Combination Product are not sold separately in finished form in such country, the Net Sales of the Royalty-Bearing Product, for the purposes of determining
payments based on Net Sales, shall be determined by multiplying the Net Sales of the Combination Product in such country by the fraction C/D where: 
 C is the average sale price, in such country, of the Royalty-Bearing Product contained in such Combination Product when sold separately and D is the average sale price, in such country, for the
Combination Product, in each case during the applicable Net Sales reporting period. 
 If the Royalty-Bearing Product is not
sold separately in finished form in the country, but all of the other product(s) included in the Combination Product in such country are sold separately, the Net Sales of the Royalty-Bearing Product, for the purposes of determining payments based on
Net Sales, shall be determined by multiplying the Net Sales of the Combination Product in such country by the fraction (D-E)/D, where: 
 D is the average sale price, in such country, of the Combination Product, and E is the average sale price of the other product(s) included in the Combination Product in finished form in such country, in
each case during the applicable Net Sales reporting period. 
 If Net Sales of the Royalty-Bearing Product when included in a
Combination Product cannot be determined using the methods above, Net Sales for the purposes of determining payments based on Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by the fraction of F/(F+G) where:

 F is the fair market value of the Royalty-Bearing Product and G is the fair market value of all other
pharmaceutical product(s) included in the Combination Product as reasonably determined in good faith by the Parties. 
 Where
the preceding sentence is applicable, OSI shall in good faith propose to AVEO an allocation of relative value of the Royalty-Bearing Product and all other product(s) included in the Combination Product, AVEO shall in good faith consider such
proposal, and the Parties shall seek to reach agreement on such allocation. If the Parties are unable to reach such agreement within thirty (30) days (or such longer period as the Parties may agree) after OSI provides such proposal, the issue
shall be referred for binding resolution to a mutually agreeable individual (not affiliated with either Party) with expertise in the marketing and sales of similar pharmaceutical products (including experience in pricing and reimbursement), such
resolution to occur within thirty (30) days after such referral. 
  

 - 13 - 

 1.68 “Nominated Target”. Nominated Target means a Candidate Target that has
been designated by the JSC either (i) for further validation pursuant to a Nominated Target Package Plan, as further described in Section 3.7(b) or (ii) pursuant to Section 3.7(c)(iii) below. 
 1.69 “Non-Antibody Compound”. Non-Antibody Compound means any composition of matter other than an Antibody. For purposes of
clarity, Non-Antibody Compound includes (a) small-molecule compounds having a molecular weight that is less than or equal to 1,000 daltons, [**]. 
 1.70 “Non-Antibody Compound Intellectual Property”. Non-Antibody Compound Intellectual Property means Collaboration Intellectual Property relating to the composition of a Non-Antibody
Compound. 
 1.71 “Non-Antibody Product”. Non-Antibody Product means any product that contains a Non-Antibody
Compound. 
 1.72 “Original Effective Date”. Original Effective Date means September 28, 2007. 

1.73 “OSI Active Program Models”. OSI Active Program Models means tumor models driven by the OSI Active Program Targets,
other than the [**] Models, that have been or may be developed by AVEO pursuant to the Research Plan. The Tumor models known as the “[**] Model” and the “[**] Model” shall be deemed OSI Active Program Models (for the [**] program
and the [**] program, respectively), as if they were driven by OSI Active Program Targets. 
 1.74 “OSI Active Program
Target(s)”. OSI Active Program Targets means [**] and those Targets agreed to by the Parties prior to the Original Effective Date. 
 1.75 “OSI Active Program Translational Research Intellectual Property”. OSI Active Program Translational Research Intellectual Property means the OSI Active Program Translational Research
Know-How and the OSI Active Program Translational Research Patent Rights. 
 1.76 “OSI Active Program Translational
Research Know-How”. OSI Active Program Translational Research Know-How means, with respect to OSI Active Program Targets, Know-How developed: [**]. 
 1.77 “OSI Active Program Translational Research Patent Rights”. OSI Active Program Translational Research Patent Rights means Patent Rights that claim OSI Active Program Translational
Research Know-How. 
 1.78 “OSI Existing Targets”. OSI Existing Targets means Targets other than the AVEO
Existing Targets that are included on the Candidate Target List pursuant to Section 3.7(b)(i) and identified as OSI Existing Targets on the Candidate Target List. 
  

 - 14 - 

 1.79 “OSI Know-How”. OSI Know-How means Know-How other than Collaboration
Know-How that (a) is Controlled by OSI as of the Original Effective Date or during the Term, and (b) is (i) necessary or reasonably useful to conduct the Research Program or to research, develop, make and have made, use, offer for
sale, sell or import a Product or (ii) developed or made by or on behalf of OSI or its Affiliates in the research, development, manufacture or commercialization of a Royalty-Bearing Product. For purposes of clarity, OSI Know-How includes all
Know-How Controlled by OSI as of the Original Effective Date or during the Term and related to the OSI Existing Targets and the OSI Active Program Targets. 
 1.80 “OSI Patent Rights”. OSI Patent Rights means any Patent Rights Controlled by OSI during the Term that claim OSI Know-How. 
 1.81 “OSI Intellectual Property”. OSI Intellectual Property means the OSI Know-How and the OSI Patent Rights. 

1.82 “Party” and “Parties”. Party means OSI or AVEO singly, and Parties means OSI and AVEO
collectively. 
 1.83 “Patent Rights”. Patent Rights means the rights and interests in and to all issued
patents and pending patent applications in any country or jurisdiction, including all provisional applications, substitutions, utility applications, divisions, continuations, continuations-in-part, registrations, re-examinations, reissues,
extensions and restorations by existing or future extension or restoration mechanisms, supplementary protection certificates and restorations of patent term. 
 1.84 “Phase I Clinical Trial”. Phase I Clinical Trial means a human clinical trial in any country that meets the requirements of 21 CFR §312.21(a). Each Phase I Clinical Trial shall
be deemed commenced upon dosing of the first participant in such trial. 
 1.85 “Phase II Clinical Trial”.
Phase II Clinical Trial means a human clinical trial in any country that meets the requirements of 21 CFR §312.21(b). Each Phase II Clinical Trial shall be deemed commenced upon dosing of the first participant in such trial. 
 1.86 “Phase III Clinical Trial”. Phase III Clinical Trial means a human clinical trial in any country in the Territory that
meets the requirements of 21 CFR §312.21(c). Each Phase III Clinical Trial shall be deemed commenced upon dosing of the first participant in such trial. 
 1.87 “Phase IV Clinical Trial”. Phase IV Clinical Trial means a post-registrational Clinical Trial conducted in any country or countries and required as a condition to, or for the
maintenance of, any Regulatory Approval for a Product. 
 1.88 “[**] Compound”. [**] Compound means any
Non-Antibody Compound for which the primary mechanism of action is the inhibition [**]. 
  

 - 15 - 

 1.89 “[**] Product”. [**] Product means any preparation in final form
(other than a Product), either for sale by prescription, over-the-counter or any other method, or for administration to patients in Clinical Trials, for any and all uses in the Field, where such preparation (a) contains a [**] Compound, and
(b) the Regulatory Approval of such [**] Product includes a label claim for the identification of a targeted patient population (including where such population is characterized by one or more biomarkers) Covered by OSI Patent Rights based on
AVEO [**] Know How. 
 1.90 “Pre-Collaboration Target(s)”. Pre-Collaboration Target means one or more of the
[**] Targets for which AVEO has compiled a target package as of the Original Effective Date. The Pre-Collaboration Targets have been identified to OSI prior to the Original Effective Date. 
 1.91 “Pre-Selected Antibody Targets”. Pre-Selected Antibody Targets means [**] of the Targets set forth on Schedule
1.91 selected by OSI upon written notice to AVEO within [**] of the Restatement Effective Date. During such [**] period, additional Targets may be listed on Schedule 1.91 upon mutual agreement of the Parties. 
 1.92 “Product”. Product means any preparation in final form, either for sale by prescription, over-the-counter or any other
method, or for administration to human patients in Clinical Trials, for any and all uses in the Field, which preparation contains a Collaboration Compound, but expressly excluding any [**] Product. 
 1.93 “Product Patent Rights”. Product Patent Rights means any Patent Rights other than Collaboration Patent Rights that
Cover any Product (including its composition, characteristics, properties, formulation, methods of use, methods of manufacture or methods of delivery). 
 1.94 “Regulatory Approval”. Regulatory Approval means, with respect to a Product, the granting, whether through lapse of time or otherwise, by the FDA or a comparable Regulatory Authority
of approval to market a drug product in a country or other jurisdiction in the Territory. 
 1.95 “Regulatory
Authority”. Regulatory Authority means any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a Royalty-Bearing Product or an Antibody Product, as the
case may be, in the Territory, including, in the United States, the United States Food and Drug Administration and any successor governmental authority having substantially the same function. 
 1.96 “Research Program”. Research Program means the research activities undertaken by the Parties pursuant to this
Agreement and the Research Plan. The preliminary Research Plan was exchanged between the Parties prior to the Original Effective Date. 
 1.97 “Research Program Year”. Research Program Year means the annual period commencing on the Research Program Commencement Date and ending twelve months thereafter (the “First Research Program Year”), and
each succeeding twelve

  

 - 16 - 

 
(12) month period thereafter during the Research Program Term (referred to as the “Second Research Program Year”, the “Third Research Program Year”, and
Fourth Research Program Year”; provided that, the Fourth Research Program Year shall only be comprised of the eight (8)-month period ending June 30, 2011. 
 1.98 “Royalty-Bearing Product”. Royalty-Bearing Product means any Product or [**] Product. 
 1.99 “Specified Antibody Targets”. Specified Antibody Targets means the Pre-Selected Antibody Targets and any Additional
Antibody Targets. 
 1.100 “Specified Antibody Intellectual Property”. Specified Antibody Intellectual Property
means Collaboration Intellectual Property relating to the composition of a Collaboration Antibody. 
 1.101
“Sublicensee”. Sublicensee means a Third Party to whom a Party (or its Affiliate) has granted a license or sublicense under the AVEO Intellectual Property, AVEO Platform Intellectual Property, AVEO Bioinformatics Data, the
Collaboration Intellectual Property, the AVEO [**] Know-How or the OSI Intellectual Property, as the case may be, to research, develop, make and have made, offer for sale, sell or import a Royalty-Bearing Product, Non-Antibody Product or
Collaboration Antibody, as the case may be; provided, however, that a Sublicensee shall not include any distributor, dealer or reseller or the like. 
 1.102 “Target”. Target means a protein, including all expressed and modified, ligand-bound variants of such protein and genes encoding such proteins, and any stably associated
multiprotein complex in which such protein is known to be active. 
 1.103 “Target Intellectual Property”.
Target Intellectual Property means any Collaboration Intellectual Property which specifically relates to the identification, properties, characteristics or uses of any Candidate Target, Nominated Target or Collaboration Target. For clarity, Target
Intellectual Property excludes (a) the OSI Active Program Targets and any intellectual property rights therein, (b) Targets driving [**] Models and (c) therapeutic uses of any modulator of a Target. 
 1.104 “Territory”. Territory means all countries in the world. 
 1.105 “Third Party”. Third Party means an entity other than OSI and its Affiliates, and AVEO and its Affiliates.

 1.106 “Third Party Target(s)”. Third Party Target(s) means one or more of the [**] Targets with respect to
which AVEO has previously granted rights in the Field to a Third Party, provided that any such Target shall cease to be a Third Party Target if and when such Target is no longer subject to such previously granted rights. 
  

 - 17 - 

 1.107 “Transferred Cell Line”. Transferred Cell Line shall mean a frozen
in vitro propagated cell line derived from an OSI Active Program Model or a Collaboration Model, which cell line has been characterized and shown to express the gene of interest without the expression of the doxycycline induced gene.

 1.108 “Translational Research Intellectual Property”. Translational Research Intellectual Property means the
Translational Research Know-How and the Translational Research Patent Rights. 
 1.109 “Translational Research
Know-How”. Translational Research Know-How means, with respect to Nominated Targets, Specified Antibody Targets and Collaboration Targets, and on a Nominated Target-by-Nominated Target, Specified Antibody Target-by-Specified Antibody Target
and Collaboration Target-by-Collaboration Target basis (as the case may be), Collaboration Know-How: [**]. 
 1.110
“Translational Research Patent Rights”. Translational Research Patent Rights means Patent Rights that claim Translational Research Know-How. 
 1.111 “Valid Claim”. Valid Claim means any claim of an issued and unexpired Patent Right that has not been revoked or held unenforceable or invalid by a final decision of a court or other
Governmental Authority of competent jurisdiction, which decision is not appealable or has not been appealed within the time allowed for appeal, and that has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue or
disclaimer or otherwise. 
 1.112 Each of the following definitions is set forth in the section of this Agreement indicated
below: 
  

			
	 Definition:
	  	 Section:

		
	 Annual FTE Rate
	  	6.3(a)
	 Antibody Target
	  	1.7
	 Additional Tumor Models
	  	2.16
	 Agreement
	  	Preamble
	 AVEO
	  	Preamble
	 AVEO Genetic Screens
	  	1.11
	 AVEO Label Claim Product
	  	6.18(a)
	 AVEO Target Translational Research Patent Rights
	  	7.2
	 Bioinformatics Improvements
	  	10.6
	 Bioinformatics Tools Updates
	  	10.2(a)
	 Collaboration Expansion Option
	  	10.1
	 Collaboration Target Translational Research Intellectual Property
	  	3.2
	 Designated Product
	  	6.19
	 Designation Notice
	  	6.19

  

 - 18 - 

			
	 Definition:
	  	 Section:

		
	 Dispute
	  	11.1
	 Expansion Date
	  	10.2
	 Expansion Notice
	  	10.1
	 Escrow Agent
	  	3.5(d)(iii)
	 Escrow Agreement
	  	3.5(d)(iii)
	 Final Nominated Targets
	  	3.7(c)(iii)
	 [**] Models
	  	2.17
	 FTE
	  	6.3(a)
	 Initial License Expansion Fee
	  	6.1(f)(i)
	 Joint Intellectual Property
	  	3.3(a)(ii)
	 Joint Patent Rights
	  	3.3(a)(ii)
	 Joint Steering Committee
	  	2.4
	 License Expansion Fee
	  	6.1(f)
	 JSC
	  	2.4
	 Materials
	  	2.5
	 Model Improvements
	  	10.6(b)
	 Model Patent Rights
	  	7.2
	 [**] Intellectual Property
	  	10.2(e)
	 Nominated Target Package
	  	3.7(b)(iii)
	 Nominated Target Package Plan
	  	3.7(b)(iii)
	 Non-Antibody Compound Patent Rights
	  	7.1
	 Non-Validated Collaboration Target
	  	3.7(c)(iii)
	 Option
	  	3.7
	 Option Period
	  	3.7(c)(i)
	 Original Agreement
	  	Introduction
	 OSI
	  	Preamble
	 [**]
	  	1.16
	 [**] Notice
	  	3.8(b)
	 [**] Index
	  	Schedule 1.15
	 Pre-Collaboration Target Package
	  	3.7(a)
	 Project Leader
	  	2.3(b)
	 Research Plan
	  	2.1
	 Research Program Commencement Date
	  	2.2
	 Research Program Term
	  	2.2
	 Restatement Effective Date
	  	Preamble
	 Restricted Period
	  	4.3(b)
	 Reverted Target
	  	3.7(c)(ii)
	 [**]
	  	2.11
	 Royalty Term
	  	6.6(e)
	 Specified Models
	  	3.5(a)
	 Target Patent Rights
	  	7.2
	 Technology Transfer
	  	10.4(b)
	 Tech Transfer Period
	  	10.4(b)

  

 - 19 - 

			
	 Definition:
	  	 Section:

		
	 Tech Transfer Plan
	  	10.4(a)
	 Term
	  	9.1
	 Tumor Archives
	  	10.2(c)
	 Validation Criteria
	  	3.7(b)(iii)

 ARTICLE II 
 RESEARCH PROGRAM 
 2.1 General. AVEO and
OSI shall engage in the Research Program upon the terms and conditions set forth in this Agreement. The activities to be undertaken in the course of the Research Program are set forth in a yearly research plan which may be amended from time to time
upon the agreement of the JSC (as defined below) (including, an amendment to be completed by the Restatement Effective Date) (as so amended, the “Research Plan”). Pursuant to and in compliance with the Original Agreement, the
Parties finalized the Research Plan for the First Research Program Year within thirty (30) days after the Original Effective Date, and such final Research Plan included the agreed Candidate Target List developed by the Parties pursuant to
Section 3.7(b)(i). 
 2.2 Research Program Term. Except as otherwise provided herein, the term of the Research
Program commenced on October 29, 2007 (the “Research Program Commencement Date”) and shall expire on June 30, 2011 (the “Research Program Term”). 
 2.3 Conduct of the Research Program; Project Leaders. 
 (a) AVEO and OSI shall each use Commercially Reasonable Efforts to conduct the Research Program in good scientific manner and to achieve their objectives efficiently and expeditiously. AVEO and OSI shall
use Commercially Reasonable Efforts to (i) proceed diligently with the work set out in the Research Plan, (ii) allocate sufficient time, effort, equipment and facilities to the Research Program, and (iii) use personnel with sufficient
skills and experience as are required to accomplish the Research Program in accordance with this Agreement and the Research Plan. 
 (b) Pursuant to and in compliance with the Original Agreement, each Party has appointed a senior representative having a general understanding of pharmaceutical discovery and development issues to act as its project leader under this
Agreement (the “Project Leader”). The Project Leaders serve as the contact point between the Parties, and are primarily responsible for: (i) facilitating the flow of information and otherwise promoting communication,
coordination and collaboration between the Parties; (ii) providing single point communication for seeking consensus both internally within the respective Party’s organization and together, including facilitating review of external
corporate communications; and (iii) raising cross-Party and/or cross-functional disputes in a timely manner. 
  

 - 20 - 

 (c) Either Party shall have the right to utilize the service of a Third Party to perform
its Research Program obligations upon the prior written consent of the other Party. Notwithstanding any such consent, such Party shall remain at all times fully liable for its responsibilities under the Research Program and this Agreement.

 (d) AVEO and OSI shall conduct the Research Program in accordance with all applicable Laws, including, all current
governmental regulatory requirements concerning Good Laboratory Practices. In addition, if animals are used in the conduct of the Research Program, AVEO and OSI will comply with the Animal Welfare Act and the requirements of the American Association
for the Accreditation of Laboratory Animal Care or any other applicable Laws relating to the care and use of laboratory animals. The Parties are each encouraged to use the highest standards of animal care and husbandry, such as those set forth in
the Guide for the Care and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of research animals. To the best of its knowledge, each Party hereby certifies that it will not employ or otherwise use in any capacity the
services of any person debarred under 21 USC §335a in performing any activities hereunder. 
 2.4 Governance; Joint
Steering Committee. Pursuant to and in compliance with the Original Agreement, the Parties established a joint steering committee (the “Joint Steering Committee” or “JSC”) to oversee and facilitate the Research
Program. 
 (a) Composition of the Joint Steering Committee. The JSC shall be comprised of three (3) named
representatives of OSI and three (3) named representatives of AVEO (or such other number as the Parties may agree). Pursuant to and in compliance with the Original Agreement, each Party designated by written notice to the other Party its
initial representatives on the JSC within thirty (30) days after the Original Effective Date. Each Party may replace one or more of its representatives, in its sole discretion, effective upon notice to the other Party of such change. These
representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research Program. Notwithstanding the foregoing, the leading representative of each Party on the JSC shall be the Senior Vice
President, Oncology Research of OSI and the Vice President, Translational Research of AVEO. Additional representatives or consultants may from time to time, by mutual consent of the Parties, be invited to attend JSC meetings, subject to such
representative’s and consultant’s written agreement to comply with confidentiality obligations substantially the same as those set forth in Article V. Each Party shall bear its own expenses related to the attendance of JSC meetings by its
representatives. The JSC shall be chaired by a representative of the Parties, to alternate during each Research Program Year, with the chair for the First Research Program Year previously appointed by OSI. The JSC shall be disbanded upon expiration
of the Research Program Term. 
 (b) Meetings of the JSC During the Research Program Term. The JSC shall meet in
accordance with a schedule established by mutual written agreement of the Parties, but no less frequently than once per Calendar Quarter, with the location of such meetings alternating between AVEO and OSI facilities (or such other location as is
determined by the JSC). Alternatively, the JSC may meet by means of teleconference, videoconference or other similar communications equipment. 
  

 - 21 - 

 (c) Function and Powers of the JSC. The JSC’s responsibilities shall include:

 (i) approving the Research Plan for each Research Program Year; 
 (ii) approving any changes to the Parties’ Project Leaders; 
 (iii) facilitating ongoing cooperation and communication between the Parties with respect to the Research Program; 
 (iv) providing a forum for discussion of the Research Plans, the status of the Research Program, and relevant data; 
 (v) considering and advising on technical issues and issues of priority that arise in the conduct of the Research Program; 
 (vi) review and track the exchange and use of Materials (as defined below) pursuant to Section 2.5; 
 (vii) reviewing and advising on any budgetary and economic matters relating to the Research Program, including establishing a budget for
significant out of pocket expenses (e.g. sequencing, microarray analyses, etc.); 
 (viii) determining if additional validation
work is warranted with respect to any Nominated Target Package, and overseeing any such additional validation work; 
 (ix)
developing the Candidate Target List, and adding and removing Targets to or from the Candidate Target List; 
 (x) prioritizing
Candidate Targets; 
 (xi) designating Nominated Targets and establishing the number of Candidate Targets to be designated as
Nominated Targets; 
 (xii) on a Nominated Target-by-Nominated Target basis, establishing the requirements for each Nominated
Target Package; 
 (xiii) establishing a list of Final Nominated Targets as of the expiration of the Candidate Target
Exclusivity Period pursuant to Section 3.7(c)(iii); 
 (xiv) the allocation of resources (FTEs) pursuant to the Research
Plans; 
 (xv) serving as a forum for informal resolution of disagreements that may arise in the relation to the Parties
activities under the Research Program; 
  

 - 22 - 

 (xvi) determining and approving the overall strategy for publications and presentations
pursuant to Sections 5.3 and 5.4; 
 (xvii) determining which Additional Tumor Models are created pursuant to the Research
Plan; 
 (xviii) determining which Tumor Archives are created and the timing of such creation under the Research Plan;

 (xix) determining which cell lines are created in support of (a) the development of new DC tumor models, (b) the
development of chimeric mouse tumor models and (c) drug discovery efforts on Collaboration Targets; 
 (xx) reviewing
requests regarding the use of the AVEO bioinformatics platform pursuant to the Research Plan, and overseeing the training of OSI team members on using the AVEO bioinformatics platform in accordance with Section 2.15; and 
 (xxi) developing the Tech Transfer Plan and facilitating ongoing cooperation and communication with respect to the Technology Transfer.

 (d) Decision-making. At least [**] JSC representatives from each Party must participate in a meeting of the JSC (or
any subcommittee thereof) in order for there to be a quorum for such meeting. All decisions of the JSC shall be made by the unanimous vote of the members of the JSC, with the JSC representatives of each Party collectively having one vote. The
Parties shall use reasonable good faith efforts to reach consensus on all issues within the jurisdiction of the JSC. If members of the JSC cannot agree with respect to a particular issue within the JSC’s jurisdiction, then the OSI
representative(s) will have the right to resolve the issue at their discretion, and their decision will be deemed the decision of the JSC; provided that [**]. 
 (e) Limitations on JSC Authority. The JSC shall have no power to amend, modify or waive compliance with this Agreement. It shall have only such powers as are specifically set forth in this
Agreement for the JSC to perform. The JSC’s meeting minutes, regardless of whether signed by senior representatives of both Parties, shall not be deemed to amend, modify or waive compliance with this Agreement. Notwithstanding any other
provision of this Section 2.4, no decision shall be made by the JSC or either Party which is inconsistent with this Agreement or imposes any obligation or burden on the other Party that is outside the scope of this Agreement. 
 2.5 Materials Transfer. In order to facilitate the Research Program, either Party may provide to the other Party certain tangible
biological materials or chemical compounds, including AVEO’s proprietary Models and Transferred Cell Lines derived from such Models, Collaboration Compounds, receptors, assays, reagents and screens (collectively, “Materials”)
owned by or licensed to the supplying Party (other than under this Agreement) for use by the other Party in furtherance of the Research Program. For purposes of clarity, biological materials and chemical compounds, including the Additional Tumor
Models and Tumor Archives, transferred pursuant to Section 10.2 shall not be considered Materials under this Agreement. The transfer of any such Materials shall be conducted pursuant to the terms of this Agreement, including the following:

 (a) Any Know-How or Inventions, including any intellectual property rights therein, developed, made or conceived through use
of the Materials (other than (i) [**] Models, (ii) the OSI Active Program Models, (iii) the [**] Models and (iv) the Transferred Cell Lines derived from OSI Active Program Models) shall be deemed Collaboration Intellectual
Property under this Agreement. 
  

 - 23 - 

 (b) All Materials supplied by one Party to the other Party shall remain the sole property
of the supplying Party and shall be used (i) only in furtherance of the Research Program or for the specific purpose provided for in the Research Plan, and (ii) solely under the control of the receiving Party. In the event a Party uses
Materials provided by the other Party for purposes other than in furtherance of the Research Program or for the specific purpose provided in the Research Plan, the other Party shall solely own any results, discoveries or inventions arising out of
such use. The Materials may not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not be used in research or testing involving human subjects, except as expressly
contemplated as a part of the Research Program. All Materials shall be returned to the supplying Party or destroyed (at the election of the supplying Party) promptly after completion of the permitted use. The use of the Materials shall comply with
restrictions and conditions on use (if any) imposed by Third Parties. Notwithstanding anything to the contrary herein, the obligations set forth in this Section 2.5(b) shall not apply to any [**] Models transferred pursuant to Section 2.12
below. 
 (c) The Parties shall cooperate in determining if one or more Third Party licenses are necessary to use the Materials
as contemplated under the Research Program. OSI shall be solely responsible for obtaining any necessary Third Party licenses prior to receiving Materials from AVEO. AVEO has disclosed to OSI all necessary Third Party licenses relating to AVEO’s
basic modeling technology of which it is aware as of the Restatement Effective Date. 
 (d) THE MATERIALS ARE PROVIDED “AS
IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT
OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. Any Materials supplied by one Party to the other Party must be used with prudence and appropriate caution in any experimental work, since not all of their characteristics may be known. 
 2.6 Records and Reports. 
 (a) Records. Each Party shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work
done and results achieved in the performance of the Research Program by or on behalf of such Party. 
  

 - 24 - 

 (b) Reports to the JSC. At each JSC meeting, each Party shall provide to the other
Party a report on the progress of the Research Program, evaluating the work performed in relation to the goals of the Research Program. Each Party shall provide such other information required by the Research Program or reasonably requested by the
other Party relating to the progress of the goals or performance of the Research Program. In addition, at each JSC meeting AVEO and OSI shall disclose to the JSC the development, making, conception and/or reduction to practice of any Collaboration
Know-How. 
 (c) Activities after Research Program Term. After the expiration of the Research Program Term, OSI shall
continue to keep AVEO apprised, once each Calendar Quarter, of the status of OSI’s research, development and/or commercialization activities regarding (i) Collaboration Targets, Collaboration Compounds and Royalty-Bearing Products, and
(ii) OSI Active Program Targets and corresponding products by providing written summaries regarding relevant Collaboration Targets, Collaboration Compounds and Royalty-Bearing Products to AVEO within thirty (30) days after the expiration
of each Calendar Quarter commencing with the first Calendar Quarter following the expiration of the Research Program Term. In addition, upon either Party’s request to be exercised no more than twice in any Calendar Year, a meeting of the
Parties shall be convened to review OSI’s activities with respect to the research, development and/or commercialization of Collaboration Targets, Collaboration Compounds and Royalty-Bearing Products. Such meeting shall be held at the facilities
of the Party not requesting the meeting, or at a mutually agreed location, and shall be attended by at least two (2) representatives of AVEO and at least two (2) representatives of OSI responsible for the continued development and
commercialization of Collaboration Targets, Collaboration Compounds and Royalty-Bearing Products. Each Party shall bear its own expenses in connection with attending any such meetings. 
 2.7 Exclusivity Regarding Targets. 
 (a) Subject to the exceptions set forth in Section 2.8, except with respect to research and development activities pursuant to this Agreement, neither AVEO nor its Affiliates shall, nor shall any of
them grant rights to Third Parties to, conduct any research program having the goal of validating or conducting biomarker research on any Candidate Target for the discovery or development of Non-Antibody Compounds for use in the Field during the
Candidate Target Exclusivity Period. 
 (b) After the Candidate Target Exclusivity Period and during the remainder of the
Research Program Term, subject to the exceptions set forth in Section 2.8, except with respect to research and development activities pursuant to this Agreement, neither AVEO nor its Affiliates shall, nor shall any of them grant rights to Third
Parties to, conduct any research program having the goal of validating or conducting biomarker research on any Nominated Target for the discovery or development of Non-Antibody Compounds for use in the Field. 
  

 - 25 - 

 (c) After the Candidate Target Exclusivity Period and during the remainder of the Research
Program Term, subject to the exceptions set forth in Section 2.8, except with respect to research and development activities pursuant to this Agreement, neither AVEO nor its Affiliates shall, nor shall any of them grant rights to Third Parties
to, conduct any research program having the goal of validating or conducting biomarker research on any Pre-Selected Antibody Target to which OSI has exercised its Option pursuant to Section 3.7(c) below, for the discovery or development of the
applicable Collaboration Antibody for use in the Field. 
 2.8 Exceptions. The prohibitions set forth in Section 2.7
do not apply to any of the following: 
 (a) Excluded Targets and Non-Antibody Compounds Directed to Excluded Targets;

 (b) [**] and [**] and Non-Antibody Compounds Directed to [**] and [**]; 
 (c) OSI Active Program Targets and Non-Antibody Compounds Directed to OSI Active Program Targets; 
 (d) AVEO Targets and Non-Antibody Compounds Directed to AVEO Targets; 
 (e) Antibodies directed to any Target other than the Specified Antibody Targets; and 
 (f) where AVEO’s involvement in such activity results from AVEO’s acquisition of or by a Third Party (by merger or otherwise),
and such Third Party was engaged in such activity prior to such acquisition or merger; provided that (i) AVEO shall not provide any such Third Party with rights or access to (A) OSI Intellectual Property, or (B) Collaboration
Intellectual Property for use in connection with activities prohibited by Section 2.7 if undertaken by AVEO, and (ii) in the case where AVEO acquires a Third Party (by merger or otherwise), AVEO does not expand the scope of, or increase
the financial commitment to, such Third Party activities, from what it was immediately prior to the acquisition. 
 2.9 AVEO
Targets. Notwithstanding any other provision of this Agreement, if, at any time during the Research Program Term, a Target becomes an AVEO Target, and AVEO has not entered into an agreement with a Third Party that grants rights to such Third
Party inconsistent with the rights that would be licensed to OSI under Sections 3.5 and 3.9 were such AVEO Target a Collaboration Target, OSI may, on written notice to AVEO, request that AVEO include such AVEO Target in the Research Program. AVEO
shall promptly consider OSI’s request in good faith, and if, in its sole discretion, AVEO agrees to include such AVEO Target in the Research Program, such AVEO Target shall be designated as a Nominated Target. 
  

 - 26 - 

 2.10 AVEO Third Party Programs. 
 (a) If, at any time during the Research Program Term, AVEO, alone or in collaboration with a Third Party, wishes to commence activities
with respect to a Target that would otherwise violate the provisions of Section 2.7(a) (and such activities are not covered by an exception set forth in Section 2.8), AVEO may request, by written notice to OSI, that such Target be
designated as an Excluded Target. OSI shall promptly consider AVEO’s request in good faith, and if, in its sole discretion, OSI agrees to designate such Target as an Excluded Target, such Target shall be designated as an Excluded Target and the
provisions of Section 2.7 shall no longer apply to such Target. 
 (b) With respect to any Third Party Target, AVEO agrees
to promptly notify OSI of the identity of such Third Party Target if and when AVEO is no longer subject to confidentiality restrictions regarding the disclosure of such Third Party Target. 
 2.11 Partnering of AVEO Antibody Programs. If, at any time during the Candidate Target Exclusivity Period, AVEO elects to seek a
partner specifically with respect to a single program for the research, development or commercialization of Antibody Products Directed to (a) the Targets known as [**], or (b) the Target known as [**], (c) the Target known as [**], or
(d) any Nominated Target or Collaboration Target, then AVEO will contact OSI and provide OSI access to information related thereto and relevant to OSI’s determination of interest in initiating partnering discussions, to the same extent as
such information is being provided to other interested Parties; provided that AVEO shall also be free to engage in partnering discussions with Third Parties concurrently with any discussions with OSI, and this provision shall not be construed
as granting OSI any priority in such negotiations. Negotiations regarding strategic partnerships involving multiple programs or merger and acquisition discussions shall be excluded from the application of this provision. 
 2.12 [**] Models. AVEO has delivered, and OSI acknowledges receipt of, the [**] Model specified in Section 2.12 of the Original
Agreement. AVEO hereby agrees to use Commercially Reasonable Efforts to deliver additional [**] Models to OSI, as selected and requested by OSI, within [**] days after OSI’s written request. Notwithstanding anything to the contrary herein, OSI
may transfer an [**] Model (including the rights to use such [**] Model as provided in Section 3.5(b)(i)) only to a Third Party in connection with the sublicense by OSI to such Third Party of (a) rights to research, develop, make and have
made, use, offer for sale, sell and import Non-Antibody Compounds or Collaboration Antibodies related to such [**] Model, or (b) the right to develop diagnostics associated with Non-Antibody Compounds or Collaboration Antibodies related to such
[**] Model. 
 2.13 OSI Active Program Model(s) and Activities. AVEO will use Commercially Reasonable Efforts to
(a) develop and deliver to OSI an OSI Active Program Model if requested by OSI, and (b) conduct research using the Human Response PredictionTM Research, in each case pursuant to the Research Plan. 
 2.14 Transfer of Transferred Cell Lines. Upon written request by OSI, AVEO shall [**]. Notwithstanding anything in this Agreement to
the contrary, AVEO hereby agrees that Transferred Cell Lines shall be treated as Materials under the Agreement and, except as set forth in this Section 2.14, subject to all provisions regarding transfer of Materials as set forth in the
Agreement. Upon payment of the Milestone by OSI to AVEO set forth in 6.4(a)(ii), notwithstanding the provisions of Section 2.5(b), OSI shall not be required to return the Transferred Cell Lines. 
  

 - 27 - 

 2.15 Access to AVEO Bioinformatics Platform. Under the direction of the Project
Leaders, AVEO shall provide remote access during the Research Program Term to the AVEO Bioinformatics Tools and AVEO Bioinformatics Data to [**] of OSI at a time) to utilize the AVEO Bioinformatics Tools in the exercise of the license granted to OSI
under Section 3.5(d) below. The AVEO Bioinformatics Tools and AVEO Bioinformatic Data shall be deemed AVEO Confidential Information and subject to Article V of this Agreement. OSI agrees that it will not (a) sell, lease, rent, display,
license, sublicense, transfer, provide, disclose, or otherwise make available to, or permit the use of, or access to, the AVEO Bioinformatics Tools, in whole or in part, to any Third Party, or otherwise use the AVEO Bioinformatics Tools on a
“service bureau” basis. 
 2.16 Creation of Additional Tumor Models. Upon the Restatement Effective Date, the
Parties agree to amend the Research Plan to include use by AVEO of Commercially Reasonable Efforts to create the chimeric tumor models and DC tumor models driven by Targets other than Collaboration Targets for use in the Research Program (the
“Additional Tumor Models”). For purposes of clarification, Additional Tumor Models shall not include Target-specific tumor models Directed to Excluded Targets. 
 2.17 Delivery of Additional [**] Models. Upon the mutual agreement of the Parties and payment of the fee set forth in
Section 6.1(e) below, AVEO shall deliver to OSI up to [**] tumor models driven by the Targets known as [**] (“[**] Models”). 
 ARTICLE III 
 INTELLECTUAL PROPERTY RIGHTS AND GRANTS OF RIGHTS

 3.1 Intellectual Property and Materials Solely Owned by AVEO. AVEO shall own the entire right, title and
interest in and to: (a) the AVEO Intellectual Property; (b) the Model Intellectual Property, (c) the Target Intellectual Property, (d) the AVEO Bioinformatics Tools, (e) the AVEO Bioinformatics Data, (f) the AVEO
Bioinformatics Source Code, (g) the AVEO Platform Intellectual Property, (h) the AVEO [**] Know-How and (i) the [**] Intellectual Property. 
 3.2 Intellectual Property Solely Owned by OSI. OSI shall own the entire right, title and interest in and to: (a) OSI Intellectual Property; (b) Product Patent Rights, (c) OSI Active
Program Translational Research Intellectual Property; (d) Non-Antibody Compound Intellectual Property; (e) Specified Antibody Intellectual Property, (f) Additional Tumor Model Translational Research Intellectual Property;
(g) Translational Research Intellectual Property relating directly to Pre-Selected Antibody Targets and (h) upon exercise of the Option with respect to a particular Collaboration Target, the Translational Research Intellectual Property
relating directly to such Collaboration Target (“Collaboration Target Translational Research Intellectual Property”). 
  

 - 28 - 

 3.3 Intellectual Property and Materials Jointly Owned by the Parties. 
 (a) The Parties will jointly own: 
 (i) Translational Research Intellectual Property relating directly to a Nominated Target (the “Nominated Target Translational Research Intellectual Property”); and 
 (ii) all Collaboration Intellectual Property other than (A) Model Intellectual Property; (B) Target Intellectual Property;
(C) Collaboration Target Translational Research Intellectual Property (including Translational Research Intellectual Property relating directly to Pre-Selected Antibody Targets), (D) OSI Active Program Translational Research Intellectual
Property, (E) Additional Tumor Model Translational Research Intellectual Property, (F) Specified Antibody Intellectual Property and (G) Non-Antibody Compound Intellectual Property. 
 The Nominated Target Translational Research Intellectual Property and the Collaboration Intellectual Property identified in Section 3.3(a)(ii) shall be
referred to herein as the “Joint Intellectual Property”, and Patent Rights within the Joint Intellectual Property shall be referred to herein as “Joint Patent Rights.” 
 (b) Subject to the licenses granted in Sections 3.6(b) and 3.8(a), either Party may use or license or sublicense to Affiliates or Third
Parties all or any portion of its interest in Joint Intellectual Property throughout the world without the prior written consent of the other Party, without restriction and without the obligation to provide compensation to the other Party;
provided that (i) OSI shall have no right to use, license or sublicense its interest in the Nominated Target Translational Research Intellectual Property except as required to perform its obligations under the Research Program, and
(ii) AVEO shall have no right to use, license or sublicense its interest in Nominated Target Translational Research Intellectual Property except (A) as required to perform its obligations under the Research Program, (B) in connection
with the discovery, development and commercialization of Antibody Products and associated diagnostics, and (C) in connection with the discovery, development and commercialization of Non-Antibody Products Directed to AVEO Targets and associated
diagnostics. 
 (c) Subject to Section 3.3(b)(i), OSI covenants not to use the Translational Research Intellectual
Property for any purpose other than (i) the discovery, development and commercialization of diagnostics related to Non-Antibody Products and Collaboration Antibodies, (ii) the discovery, development and commercialization of Non-Antibody
Products and Collaboration Antibodies in the Field, unless OSI delivers the Expansion Notice and pays the Initial License Expansion Fee, in which case OSI shall be entitled to use the Translational Research Intellectual Property for the discovery,
development and commercialization of OSI Non-Antibody Products and Collaboration Antibodies, (iii) the sublicense of the Translational Research Intellectual Property in

  

 - 29 - 

 
connection with the discovery, development and commercialization of diagnostics related to Non-Antibody Products and Collaboration Antibodies, and (iv) the sublicense of the Translational
Research Intellectual Property in connection with the discovery, development and commercialization of Non-Antibody Products and Collaboration Antibodies in the Field, unless OSI delivers the Expansion Notice and pays the Initial License Expansion
Fee, in which case OSI shall be entitled to sublicense the Translational Research Intellectual Property in connection with the discovery, development and commercialization of OSI Non-Antibody Products and Collaboration Antibodies, all in accordance
with this Agreement. 
 3.4 Inventorship; Implementation of Sole and Joint Ownership. 
 (a) For purposes of this Agreement, inventorship shall be determined in accordance with United States patent Laws. 
 (b) To implement the rights of sole and joint ownership throughout the world as provided for in Sections 3.1, 3.2 and 3.3, each Party
hereby assigns to the other Party, and hereby grants to the other Party all consents, licenses and waivers, in each case that are necessary to achieve such sole or joint ownership and the rights associated with such sole or joint ownership
worldwide, and agrees to provide documents evidencing or that may be required to record such assignments, consents, licenses and waivers promptly upon the other Party’s request. Each of the foregoing assignments and other grants is coupled with
an interest. Promptly after requested in writing, each Party shall provide to the other all documents and instruments required to evidence or record any such assignments, consents, licenses or waivers, or (to the extent otherwise consistent with
this Agreement) to enforce rights in the assigned Patent Rights. Each Party hereby appoints the other Party as the appointing Party’s attorney-in-fact to execute and deliver each of the foregoing documents and instruments if the other Party is
unable, after making reasonable inquiry, to obtain the appointing Party’s signature on any such documents and instruments. This Section 3.4 shall not be deemed, read, or used to contradict or undermine the Parties’ rights and
obligations as otherwise set forth in this Article III, or as set forth in Article VI and Article VII. 
 3.5 Licenses to
OSI. 
 (a) Research License. During the Research Program Term, AVEO grants to OSI, and OSI accepts, a world-wide,
royalty-free, non-exclusive license, without the right to grant sublicenses, under the AVEO Intellectual Property, and AVEO’s interest in the Collaboration Intellectual Property (including AVEO’s interest in the Model Intellectual Property
and the Target Intellectual Property), solely to the extent necessary to conduct activities assigned to it under the Research Plan; provided that, AVEO hereby agrees, during the Research Program Term, not to grant any rights to a Third Party
with respect to Model Intellectual Property specific to OSI Active Program Models known as the [**] Models and [**] Models (the “Specified Models”). For purposes of clarification, AVEO shall retain the ability to use the Model
Intellectual Property related to the Specified Models for research and development purposes, including for the conduct of research or development activities on behalf of or in collaboration with Third Parties. 
  

 - 30 - 

 (b) License Right to Models. 
 (i) AVEO hereby grants to OSI a non-exclusive, perpetual, royalty free license, including the right to grant sublicenses in accordance with
Section 3.9(b), to use any [**] Model delivered pursuant to Section 2.12 solely for OSI’s internal research, development and commercialization purposes to test Non-Antibody Compounds or Collaboration Antibodies. 
 (ii) AVEO hereby grants to OSI a non-exclusive, perpetual royalty-free license, including the right to grant sublicenses in accordance with
Section 3.9(b) to use the OSI Active Program Models delivered pursuant to Section 2.13 solely for its internal research, development and commercialization purposes to test Non-Antibody Compounds against the OSI Active Program Targets,
without restriction or further obligation to AVEO, other than the payment obligations set forth in Section 6.8. 
 (iii)
AVEO hereby grants to OSI a non-exclusive, perpetual, royalty free license, including the right to grant sublicenses in accordance with Section 3.9(b), to use the [**] Models delivered pursuant to Section 2.17 solely for its internal
research, development and commercialization purposes to test Non-Antibody Compounds without restriction or further obligation to AVEO, other than the payment obligations set forth in Section 6.1(e). 
 (c) AVEO [**] Index. Subject to the provisions of Section 3.8(b), AVEO hereby grants to OSI an exclusive, world-wide,
royalty-bearing, perpetual (subject to Article IX below) license, including the right to grant sublicenses in accordance with Section 3.9(b), under the AVEO [**] Know-How, to research, develop, make and have made, use, offer for sale, sell and
import [**] Compounds and [**] Products and associated diagnostics; provided that, AVEO shall retain the right to (i) use the AVEO [**] Know-How for any research (including internal use related to existing and future Third-Party
collaborations), development and commercialization of products and associated diagnostics, and (ii) grant licenses under the AVEO [**] Know-How in connection with any research, development and commercialization of AVEO’s proprietary
compound know as tivozanib (AV-951). 
 (d) AVEO Bioinformatics Platform. 
 (i) AVEO hereby grants to OSI a non-exclusive, world-wide, royalty-free license, without the right to grant sublicenses, during the
Research Program Term to use the then current version of the AVEO Bioinformatics Tools, as in existence during the Research Program Term, in object code form only, via remote access as set forth in Section 2.15 above, to research, develop and
commercialize Non-Antibody Compounds, Collaboration Antibodies and associated diagnostics. OSI may freely use the resultant data from use of the AVEO Bioinformatics Tools without restriction. 
  

 - 31 - 

 (ii) AVEO hereby grants to OSI a non-exclusive, world-wide, perpetual (subject to Article
IX below), royalty-free license, including the right to grant sublicenses in accordance with Section 3.9(b), to use, copy, manipulate and modify the AVEO Bioinformatics Data to research, develop and commercialize Non-Antibody Compounds,
Collaboration Antibodies and associated diagnostics. 
 (iii) Effective as of the date of expiration of the Research Program
Term and subject to the payment of either the fee set forth in Section 6.1(g) below or the Initial License Expansion Fee set forth in Section 6.1(f)(i) AVEO shall grant to OSI a non-exclusive, world-wide, perpetual (subject to Article IX
below), royalty-free license, without the right to grant sublicenses, to use the AVEO Bioinformatics Tools in existence as of the Restatement Effective Date, including the Bioinformatics Tools Source Code, to research, develop and commercialize
Non-Antibody Compounds, Collaboration Antibodies and associated diagnostics, including the right to modify, enhance and create derivative works of the AVEO Bioinformatics Tools; provided that, OSI shall not take any action that would cause
the AVEO Bioinformatics Tools, including the Bioinformatics Tools Source Code, to be placed in the public domain. Upon payment of the fee set forth in Section 6.1(g), AVEO shall (A) deliver to OSI the Bioinformatics Tools Source Code in a
medium to be agreed by the Parties by no later than [**] days after the expiration of the Research Program Term, (B) use Commercially Reasonable Efforts to provide OSI with technical support in order to enable OSI to independently utilize the
AVEO Bioinformatics Tools, including the Bioinformatics Tools Source Code and (C) deliver, contemporaneously with the Bioinformatics Tools Source Code, the documentation set forth in Schedule 3.5(d)(iii). Promptly after the Restatement
Effective Date, AVEO will deposit a current copy of the Bioinformatics Tools Source Code with a mutually agreed Third Party escrow agent (the “Escrow Agent”). In addition, within [**] months of the Restatement Effective Date, AVEO
will deposit materials and annotations related to the Bioinformatics Tools Source Code in a form usable by a reasonably trained programmer with the Escrow Agent. The Escrow Agent will maintain the Bioinformatics Tools Source Code and such related
materials and annotations pursuant to an escrow agreement (the “Escrow Agreement”) in a form and with terms acceptable to AVEO and OSI, to be entered into by AVEO, OSI and the Escrow Agent within [**] month after the Restatement
Effective Date. The Bioinformatics Tools Source Code and such related materials and annotations shall be released to OSI from the Escrow Agent upon the payment to AVEO of either the fee set forth in Section 6.1(g) or the Initial License
Expansion Fee set forth in Section 6.1(f)(i), as detailed more fully in the Escrow Agreement. 
 (iv) Subject to
Section 8.2(g) OSI shall be solely responsible for obtaining any necessary Third Party licenses prior to receiving the rights granted to OSI under Section 2.15 and this Section 3.5(d). 
 (e) License to Antibodies for Diagnostic Use. AVEO hereby grants to OSI a non-exclusive, perpetual (subject to Article IX above),
world-wide, royalty-free license, including the right to grant sublicenses in accordance with Section 3.9, under the AVEO Intellectual Property and AVEO’s interest in the Collaboration Intellectual Property to research, develop, make and
have made, use, offer for sale, sell and import Antibodies solely for diagnostic use in connection with OSI products. 
  

 - 32 - 

 3.6 Licenses to AVEO. 
 (a) Non-Exclusive Licenses During Research Program Term. During the Research Program Term, OSI grants to AVEO, and AVEO accepts, a
worldwide, royalty-free non-exclusive license, without the right to grant sublicenses, under the OSI Intellectual Property, and OSI’s interest in the Collaboration Intellectual Property (including OSI’s interest in the Translational
Research Intellectual Property) and Product Patent Rights, solely to the extent necessary to conduct activities assigned to it under the Research Plan. 
 (b) Exclusive Licenses to Collaboration Intellectual Property. OSI hereby grants to AVEO an exclusive, world-wide, perpetual (subject to Article IX below) license, with the right to grant
sublicenses, under OSI’s interest in the Collaboration Intellectual Property, other than the Non-Antibody Compound Intellectual Property and Specified Antibody Intellectual Property, (i) to make and have made, use, offer for sale, sell and
import Antibody Products Directed to any Target other than Specified Antibody Targets, and associated diagnostics, and (ii) to make, have made, use, offer for sale, sell and import Non-Antibody Products Directed to AVEO Targets and associated
diagnostics. 
 (c) Exclusive Licenses to Additional Tumor Model Translational Research Intellectual Property. OSI
hereby grants to AVEO an exclusive, world-wide, perpetual license, with the right to grant sublicenses, under the Additional Tumor Model Translational Research Intellectual Property to make and have made, use, offer for sale, sell and import
Antibody Products Directed to any Target other than Specified Antibody Targets, and associated diagnostics. 
 3.7 Exclusive
Option for Collaboration Targets. For each of the Final Nominated Targets (as defined below) and Additional Antibody Targets, AVEO hereby grants to OSI, on a Nominated Target-by-Nominated Target and Additional -Antibody-Target-by-
Additional-Antibody-Target basis, an exclusive option to obtain an exclusive (even as to AVEO) license (in accordance with Section 3.8) to up to [**] of such Collaboration Targets during the Research Program Term, pursuant to and subject to the
provisions of this Section 3.7 (the “Option”); provided that, an Additional Antibody Target shall be subject to the provisions of Sections 3.7 and 3.8 but shall not be counted as one of such [**] Collaboration Targets.

 (a) Initial Procedure for Pre-Collaboration Targets. Prior to the Restatement Effective Date, AVEO submitted to OSI
target packages with respect to each of the [**] Pre-Collaboration Targets (each a “Pre-Collaboration Target Package”) pursuant to and in compliance with the Original Agreement. Pursuant to the terms of the Original Agreement, OSI
elected to exercise its Option with respect to [**] of the Pre-Collaboration Targets and, accordingly, the remaining [**] Pre-Collaboration Targets became both AVEO Targets and Reverted Targets (as defined in Section 3.7(c)(ii) below).

  

 - 33 - 

 (b) Initial Procedure for Candidate Targets. 
 (i) Pursuant to and in compliance with the terms of the Original Agreement, the Parties evaluated and prioritized the AVEO Existing Targets
and the OSI Existing Targets and prepared a Candidate Target List, identifying those Targets that were to be included in the Research Program within [**] days after the Original Effective Date. From time to time during the Candidate Target
Exclusivity Period the JSC may add Targets to (provided rights are available), or remove Targets from, the Candidate Target List. Any AVEO Existing Target that is not on the Candidate Target List and any AVEO Existing Target or OSI Existing Target
that is removed from the Candidate Target List by the JSC, shall be deemed to be an AVEO Target hereunder. 
 (ii) During the
Research Program Term, the JSC shall prioritize the Candidate Targets and select Candidate Targets from the Candidate Target List for validation studies by the Parties. Upon each such selection by the JSC, the applicable Candidate Target shall be
designated as a Nominated Target hereunder, and the remaining provisions of this Section 3.7(b) shall apply. The JSC shall designate a number of Nominated Targets based on the available resources under the Research Plan to conduct the intended
validation studies. 
 (iii) Promptly after the JSC’s selection of any Candidate Target as a Nominated Target, the JSC
shall approve a specific research plan designed to develop a target package with respect to such Nominated Target (respectively, the “Nominated Target Package Plan” and the “Nominated Target Package”). Each
Nominated Target Package Plan shall provide for the conduct of further validation studies by both AVEO and OSI, including the application of AVEO’s Model and OSI’s EMT assays and associated technology, and shall set forth specific
validation criteria for the Nominated Target (the “Validation Criteria”). In connection with the development of Validation Criteria for a specific Nominated Target, the Parties may agree to deliver a Collaboration Model Directed to
such Nominated Target as set forth in the applicable Research Plan. 
 (iv) Upon completion of the work required by any
Nominated Target Package Plan and confirmation by the JSC that the Validation Criteria have been met AVEO shall promptly deliver such Nominated Target Package to OSI, and OSI shall have [**] days from its receipt of the Nominated Target Package to
exercise its Option to the applicable Nominated Target pursuant to Section 3.7(c). 
 (v) If, with respect to any
Nominated Target, the JSC determines that the Validation Criteria are not met, or if the JSC determines at any time (including prior to completion of the work required by any Nominated Target Package Plan) that the data generated pursuant to the
conduct of any Nominated Target Package Plan does not support the designation of such Nominated Target as a Collaboration Target, either (A) on a JSC determination made within [**] days after completion of the Nominated Target Package Plan that
additional validation work is warranted, the JSC shall, within [**] days after making such determination, establish a research plan specifying the further validation work to be conducted by the Parties, and such additional validation work will be
deemed a Nominated Target Package Plan for purposes of Section 3.7(b)(iii), above, or (B) if the JSC does not determine within [**]

  

 - 34 - 

 
days after completion of the Nominated Target Package Plan that additional validation work is warranted, then any such Nominated Target shall automatically be deemed to be an AVEO Target.

 (c) Option Exercise. 
 (i) With respect to each Nominated Target, OSI shall have a period of [**] days after its receipt of each Nominated Target Package, but in no case more than [**] days following the expiration of the
Research Program Term (the “Option Period”), to exercise its Option to obtain the exclusive license set forth in Section 3.8 with respect to such Nominated Target, such Option to be exercised by written notice to AVEO prior to
expiration of the applicable Option Period. OSI may elect at any time during the Research Program Term to exercise its Option to obtain the exclusive license set forth in Section 3.8 with respect to a mutually agreed to Additional Antibody
Target. If OSI exercises its Option with respect to a Nominated Target or Additional Antibody Target, as the case may be, prior to expiration of the Option Period with respect to a Nominated Target or prior to expiration of the Research Program Term
with respect to an Additional Antibody Target, (A) such Nominated Target or Additional Antibody Target shall be designated as a Collaboration Target hereunder, effective as of the date of OSI’s exercise of its Option, (B) OSI shall
pay AVEO the milestone set forth in Section 6.1(d) solely with respect to the exercise of an Option in connection with an Additional Antibody Target, (C) AVEO shall assign to OSI its entire right, title and interest in, to and under the
Collaboration Target Translational Research Intellectual Property relating to such Collaboration Target, and (D) the exclusive license set forth in Section 3.8(a) shall apply to such Collaboration Target. 
 (ii) If OSI fails to exercise its Option with respect to any Nominated Target prior to expiration of the applicable Option Period (each, a
“Reverted Target”), then effective as of the expiration of the Option Period, (A) the rights and licenses granted to OSI pursuant to Section 3.5(a) shall no longer apply to such Reverted Target or any AVEO Intellectual
Property or Collaboration Intellectual Property related thereto, (B) for a period of [**] months after the expiration of the Option Period for such Nominated Target, neither OSI nor its Affiliates shall, nor shall any of them grant rights to a
Third Party to, conduct any research or development program with respect to such Reverted Target unless otherwise agreed to by the Parties; and (C) the exclusive licenses to AVEO set forth in Section 3.6(b) shall apply to such Reverted
Target; provided that the provisions of subsection 3.7(c)(ii)(B) shall not apply where OSI’s involvement in such activity results from OSI’s acquisition of or by a Third Party (by merger or otherwise), and such Third Party was
engaged in such activity prior to such acquisition or merger; provided that (1) OSI shall not provide any such Third Party with rights or access to AVEO Intellectual Property, or Collaboration Intellectual Property for use in connection
with activities prohibited by subsection 3.7(c)(ii)(B) if undertaken by OSI, and (2) in the case where OSI acquires a Third Party (by merger or otherwise), OSI does not expand the scope of, or increase the financial commitment to, such Third
Party activities, from what it was immediately prior to the acquisition. Notwithstanding anything to the contrary herein, but subject to Section 3.7(c)(ii)(A), Section 3.7(c)(ii)(B) shall not prohibit OSI from in-licensing Antibodies
Directed to such Reverted Target from a Third Party. 
  

 - 35 - 

 (iii) On or before December 31, 2009, the Parties hereby agree to designate as
Nominated Targets an aggregate of [**] Targets from the Candidate Target List (inclusive of the Targets designated as Nominated Targets by the Parties prior to the Restatement Effective Date pursuant to the terms of the Original Agreement but
exclusive of any Specified Antibody Targets) (the “Final Nominated Targets”). Notwithstanding anything to the contrary set forth herein, OSI may elect to exercise its Option with respect to up to [**] Final Nominated Targets (other
than the Target known as [**]) at any time during the Research Program Term without the delivery of a Nominated Target Package by AVEO (each, a “Non-Validated Collaboration Target”). 
 3.8 Exclusive Product Licenses to OSI. 
 (a) Subject to Section 3.8(b), upon exercise of its Option for a specified Collaboration Target pursuant to Section 3.7(c), AVEO hereby grants to OSI an exclusive (even as to AVEO), perpetual
(subject to Article IX), world-wide, royalty-bearing license, including the right to grant sublicenses in accordance with Section 3.9, under the AVEO Intellectual Property and AVEO’s interest in the Collaboration Intellectual Property
(including its rights in any Model or Target Intellectual Property), to research, develop, make and have made, use, offer for sale, sell and import Product(s) Directed to such Collaboration Target in the Field, and associated diagnostics. Upon
selection by OSI, pursuant to a written notice to AVEO in accordance with Section 1.91, of a Target set forth on Schedule 1.91 which is designated as a Pre-Selected Antibody Target, AVEO hereby grants to OSI an exclusive (even as to AVEO),
perpetual (subject to Article IX above), world-wide, royalty-bearing license, including the right to grant sublicenses in accordance with Section 3.9, under the AVEO Intellectual Property and AVEO’s interest in the Collaboration
Intellectual Property (including its rights in any Model or Target Intellectual Property), to research, develop, make and have made, use, offer for sale, sell and import Product(s) Directed to such Pre-Selected Antibody Target in the Field, and
associated diagnostics. 
 (b) The provisions of Section 3.8(a) notwithstanding, AVEO shall have the right, at any time
during the Term, to initiate an AVEO [**] Program, and shall provide OSI with prompt written notice thereof (the “[**] Notice”). If, prior to the date of such [**] Notice, OSI has exercised its right to receive an exclusive license
pursuant to Section 3.8(a) with respect to [**], then, effective as of the date of such [**] Notice, (i) such exclusive license shall be converted to a co-exclusive license with AVEO and (ii) the milestone and royalty obligations of
OSI with respect to [**] shall be adjusted as set forth in Section 6.7; provided that, each Party shall have the right to freely grant a single exclusive license or sublicense in any territory without the consent of the other Party. If,
prior to the date of such [**] Notice, OSI has not exercised its Option to obtain an exclusive license pursuant to Section 3.8(a) with respect to [**], but OSI exercises such Option after the date of such notice, then effective upon the grant
of such license under Section 3.8(a), (i) such exclusive license shall be automatically deemed to be a co-exclusive license with AVEO and (ii) the milestone and royalty obligations of OSI with respect to [**] shall be adjusted as set
forth in Section 6.7; provided that, each Party shall have the right to freely grant a single, exclusive license or sublicense in any territory, without the consent of the other Party. 
  

 - 36 - 

 3.9 Sublicenses. 
 (a) OSI shall have the right, at any time, to grant sublicenses under the licenses granted to it under Section 3.8(a) to
(i) OSI’s Affiliates and (ii) Third Parties. 
 (b) OSI shall have the right to grant sublicenses under the
licenses granted to it under Sections 3.5(b), 3.5(c), 3.5(d)(ii) and 3.5(e) to (i) Affiliates at any time, and (ii) Third Parties solely in connection with the sublicense by OSI to such Third Party of (A) rights to research, develop,
make and have made, use, offer for sale, sell and import associated Non-Antibody Compounds or Collaboration Antibodies, or (B) the right to develop diagnostics associated with such Non-Antibody Compounds or Collaboration Antibodies. 

(c) OSI shall provide AVEO with the following information with respect to each sublicensee provided for in Sections 3.9(a) and (b), and
with respect to any licensee of rights to a Royalty-Bearing Product: (i) the identity of the licensee or Sublicensee, and (ii) the Collaboration Target, Collaboration Compound(s), Royalty-Bearing Product, if and as applicable, that is the
subject of the license or sublicense. Any sublicense granted by OSI shall impose on the Sublicensee obligations consistent with the obligations imposed on OSI pursuant to this Agreement, and OSI shall remain responsible to AVEO for the performance
of the obligations of its Sublicensees and such Sublicensee’s compliance with the terms of this Agreement. 
 3.10
Rights Retained by the Parties. Except as expressly set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, in any Confidential Information disclosed to it
under this Agreement or under any Patent Rights or Know-How Controlled by the other Party or its Affiliates. Without limiting the generality of the foregoing, any of AVEO’s rights to AVEO Intellectual Property, AVEO Bioinformatics Tools, and
Collaboration Intellectual Property not specifically licensed to OSI shall be retained by AVEO, and any of OSI’s rights to OSI Intellectual Property, Collaboration Intellectual Property and Product Patent Rights not specifically licensed to
AVEO shall be retained by OSI. 
 3.11 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under
or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of
the U.S. Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. The Parties agree that OSI, as a licensee of such rights under this Agreement, shall retain and
may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against AVEO under the U.S. Bankruptcy Code, OSI shall be entitled to a complete duplicate of or complete
access to (as OSI deems appropriate), any such intellectual property and all embodiments of such intellectual property, provided OSI continues to fulfill its payment and/or royalty obligations as specified herein in full. Such

  

 - 37 - 

 
intellectual property and all embodiments thereof shall be promptly delivered to OSI (a) upon any such commencement of a bankruptcy proceeding upon written request therefore by OSI, unless
AVEO elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of AVEO upon written request therefore by OSI. The foregoing is
without prejudice to any rights OSI may have arising under the U.S. Bankruptcy Code or other applicable Law. 
 ARTICLE IV

 DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS; DILIGENCE 
 4.1 Responsibility for Development and Commercialization. OSI shall have full responsibility, at its sole expense, for the worldwide
development, manufacturing and commercialization of Royalty-Bearing Products in the Field. 
 4.2 Commercially Reasonable
Efforts. 
 (a) OSI shall exercise Commercially Reasonable Efforts (itself or through an Affiliate or Sublicensee) to
develop, obtain Regulatory Approval for and commercialize Products with respect to each Collaboration Target in the Major Countries. 
 (b) Without limiting the generality of the foregoing, OSI shall be deemed to have failed to exercise such Commercially Reasonable Efforts if, with respect to any Collaboration Target licensed to OSI pursuant to this Agreement, OSI fails to
initiate an internal exploratory project within [**] after the date of its designation as a Collaboration Target. Initiation of an exploratory project for the Collaboration Target may be achieved by (i) the commencement of a high throughput
screen or a virtual screen, (ii) the allocation of at least [**] FTEs (derived from either internal or external sources) for a period of at least [**], (iii) entering into a collaboration with a Third Party for the development of an
oligonucleotide-based therapeutic, in each case with respect to the applicable Collaboration Target, (iv) generation of a protein-ligand X-ray co-crystal structure and (v) with respect to a Specified Antibody Target, (A) entering into
a collaboration with a Third Party for the development of an Antibody therapeutic or (B) commencing generation of an Antibody for purposes of drug discovery. The provisions of the foregoing sentence notwithstanding, OSI shall not be deemed to
be in breach of its obligations under this subsection (b) with respect to any Collaboration Target if OSI fails to achieve at least [**] of the objectives set forth in the foregoing clauses (i), (ii), (iii) and (v) due to scientific
or technical impediments outside OSI’s control and, during such [**] period and thereafter OSI has applied and continues to apply a good faith effort to resolve such scientific or technical impediments, it being understood that OSI shall lose
its right to benefit from this Section 4.2(b) if at any time OSI ceases to apply good faith efforts to resolve such scientific or technical impediments. 
  

 - 38 - 

 4.3 OSI Election to Terminate Activities. 
 (a) OSI may, at any time and in its sole discretion, elect to terminate the research, development and/or commercialization of any or all
Collaboration Target(s) and all associated Collaboration Compounds and Products. If, at any time, OSI in its sole discretion elects to terminate the research, development and/or commercialization of a Collaboration Target and all associated
Collaboration Compounds and Products, (a) OSI shall provide AVEO with prompt written notice thereof (b) this Agreement shall terminate, effective as of the date of such notice, solely with respect to such Collaboration Target and all
Collaboration Compounds and Products Directed thereto, and (c) any such Collaboration Target that was not an OSI Active Program Target shall automatically be deemed to be an AVEO Target hereunder, effective as of the date of OSI’s notice
given pursuant to this Section 4.3. 
 (b) If OSI elects to terminate the research, development and/or commercialization
of any or all Collaboration Target(s) and all associated Collaboration Compounds and Products pursuant to Section 4.3(a), (i) the consequences set forth in Section 9.3(b) shall apply, (ii) neither OSI nor its Affiliates shall,
nor shall any of them grant rights to a Third Party to, conduct any research or development program with respect to such Collaboration Target for a period of [**] (the “Restricted Period”) after OSI’s notice pursuant to
Section 4.3(a); provided that, (I) the Restricted Period shall be [**] for any Collaboration Target that is also a Non-Validated Collaboration Target, and (II) this Section 4.3(b)(ii) shall not apply if OSI’s
involvement in such activity results from OSI’s acquisition of or by a Third Party (by merger or otherwise), and such Third Party was engaged in such activity prior to such acquisition or merger; provided further that (A) OSI
shall not provide any such Third Party with rights or access to (1) AVEO Intellectual Property, or (2) Collaboration Intellectual Property for use in connection with activities prohibited by subsection (ii) of this Section 4.3(b)
if undertaken by OSI, and (B) in the case where OSI acquires a Third Party (by merger or otherwise), OSI does not expand the scope of, or the financial commitment to, such Third Party activities, from what it was immediately prior to the
acquisition. 
 (c) The foregoing provisions of Section 4.3(a) and (b) notwithstanding, if OSI wishes to seek a Third
Party partner to continue or participate in any of the research, development and/or commercialization of any or all Collaboration Target(s) and all associated Collaboration Compounds and Products (the “Section 4.3(c) Opportunity”),
OSI will provide notice to AVEO that OSI wishes to seek such Third Party partner (the “Partnering Notice”). Upon receipt of a Partnering Notice, AVEO may request, and OSI shall promptly provide to AVEO, all information relating to
the Section 4.3(c) Opportunity and relevant to AVEO’s determination of interest in initiating partnering discussions, to the same extent as such information is or will be provided to interested Third Parties (if any). If AVEO wishes to
initiate partnering discussions with OSI regarding the Section 4.3(c) Opportunity, then AVEO shall provide OSI with notice thereof, and AVEO and OSI shall promptly commence and thereafter engage in good faith discussions with the objective of
reaching, as expeditiously as possible, an agreement regarding the Section 4.3(c) Opportunity; provided that OSI may engage in discussions with Third Parties regarding the Section 4.3(c) Opportunity concurrently with any discussions
with AVEO, and this Section 4.3(c) shall not be construed as granting AVEO any priority in such negotiations. 
  

 - 39 - 

 ARTICLE V 
 CONFIDENTIALITY AND PUBLICATION 
 5.1
Nondisclosure Obligation. The Parties agree that during the Term, and for a period of [**] years thereafter, a Party receiving Confidential Information of the other Party shall (a) maintain in confidence such Confidential Information to
the same extent such Party maintains its own most highly confidential proprietary information (but at a minimum each Party shall use Commercially Reasonable Efforts), (b) not disclose such Confidential Information to any Third Party without the
prior written consent of the other Party, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement. 
 5.2 Authorized Disclosure. Notwithstanding Section 5.1, a Party may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following
instances: 
 (a) filing for, prosecuting or maintaining Collaboration Patent Rights; 
 (b) filings with Regulatory Authorities; 
 (c) prosecuting or defending litigation with respect to Collaboration Targets, Collaboration Intellectual Property or Royalty-Bearing Products; 
 (d) complying with applicable Laws or submitting information to tax or other Governmental Authorities; provided that if the
receiving Party is required by Law to make any public disclosures of Confidential Information of the disclosing Party, to the extent it may legally do so, it will give reasonable advance notice to the disclosing Party of such disclosure and will use
its reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); 
 (e) to (i) its Affiliates, and to prospective and actual acquirers, licensees, Sublicensees, employees, consultants, agents, accountants, lawyers, advisors and investors, and (ii) others in
order to exercise such Party’s rights or fulfill its obligations under this Agreement (including commercialization or sublicensing of Royalty-Bearing Products) on a need to know basis, each of whom in (i) and (ii) prior to disclosure
must be bound by written obligations of confidentiality and non-use substantially equivalent in scope to those set forth in this Article V and that are of reasonable duration in view of the circumstances of the disclosure; and 
 (f) to the extent mutually agreed to in writing by the Parties. 
 5.3 Scientific Publications. Neither Party shall first publish or first present in a public forum the scientific or technical results
of any activities performed pursuant to this Agreement without the opportunity for prior review by the other Party, except that (a) OSI may freely publish OSI scientific or technical results related to Collaboration Compounds, Collaboration
Antibodies or Royalty-Bearing Products, and (b) AVEO may freely publish AVEO scientific or technical results related to any rights granted to OSI

  

 - 40 - 

 
pursuant to Article X herein; provided that, AVEO may not publish the Bioinformatics Tools Source Code in its entirety, or any portion of the Bioinformatics Tools Source Code that would enable
the public to substantially replicate the AVEO Bioinformatics Tools. Subject to the foregoing exception, each Party agrees to provide the other Party with the opportunity to review any proposed abstracts, manuscripts or scientific presentations
(including verbal presentations) which relate to its activities performed pursuant to this Agreement or any Collaboration Target at least thirty (30) days prior to its intended submission for publication and agrees, upon request, not to submit
any such abstract or manuscript for publication until the other Party is given a reasonable period of time to secure patent protection for any material in such publication which it believes to be patentable. Both Parties understand that a reasonable
commercial strategy may require delay of publication of information or filing of patent applications first. The Parties agree to review and decide whether to delay publication to permit filing of patent applications. Neither Party shall have the
right to publish or present Confidential Information of the other Party. Nothing contained in this Section 5.3 shall prohibit the inclusion of information necessary for a patent application, provided that the non-filing Party is given a
reasonable opportunity to review the information to be included prior to submission of such patent application and to request deletion of its Confidential Information. 
 5.4 Press Releases and Other Disclosures. The press release announcing the expansion of the Parties’ collaboration as contemplated by this Agreement will be mutually agreed upon by the
Parties, and the Parties will cooperate in the release thereof as soon as practicable after the Restatement Effective Date. No other public statement or disclosure concerning the existence or terms of this Agreement shall be made, either directly or
indirectly, by either Party, without first obtaining the written approval of the other Party. Once any public statement or disclosure has been approved in accordance with this Section 5.4, then either Party may appropriately communicate
information contained in such permitted statement or disclosure. Notwithstanding the foregoing provisions of Article V, a Party may (a) disclose the existence and terms of this Agreement or a Party’s or the Parties’ activities under
this Agreement where required, as reasonably determined by the disclosing Party, by applicable Law, by applicable stock exchange regulation or by order or other ruling of a competent court, (b) disclose the existence and terms of this
Agreement, or a Party’s or the Parties’ activities under this Agreement, under written obligations of confidentiality to existing and potential agents, advisors, contractors, investors, licensees, Sublicensees, collaborators and acquirers,
in connection with such Party’s activities hereunder and in connection with such Party’s financing activities, and (c) publicly announce any of the matters set forth in the initial press release; provided that such
announcements do not entail disclosure of non-public technical or scientific information (which, for purposes of clarity, excludes clinical trial results) and the announcing Party provides the other Party with a copy of the proposed text of such
announcement sufficiently in advance of the scheduled release or publication thereof to afford such other Party a reasonable opportunity to review and comment upon the proposed text. 
 5.5 Retained Rights. The foregoing provisions of this Article V notwithstanding, AVEO shall not be prevented from using or disclosing
AVEO Confidential Information, and OSI shall not be prevented from using or disclosing OSI Confidential Information, for applications outside the Field for any purpose. 
  

 - 41 - 

 ARTICLE VI 
 PAYMENTS; ROYALTIES AND REPORTS 
 6.1
License Payments. 
 (a) In consideration of the rights to AVEO Intellectual Property granted on the Original Effective
Date, OSI paid to AVEO Seven Million Five Hundred Thousand Dollars ($7,500,000) within ten (10) days after the Original Effective Date. 
 (b) In consideration of AVEO efforts under the first year of the Research Program, OSI paid to AVEO Two Million Five Hundred Thousand Dollars ($2,500,000) within ten (10) days after the Original
Effective Date. 
 (c) In consideration of the expansion of the Research Program as set forth in this Agreement as of the
Restatement Effective Date, OSI shall pay to AVEO Five Million Dollars ($5,000,000) within ten (10) days after the Restatement Effective Date. 
 (d) If OSI exercises its Option with respect to an Additional Antibody Target in accordance with Section 3.7, OSI will pay to AVEO [**] Dollars ($[**]) for each Additional Antibody Target selected by
the Parties within thirty (30) days after written notice to AVEO of the exercise of such Option, and within thirty (30) days after AVEO has submitted an invoice for such amount to OSI. 
 (e) In the event that AVEO delivers a [**] Model to OSI pursuant to Section 2.17, OSI will pay to AVEO [**] Dollars ($[**]) upon the
delivery of each such [**] Model, and within thirty (30) days after AVEO has submitted an invoice for such amount to OSI. 
 (f) In the event that OSI exercises its Collaboration Expansion Option pursuant to Section 10.1, OSI shall pay to AVEO an aggregate of [**] Dollars ($[**]) in consideration for the rights granted to OSI under Article X herein (the
“License Expansion Fee”) as follows: 
  

							
	 Milestone Event
	  	 Payment
	 
			
	 (i)     
	 	Upon delivery of the Expansion Notice (the “Initial License Expansion Fee”)	  	$	[	**] 
			
	 (ii)    
	 	Within thirty (30) Business Days after completion of the Technology Transfer pursuant to criteria set forth in Tech Transfer Plan	  	$	[	**] 

  

 - 42 - 

 (g) In the event that OSI elects not to exercise its Collaboration Expansion Option on or
before January 15, 2011, then OSI shall either (i) pay to AVEO [**] Dollars ($[**]) by no later than January 31, 2011, or (ii) allow certain rights under the Agreement to terminate pursuant to Section 9.5 below. 

6.2 Equity Investment. 
 (a) OSI purchased Five Million Five Hundred Thousand Dollars ($5,500,000) of Series C Preferred Stock of AVEO at Three Dollars ($3.00) per share pursuant to the terms of the Series C Convertible Preferred
Stock Purchase Agreement entered into by the Parties as of the Original Effective Date. 
 (b) OSI shall purchase Fifteen
Million Dollars ($15,000,000) of Series E Preferred Stock of AVEO at Four Dollars ($4.00) per share pursuant to the terms of the Series E Convertible Preferred Stock Purchase Agreement entered into by the Parties as of the Restatement Effective
Date. 
 6.3 Research Program Funding; Technology Transfer Funding. 
 (a) In consideration of AVEO’s performance of its obligations under the Research Program, OSI has paid AVEO for the first three
quarters of the Second Research Program Year through July 31, 2009 an amount equal to Six Hundred Twenty-Five Thousand Dollars ($625,000) per quarter. Effective August 1, 2009, OSI shall pay AVEO [**] Dollars ($[**]) per year (the
“Annual FTE Rate”) for each FTE supporting the Research Program. Each such pro-rated payment (i.e., $[**] per FTE per quarter) shall be due on or before the first day of each quarter commencing on August 1, 2009 (the
“Quarterly Payment Due Date”), provided that the last quarterly invoice will only cover a period of two months. AVEO shall submit quarterly invoices to OSI at least thirty (30) days prior to the first day of each Quarterly
Payment Due Date (provided that, the invoice for payment on August 1, 2009 shall be delivered on the Restatement Effective Date). In exchange for such funding, AVEO will devote to the Research Program a minimum of [**] FTEs in each Research
Program Year; provided however, that OSI may increase such number of FTEs devoted to the Research Program (further provided however, that, AVEO shall not be obligated to devote more than [**] FTEs in the aggregate to the Research Program in any
Research Program Year). For purposes of the foregoing, an “FTE” shall mean [**] hours of work devoted to or in support of Research Program in accordance with the Research Plan that is carried out by one or more employees, contract
personnel or consultants of AVEO, measured in accordance with AVEO’s normal time allocation practices from time to time. In no event shall an individual account for more than one FTE year in any Research Program Year. 
 (b) In addition to the amounts set forth in Section 6.3(a), except as set forth in this Section 6.3(b), OSI shall be responsible
for (i) all significant actual out-of-pocket expenses related to the Research Program, including [**], and (ii) [**] percent ([**]%) of mouse acquisition costs (the “Research Program Expenses”). AVEO shall be responsible
for [**] percent ([**]%) of mouse acquisition costs and all of the mouse housing costs related to the Research Program. The Research Program Expenses shall be

  

 - 43 - 

 
budgeted annually by the JSC. AVEO shall submit quarterly invoices to OSI for all Research Program Expenses incurred by AVEO, and OSI shall pay such invoices within thirty (30) days after
receipt thereof. 
 (c) In consideration of AVEO’s performance of its obligations pursuant to the Technology Transfer as
delineated in the Tech Transfer Plan, OSI shall pay AVEO all actual out-of-pocket expenses related to the Technology Transfer and a pro-rated portion of the Annual FTE Rate for each FTE supporting the Technology Transfer during the Tech Transfer
Period. Each such pro-rated payment (i.e., $[**] per FTE per month) and related out-of-pocket expenses shall be due in arrears upon receipt by OSI of the monthly invoice detailing such services issued. 
 6.4 Event Milestone Payments. 
 (a) Early Milestone Payments. OSI shall pay to AVEO the following non-refundable, non-creditable milestone payments with respect to each OSI Active Program Target or Collaboration Target (as
applicable) to achieve the applicable milestone event: 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 (i)     [**]
	  	$	[	**] 
		
	 (ii)    [**]
	  	$	[	**] 

 provided that, AVEO shall waive the milestone payments under (I) Section 6.4(a)(i) with
respect to the first [**] and (II) Section 6.4(a)(ii) with respect to (A) the first [**] after the Restatement Effective Date and (B) the first [**]. 
 For purposes of clarity, the milestone payments set forth in this Section 6.4(a) shall be payable once with respect to [**] (as applicable) to achieve the applicable milestone event, upon the
earliest achievement of the applicable milestone event by each such Target. 
 (b) Development Milestone Payments for the
United States. OSI shall pay to AVEO the following non-refundable, non-creditable milestone payments with respect to the first Collaboration Compound or Product (as applicable) to achieve the applicable milestone event with respect to each
Collaboration Target. 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

  

 - 44 - 

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

 For purposes of clarity, the milestone payments set forth in this Section 6.4(b) shall be
payable once with respect to each Collaboration Target upon the earliest achievement of the applicable milestone event by a Collaboration Compound or Product Directed to such Collaboration Target. 
 If, with respect to any particular Product, a later development milestone event is achieved prior to the achievement of an earlier development milestone
event, then all milestone payments due and payable for the earlier development milestone event shall be due and payable simultaneously with the payment for achievement of the subsequent development milestone event. 
 (c) Development Milestone Payments for the EU. OSI shall pay to AVEO the following non-refundable, non-creditable milestone payments
with respect to the first Product to achieve the applicable milestone event with respect to each Collaboration Target. 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

 For purposes of clarity, the milestone payments set forth in this Section 6.4(c) shall be
payable once with respect to each Collaboration Target upon the earliest achievement of the applicable milestone event by a Product Directed to such Collaboration Target. 
 If, with respect to any particular Product, a later development milestone event is achieved prior to the achievement of an earlier development milestone event, then all milestone payments due and payable
for the earlier development milestone event shall be due and payable simultaneously with the payment for achievement of the subsequent development milestone event. 
  

 - 45 - 

 (d) Development Milestone Payments for Japan. OSI shall pay to AVEO the following
non-refundable, non-creditable milestone payments with respect to the first Product to achieve the applicable milestone event with respect to each Collaboration Target. 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

 For purposes of clarity, the milestone payments set forth in this Section 6.4(d) shall be
payable once with respect to each Collaboration Target upon the earliest achievement of the applicable milestone event by a Product Directed to such Collaboration Target. 
 If, with respect to any particular Product, a later development milestone event is achieved prior to the achievement of an earlier development milestone event, then all milestone payments due and payable
for the earlier development milestone event shall be due and payable simultaneously with the payment for achievement of the subsequent development milestone event. 
 (e) Success Milestone Payments. OSI shall pay to AVEO the following non-refundable, non-creditable milestone payments with respect to each Product to achieve the applicable milestone event.

  

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

 For purposes of clarity, the milestone payments set forth in this Section 6.4(e) shall be
payable once with respect to each Product to achieve the applicable milestone event, upon the earliest achievement of the applicable milestone event by each such Product. 
 For purposes of clarity, if a Product is Directed against more than one Collaboration Target, the milestone obligations set forth above shall be paid only once with respect to such Product. 
  

 - 46 - 

 (f) [**] Milestones. OSI shall pay to AVEO the following non-refundable,
non-creditable milestone payments with respect to each [**] Compound or [**] Product, as the case may be, other than [**] Products or [**] Compounds Directed to an OSI Active Program Target, to achieve the applicable milestone event: 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

 For purposes of clarity, (A) the milestone payments set forth in this Section 6.4(f) shall
be payable once with respect to each [**] Compound or [**] Product, as the case may be, to achieve the applicable milestone event, upon the earliest achievement of the applicable milestone event by each such [**] Compound or [**] Product, and
(B) if OSI exercises its Option to select [**] as an Collaboration Target (pursuant to the provisions of Section 3.7(c)), at such time, this Section 6.4(f) shall become null and void and, accordingly, any Non-Antibody Compound
Directed at [**] shall be considered a Product hereunder and shall be subject to payments under subsections (b), (c), (d) and (e) under this Section 6.4. 
 (g) Collaboration Expansion Milestones. Solely in the event that OSI exercises its Collaboration Expansion Option pursuant to Section 10.1, OSI will pay to AVEO the following non-refundable,
non-creditable milestone payments to the extent that the following milestones are achieved during the Research Program Term: 
  

					
	 Milestone Event
	  	 Payment
	 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 
		
	 [**]
	  	$	[	**] 

 provided that, the aggregate payments made by OSI pursuant to this Section 6.4(g) shall not
exceed [**] Dollars ($[**]). 
 (h) Payment of Milestones. OSI shall provide AVEO with prompt written notice of the
achievement of the milestone events set forth in Sections 6.4(b), 6.4(c), 6.4(d), 6.4(e) and 6.4(f) and shall make the non-refundable, non-creditable milestone payments required by Sections 6.4(a), 6.4(b), 6.4(c), 6.4(d), 6.4(e), and 6.4(f) within
thirty (30) days after the earliest date on which the corresponding milestone is achieved, and within thirty (30) days after AVEO has submitted an invoice to OSI. OSI shall make the non-refundable, non-creditable milestone payments
required by Section 6.4(g) achieved prior to the Expansion Date in conjunction with the payment of the Initial Expansion Payment and, thereafter, within thirty (30) days after the earliest date on which the corresponding milestone in
Section 6.4(g) is achieved. 
  

 - 47 - 

 (i) Non-Validated Collaboration Targets. Notwithstanding anything to the contrary
herein, all payments owed by OSI under Sections 6.4(a), (b), (c), (d) and (e) with respect to a Collaboration Compound or Product which is Directed to a Non-Validated Collaboration Target shall be reduced by [**] percent ([**]%).

 (j) [**] Milestones. The Parties acknowledge that any milestones due to AVEO under Sections 6.4(a)(i) and 6.4(a)(ii)
under the Original Agreement with respect to the Collaboration Target known as [**] are waived effective as of the Restatement Effective Date. 
 6.5 Sales Milestone Payments. OSI shall make the non-refundable, non-creditable payments to AVEO set forth below upon the earliest achievement of each of the corresponding milestone events by the
first Product to achieve such milestone with respect to each Collaboration Target: 
  

							
	 Milestone Event
	  	 Payment
	 
			
	 (i)     
	 	First occurrence of aggregate worldwide Net Sales of the Product of greater than $[**] in a Calendar Year	  	$	[	**] 
			
	 (ii)    
	 	First occurrence of aggregate worldwide Net Sales of the Product of greater than $[**] in a Calendar Year	  	$	[	**] 

 provided that, all payments owed by OSI under this Section 6.5 with respect to a Product which
is Directed to a Non-Validated Collaboration Target shall be reduced by [**] percent ([**]%). 
 For purposes of clarity, the milestone payments
set forth in this Section 6.5 shall be paid once with respect to each Collaboration Target to achieve the applicable milestone event, upon the earliest achievement of the applicable milestone event by a Product Directed to such Collaboration
Target. 
 For purposes of clarity, if a Product is Directed against more than one Collaboration Target, the milestone obligations set forth
above shall be paid only once. 
 6.6 Royalty-Bearing Product Royalties. OSI shall pay to AVEO royalties on the worldwide
Net Sales of Products as provided in this Section 6.6: 
 (a) Royalty Rate for Products Sold by OSI and its
Affiliates. OSI shall pay AVEO royalties on the Net Sales of Products sold by or on behalf of OSI or its Affiliates at the following rates with respect to all such Net Sales achieved during the applicable Royalty Term: 
  

					
	 Product
	  	 Royalty Rate

			
	 (i)     
	 	Products where the milestone in Section 6.4(e)(ii) has not been achieved	  	[**] Percent ([**]%)
			
	 (ii)    
	 	Products where the milestone set forth in Section 6.4(e)(ii) has been achieved	  	[**] Percent ([**]%)

  

 - 48 - 

 provided that, all payments owed by OSI under this Section 6.6(a) with respect to a Product which is
Directed to a Non-Validated Collaboration Target shall be reduced by [**] percent ([**]%). 
 (b) Royalty Rate for Products
Sold by Sublicensees. OSI shall pay AVEO royalties on the Net Sales of Products sold by or on behalf of Sublicensees at the following rates with respect to all Net Sales by or for such Sublicensees achieved during the applicable Royalty Term:

  

					
	 Product
	  	 Royalty Rate

			
	 (i)     
	 	Products where the milestone in Section 6.4(e)(ii) has not been achieved	  	[**] Percent ([**]%)
			
	 (ii)    
	 	Products where the milestone set forth in Section 6.4(e)(ii) has been achieved	  	[**] Percent ([**]%)

 provided that, all payments owed by OSI under this Section 6.6(b) with respect to a Product
which is Directed to a Non-Validated Collaboration Target shall be reduced by [**] percent ([**]%). 
 (c) Royalty Rate for
[**] Products. 
 (i) OSI shall pay AVEO [**] Percent ([**]%) of Net Sales of [**] Products sold by or on behalf of OSI or
its Affiliates with respect to all such Net Sales achieved during the applicable Royalty Term. 
 (ii) OSI shall pay AVEO [**]
Percent ([**]%) of Net Sales of [**] Products sold by or on behalf of Sublicensees with respect to all Net Sales by or for such Sublicensees achieved during the applicable Royalty Term. 
 For purposes of clarity, if OSI exercises its Option to select the Target known as [**] as a Collaboration Target (pursuant to the terms of Section 3.7(c)), at such time, this Section 6.6(c)
shall become null and void and, accordingly, any Non-Antibody Compound Directed to the Target known as [**] shall be considered a Product hereunder and shall be subject to payments under Sections 6.6(a) and (b). 
  

 - 49 - 

 (d) Applicability of Royalty Rates to Net Sales. Royalties under this
Section 6.6 shall be paid at the rate applicable to the sale of the Royalty-Bearing Product at the time of sale in the country of sale. For purposes of clarity, (i) Net Sales of Products effected by OSI or its Affiliates to distributors,
resellers, dealers or similar Third Parties shall be subject to Section 6.6(a), irrespective of whether any agreements between OSI and any such Third Party include license or sublicense grants, and (ii) Net Sales of [**] Products effected
by OSI or its Affiliates to distributors, resellers, dealers or similar Third Parties shall be subject to Section 6.6(c)(i), irrespective of whether any agreements between OSI and any such Third Party include license or sublicense grants.

 (e) Royalty Term and Adjustments. OSI’s royalty obligations to AVEO under this Section 6.6 shall expire on
a country-by-country and Royalty-Bearing Product-by- Royalty-Bearing Product basis on the later of: (i) the expiration of the last Valid Claim (A) in the case of a Product, within the AVEO Patent Rights, Collaboration Patent Rights,
Product Patent Rights, Non-Antibody Compound Patent Rights or OSI Patent Rights Covering such Product in such country, or, (B) in the case of a [**] Product, Patent Rights Covering any associated diagnostic, (ii) the expiration of any
Marketing Exclusivity for such Royalty-Bearing Product in such country, and (iii) the tenth (10th) anniversary of the date of the First Commercial Sale by OSI or any of its Affiliates or Sublicensees to an unaffiliated Third Party of such
Royalty-Bearing Product in such country (the “Royalty Term”). The foregoing provisions of this Section 6.6(e) notwithstanding, the royalties payable with respect to Net Sales of a Royalty-Bearing Product shall be reduced to
[**] percent ([**]%) of the amounts otherwise payable pursuant to Sections 6.6(a) or 6.6(b) (as applicable, and adjusted pursuant to Section 6.7 if applicable) during any portion of the Royalty Term when (i) there is no Valid Claim within
the AVEO Patent Rights, Collaboration Patent Rights, Product Patent Rights, Non-Antibody Compound Patent Rights or OSI Patent Rights Covering such Royalty-Bearing Product in such country, and (ii) the Royalty-Bearing Product does not have
Marketing Exclusivity in such country. 
 (f) No Further Deductions. Except as expressly provided in this
Section 6.6 or in Section 6.7, OSI shall have no right to, and there shall not be any offsets to or deductions from the royalties payable pursuant to this Section 6.6. 
 (g) Royalty Discussion. In the event OSI in-licenses a Non-Antibody Compound in late-stage clinical development (e.g. Phase II or
later), and believes that a credit for some portion of the royalties otherwise payable to AVEO is appropriate under the circumstances to facilitate the development and commercialization of such in-licensed product, upon OSI’s request OSI and
AVEO shall discuss such matter in good faith and seek to reach a mutually acceptable resolution; provided that AVEO shall be under no obligation to agree upon any adjustments to such royalties. 
 6.7 Milestone and Royalty Adjustments for [**]. 
 (a) If OSI exercises its Option to select the Target known as [**] as a Collaboration Target (pursuant to the terms of Section 3.7(c)), the foregoing provisions of Sections 6.4 and 6.6
notwithstanding, with respect to any Royalty-Bearing Product Directed to the Target [**], if at the time of sale of such Royalty-Bearing Product Directed to [**], AVEO has initiated a [**]

  

 - 50 - 

 
Research Program: (i) the milestone payments set forth in Section 6.4(b), (c), (d) and (e) shall be reduced by [**] percent ([**]%), and (ii) the royalty rates set forth
in Section 6.6(a) and (b) shall be reduced by [**] percent ([**]%). 
 (b) If OSI does not exercise its Option to
select the Target known as [**] as a Collaboration Target (pursuant to the terms of Section 3.7(c)), the foregoing provisions of Sections 6.4 and 6.6 notwithstanding, with respect to any [**] Product, if at the time of sale of such [**]
Product, AVEO has initiated a [**] Research Program: (i) the milestone payments set forth in Section 6.4(f) shall be reduced by [**] percent ([**]%), and (ii) the royalty rates set forth in Section 6.6(c) shall be reduced by [**]
percent ([**]%). 
 6.8 Payments Regarding OSI Active Program Targets. With respect to each OSI Active Program Target:
(a) $[**] shall be payable by OSI to AVEO within forty-five (45) days after delivery of each OSI Active Program Model, and within thirty (30) days after AVEO has submitted an invoice to OSI, (b) the provisions of
Section 6.4(e) shall apply to any product Directed to an OSI Active Program Target (an “OSI Active Program Target Product”), except that (i) the milestone payment obligation set forth in Section 6.4(e)(i) shall be
payable at twice the amount set forth therein, (ii) the milestone payment obligation set forth in Section 6.4(e)(ii) shall be paid at four times the amount set forth therein, and (iii) the milestone obligations set forth in
Section 6.4(e)(i) and (ii) shall be based on an OSI Active Program Label Claim Product (as hereinafter defined in this Section 6.8) or a [**] Product Directed to an OSI Active Program Target; and (c) royalties as set forth in
Sections 6.6(a), 6.6(b) or 6.6(c), as applicable, but at the reduced rate of [**] percent ([**]%), shall be payable solely on the Net Sales of (A) an OSI Active Program Target Product with respect to which the Regulatory Approval includes a
labeling claim for the identification of a targeted patient population (including where such population is characterized by [**] or more biomarkers) and where such labeling claim is Covered by the OSI Active Program Translational Research Patent
Rights (an “OSI Active Program Label Claim Product”) or (B) a [**] Product Directed to an OSI Active Program Target. 
 For purposes of this Section 6.8, “Net Sales” shall have the same meanings as set forth in Section 1.69, except that all references to “Products” therein shall be replaced with “OSI Active Program Label
Claim Products”. Sections 6.10 through 6.17 shall apply to this Section 6.8 except that all references to “Product” shall be replaced with “OSI Active Program Label Claim Product”. 
 6.9 [**] Model Payment. OSI paid to AVEO, on January 25, 2008, the amount of $[**] pursuant to AVEO’s delivery of an [**]
Model pursuant to and in compliance with the terms of the Original Agreement. Subject to the FTE costs set forth in Section 6.3, any additional [**] Models provided to OSI pursuant to Section 2.12 shall be at no cost to OSI. 
 6.10 Reports; Payments. Within forty-five (45) days after the end of each Calendar Quarter during which there are Net Sales
giving rise to a payment obligation under Sections 6.5 or 6.6, OSI shall submit to AVEO a report identifying for each Royalty-Bearing Product, the Net Sales for such Royalty-Bearing Product for each country for such Calendar Quarter and the
royalties and the sales milestones payable to AVEO. Concurrently with each such report, OSI shall pay to AVEO all royalties and sales milestones payable by it under Sections 6.5 and 6.6. 
  

 - 51 - 

 6.11 Books and Records; Audit Rights. 
 (a) OSI shall keep complete and accurate records of the underlying revenue and expense data relating to the calculations of Net Sales and
payments required by Sections 6.4, 6.5 and 6.6. AVEO shall have the right, once annually at its own expense, to have an independent, certified public accounting firm, selected by AVEO and reasonably acceptable to OSI, review any such records of OSI
in the location(s) where such records are maintained by OSI upon reasonable notice (which shall be no less than thirty (30) days prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of
verifying the basis and accuracy of payments made under Sections 6.4, 6.5 and 6.6 within a [**] period preceding the date of the request for review provided that only completed Calendar Years may be audited. The report of such accounting firm shall
be limited to a certificate stating whether any report made or payment submitted by OSI during such period is accurate or inaccurate and the actual amounts of Net Sales, milestones and royalties due for such period. OSI shall receive a copy of each
such report concurrently with receipt by AVEO. Should such inspection lead to the discovery of a discrepancy to AVEO’s detriment, OSI shall pay the amount of the discrepancy within five (5) Business Days after its receipt from the
accounting firm of the certificate showing the amount of the discrepancy. AVEO shall pay the full cost of the review unless the underpayment of milestones and royalties is greater than five percent (5%) of the amount due for the applicable
period, in which case OSI shall pay the reasonable cost charged by such accounting firm for such review. Any overpayment of royalties by OSI revealed by an examination shall be fully creditable against future milestone and royalty payments.

 (b) AVEO shall keep complete and accurate records of the underlying revenue and expense data relating to (i) the FTE
expenses and Research Program Expenses required by Section 6.3 and (ii) the calculations of Net Sales and payments required by Section 6.18. OSI shall have the right, once annually at its own expense, to have an independent, certified
public accounting firm, selected by OSI and reasonably acceptable to AVEO, review any such records of AVEO in the location(s) where such records are maintained by AVEO upon reasonable notice (which shall be no less than thirty (30) days prior
notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under Sections 6.3 and 6.18 within a [**] period preceding the date of the request for
review provided that only completed Calendar Years may be audited. The report of such accounting firm shall be limited to a certificate stating whether any report made or payment submitted by AVEO during such period is accurate or inaccurate and the
actual amounts of Net Sales, milestones, royalties, FTE expenses and Research Program Expenses due for such period. AVEO shall receive a copy of each such report concurrently with receipt by OSI. Should such inspection lead to the discovery of a
discrepancy to OSI’s detriment, AVEO shall pay the amount of the discrepancy within five (5) Business Days after its receipt from the accounting firm of the certificate showing the amount of the discrepancy. OSI shall pay the full cost of
the review unless the underpayment of milestones and royalties together with any overcharge of expenses is greater than five percent (5%) of the amount due for the applicable period, in which case AVEO shall pay

  

 - 52 - 

 
the reasonable cost charged by such accounting firm for such review. Any overpayment of royalties by AVEO or underpayment of expenses by OSI revealed by an examination shall be fully creditable
against future milestone, royalty and expense payments. 
 6.12 Taxes. AVEO shall pay any and all taxes levied on account
of all payments it receives under this Agreement. If laws or regulations require that taxes be withheld, OSI will (a) deduct those taxes from the remittable payment, (b) timely pay the taxes to the proper taxing authority, and
(c) send proof of payment to AVEO within thirty (30) days after receipt of confirmation of payment from the relevant taxing authority. OSI will reasonably cooperate with AVEO to obtain the benefit of any applicable tax law or treaty,
including the pursuit of any refund or credit of such tax to AVEO. 
 6.13 United States Dollars. All dollar
($) amounts specified in this Agreement are United States dollar amounts. 
 6.14 Payment Method and Currency
Conversion. All payments to be made by OSI to AVEO shall be in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at OSI’s election, to
such bank account as AVEO shall designate in a notice at least ten (10) days before the payment is due. For the purposes of determining the amount of any sales milestone payment under Section 6.5 or royalties due for the relevant Calendar
Quarter under Section 6.6, the amount of Net Sales in any foreign currency shall be converted into United States dollars in a manner consistent with OSI’s normal practices used to prepare its audited financial reports; provided that
such practices use a widely accepted source of published exchange rates. 
 6.15 Blocked Payments. If by reason of
applicable Laws in any country in the Territory, it becomes impossible or illegal for OSI or its Affiliates or Sublicensees to transfer, or have transferred on its behalf, milestones, royalties or other payments to AVEO, OSI shall promptly notify
AVEO of the conditions preventing such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of AVEO in a recognized banking institution designated by AVEO or, if none is designated
by AVEO within thirty (30) days, in a recognized banking institution selected by OSI or its Affiliate or Sublicensee, as the case may be, and identified in a notice given to AVEO. If so deposited in a foreign country, OSI shall provide, or
cause its Affiliate or Sublicensee to provide, reasonable cooperation to AVEO so as to allow AVEO to assume control over such deposit as promptly as practicable. 
 6.16 Late Payments. If a Party shall fail to make a timely payment pursuant to the terms of this Agreement, interest shall accrue on the past due amount at the thirty-day U.S. dollar LIBOR rate
effective for the date that payment was due (as published in the Wall Street Journal) plus [**]% per annum, computed for the actual number of days the payment was past due. 
 6.17 Inter-Company Sales. Sales between or among OSI, its Affiliates and Sublicensees shall not be subject to such milestones or
royalties under Sections 6.5 or 6.6; royalties shall only be calculated upon Net Sales to a Third Party that is not a Sublicensee. OSI shall be responsible for accounting for and paying milestone payments and royalties on Net Sales by its Affiliates
and Sublicensees. 
  

 - 53 - 

 6.18 Payments by AVEO. In consideration of the exclusive licenses granted to AVEO
pursuant to Section 3.6, AVEO shall pay to OSI: 
 (a) a non-refundable, non-creditable milestone payment in the amount of
[**] dollars ($[**]) upon the first Regulatory Approval of each Antibody Product or Non-Antibody Product in respect of which the Regulatory Approval includes a labeling claim for the identification of a targeted patient population (including where
such population is characterized by one or more biomarkers) and where such labeling claim is Covered by Translational Research Patent Rights (an “AVEO Label Claim Product”). For purposes of clarity, such milestone payments shall be
payable once with respect to each Target to achieve the milestone event (regardless of whether achieved by an Antibody Product or a Non-Antibody Product), upon the earliest achievement of the milestone event by an AVEO Label Claim Product Directed
to such Target; and 
 (b) royalties at the rate of (i) [**] percent ([**]%) of Net Sales of AVEO Label Claim Products
sold by or on behalf of AVEO, its Affiliates or Sublicensees if, at the time of First Commercial Sale of such AVEO Label Claim Product, OSI is not engaged in the clinical development of, or is not commercializing, a Product Directed at the same
Target as the AVEO Label Claim Product, and (ii) [**] percent ([**]%) of Net Sales of AVEO Label Claim Products sold by or on behalf of AVEO, its Affiliates or Sublicensees if, at the time of First Commercial Sale of such AVEO Label Claim
Product, OSI is engaged in the clinical development of, or is commercializing, a Product Directed at the same Target as the AVEO Label Claim Product. Such royalty obligation shall expire on a country-by-country basis on the later of: (A) the
expiration of the last Valid Claim within the Translational Research Patent Rights Covering an AVEO Label Claim Product, (B) the expiration of any Marketing Exclusivity for such AVEO Label Claim Product in such country, and (C) the 10th
anniversary of the date of the First Commercial Sale by AVEO or any of its Affiliates or Sublicensees to an unaffiliated Third Party of such AVEO Label Claim Product in such country. 
 For purposes of this Section 6.18, “First Commercial Sale”, “Marketing Exclusivity”, “Net Sales” and “Regulatory Approval” shall have the same meanings as set
forth in Sections 1.54, 1.64, 1.69 and 1.96, respectively, except that all references to “Products” therein shall be replaced with “AVEO Label Claim Products.” Sections 6.10 through 6.17 above shall apply to this
Section 6.18 except that all references to “OSI” therein shall be replaced with “AVEO” and all references to “AVEO” shall be replaced with “OSI”. 
 6.19 Milestone and Royalty Adjustments Related to Designated Product. OSI will have the right to designate one Royalty-Bearing
Product as a “Designated Product” upon providing written notice to AVEO (the “Designation Notice”). Notwithstanding anything herein to the contrary, all payments under Sections 6.4(b), 6.4(c), 6.4(d), 6.4(e), 6.5,
6.6(a) and 6.6(b) to a Designated Product shall be reduced by [**] percent ([**]%) of the amount otherwise owed solely with respect to the Designated Product. For

  

 - 54 - 

 
purposes of clarity, any payments owed or paid by OSI with respect to such Designated Product prior to the date that OSI delivers the Designation Notice to AVEO shall be due in full to AVEO (to
the extent not previously paid by OSI). 
 ARTICLE VII 
 PATENTS 
 7.1 OSI Prosecution and
Maintenance of Patent Rights. OSI shall be responsible for preparing, filing, prosecuting and/or maintaining the OSI Patent Rights, Product Patent Rights, Patent Rights within the Non-Antibody Compound Intellectual Property (the
“Non-Antibody Compound Patent Rights”), Specified Antibody Intellectual Property, Patent Rights within the Collaboration Target Translational Research Patent Rights, Additional Tumor Model Translational Research Patent Rights, OSI
Active Program Translational Research Patent Rights and Joint Patent Rights, including any related interference, opposition, re-examination, re-issue, revocation or any official proceeding involving the foregoing Patent Rights. In advance of filing
any patent application or other substantive papers in any patent office covering Collaboration Target Translational Research Patent Rights, Additional Tumor Model Translational Research Patent Rights, or Joint Patent Rights, OSI shall provide AVEO
with an opportunity to review and comment before such filing. OSI shall consider in good faith any AVEO comments and/or suggestions concerning such filings, including comments and suggestions regarding the choice of countries in which patent
applications are filed. The cost of preparing, filing, prosecuting and maintaining OSI Patent Rights, Product Patent Rights, Non-Antibody Compound Patent Rights, Collaboration Target Translational Research Patent Rights, Additional Tumor Model
Translational Research Patent Rights, OSI Active Program Translational Research Patent Rights and Joint Patent Rights shall be borne one-hundred percent (100%) by OSI. OSI shall keep AVEO reasonably informed of the status of all pending
Collaboration Target Translational Research Patent Rights, Additional Tumor Model Translational Research Patent Rights and Joint Patent Rights. OSI shall not decline to file or abandon any Collaboration Target Translational Research Patent Right,
Additional Tumor Model Translational Research Patent Rights or Joint Patent Right without at least ninety (90) days’ prior written notice to AVEO. Upon receiving such notice, AVEO shall have the right to prepare and file or assume
responsibility for prosecuting and/or maintaining any such Collaboration Target Translational Research Patent Right or Joint Patent Right at AVEO’s expense, and upon AVEO’s request, OSI agrees to grant AVEO a power of attorney sufficient
to enable AVEO to file all necessary legal documents to prepare and file or to continue prosecution and/or to maintain such Collaboration Target Translational Research Patent Rights or Joint Patent Rights on behalf of OSI, at AVEO’s sole
discretion and sole expense. OSI will cooperate with AVEO in the timely execution and filing of documents reasonably necessary for AVEO to prosecute and/or maintain such Patent Rights. 
 7.2 AVEO Prosecution and Maintenance of Patent Rights. AVEO shall be responsible for preparing, filing, prosecuting and/or
maintaining (a) the AVEO Patent Rights, (b) Patent Rights within the Model Intellectual Property (“Model Patent Rights”), (c) Patent Rights within the Target Intellectual Property (“Target Patent
Rights”), (d) Translational Research Patent Rights relating

  

 - 55 - 

 
directly to AVEO Targets (the “AVEO Target Translational Research Patent Rights”), and AVEO Platform Patent Rights at its sole expense. AVEO shall keep OSI reasonably informed of
the status of all pending Target Patent Rights covering Nominated Targets and Collaboration Targets, and any Model Patent Rights relating thereto. AVEO shall not decline to file or abandon any AVEO Patent Right, Target Patent Right or Model Patent
Right that covers a Collaboration Model, Nominated Target or Collaboration Target without at least [**] days’ prior written notice to OSI. Upon receiving such notice, OSI shall have the right to prepare and file or assume responsibility for
prosecuting and/or maintaining any such Patent Rights on behalf of AVEO, and upon OSI’s request, AVEO agrees to grant OSI a power of attorney sufficient to enable OSI to file all necessary legal documents to prepare and file or to continue
prosecution and/or to maintain such Patent Rights on behalf of AVEO, at OSI’s sole discretion and sole expense. AVEO will cooperate with OSI in the timely execution and filing of documents reasonably necessary for OSI to prosecute and/or
maintain such Patent Rights. 
 7.3 Third Party Infringement. 
 (a) Notice. Each Party shall promptly report in writing to the other Party any known or suspected (i) infringement of any of the
Collaboration Patent Rights, AVEO Patent Rights, OSI Patent Rights or Product Patent Rights, or (ii) unauthorized use or misappropriation of any of the Collaboration Know-How, AVEO Know-How or OSI Know-How of which such Party becomes aware, and
shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use. 
 (b) Initial Right to Enforce. Subject to Section 7.3(c), OSI shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the Collaboration Target Translational Research
Patent Rights, Non-Antibody Compound Patent Rights, Product Patent Rights, Joint Patent Rights relating to Collaboration Targets or Royalty-Bearing Products in the Field, Target Patent Rights relating to Collaboration Targets or Royalty-Bearing
Products in the Field, Model Patent Rights relating to Collaboration Targets in the Field, and OSI Patent Rights. Notwithstanding the foregoing sentence, OSI shall not initiate any such lawsuit or other enforcement action asserting any such
Collaboration Target Translational Research Patent Rights, Joint Patent Rights, Target Patent Rights or Model Patent Rights without first consulting with AVEO and giving good faith consideration to any reasonable objection from AVEO regarding
OSI’s proposed course of action. Any lawsuit by OSI asserting such Collaboration Target Translational Research Patent Rights, Product Patent Rights, Joint Patent Rights, Target Patent Rights, Model Patent Rights or the OSI Patent Rights shall
be in the name of AVEO and/or OSI, including their respective Affiliates, as determined by the wishes of the Parties and/or the Law of the forum. For this purpose, AVEO shall execute such legal papers and cooperate in the prosecution of such suit as
may be reasonably requested by OSI; provided that OSI shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by AVEO in connection with such cooperation. 
 (c) Step-In Right. If OSI does not initiate a lawsuit or take other reasonable action pursuant to Section 7.3(b) with respect
to any infringement of a Collaboration Target Translational Research Patent Right relating to an Antibody Product, Joint

  

 - 56 - 

 
Patent Rights relating to Collaboration Targets or Products in the Field, Target Patent Rights relating to Collaboration Targets or Products in the Field, or Model Patent Rights relating to
Collaboration Targets or Products in the Field, then AVEO shall have the right (in cases where AVEO has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing [**] days notice to OSI and giving good
faith consideration to OSI’s reason(s) for not initiating a lawsuit or taking other action. Any such lawsuit by AVEO shall be in the name of AVEO and/or OSI, including their respective Affiliates, as determined by the wishes of the Parties
and/or the Law of the forum. For this purpose, OSI shall execute such legal papers and cooperate in the prosecution of such suit as may be reasonably requested by AVEO; provided that AVEO shall promptly reimburse all out-of-pocket expenses
(including reasonable counsel fees and expenses) actually incurred by OSI in connection with such cooperation. 
 (d)
Conduct of Certain Actions; Costs. The Party initiating legal action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section 7.3(b) or 7.3(c) (the “Initiating Party”).
The Initiating Party shall bear its own out-of-pocket costs incurred in any such legal action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal
action (in cases where such other Party has standing) by its own counsel at its own expense. 
 (e) Recoveries. The
Initiating Party (as defined in Section 7.3(d)) shall be entitled to receive [**] percent ([**]%) of any damage award or settlement recovered, after deducting its actual out-of-pocket costs (including reasonable attorneys’ fees and
expenses). The other Party shall be entitled to receive the remaining [**] percent ([**]%). 
 7.4 Patent Invalidity
Claim. Each Party shall promptly notify the other in the event of any legal or administrative action by any Third Party against an AVEO Patent Right, Collaboration Patent Right, OSI Patent Right or Product Patent Right of which it becomes aware,
including any nullity, revocation, reexamination or compulsory license proceeding. OSI shall have the first right, but not the obligation, at its expense, to defend against any such action relating to the OSI Patent Rights, Product Patent Rights,
Non-Antibody Compound Patent Rights, Joint Patent Rights relating to Collaboration Targets or Products in the Field, Target Patent Rights relating to Collaboration Targets or Products in the Field or Model Patent Rights relating to Collaboration
Targets or Products in the Field. If OSI does not defend against any such action involving a Target Patent Right, Joint Patent Right or Model Patent Right then (in cases where AVEO has standing) AVEO shall have the right, but not the obligation, to
defend such action at AVEO’s expense. 
 7.5 Patent Term Extensions. The Parties shall cooperate with each other in
obtaining patent term extensions or supplemental protection certificates or their equivalents in any country in the Territory, where applicable to AVEO Patent Rights, Collaboration Patent Rights, Product Patent Rights and OSI Patent Rights.

 7.6 Patent Marking. OSI shall comply with the patent marking statutes in each country in which a Product is sold by
OSI, its Affiliates and/or its Sublicensees. 
  

 - 57 - 

 7.7 Certification under Drug Price Competition and Patent Restoration Act.

 (a) Notice. If a Party becomes aware of any certification filed pursuant to 21 U.S.C. §355(b)(2)(A) or
§355(j)(2)(A)(vii)(IV) claiming that any Collaboration Patent Rights Covering a Product in the Field, are invalid or otherwise unenforceable, or that infringement will not arise from the manufacture, use, import or sale of a product by a Third
Party (a “Paragraph IV Claim”), such Party shall promptly notify the other Party in writing within five (5) Business Days after its receipt thereof. 
 (b) Cooperation. The Parties shall reasonably cooperate in the prosecution of any Paragraph IV Claim, and share any compensation
recovered as a result of such prosecution, as set forth in Section 7.3(e); provided that the Party controlling such Paragraph IV Claim shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses)
actually incurred by the other Party in connection with such cooperation. 
 ARTICLE VIII 
 REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 
 8.1 Representations and Warranties of the Parties. OSI and AVEO each represent, warrant and covenant to the other, as of the Restatement Effective Date, that: 
 (a) it has the authority and right to enter into and perform this Agreement and grant the rights embodied herein, and it is not aware of
any legal impediment that could inhibit its ability to perform its obligations under this Agreement; 
 (b) its execution,
delivery and performance of this Agreement does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a party or is otherwise bound; 
 (c) it shall comply in all material respects with all Laws applicable to its actions under this Agreement; and 
 (d) no consent of any Third Party is required for such Party to grant the licenses and rights granted to the other Party under this
Agreement or to perform its obligations hereunder; and 
 (e) all of such Party’s personnel and employees, and Third
Parties hired by such Party and involved in the Research Program or in the research, development, manufacture or commercialization of Collaboration Compounds or Products are or will be under a written obligation to assign to such Party any rights
they may have to any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of activities pursuant to the Research Program or in the research, development, manufacture or commercialization of any Collaboration
Compound or Product. 
  

 - 58 - 

 8.2 Representations and Warranties of AVEO. AVEO represents, warrants and covenants
to OSI, as of the Restatement Effective Date, that: 
 (a) AVEO has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in AVEO Intellectual Property in a manner inconsistent with the terms hereof. 
 (b)
AVEO’s execution, delivery and performance of this Agreement does not conflict with, or constitute a breach of, any term or condition of any agreement to which AVEO is a party, including its agreement with the Existing Licensee. 
 (c) Except with respect to patent and patent applications licensed to AVEO, AVEO is the legal and beneficial owner of the AVEO Patent
Rights existing as of the Restatement Effective Date, free and clear of any liens, charges and encumbrances, and AVEO has valid and existing licenses to the AVEO Patent Rights not owned by AVEO. 
 (d) To AVEO’s knowledge as of the Restatement Effective Date, the list of AVEO Existing Targets provided to OSI as of the Original
Effective Date was a complete list of all Targets identified by AVEO as of the Original Effective Date through use of the AVEO Genetic Screens, other than the Excluded Targets and the OSI Active Program Targets. 
 (e) AVEO has not received any complaint or allegation from a Third Party regarding infringement or misappropriation of any Third-Party
intellectual property rights in connection with AVEO’s use of the AVEO Bioinformatics Tools, AVEO Bioinformatics Data and Models. 
 (f) To the best of AVEO’s knowledge, OSI’s use of the AVEO Bioinformatics Tools, AVEO Bioinformatics Data, Models and AVEO Platform Intellectual Property will not infringe any Third-Party
intellectual property rights, provided that, OSI obtains licenses from the Third Parties set forth on Schedule 8.2(f). Schedule 8.2(f) lists all the Third Party licenses (including license fees) obtained by AVEO in connection with its
use of the AVEO Bioinformatics Tools, AVEO Bioinformatics Data and AVEO Platform Intellectual Property. AVEO expressly disclaims any representation or warranty that the licenses listed in Schedule 8.2(f) will be available to OSI on the same
terms and conditions under which the licenses were obtained by AVEO. 
 (g) In the event that any license listed in Schedule
8.2(f) is necessary for OSI to use the AVEO Bioinformatics Tools and AVEO Platform Intellectual Property and the cost of such license to OSI would significantly exceed the amount shown in Schedule 8.2(f), the Parties will, in good faith,
negotiate a reasonable cost-sharing arrangement with respect to the marginal cost of the license, provided that OSI notifies AVEO in advance of obtaining such license. 
 8.3 No Other Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND PARTICULARLY THAT
COLLABORATION TARGETS WILL BE IDENTIFIED OR THAT PRODUCT(S) WILL BE

  

 - 59 - 

 
SUCCESSFULLY DEVELOPED HEREUNDER, AND IF PRODUCT(S) ARE DEVELOPED, WITH RESPECT TO SUCH PRODUCT(S), THE PARTIES DISCLAIM ALL IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE. AVEO MAKES NO REPRESENTATION OR WARRANTY THAT ALL ERRORS HAVE BEEN OR CAN BE ELIMINATED FROM THE AVEO BIOINFORMATICS TOOLS, INCLUDING THE BIOINFORMATICS TOOLS SOURCE CODE, THAT THE AVEO BIOINFORMATICS TOOLS WILL
OPERATE WITHOUT INTERRUPTION OR THAT IT WILL OPERATE WITH ANY OTHER PRODUCTS. 
 8.4 Indemnification by OSI. OSI shall
indemnify, hold harmless and defend AVEO, its Affiliates and all of their respective officers, directors, employees, agents, licensors and shareholders (collectively, the “AVEO Indemnitees”) from and against any and all losses,
damages, liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense (including reasonable attorneys’ fees and witness fees) resulting from any demand, claim, action or proceeding brought or initiated by a Third
Party (each a “Third Party Claim”) against any AVEO Indemnitees(s) arising out of (a) the breach or alleged breach by OSI of any representation, warranty or covenant under this Agreement; (b) the negligence or willful
misconduct of OSI or its Affiliates or any of their respective licensees, Sublicensees, agents, directors, officers, employees or shareholders; (c) the research, development, manufacture, storage, handling, use, sale, offer for sale or
importation of Royalty-Bearing Products; or (d) the use, handling, storage or disposal by OSI of any Materials, Tumor Archives or Additional Tumor Models provided to it by AVEO, provided that (i) the AVEO Indemnitees shall comply
with the procedures set forth in Section 8.6; and (ii) such indemnity shall not apply to the extent such Third Party Claim is caused by the gross negligence, willful misconduct or violation of Law by an AVEO Indemnitee. 
 8.5 Indemnification by AVEO. AVEO shall indemnify, hold harmless and defend OSI, its Affiliates and all of their respective officers,
directors, employees, agents, licensors and shareholders (collectively, the “OSI Indemnitees”) from and against any and all losses, damages, liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense
(including reasonable attorneys’ fees and witness fees) resulting from any Third Party Claim against any OSI Indemnitees(s) arising out of (a) the breach or alleged breach by AVEO of any representation, warranty or covenant under this
Agreement; (b) the negligence or willful misconduct of AVEO or its Affiliates or any of their respective licensees, Sublicensees, agents, directors, officers, employees or shareholders; (c) the research, development, manufacture, storage,
handling, use, sale, offer for sale or importation of AVEO Label Claim Products; or (d) the use, handling, storage or disposal by AVEO of any Materials provided to it by OSI, provided that (i) the OSI Indemnitees shall comply with
the procedures set forth in Section 8.6; and (ii) such indemnity shall not apply to the extent such Third Party Claim is caused by the gross negligence, willful misconduct or violation of Law by an OSI Indemnitee. 
 8.6 Procedure. To be eligible for the AVEO Indemnitees to be indemnified hereunder, AVEO shall provide OSI with prompt notice of the
Third Party Claim giving rise to the indemnification obligation under this Article VIII and the exclusive ability

  

 - 60 - 

 
to defend or settle any such claim; provided however that OSI shall not enter into any settlement for damages without AVEO’s prior written consent, such consent not to be
unreasonably withheld, delayed or conditioned. AVEO shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by OSI. To be eligible for the OSI Indemnitees to
be indemnified hereunder, OSI shall provide AVEO with prompt notice of the Third Party Claim giving rise to the indemnification obligation under this Article VIII and the exclusive ability to defend or settle any such claim; provided
however that AVEO shall not enter into any settlement for damages without OSI’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. OSI shall have the right to participate, at its own expense and
with counsel of its choice, in the defense of any claim or suit that has been assumed by AVEO. 
 8.7 Insurance. OSI
shall procure and maintain insurance or self-insurance, including product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated, at all times
during which any Product is being developed, clinically tested in human subjects or commercially distributed or sold by or on behalf of OSI, its Affiliates or Sublicensees. AVEO shall procure and maintain insurance or self-insurance, including
product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated, at all times during which any AVEO Label Claim Product is being developed,
clinically tested in human subjects or commercially distributed or sold by or on behalf of AVEO, its Affiliates or Sublicensees. It is understood that such insurance or self-insurance shall not be construed to create a limit of a Party’s
liability with respect to its indemnification obligations under this Article VIII. Each Party shall provide the other Party with written evidence of such insurance or self-insurance upon request. Each Party shall provide the other Party with written
notice at least thirty (30) days prior to the cancellation, non renewal or material change in such insurance or self-insurance which could adversely affect rights hereunder. 
 ARTICLE IX 
 TERM AND TERMINATION

 9.1 Term and Expiration. This Agreement shall be effective as of the Original Effective Date and unless
terminated earlier pursuant to Section 9.2, this Agreement shall continue in effect until the expiration of all royalty obligations hereunder (the “Term”). Notwithstanding anything to the contrary herein, upon expiration of
this Agreement, OSI’s license pursuant to Section 3.5 and 3.8(a) shall become fully paid-up and non-exclusive. 
 9.2
Termination of Agreement for Cause. This Agreement may be terminated at any time during the Term upon written notice by either Party if the other Party is in breach of its material obligations hereunder and has not cured such breach within
[**] days after notice requesting cure of the breach (other than for non-payment which must be cured within [**] days); provided however in the event of a good faith Dispute with respect to the existence of a material breach, the [**]
day or [**] day cure period shall be tolled until such time as the Dispute is resolved pursuant to Article XI. 
  

 - 61 - 

 9.3 Effect of Termination for Cause on Licenses. 
 (a) If OSI terminates this Agreement under Section 9.2, (i) AVEO’s license pursuant to Section 3.6(a) shall terminate,
(ii) AVEO’s license pursuant to 3.6(b) shall terminate solely with respect to subject matter within the Collaboration Intellectual Property that was solely invented by employees or others acting on behalf of OSI, and shall remain in effect
with respect to all other subject matter within the Collaboration Intellectual Property (other than the Non-Antibody Compound Intellectual Property) and (iii) OSI’s license pursuant to Section 3.8 shall become a perpetual license;
provided however that OSI shall continue to fulfill OSI’s payment and/or royalty obligations as specified herein; and provided further OSI may reduce such payment and/or royalty obligations by the amount of monetary
damage suffered by OSI as a direct result of AVEO’s breach of this Agreement, as determined (A) in a final decision of a court of competent jurisdiction, which decision is not appealable or has not been appealed within the time allowed for
appeal, or (B) by the Parties in a settlement agreement. 
 (b) If AVEO terminates this Agreement under Section 9.2,
or if OSI terminates this Agreement solely with respect to one or more Collaboration Targets pursuant to Section 4.3, then, (i) OSI’s licenses pursuant to Sections 3.5(a) and 3.8 shall terminate as of the effective date of termination
with respect to all Candidate Targets, Nominated Targets and Collaboration Targets in the case of a termination under Section 9.2, and with respect to the applicable Collaboration Targets in the case of a termination under Section 4.3,
(ii) solely in the case of a termination under Section 9.2, OSI’s licenses and rights, and AVEO’s respective obligations, pursuant to Sections 2.15, 3.3(c)(ii) and (iv) (but only with respect to the rights granted to OSI
after delivery of the Expansion Notice), 3.5(c), 3.5(d), 3.5(e), 10.1 and 10.2 shall terminate as of the effective date of termination, (iii) the Collaboration Target or Targets that are the subject matter of the termination pursuant to
Section 4.3, or all Nominated Targets and Collaboration Targets upon any termination by AVEO pursuant to Section 9.2, shall automatically be deemed to be AVEO Targets hereunder, effective as of the effective date of termination,
(iv) AVEO’s licenses under Section 3.6(a) shall become perpetual licenses and (for purposes of clarity) the license granted to AVEO pursuant to Section 3.6(a) shall apply to all Collaboration Targets deemed to be AVEO Targets
pursuant to Section 9.3(b)(iii), (v) OSI shall, within thirty (30) days after the effective date of termination, return or cause to be returned to AVEO, copies of all Confidential Information, AVEO Intellectual Property, AVEO Platform
Intellectual Property and Collaboration Know-How owned by AVEO or by AVEO and OSI jointly (including Translational Research Intellectual Property), and all Materials (including any Models) in each case with respect to any Collaboration Target that
is the subject of such termination, as well as all Additional Tumor Models and Tumor Archives; (vi) solely in the case of a termination under Section 9.2 due to a breach of Sections 2.15, 3.5(d), 6.1(f)(ii) and10.2(a), OSI shall destroy
all copies and electronic versions of the AVEO Bioinformatics Tools and Bioinformatics Tools Updates including the Bioinformatics Tools Source Code, and (vii) AVEO shall continue to fulfill AVEO’s payment and/or royalty obligations as
specified under Section 6.18; provided that, in the case of a termination of this Agreement by AVEO pursuant to Section 9.2, AVEO may reduce such payment and/or royalty obligations by the

  

 - 62 - 

 
amount of monetary damage suffered by AVEO as a direct result of OSI’s breach of this Agreement, as determined (A) in a final decision of a court of competent jurisdiction, which
decision is not appealable or has not been appealed within the time allowed for appeal, or (B) by the Parties in a settlement agreement. 
 9.4 Obligations on Termination by OSI for Cause. Within sixty (60) days after any termination of this Agreement by OSI pursuant to Section 9.2, AVEO shall promptly: (a) provide to
OSI copies of all Confidential Information, OSI Intellectual Property and Collaboration Know-How owned by OSI, or by OSI and AVEO jointly, including Translational Research Intellectual Property, Compound Intellectual Property, Collaboration
Intellectual Property covering a Product and Joint Intellectual Property; (b) provide to OSI all OSI Materials, Collaboration Compounds or Product in AVEO possession; and (c) provide OSI with copies of all reports and data generated or
obtained by AVEO or its Affiliates pursuant to this Agreement that relate to any Translational Research Intellectual Property, OSI Active Program Translational Research Intellectual Property, Additional Tumor Model Translational Research
Intellectual Property, Collaboration Compound or Product that have not previously been provided to OSI. 
 9.5 Termination of
Certain Perpetual Licenses. Notwithstanding either Party’s rights in connection with termination as set forth in Sections 9.2, 9.3 and 9.4, if OSI does not deliver the payment set forth in Section 6.1(g) on or before January 31,
2011, then (a) the licenses granted under Section 3.5(d) to the AVEO Bioinformatics Tools and AVEO Bioinformatics Data shall immediately terminate, (b) any of OSI’s rights under this Agreement to Collaborations Targets selected
by OSI pursuant to its exercise of an Option on or after the Restatement Effective Date and to Collaboration Compounds and Products which are Directed to such Collaboration Targets shall immediately terminate and all such Collaboration Targets shall
be considered AVEO Targets effective as of January 31, 2011, (c) any of OSI’s rights under this Agreement to the Collaboration Target known as [**] and to Collaboration Compounds or Products which are Directed to the Collaboration
Target known as [**] shall immediately terminate and such [**] Collaboration Target shall be considered an AVEO Target effective as of January 31, 2011, and (d) neither OSI nor its Affiliates shall, nor shall any of them grant rights to a
Third Party to, conduct any research or development program with respect to any Collaboration Targets selected by OSI pursuant to its exercise of an Option on or after the Restatement Effective Date and the Collaboration Target known as [**], in
each case, through January 31, 2012; provided that, (i) the provisions of Section 9.5(d) shall not apply where OSI’s involvement in such activity results from OSI’s acquisition of or by a Third Party (by merger or
otherwise), and such Third Party was engaged in such activity prior to such acquisition or merger, and provided that (1) OSI shall not provide any such Third Party with rights or access to (A) AVEO Intellectual Property, or
(B) Collaboration Intellectual Property for use in connection with activities prohibited by subsection 9.5(d) if undertaken by OSI, and (2) in the case where OSI acquires a Third Party (by merger or otherwise), OSI does not expand the
scope of, or increase the financial commitment to, such Third Party activities, from what it was immediately prior to the acquisition, and (ii) the provisions of Section 9.5(c) shall not apply to the Collaboration Target known as [**] and
to the Collaboration Compound or Products which are Directed to the Collaboration target known as [**] if OSI makes a payment to AVEO in the amount of [**] Dollars ($[**]) by no later than January 31, 2011. 
  

 - 63 - 

 9.6 Effect of Expiration or Termination; Survival. Expiration or termination of the
Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or
accruing under this Agreement prior to expiration or termination, including the obligation to pay royalties for Royalty-Bearing Product(s) or Collaboration Compound(s) sold prior to such expiration or termination. The provisions of Articles I, V, XI
and XII, and Sections 2.5(b), 2.5(d), 2.14 (the last two sentences) , 3.1, 3.2, 3.3, 3.4, 3.5(b), 3.10, 3.11, 6.4, 6.5, 6.6, 6.7, 6.8, 6.10, 6.11, 6.12, 6.13, 6.14, 6.15, 6.16, 6.17, 6.18, 6.19, 7.3(e), 7.7(b), 8.3, 8.4, 8.5, 8.6, 8.7, 9.1, 9.3,
9.4, 9.5, 9.6, 10.3 and 10.6 shall survive the expiration or termination of the Agreement. 
 ARTICLE X 
 OPTION TO EXPAND OSI RIGHTS TO CERTAIN AVEO TECHNOLOGY 
 10.1 Collaboration Expansion Option. AVEO hereby grants to OSI an option (the “Collaboration Expansion Option”) to
obtain the rights contained in Section 10.2 below. OSI may exercise its Collaboration Expansion Option by delivering to AVEO a written notice of election by no later than [**] (the “Expansion Notice”). 
 10.2 Non-Exclusive Expansion License to OSI. Upon receipt by AVEO of the Expansion Notice and subject to payment of the Initial
License Expansion Fee per Section 6.1(f)(i) (the date of receipt of such payment being, the “Expansion Date”) and the restrictions contained in Section 3.7(c)(ii)(B), AVEO shall take the following actions and shall grant
the following rights to OSI: 
 (a) The licenses granted to OSI pursuant to Section 3.5(d)(iii) shall commence on the
Expansion Date and include any and all improvements and enhancements made to the AVEO Bioinformatics Tools during the Research Program Term, including any source code underlying such improvements and enhancements (the “Bioinformatics Tools
Updates”). AVEO shall deliver to OSI the version of the AVEO Bioinformatics Tools that includes Bioinformatics Tools Updates pursuant to the Technology Transfer Plan. 
 (b) AVEO shall grant to OSI a non-exclusive, perpetual (subject to Article IX above), world-wide, royalty-free license, without the right
to grant sublicenses, under the AVEO Platform Intellectual Property solely to research, develop, use, make, have made, sell, offer for sale and import Non-Antibody Compounds, Collaboration Antibodies and associated diagnostics, other than
Non-Antibody Compounds Directed to the Targets set forth on Schedule 1.47. 
 (c) AVEO shall transfer to OSI, no later than the
expiration of the Tech Transfer Period and as further outlined in the Technology Transfer Plan, the proprietary tumor cells derived from various tumor models developed by AVEO and in existence on June 30, 2011, to the extent such materials were
developed by AVEO and supported by OSI pursuant to the Research Plan (the “Tumor Archives”), which may include the Tumor Archives listed on Schedule 10.2(c) as agreed to by the Parties pursuant to the

  

 - 64 - 

 
applicable Research Plan; provided that, if the Tech Transfer Period expires prior to June 30, 2011, AVEO shall promptly transfer any additional Tumor Archives developed by AVEO and
supported by OSI after the expiration of the Tech Transfer Period and prior to June 30, 2011 as set forth in the Tech Transfer Plan. 
 (d) AVEO shall transfer to OSI, no later than the expiration of the Tech Transfer Period and as further outlined in the Technology Transfer Plan, any Additional Tumor Models created by AVEO prior to the
expiration of the Tech Transfer Period. 
 (e) AVEO shall grant to OSI a non-exclusive, world-wide,
royalty-free license, without the right to grant sublicenses, to the recurrence data (i.e., gene identity and associated number of recurrent hits across three tumor models) generated by AVEO prior to the Restatement Effective Date from the [**] (the
“[**] Intellectual Property”) solely to research, develop, use, make, have made, sell, offer for sale and import Non-Antibody Compounds, Collaboration Antibodies and associated diagnostics, other than Non-Antibody Compounds Directed
to the Excluded Targets, such license rights set forth in this Section 10.2(e) to expire on the fifth (5th) anniversary of the Expansion Date. 
 Notwithstanding anything to the contrary herein, the Bioinformatics Tools Updates, Tumor Archives and Additional Tumor Models are provided “as is” and without any representation or warranty,
express or implied, including any implied warranty of merchantability or of fitness for any particular purpose or any warranty that the use of such materials, information and technology will not infringe or violate any patent or other proprietary
rights of any Third Party. Subject to Section 8.2(g) above, OSI shall be solely responsible for obtaining any necessary Third Party licenses prior to receiving the Bioinformatics Tools Updates, Tumor Archives and Additional Tumor Models from
AVEO. The Tumor Archives, Additional Tumor Models and Model Improvements (as defined in Section 10.6 below) may not be used or delivered by OSI or its Affiliates to or for the benefit of any Third Party without the prior written consent of
AVEO, provided that, (i) OSI may grant rights to and deliver the Additional Tumor Models and Model Improvements to Third Parties subject to the restrictions on sublicensing of model rights set forth in Section 3.9(b), and (ii) the
Tumor Archives may be used solely for research, development and commercialization in connection with Non-Antibody Compounds and Collaboration Antibodies, other than Non-Antibody Compounds Directed to the Excluded Targets. 
 10.3 AVEO Rights Retained. Except as expressly set forth in this Article X, OSI shall not acquire any license or other intellectual
property interest, by implication or otherwise, in any Confidential Information disclosed to it or under any Patent Rights or Know-How Controlled by AVEO or its Affiliates pursuant to the Technology Transfer. Without limiting the generality of the
foregoing, any of AVEO’s rights to AVEO Platform Intellectual Property, AVEO Bioinformatics Updates, Tumor Archives, Additional Tumor Models and [**] Intellectual Property not specifically licensed to OSI shall be retained by AVEO. 

 

 - 65 - 

 10.4 Technology Transfer. 
 (a) Within [**] days after the Expansion Date, the Parties shall in good faith prepare and complete a mutually agreeable plan for the
Technology Transfer (“Tech Transfer Plan”). The Tech Transfer Plan shall (i) be based on the deliverables set forth in Schedule 10.4(a), (ii) specify goals for the achievement of the Technology Transfer and specify
specific criteria for successful achievement of the Technology Transfer; (iii) set forth those obligations assigned to each Party with respect to Technology Transfer, and (iv) if applicable, include details relating to the continued
delivery of the Tumor Archives after the Tech Transfer Period if OSI exercised its Collaboration Expansion Option prior to [**]. The Technology Transfer Plan may be amended from time to time through written amendments unanimously approved by both
Parties. 
 (b) AVEO shall use Commercially Reasonable Efforts to complete all activities necessary to effect the transfer of
the intellectual property and materials licensed to OSI pursuant to Section 10.2 (the “Technology Transfer”) pursuant to the Technology Transfer Plan, no later than [**] after the Expansion Date (the “Tech Transfer
Period”). During the Tech Transfer Period, AVEO shall (i) make available such number of technical personnel as are reasonably necessary to accomplish the Technology Transfer and answer questions or provide instructions as reasonably
requested by OSI concerning the intellectual property and materials delivered with respect to the exercise of the Collaboration Expansion Option and (ii) allow an appropriate number of qualified individuals from OSI, to be specified in the Tech
Transfer Plan, to be present at AVEO for purposes of training and instruction related to the intellectual property and materials delivered with respect to the exercise of the Collaboration Expansion Option. OSI shall pay for the Tech Transfer in
accordance with Section 6.3(c). 
 (c) The purpose of the Tech Transfer Plan is to teach and enable OSI to practice
certain aspects of the AVEO Platform Intellectual Property, as set forth herein. However, the Parties acknowledge that it is OSI’s responsibility to develop the appropriate infrastructure to utilize the intellectual property and materials
delivered with respect to the exercise of the Collaboration Expansion Option and that AVEO shall have no obligation to provide further services related to the Technology Transfer after such Tech Transfer Period. In the event there are any conflicts
or inconsistencies between this Agreement and the Tech Transfer Plan, this Agreement shall govern. 
 10.5 Exclusivity
Regarding Option. During the Research Program Term, AVEO shall not grant to any Third Party, other than OSI, any rights to the Tumor Archives and related AVEO Platform Intellectual Property for use in the discovery, development and
commercialization of Non-Antibody Compounds; provided that, (a) such prohibition set forth in this Section 10.5 shall in no manner restrict AVEO’s (or its successor’s-in-interest pursuant to Section 12.7(b) below) internal
use of the Tumor Archives or the AVEO Platform Intellectual Property (including internal use related to existing and future Third Party collaborations), (b) AVEO (or its successor-in-interest) may grant all or a portion of any rights to the
Tumor Archives and related AVEO Platform Intellectual Property to any AVEO Affiliate or any successor-in-interest pursuant to Section 12.7 below; (c) AVEO shall be allowed to grant all or a portion of any rights to the Tumor Archives and
related AVEO Platform Intellectual Property in connection with the partnering

  

 - 66 - 

 
of the existing AVEO drug discovery and/or development programs set forth on Schedule 10.5, and (d) this Section 10.5 shall terminate if OSI fails to make the payment set forth
in Section 6.1(f)(ii) when due. 
 10.6 Rights With Respect to Improvements. 
 (a) It is contemplated that, in the exercise of their respective rights or performance of their respective obligations under this
Agreement, both Parties will make modifications, enhancements or derivative works of the AVEO Bioinformatics Tools, including the Bioinformatics Source Code (“Bioinformatics Improvements”). The Parties hereby covenant that neither
Party nor its Affiliates, licensees, sublicensees or collaboration partners shall commence or maintain any suit against the other Party, or such other Party’s Affiliates, licensees, sublicensees, collaboration partners or customers, whether at
law or in equity, asserting patent or copyright infringement or misappropriation of trade secrets with respect to such Bioinformatics Improvements. This covenant shall be binding upon, and inure to the benefit of, the Parties, their successors, and
assigns. This covenant shall be binding upon any assignee of Patent Rights that claim any such Bioinformatics Improvements, and the Parties shall impose this covenant on any Third Party to whom such Party may assign any Patent Rights that claim any
such Bioinformatics Improvements. 
 (b) OSI hereby grants to AVEO a non-exclusive, world-wide, perpetual license, with the
right to grant sublicenses, under Patent Rights containing claims directed to methods of making or using chimeric mouse tumor models, DC tumor models or HIM models, to the extent such methods are invented by or on behalf of OSI or its Affiliates
through use of the AVEO Platform Intellectual Property (“Model Improvements”). 
 ARTICLE XI 

DISPUTE RESOLUTION 
 11.1 Seeking Consensus. If any dispute arises out of, in connection with or related to this Agreement, including disputes over the interpretation, performance, enforcement or breach of this
Agreement, including any dispute that is not within the jurisdiction of the JSC (a “Dispute”), then upon the written request of either Party, the matter shall be referred to the Chief Executive Officer of OSI and the Chief Executive
Officer of AVEO, who shall meet in a good faith effort to resolve the dispute within thirty (30) days. If the Parties’ respective Chief Executive Officers cannot agree on a resolution of the Dispute within such thirty (30) day period,
then it shall be resolved pursuant to the remaining provisions of this Article XI. 
 11.2 Arbitration, Rules and Place.
Any Dispute not resolved pursuant to Section 11.1 may be referred by either Party to final and binding arbitration in accordance with the remainder of this Article XI by written notice to the other Party. Any such Dispute shall be resolved by
final and binding arbitration by a single arbitrator in New York, New York under the auspices and administration of JAMS and pursuant to the JAMS Comprehensive Arbitration Rules and Procedures. The arbitration hearing shall commence within four
months of the demand for arbitration. Each Party shall have up to five (5) days to present its case, including

  

 - 67 - 

 
cross examination of the other Parties’ witnesses. In no event shall the arbitrator be authorized to assess multiple or punitive damages in the award. However, the arbitrator may provide in
the award for reasonable attorneys’ fees to the prevailing Party. 
 11.3 Injunctive Relief. Provided a Party has
made a sufficient showing, the arbitrator shall have the freedom to invoke, and the Parties agree to abide by, injunctive measures after either Party submits in writing for arbitration claims requiring immediate relief. Notwithstanding the foregoing
or any other provision of this Article XI, the Parties shall have the right to request one or more provisional equitable remedies from a court of competent jurisdiction in aid of arbitration. 
 11.4 Payment and Enforcement of Awards. Any monetary award shall be paid in U.S. dollars free of any tax, deduction or offset; and
any reasonable legal fees and costs incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting enforcement. Each Party agrees that any award may be entered in a court of competent
jurisdiction, if necessary, to its enforcement. 
 11.5 Confidentiality. The JAMS proceeding shall be confidential and
the arbitrator shall issue appropriate protective orders to safeguard each Party’s Confidential Information. Except as required by Law, no Party shall make (or instruct the arbitrator to make) any public announcement with respect to the
proceedings or decision of the arbitrator without prior written consent of each other Party. The existence of any Dispute submitted to JAMS, and the award, shall be kept in confidence by the Parties and the arbitrator, except as required in
connection with the enforcement of such award or as otherwise required by applicable Law. 
 11.6 Waiver. By agreeing to
binding arbitration, the Parties understand that they are waiving certain rights and protections which may otherwise be available if a Dispute were determined by a litigation in court, including the right to seek or obtain certain types of damages
precluded by the arbitration procedures set forth in this Article XI, the right to a trial by jury, and the right to invoke formal rules of procedure and evidence. 
 11.7 Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement for any reason. 
 ARTICLE XII 
 MISCELLANEOUS 
 12.1 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, other than any principle of conflict or choice of laws that would cause the application of the laws of any other jurisdiction. 
 12.2 Waiver. Waiver by a Party of a breach hereunder by the other Party shall not be construed as a waiver of any succeeding breach
of the same or any other provision. No delay or omission by a Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder shall operate as a waiver of any right, power or privilege by such Party. No waiver
shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the Party granting the waiver. 
  

 - 68 - 

 12.3 Notices. All notices, instructions and other communications hereunder or in
connection herewith shall be in writing, shall be sent to the address specified in this Section 12.3 and shall be: (a) delivered personally; (b) sent by registered or certified mail, return receipt requested, postage prepaid; or
(c) sent via a reputable nationwide overnight courier service. Any such notice, instruction or communication shall be deemed to have been delivered upon receipt if delivered by hand, three (3) Business Days after it is sent by registered
or certified mail, return receipt requested, postage prepaid, one (1) Business Day after it is sent via a reputable nationwide overnight courier service, or when transmitted with electronic confirmation of receipt, if transmitted by facsimile
(if such transmission is on a Business Day; otherwise, on the next Business Day following such transmission). 
  

			
	If to AVEO, to:	 	 AVEO Pharmaceuticals, Inc.
 75 Sidney Street, Fourth Floor
 Cambridge, MA 02139
 Attention: Chief Business Officer
 Telephone: 617-299-5950
 Facsimile: 617-995-4995

		
	with a copy to:	 	 AVEO Pharmaceuticals, Inc.
 75 Sidney Street, Fourth Floor
 Cambridge, MA 02139
 Attention: Legal Department
 Telephone: 617-299-5000
 Facsimile: 617-995-4995

		
		 	 Wilmer Cutler Pickering Hale and Dorr LLP
 60 State Street
 Boston, MA 02109
 Attention: Steven Singer
 Telephone: 617-526-6410
 Facsimile: 617-526-5000

		
	If to OSI, to:	 	 OSI Pharmaceuticals, Inc.
 41 Pinelawn Road
 Melville, NY 11747
 Telephone: (631) 962-2000
 Facsimile: (631) 752-3880
 Attention: General Counsel

  

 - 69 - 

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day; (b) on the business day after dispatch if sent by nationally-recognized
overnight courier; and/or (c) on the fifth business day following the date of mailing if sent by mail. 
 12.4 Entire
Agreement; Amendment. This Agreement (including Schedules) contains the complete understanding of the Parties with respect to the development, manufacture and commercialization of Royalty-Bearing Products and supersedes all prior understandings
and writings relating to such subject matter. In particular, it supersedes and replaces the Original Agreement and the Confidentiality Agreement dated February 11, 2007 between the Parties and any and all term sheets relating to the
transactions contemplated by this Agreement and exchanged between the Parties prior to the Original Effective Date. No amendment, change or addition to this Agreement will be effective or binding on either Party unless reduced to writing and duly
executed on behalf of both Parties. 
 12.5 Headings. Headings in this Agreement are for convenience of reference only
and shall not be considered in construing this Agreement. 
 12.6 Severability. If any provision of this Agreement is
held unenforceable by a court or tribunal of competent jurisdiction because it is invalid or conflicts with any applicable Law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected. In such event, the Parties
shall negotiate a substitute provision that, to the extent possible, accomplishes the original business purpose. 
 12.7
Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by any Party without the consent of the other Party; provided, however, that any Party may, without such consent,
assign this Agreement, in whole or in part: (a) to any of its respective Affiliates; provided that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned and such
Affiliate has acknowledged and confirmed in writing that effective as of such assignment or other transfer, such Affiliate shall be bound by this Agreement as if it were a party to it as and to the identical extent applicable to the transferor,
(b) to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates (an “M&A Event”); provided that such successor agrees in writing to be
bound by the terms of this Agreement as if it were the assigning party, or (c) OSI may assign its rights and obligations with respect to a Royalty-Bearing Product, provided that the assignee agrees in writing to be bound by the terms of this
Agreement as if it were, with respect to such assigned Royalty-Bearing Product, OSI. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with an M&A
Event, such assignment shall not provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party. 
  

 - 70 - 

 12.8 Counterparts. This Agreement may be executed in any number of counterparts, each
of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
 12.9 Force
Majeure. No Party shall be liable for failure of or delay in performing obligations set forth in this Agreement, and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire,
flood, tornadoes, thunderstorms, earthquake, war, terrorism, riots, embargo, losses or shortages of power, labor stoppage, substance or material shortages, damage to or loss of product in transit, events caused by reason of laws of any Governmental
Authority, events caused by acts or omissions of a Third Party, or any other cause reasonably beyond the control of such Party. 
 12.10 Third-Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party other than an AVEO Indemnitee or OSI Indemnitee under Section 8.4. No such Third Party shall
obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party. 
 12.11 Relationship of the Parties. Each Party shall bear its own costs incurred in the performance of its obligations hereunder
without charge or expense to the other, except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of the other Party’s employees or for any employee compensation or
benefits of the other Party’s employees. No employee or representative of a Party shall have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on
the other Party without said other Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the legal relationship under this Agreement of each Party to the other Party shall be that of
independent contractor. Nothing in this Agreement shall be construed to establish a relationship of partners or joint venturers between the Parties. 
 12.12 Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations and shall
guarantee performance of this Agreement by its Affiliates. If any disagreement arises out of the performance of this Agreement by an Affiliate of a Party, or the alleged failure of an Affiliate or the alleged failure of an Affiliate to comply with
the conditions and obligations of this Agreement, the Party seeking to resolve such dispute shall have the right do so directly with the other Party, without any obligation to first pursue an action against, or recovery from, the Affiliate which is
alleged to have caused a breach of this Agreement. 
 12.13 Construction. Each Party acknowledges that it has been
advised by counsel during the course of negotiation of this Agreement, and, therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted.
Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be,
this Agreement. Except where the context otherwise requires, (a) wherever used, the use of any

  

 - 71 - 

 
gender will be applicable to all genders, (b) the word “or” is used in the inclusive sense (and/or), (c) any definition of or reference to any agreement, instrument or other
document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (d) any
reference to any Laws refers to such Laws as from time to time enacted, repealed or amended, (e) the words “herein”, “hereof” and hereunder”, and words of similar import, refer to this Agreement in its entirety and not
to any particular provision hereof, (f) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “but not limited to”, “without limitation” or words of
similar import. 
 12.14 No Consequential or Punitive Damages. NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT,
INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 12.14 IS INTENDED TO LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS, OR WITH RESPECT TO THE INFRINGEMENT OR MISAPPROPRIATION OF THE OTHER PARTY’S INTELLECTUAL PROPERTY RIGHTS OR CONFIDENTIAL
INFORMATION. 
 12.15 Restriction on Employment. 
 (a) During the Research Program Term and for a period of [**] years thereafter, OSI and its Affiliates agree not to hire or retain any
employee of AVEO, or to solicit or induce any employee of AVEO to terminate his or her employment or other relationship with AVEO; provided that, such restriction shall not apply to (i) any employee for whom AVEO has provided prior written
consent to OSI to hire or retain, (ii) any employee of AVEO which AVEO has terminated prior to such solicitation, inducement, employment or retention by OSI or (iii) any employee of AVEO whose employment has been terminated (other than as
set forth in subsection (ii)) for a period of at least [**] months prior to the date of such solicitation, employment or retention. 
 (b) During the Research Program Term and for a period of [**] years thereafter, AVEO and its Affiliates agree not to hire or retain any employee of OSI, or to solicit or induce any employee of OSI to terminate his or her employment or other
relationship with OSI; provided that, such restriction shall not apply to (i) any employee for whom OSI has provided prior written consent to AVEO to hire or retain, (ii) any employee of OSI which OSI has terminated prior to such
solicitation, inducement, employment or retention by AVEO or (iii) any employee of OSI whose employment has been terminated (other than as set forth in subsection (ii)) after a period of at least [**] months prior to the date of such
solicitation, employment or retention. 
 [Remainder of page intentionally left blank] 
  

 - 72 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective
Date. 
  

									
	OSI PHARMACEUTICALS, INC.	 		 	AVEO PHARMACEUTICALS, INC.
					
	BY:	 	 /s/ Colin Goddard
	 		 	BY:	 	 /s/ Tuan Ha-Ngoc

					
	TITLE:	 	 CEO
	 		 	TITLE:	 	 President

					
	DATE:	 	 July 16, 2009
	 		 	DATE:	 	 7-16-09

  

 - 73 - 

 Schedule 1.9 
 Bioinformatics Data 
 [See attached excel
spread sheet] 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment. A total of two pages were omitted. 
  

 - 74 - 

 Schedule 1.10 
 AVEO Bioinformatics Tools 
 [**] 
  

 - 75 - 

 Schedule 1.15 
 [**] Index 
 [**] 
  

 - 76 - 

 Schedule 1.44 
 [**] Models 
 [**] 
  

 - 77 - 

 Schedule 1.47 
 Excluded Targets 
 [**] 
  

 - 78 - 

 Schedule 1.91 
 Pre-Selected Antibody Targets 
 [**]

  

 - 79 - 

 Schedule 3.5(d)(iii) 
 Source Code Documentation 
  

	 	•	 	 User documentation (FAQ, help, training). 

  

	 	•	 	 Administrative documentation for maintenance and troubleshooting. 

  

	 	•	 	 Code documentation, to include in-line commenting and a reference guide that provides a layout to the overall organization of the code base, detailing
which application tools are used and where, the methods and functions utilized and the details of how interfaces are implemented between the application tools. 

  

	 	•	 	 Code should not be obfuscated and should be readable by a developer who is familiar with the environment used. 

  

 - 80 - 

 Schedule 8.2(f) 
 Third Party Licenses 
  

											
	 Subject
	 	 Third Party
	 	 Use
	 	 Up-front
	 	 Annual
	 	 License

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 	 [**]

	 [**]
	 	 [**]
	 	 [**]
	 	 [**]
	 		 	 [**]

	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	
	 [**]
	 		 		 		 		 	

 Notes: 
  

 - 81 - 

	 	1.	The up-front and annual amounts shown are amounts actually paid by AVEO, which do not necessarily represent current or future costs for corresponding licenses.

  

	 	2.	Whether a given license is necessary for making or using any given model will depend on factors such as: [**] 

  

	 	3.	When human tissue is obtained from a hospital or clinic, availability may depend on IRB approval at the supplying institution. 

  

 - 82 - 

 Schedule 10.2(c) 
 Propagatable Tumor Archives 
 [**] 
  

 - 83 - 

 Schedule 10.4(a) 
 Tech Transfer Plan 
 [**] 
  

 - 84 - 

 Schedule 10.5 
 AVEO Existing Programs 
  

	 	1.	AV-951 (triple VEGFR inhibitor) 

  

	 	2.	AV-412 (irreversible [**] inhibitor) 

  

	 	3.	AV-299 (HGF/c-Met inhibitor) 

  

	 	4.	AV-368 (and all related [**] inhibitors) 

  

	 	5.	AV-203 (and all related ErbB3 inhibitors) 

  

	 	6.	AV-370, AV-369, AV-325, AV-371 (and all related [**] inhibitors) 

  

	 	7.	AV-323, AV-232, AV-353 (and all related [**] inhibitors) 

  

	 	8.	[**] 

  

 - 85 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]